VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Human Immunodeficiency Virus

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
    4. Microbial Pathogenesis
    5. Host Ranges and Animal Models
    6. Host Protective Immunity
  2. Vaccine Related Pathogen Genes
    1. HIV complete genome (Other)
    2. nef from subtype B (Other)
    3. Nef SIV (Other)
    4. pol from subtype B (Other)
    5. Pol SIV (Other)
    6. Polymerase protein (Other)
    7. pro (Other)
    8. rev MN isolate (Other)
    9. vif (Other)
    10. vpr (Other)
    11. vpu (Other)
    12. env (Protective antigen)
    13. env from clade B (Protective antigen)
    14. env from HIV 2 (Protective antigen)
    15. env from HIV-1 isolate 037 clone 08 (Protective antigen)
    16. env from HIV-1 isolate 715 (Protective antigen)
    17. env from HIV-1 strain 96ZM651 (Protective antigen)
    18. env from HIV-1 strain 976 clone 17 (Protective antigen)
    19. env from HIV-1 strain Ba-L (Protective antigen)
    20. env from SHIV-89.6 (Protective antigen)
    21. env from SHIV89.6P (Protective antigen)
    22. env from SIV (Protective antigen)
    23. Env Gp160 (Protective antigen)
    24. env MN isolate (Protective antigen)
    25. Envelope polyprotein from HXB2 (Protective antigen)
    26. gag from clade A (Protective antigen)
    27. Gag from HIV 1 (Protective antigen)
    28. gag from HIV 2 (Protective antigen)
    29. gag from HIV subtype B (Protective antigen)
    30. gag from HIV-1 vector pNL4-3 (Protective antigen)
    31. gag from HXB2 (Protective antigen)
    32. gag from SHIV-89.6 (Protective antigen)
    33. Gag protein from SIV-mnd 2 (Protective antigen)
    34. gag-pol (Protective antigen)
    35. gag-pol SIV (Protective antigen)
    36. gp120 (Protective antigen)
    37. gp120 (Protective antigen)
    38. gp120 from MN (Protective antigen)
    39. gp120 Indian subtype C (Protective antigen)
    40. gp41 (Protective antigen)
    41. Nef (Protective antigen)
    42. nef from HIV 2 (Protective antigen)
    43. pol from HIV 1 (Protective antigen)
    44. pol from SHIV-89.6 (Protective antigen)
    45. rev from HIV 1 (Protective antigen)
    46. rev from SHIV-89.6 (Protective antigen)
    47. Tat (Protective antigen)
    48. tat from HIV 2 (Protective antigen)
    49. tat from SHIV-89.6 (Protective antigen)
    50. vif from SHIV-89.6 (Protective antigen)
    51. vpr from SHIV-89.6 (Protective antigen)
    52. vpu from SHIV-89.6 (Protective antigen)
  3. Vaccine Related Host Genes
    1. ANXI
    2. human IFNG
    3. IFNG
    4. Ifng (Interferon gamma)
    5. IFNG from Macaca nemestrina
    6. IgA
    7. IgA Fc fragment
    8. IgG
    9. IgG Fc fragment
    10. IgG2b
    11. Ighg1
    12. Ighv1-9
    13. IL-6
    14. Il12a
    15. Il2
    16. IL2
    17. IL2
    18. IL4
    19. Il4 (interleukin 4)
    20. Il5
    21. TNF
    22. TNF-a from Papio anubis
    23. TNF-alpha
  4. Vaccine Information
    1. Adenoviral vector Ad5 expressing SIV gag protein
    2. ALVAC-HIV-2
    3. ALVAC-HIV-2- env/gag/pol
    4. ALVAC-SIV/gp120
    5. CVB4/p24(73(3))
    6. DNA and poxvirus priming-boosting SHIV vaccine
    7. DNA vaccine expressing multiple HIV epitopes
    8. Gag-VRPs
    9. gp120 recominant with GMDP adjuvant
    10. gp120 recominant with MDP adjuvant
    11. gp140, Gag and Tat Protein Vaccine with MF59
    12. HIV DNA and adenoviral vector Ad5 expressing SIV gag protein
    13. HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag
    14. HIV DNA vaccine pCMN160
    15. HIV DNA vaccine pHIS-SHIV-B
    16. HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
    17. HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost
    18. HIV DNA vaccine VlJns-tPA-gp120
    19. HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein
    20. HIV recombinant gp160 Protein Vaccine
    21. HIV recombinant vector vaccine MVA-gag encoding gag
    22. HIV recombinant vector vaccine MVA.HIVA encoding env and rev
    23. HIV-1 gp120 with mCT E112K
    24. HIV-2 DNA vaccine
    25. Inactivated HIV-2 Vaccine with PMMA
    26. L. T -HIV-1 Gag
    27. MVA expressing HIV Gag, Pol and Env proteins
    28. NYVAC-HIV-1
    29. NYVAC-HIV-2
    30. NYVAC-SIV
    31. rBCG-SIVgag and rDIsSIVgag Prime-boost SHIV vaccine
    32. Recombinant HIV gp120 with adjuvant NanoEmulsion
    33. rgp120 HIV Vaccine with immunoliposomes
    34. rMVA-SIV-CD40L
    35. rMVTT-SIV-gpe
    36. SHIV DNA vaccine encoding env and gag
    37. SHIV(Ba-L) DNA vaccine encoding env and gag
    38. V3 VLPs with Gamma inulin adjuvant
    39. YF17D- HIV-1 p24
  5. References
I. General Information
1. NCBI Taxonomy ID:
12721
2. Disease:
Acquired Immunodeficiency Syndrome (AIDS)
3. Introduction
Human immunodeficiency virus (HIV) is the retrovirus that causes acquired immunodeficiency syndrome (AIDS). Within bodily fluids, HIV is present as both free virus particles and as virus within infected immune cells. So far, AIDS has killed more than 25 million people since it was first recognized in 1981, making it one of the most destructive pandemics in recorded history. Antiretroviral treatment reduces both the mortality and the morbidity of HIV infection, but routine access to antiretroviral medication is not available in all countries. Most HIV-infected individuals develop AIDS and die; however, about 10% remains healthy for many years, with no noticeable symptoms. Treatment with anti-retrovirals increases the life expectancy of people infected with HIV (Palella et al., 1998; Buchbinder et al., 1994).
4. Microbial Pathogenesis
The 3 major routes of HIV transmission are sexual intercourse, contaminated needles, and transmission from an infected mother to her baby at birth, or through breast milk. HIV primarily infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. This decreases CD4+ T cells through direct viral killing of infected cells, increased rates of apoptosis in infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity (CMI) is lost, and the body becomes progressively more susceptible to opportunistic infections (Chan et al., 1997).
5. Host Ranges and Animal Models
AIDS has killed more than 25 million people since it was first recognized in 1981. Globally, ~40 million people currently live with HIV. Sub-Saharan Africa remains by far the worst-affected region. More than 64% of all people living with HIV are in sub-Saharan Africa, as are more than three quarters of all women living with HIV. Two-thirds of HIV/AIDS infections in Asia occur in India, with an estimated 6 million infections, surpassing South Africa's 5.5 million infections, making India the country with the highest number of HIV infections in the world (Palella et al., 1998).
6. Host Protective Immunity
HIV can infect a variety of immune cells such as CD4+ T cells, macrophages, and microglial cells. HIV-1 entry to macrophages and T cells is mediated through interaction of the virion envelope glycoproteins (gp120) with the CD4 molecule on target cells and also with chemokine coreceptors. Macrophages play a key role in several critical aspects of HIV infection. They appear to be the first cells infected by HIV and perhaps the source of HIV production when CD4+ cells become depleted in the patient. T-tropic isolates, or syncitia-inducing (SI) strains replicate in primary CD4+ T cells as well as in macrophages. Dual-tropic HIV-1 strains are thought to be transitional strains of the HIV-1 virus. HIV can also infect a subtype of myeloid dendritic cells, which probably constitute a reservoir that maintains infection when CD4+ T cell numbers have declined to extremely low levels (Chan et al., 1997; Coakley et al., 2005; Deng et al., 1996; Knight et al., 1990).
1. env
  • Gene Name : env
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Gene ID : 155971
  • NCBI Protein GI : 9629363
  • Locus Tag : HIV1gp8
  • Genbank Accession : AF033819
  • Protein Accession : NP_057856
  • Taxonomy ID : 11676
  • Gene Starting Position : 5770
  • Gene Ending Position : 8340
  • Gene Strand (Orientation) : +
  • Protein Name : Envelope surface glycoprotein gp160, precursor
  • Protein pI : 9.19
  • Protein Weight : 91753.45
  • Protein Length : 856
  • DNA Sequence : Show Sequence
    >gi|9629357:5770-8340 Human immunodeficiency virus 1, complete genome
    AATGAGAGTGAAGGAGAAATATCAGCACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGG
    ATGTTGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGG
    AAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGC
    CACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTT
    AACATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAA
    AGCCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATAC
    CAATAGTAGTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACA
    AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATG
    ATACTACCAGCTATAAGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTT
    TGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTC
    AATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAA
    CTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAA
    TGCTAAAACCATAATAGTACAGCTGAACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACA
    AGAAAAAGAATCCGTATCCAGAGAGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGA
    GACAAGCACATTGTAACATTAGTAGAGCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAG
    AGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACG
    CACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGTTTA
    ATAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAAT
    AAAACAAATTATAAACATGTGGCAGAAAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATT
    AGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGA
    TCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAA
    AATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTG
    GGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGC
    TGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGA
    GGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTG
    GAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTG
    CTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGA
    GTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAA
    GAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAA
    ATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGC
    TGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACC
    CCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTC
    GATTAGTGAACGGATCCTTGGCACTTATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCG
    CTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTC
    AAATATTGGTGGAATCTCCTACAGTATTGGAGTCAGGAACTAAAGAATAGTGCTGTTAGCTTGCTCAATG
    CCACAGCCATAGCAGTAGCTGAGGGGACAGATAGGGTTATAGAAGTAGTACAAGGAGCTTGTAGAGCTAT
    TCGCCACATACCTAGAAGAATAAGACAGGGCTTGGAAAGGATTTTGCTATA
  • Protein Sequence : Show Sequence
    >gi|9629363|ref|NP_057856.1| Envelope surface glycoprotein gp160, precursor [Human immunodeficiency virus 1]
    MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWA
    THACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNT
    NSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSF
    EPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDN
    AKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
    EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRI
    KQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVK
    IEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIE
    AQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWME
    WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA
    VLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHR
    LRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAI
    RHIPRRIRQGLERILL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): ALVAC-HIV-2- env/gag/pol , HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag , HIV DNA vaccine pHIS-SHIV-B , HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) , HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein , HIV recombinant vector vaccine MVA.HIVA encoding env and rev , NYVAC-HIV-2
2. env from clade B
  • Gene Name : env from clade B
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 58043865
  • Other Database IDs : CDD:109567
    CDD:197369
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope glycoprotein
  • Protein Length : 852
  • Protein Note : clone can be used to generate pseudotyed infectious virions that use the CCR5 coreceptor subtype: B
  • Protein Sequence : Show Sequence
    >gi|58043865|gb|AAW64267.1| envelope glycoprotein [Human immunodeficiency virus 1]
    MRVKEIRKNYRHLWKWGIMLLGMLMICSATENLWVTVYYGVPVWKEATTTLFCASDAKGYEKEVHNVWAT
    HACVPTDPNPQEVVLENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCSDVNTTSVNT
    TASSMEGGEIKNCSFNTTTSMSDKMQKEYALFYTLDVVPIVKENNTYRLISCNTSVITQACPKVSFEPIP
    IHYCAPAGFAILMCNNKTFDGKGPCNNVSTVQCTHGIKPVVSTQLLLNGSLAEEEVVIRSDNFTDNAKTI
    IVHLNESIEITCTRPNNNTSKSITIGPGRAFYATGRIIGDIRKAHCNISGEKWHNALEQIVKKLGEKFEN
    ATTIRFNQSSGGDQEIVMHTFNCGGEFFYCNSTQLFNSTWWPNGTTTEWSNETSNGTITLPCRIKQIINM
    WQEVGKAMYAPPISGPISCSSNITGLLLVRDGGNDNETNGTETFRPGGGDMRDNWRSELYKYKVVKIEPL
    GVAPTKAKRRVVQREKRAVGLGAMFLGFLGAAGSTMGAASITLTVQARLLLSGIVQQQNNLLRAIEAQQH
    LLQLTVWGIKQLQARVLAIERYLKDQQLLGIWGCSGKLICTTAVPWNSSWSNKSLKWIWDNMTWMEWEKE
    IDNYTGIIYNLLEESQNQQDKNEKELLELDKWASLWTWFDITNWLWYIKIFIMIVGGLVGLRIVFAVLSI
    VNRVRQGYSPLSFQTRLPAPRGLDRPEGTEEEGGDRDKDRSIRLVDGFLALIWDDLRSLCLFSYHRLRDL
    LLIVARVVEILGHRGWEILKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRIIEVLQRIGRAILHIP
    TRIRQGLERALL
  • Molecule Role : Protective antigen
3. env from HIV 2
  • Gene Name : env from HIV 2
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 2
  • NCBI Protein GI : 1845209
  • Other Database IDs : CDD:109567
    CDD:197369
  • Taxonomy ID : 11709
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope polyprotein
  • Protein Length : 865
  • Protein Note : similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542
  • Protein Sequence : Show Sequence
    >gi|1845209|gb|AAB47784.1| envelope polyprotein [Human immunodeficiency virus 2]
    MEPGRNQLLAVILLTSACLIYCKQYVTVFYGVPVWRNASIPLFCATKNRDTWGTIQCLPDNDDYQEIPLN
    VTEAFDAWDNTVTEQAIEDVWRLFETSIKPCVKLTPLCVAMNCNPVTGNNTNATAKPTAARPTTNPSYLT
    IINESSTCVGADNCTGLGDEGMVNCKFNMTGLEQDKIKGYTDTWYSDDVVCDSTNKTGTNTTCYMRHCNT
    SVIKESCDKHYWDSMKFRYCTPPGYALLRCNDTNYSGFAPNCPKVVAASCTRMMETQTSTWFGFNGTRAE
    NRTYIYWHGRDNRTIISLNKHYNLTMHCKRPGNKTVVPITLMSGHRFHSQAVINKKPRQAWCWFKGNWKG
    AMQEVKQTLAGHPRYKGTNDTSKINFVKPGVGSDPEVTYMWTNCRGEFFYCNMTWFLNWVENRTSQKQRN
    YAPCHIRQIINTWHKVGQYVYLPPREGELTCNSTVTSIIANIDTDGNQTNITFSAEVAELYRLELGDYKL
    IEITPIGFAPTSEKRYSSAPARNKRGVFVLGLLGFLATAGSAMGAASLTLSAQSRTLLAGIVQQQQQLLD
    IVKRQQELLRLTVWGTKNLQARVTAIEKYLKDQAQLNSWGCTFRQVCHTTVPWVNDSLTPRWNNMTWQEW
    EKQVRYLEANISQSLEEAQIQQEKNMYELQKLNSWDVFGNWFDLTSWIKYIQYGVYIVVGIIALRIAIYV
    VQLLSRFRKGYRPVFSSPPGYLQQIHIHTDRGQPANEETEGDAGDASGYDFWPWPINYIQLLIHLLTRLL
    TGLYSICRDLLSANSPTRRLISQNLTAIRDWLRLKAAYLQYGCEWIQEAFQAIARTARETLAGAWRGLCK
    AVQRIGRGILAVPRRIRQGAEIALL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): ALVAC-HIV-2 , HIV-2 DNA vaccine , NYVAC-HIV-1
4. env from HIV-1 isolate 037 clone 08
  • Gene Name : env from HIV-1 isolate 037 clone 08
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 isolate 037 clone 08
  • NCBI Protein GI : 487257
  • Other Database IDs : CDD:109567
    CDD:197369
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope glycoprotein
  • Protein Length : 856
  • Protein Note : Envelope glycoprotein GP120; pfam00516
  • Protein Sequence : Show Sequence
    >gi|487257|gb|AAB05027.1| envelope glycoprotein, partial [Human immunodeficiency virus 1]
    VMGIERNYPCWWTWGIMILGMIIICNTAENLWVTVYYGVPVWKDAETTLFCASDAKAYDTEVHNVWATHA
    CVPTDPNPQEIYMENVTEEFNMWKNNMVEQMHTDIISLWDQSLKPCVQLTPLCVTLDCSYNITNNITNSI
    TNSSVNMREEIKNCSFNMTTELRDKNRKVYSLFYKLDVVQINNGNNSSNLYRLINCNTSALTQACPKVTF
    EPIPIRYCAPAGYAILKCNDKEFNGTGLCKNVSTVQCTHGIRPVVSTQLLLNGSLAEGKVMIRSENITNN
    VKNIIVQLNETVTINCTRPNNNTRKSVRIGPGQTFYATGDIIGDIRQAHCNVSGSQWNRALHQVVGQLRE
    YWNTTIIFKNSSGGDLEITTHSFNCGGEFFYCNTSGLFNSNWTHNDTASMKPNDTITLPCRIKQIINMWQ
    RVGQAIYAPPIQGVIRCESNITGLILTRDGGGNINESQIFRPGGGDMRDNWRSELYKYKVVRIEPLGVAP
    TKAKRRVVEREKRAVVELGAVFIGFLGTAGSTMGAASITLTVQVRKLLSGIVQQQSNLLRAIEAQQHLLK
    LTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTNVPWNSSWSNKSEREIWENMTWLQWDKEISN
    YTHIIYELIEESQKQQEKNEQELLELDKWANLWNWFDISNWLWYIKIFIMIVGGLIGLRIVFAVLSVINR
    VRQGYSPLSFQTLTPNPRDPDRPGRIEGEGGEQDRGRSIRLVSGFLALAWDDLRNLCLSSYHQLRDFILI
    VARTVELLGHSSLKGLRLGWEGLKYLGNLLLYWGRELKTSAINLFDTIAIVVAGWTDRVIEVGQRLGRAI
    LNIPRRIRQGLERALL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): SHIV(Ba-L) DNA vaccine encoding env and gag
5. env from HIV-1 isolate 715
  • Gene Name : env from HIV-1 isolate 715
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 isolate 715 from Baltimore clone 6
  • NCBI Protein GI : 475647
  • Other Database IDs : CDD:109567
    CDD:197369
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope glycoprotein
  • Protein Length : 852
  • Protein Note : Envelope glycoprotein GP120; pfam00516
  • Protein Sequence : Show Sequence
    >gi|475647|gb|AAB04079.1| envelope glycoprotein [Human immunodeficiency virus 1]
    VTGIRKNCQHWWKWGIMLLGILMICNATEKLWVTVYYGVPVWKEANTTLFCASDAKAYDTEVHNVWATHA
    CVPTDPDPQEVELENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTNLRNDTNTTRN
    ATNTTSSETMMEEGEIKNCSFNITTSIRDKVQKEFALFYKLDVVPIENDTTSYRLISCNTSVLTQACPKV
    SFEPIPIHFCAPAGFAILKCKDKKFNGTGPCTNVSTVQCTHGIKPVVSTQLLLNGSLAEEEVVIRSANLS
    DNAKTIIVQLNESVQMNCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHCNLSRTKWNETLKRIVIKL
    REQYENKTIVFNQSSGGDPEIVMLSFNCGGEFFYCNSTKLFNSTWNGTESNNTGDDPIVLPCRIKQVINM
    WQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGGNSNETNTTEIFRPGGGNMKDNWRSELYKYKVVRIEPL
    GIAPTRAKRRVVQREKRAAGLGVMFLGFLGAAGSTMGAASIALTVQARQLLSGIVQQQNNLLRAIEAQQH
    MLQLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTTVPWNASWSNKSHDQIWQNMTWMQWEKE
    IDNYTSLIYNLIEVSQNQQEKNEQELLELDKWASLWNWFDITNWLWYIKIFIMIVGGLIGLRIVFIVLSI
    VNRVRQGYSPLSFQTHLPARRGPDRPEGIEEEGGERDRDRSGQLVTGFLAIIWVDLRSLCLFSYHRLRDL
    LLIVARIVELLGRRGWEILKYWWNLLQYWSQELKSGAVSLLNATAIAVAEGTDRVIEVLQRAGRAILHIP
    RRIRQGFERALL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): SHIV DNA vaccine encoding env and gag , SHIV(Ba-L) DNA vaccine encoding env and gag
6. env from HIV-1 strain 96ZM651
  • Gene Name : env from HIV-1 strain 96ZM651
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 strain 96ZM651
  • NCBI Protein GI : 13569225
  • Other Database IDs : CDD:109567
    CDD:197369
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope glycoprotein
  • Protein Length : 868
  • Protein Note : isolated in 1996
  • Protein Sequence : Show Sequence
    >gi|13569225|gb|AAK30970.1|AF286224_8 envelope glycoprotein [Human immunodeficiency virus 1]
    MRVREILRNWQRWWTWGILGFWMLMICNVWGNLWVTVYYGVPVWKEAKTTLFCASDAKSYEKEVHNVWAT
    HACVPTDPNPQEIVLGNVTENFNMWKNDMVDQMHEDIISLWDQSLKPCVKLTPLCVTLNCTEVNVTRNVN
    NSVVNNTTNVNNSMNGDMKNCSFNITTELKDKKKNVYALFYKLDIVSLNETDDSETGNSSKYYRLINCNT
    SALTQACPKVSFDPIPIHYCAPAGYAILKCNNKTFNGTGPCHNVSTVQCTHGIKPVVSTQLLLNGSLAEE
    GIIIRSENLTNNVKTIIVHLNRSIEIVCVRPNNNTRQSIRIGPGQTFYATGDIIGDIRQAHCNISRTNWT
    KTLREVRNKLREHFPNKNITFKPSSGGDLEITTHSFNCRGEFFYCNTSGLFSINYTENNTDGTPITLPCR
    IRQIINMWQEVGRAMYAPPIEGNIACKSDITGLLLVRDGGSTNDSTNNNTEIFRPAGGDMRDNWRSELYK
    YKVVEIKPLGIAPTEAKRRVVEREKRAVGIGAVFLGFLGAAGSTMGAASITLTAQARQVLSGIVQQQSNL
    LRAIEAQQHLLQLTVWGIKQLQTRVLAIERYLKDQQLLGLWGCSGKLICTTAVPWNISWSNKSKTDIWDN
    MTWMQWDREISNYTNTIYRLLEDSQSQQEQNEKDLLALDSWNNLWNWFDITKWLWYIKIFIMIVGGLIGL
    RIIFAVLSIVNRVRQGYSPLSFQTLIPNPREPDRPGRIEEEGGEQDKERSVRLVSGFLALAWDDLRSLCL
    FSYHRLRDFILVTARAVELLRRSSLKGLQRGWEALKYLGSLVQYWGLELKKSAISLLDTIAIAVAEGTDR
    IIELIQGICRAIRNVPRRIRQGFETALL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): SHIV DNA vaccine encoding env and gag , SHIV(Ba-L) DNA vaccine encoding env and gag
7. env from HIV-1 strain 976 clone 17
  • Gene Name : env from HIV-1 strain 976 clone 17
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 strain 976 clone 17
  • NCBI Protein GI : 475668
  • Other Database IDs : CDD:109567
    CDD:197369
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope glycoprotein
  • Protein Length : 854
  • Protein Note : Envelope glycoprotein GP120; pfam00516
  • Protein Sequence : Show Sequence
    >gi|475668|gb|AAB04093.1| envelope glycoprotein [Human immunodeficiency virus 1]
    VKETQMNWPNLWKWGTLILGLVIICSASDNLWVTVYYGVPVWKDADTTLFCASDAKAHETEVHNVWATHA
    CVPTDPNPQEIHLENVTENFNMWKNKMVEQMQEDVISLWDQSLKPCVKLTPLCVTLTCTNATLNCTNLTN
    GNKTTNVSNIIGNLTDEVRNCSFHMTTELRDKKQKVYALFYKLDIVQINSSEYRLINCNTSVIKQACPKI
    SFDPIPIHYCTPAGYAILKCNDKNFNGTGPCKNVSSVQCTHGIKPVVSTQLLLNGSLAEEEIIISSENLT
    NNAKTIIVHLNKSVEISCTRPSTNTRTSIRIGPGQVFYRTGDITGDIRKAYCEINETKWNEALKQVAGKL
    KEHFNKTIIFQPPSGGDLEITMHHFNCRGEFFYCDTTQLFNRTWGENETREGRNITLPCKIKQIVNMWQG
    AGQAMYAPPISGIIKCVSNITGILLTRDGGANNSASETFRPGGGNIKDNWRSELYKYKVVQIEPLGIAPT
    RAKRRVVEREKRAVGIGAMIFGFLGAAGSTMGAASITLTVQARQLLSGIVQQQSNLLRAIEAQQHLLQLT
    VWGIKQLQARVLAVERYLKDQKFLGLWGCSGKIICTTAVPWNSTWSNKSYEEIWNNMTWIEWEREISNYT
    NQIYEILTESQDQQDRNEKDLLELDKWASLWNWFDITNWLWYIKIFIMIVGGLIGLRIIFAVLSIVNRVR
    QGYSPLSFQIPFHHQREPDRPERIEEGGGEQGRDRSVRLVSGFLALAWDDLRSLCLFLYHRLRDLLLIAT
    RTVEILGHSSLKGLRRGWEGLKYLGNLLIYWGQELRISAISLLNATAIAVGGWTDRIIEVAQRAWRAILR
    IPRRIRQGLERSLL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): SHIV DNA vaccine encoding env and gag , SHIV(Ba-L) DNA vaccine encoding env and gag
8. env from HIV-1 strain Ba-L
  • Gene Name : env from HIV-1 strain Ba-L
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 strain Ba-L subtype B
  • NCBI Nucleotide GI : 326367
  • NCBI Protein GI : 326371
  • Other Database IDs : CDD:109567
    CDD:197369
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Length : 855
  • Protein Note : Envelope glycoprotein GP120; pfam00516
  • Protein Sequence : Show Sequence
    >gi|326371|gb|AAA44191.1| env [Human immunodeficiency virus 1]
    MRVTEIRKSYQHWWRWGIMLLGILMICNAEEKLWVTVYYGVPVWKEATTTLFCASDRKAYDTEVHNVWAT
    HACVPTDPNPQEVELKNVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNATNGN
    DTNTTSSSRGMVGGGEMKNCSFNITTNIRGKVQKEYALFYKLDIAPIDNNSNNRYRLISCNTSVITQACP
    KVSFEPIPIHYCAPAGFAILKCKDKKFNGKGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSAN
    FADNAKVIIVQLNESVEINCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHCNLSRAKWNDTLNKIVI
    KLREQFGNKTIVFKHSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWNVTEESNNTVENNTITLPCRIKQ
    IINMWQEVGRAMYAPPIRGQIRCSSNITGLLLTRDGGPEDNKTEVFRPGGGDMRDNWRSELYKYKVVKIE
    PLGVAPTKAKRRVVQREKRAVGIGAVFLGFLGAAGSTMGAAAMTLTVQARLLLSGIVQQQNNLLRAIEAQ
    QHLLQLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTAVPWNASWSNKSLNKIWDNMTWIEWD
    REINNYTSIIYSLIEESQNQQEKNEQELLELDKWASLWNWFDITKWLWYIKIFIMIVGGLIGLRIVFSVL
    SIVNRVRQGYSPLSFQTHLPSSRGPDRPGGIEEEGGERDRDRSGPLVNGFLALIWVDLRSLFLFSYHRLR
    DLLLIVMRIVELLGLAGGWEVLKYWWNLLQYWSQELKNSAVSLLNATAVAVAEGTDRVIEVLQRAVRAIL
    HIPRRIRQGLERALL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): SHIV DNA vaccine encoding env and gag , SHIV(Ba-L) DNA vaccine encoding env and gag
9. env from SHIV-89.6
  • Gene Name : env from SHIV-89.6
  • Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
  • NCBI Protein GI : 2828045
  • Other Database IDs : CDD:109567
    CDD:197369
  • Taxonomy ID : 57667
  • Gene Strand (Orientation) : ?
  • Protein Name : env
  • Protein Length : 854
  • Protein Note : Envelope glycoprotein GP120; pfam00516
  • Protein Sequence : Show Sequence
    >gi|2828045|gb|AAB99966.1| env [Simian-Human immunodeficiency virus]
    MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWREATTTLFCASDAKAYDTEVHNVWA
    THACVPTDPNPQEVVLGNVTENFNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLCVTLNCTNLNITKNT
    TNPTSSSWGMMEKGEIKNCSFYITTSIRNKVKKEYALFNRLDVVPIENTNNTKYRLISCNTSVITQACPK
    VSFQPIPIHYCVPAGFAMLKCNNKTFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEDIVIRSENF
    TDNAKTIIVQLNESVVINCTRPNNNTRRRLSIGPGRAFYARRNIIGDIRQAHCNISRAKWNNTLQQIVIK
    LREKFRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTEGNDIITLQCRIKQI
    INMWQKVGKAMYAPPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPGGGDMRDNWRSELYKYKVVRIE
    PIGVAPTRAKRRTVQREKRAVGIGAVFLGFLGAAGSTMGAASVTLTVQARLLLSGIVQQQNNLLRAIEAQ
    QHMLQLTVWGIKQLQARVLALERYLRDQQLMGIWGCSGKLICTTSVPWNVSWSNKSVDDIWNNMTWMEWE
    REIDNYTDYIYDLLEKSQTQQEKNEKELLELDKWASLWNWFDITNWLWYIRLFIMIVGGLIGLRIVFAVL
    SIVNRVRQGYSPLSFQTLLPASRGPDRPEGTEEEGGERDRDRSGPLVNGSLALIWDDLRSLCLFSYHRLR
    DLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRH
    IPRRIRQGLERILL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
10. env from SHIV89.6P
  • Gene Name : env from SHIV89.6P
  • Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV89.6P
  • NCBI Protein GI : 72398919
  • Other Database IDs : CDD:109567
  • Taxonomy ID : 57667
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope protein
  • Protein Length : 378
  • Protein Note : Envelope glycoprotein GP120; pfam00516
  • Protein Sequence : Show Sequence
    >gi|72398919|gb|AAZ72871.1| envelope protein [Simian-Human immunodeficiency virus]
    LNCTNLNITKNTTNPTSSSWGMMEEGEIKNCSFYITTSIRDKVKKEYALFNRLDVVPVENTSYRLISCNT
    SVITQACPKVSFQPIPIHYCVPAGFAILKCNNKTFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEE
    DIVIRSENFTNNVKNIIVQLNESVVINCTRPNNNTRERLSIGPGRAFYARRNIIGDIRQAHCNISRAKWN
    NTLQQIVIKLREKYRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTKGSDII
    TLQCRIKQIINMWQKVGKAMYAPPIKGQIRCSSNITGLLLTRDGGSSTETEPEIFRPGGGDMRDNWRSEL
    YKYKVVRIEPIGVAPTRAKRRTVQREKR
  • Molecule Role : Protective antigen
  • Related Vaccine(s): DNA and poxvirus priming-boosting SHIV vaccine , HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost
11. env from SIV
  • Gene Name : env from SIV
  • Sequence Strain (Species/Organism) : Simian immunodeficiency virus
  • NCBI Gene ID : 1490007
  • NCBI Protein GI : 9627208
  • Locus Tag : SIVgp6
  • Genbank Accession : M58410
  • Protein Accession : NP_054372
  • Taxonomy ID : 11723
  • Gene Starting Position : 6201
  • Gene Ending Position : 8765
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope protein
  • Protein pI : 8.73
  • Protein Weight : 91594.7
  • Protein Length : 854
  • DNA Sequence : Show Sequence
    >gi|9627204:6201-8765 Simian immunodeficiency virus, complete genome
    TATGGGGAGATTGCTTATAAAAATACTAATAATAGCAATAGGGATAAGTATAGGAATAGGTAACCTGTAT
    GTGACAGTGTTTTATGGAATCCCAGTATGGAAAAATTCAACAGTTCAGGCATTTTGCATGACGCCCAATA
    CCAATATGTGGGCAACCACCAACTGCATACCAGATGATCATGATAATACAGAGGTGCCTCTAAACATTAC
    AGAAGCTTTCGAGGCTTGGGATAATCCGCTGGTAAAACAAGCAGAGAGTAATATACATCTACTCTTTGAA
    CAAACGATGAGGCCTTGTGTTAAGCTCTCCCCCATATGTATTAAAATGTCCTGTGTAGAGCTGAATGGTA
    CAGCCACGACAAAGGCCACCACTACTGCAACTACAACAATGACTACCCCCTGTCAGAATTGCAGTACAGA
    GCAGATAGAAGGAGAAATGGCAGAGGAACCAGCATCCAACTGCACTTTTGCAATTGCAGGATATCAAAGA
    GATGTAAAAAAGAATTATAGCATGACCTGGTATGATCAGGAGTTAGTCTGCAATAATAAAACAGGAAGTG
    AAAAGGGAAGTAAGGATTGTTACATGATACATTGTAATGATTCAGTGATAAAAGAAGCTTGTGATAAAAC
    ATATTGGGATACTTTAAGAGTAAGATACTGTGCACCAGCAGGGTATGCTTTGCTAAAATGTAATGATAAG
    GATTATAGAGGCTTTGCTCCAAAGTGCAAGAATGTTTCAGTAGTGCATTGTACTAGATTAATCAATACTA
    CTATAACTACAGGGATAGGATTAAATGGTAGTAGATCAGAAAATAGAACAGAGATATGGCAGAAAGGAGG
    AAATGATAATGATACAGTTATAATAAAGTTGAATAAGTTTTACAACTTGACAGTGAGATGCCGAAGACCT
    GGTAATAAAACAGTGTTGCCAGTAACAATCATGGCAGGGTTAGTATTTCACTCTCAGAAATATAATACCA
    GGTTAAAACAAGCGTGGTGCCACTTCCAAGGAGATTGGAAAGGGGCATGGAAAGAAGTCAGAGAAGAAGT
    AAAGAAAGTGAAAAATCTTACAGAAGTAAGCATAGAAAATATACATCTGAGAAGGATATGGGGAGATCCA
    GAATCAGCGAATTTTTGGTTCAATTGTCAAGGTGAATTTTTCTATTGTAAGATGGACTGGTTTATCAATT
    ATCTAAACAATCGAACAGAAGATGCAGAAGGTACTAATAGGACCTGTGACAAAGGGAAGCCAGGACCAGG
    ACCATGTGTTCAGAGAACTTATGTTGCCTGCCATATACGACAAGTAGTAAATGATTGGTACACTGTCTCT
    AAAAAGGTATATGCTCCACCAAGGGAAGGTCATTTGGAGTGTAACTCATCAGTCACGGCACTATACGTGG
    CAATAGATTATAACAACAAGTCTGGCCCAATAAATGTGACCCTAAGTCCTCAGGTACGCAGCATATGGGC
    GTACGAACTGGGAGACTATAAATTAGTAGAGATAACACCAATTGGCTTTGCTCCTACAGATGTAAGAAGA
    TATACTGGCCCCACAAGAGAAAAAAGGGTGCCATTCGTGCTAGGGTTTCTAGGCTTCTTGGGAGCTGCTG
    GAACTGCAATGGGCGCAGCGGCAACAACGCTGACAGTCCAGTCTCGGCATTTGCTTGCTGGGATATTGCA
    GCAGCAGAAGAACTTGCTGGCGGCTGTGGAACAGCAACAACAGTTGTTGAAGCTGACCATTTGGGGTGTG
    AAAAACCTCAATGCCCGCGTCACAGCTCTCGAGAAGTACCTAGAGGATCAGGCACGGCTAAATTCATGGG
    GATGTGCGTGGAAACAAGTATGTCACACCACAGTGCCATGGAAGTATAATAACACTCCTAAGTGGGACAA
    TATGACTTGGTTGGAGTGGGAGAGACAAATTAATGCCTTGGAAGGCAACATAACTCAACTATTGGAAGAA
    GCACAAAATCAGGAATCAAAGAATCTGGATCTGTACCAGAAATTGGATGATTGGTCAGGGTTCTGGTCAT
    GGTTCTCACTGTCAACTTGGTTAGGCTATGTTAAAATAGGATTTTTAGTGATAGTGATTATTCTAGGATT
    AAGATTTGCATGGGTATTATGGGGATGTATCAGAAATATTAGGCAGGGATATAATCCTCTCCCCCAGATC
    CATATCCACAGTTCAGCGGAACGGCCAGACAACGGAGGAGGGCAAGACAGAGGTGGAGAAAGCAGCAGCA
    GCAAATTGATAAGATTGCAGGAAGAGTCCTCAACACCTTCGAGGATCAACAACTGGTGGCTCAACTTCAA
    GAGCTGCAGCTTGAGAATAAGGACTTGGTGTTACAACATCTGCCTGACCCTCCTCATATTCATCAGGACA
    GCAGTGGGATACCTGCAGTATGGGCTCCAGCAACTCCAAGAGGCAGCAACAGGGCTTGCTCAAGCTCTGG
    CGAGGGCTGCGAGGGAAGCCTGGGGCAGACTGGGTGCTATTGTCCGATCCGCTTATCGGGCAGTCATCAA
    CAGTCCAAGAAGAGTGCGGCAAGGCCTTGAAAAAGTCCTGGGGTA
  • Protein Sequence : Show Sequence
    >gi|9627208|ref|NP_054372.1| envelope protein [Simian immunodeficiency virus]
    MGRLLIKILIIAIGISIGIGNLYVTVFYGIPVWKNSTVQAFCMTPNTNMWATTNCIPDDHDNTEVPLNIT
    EAFEAWDNPLVKQAESNIHLLFEQTMRPCVKLSPICIKMSCVELNGTATTKATTTATTTMTTPCQNCSTE
    QIEGEMAEEPASNCTFAIAGYQRDVKKNYSMTWYDQELVCNNKTGSEKGSKDCYMIHCNDSVIKEACDKT
    YWDTLRVRYCAPAGYALLKCNDKDYRGFAPKCKNVSVVHCTRLINTTITTGIGLNGSRSENRTEIWQKGG
    NDNDTVIIKLNKFYNLTVRCRRPGNKTVLPVTIMAGLVFHSQKYNTRLKQAWCHFQGDWKGAWKEVREEV
    KKVKNLTEVSIENIHLRRIWGDPESANFWFNCQGEFFYCKMDWFINYLNNRTEDAEGTNRTCDKGKPGPG
    PCVQRTYVACHIRQVVNDWYTVSKKVYAPPREGHLECNSSVTALYVAIDYNNKSGPINVTLSPQVRSIWA
    YELGDYKLVEITPIGFAPTDVRRYTGPTREKRVPFVLGFLGFLGAAGTAMGAAATTLTVQSRHLLAGILQ
    QQKNLLAAVEQQQQLLKLTIWGVKNLNARVTALEKYLEDQARLNSWGCAWKQVCHTTVPWKYNNTPKWDN
    MTWLEWERQINALEGNITQLLEEAQNQESKNLDLYQKLDDWSGFWSWFSLSTWLGYVKIGFLVIVIILGL
    RFAWVLWGCIRNIRQGYNPLPQIHIHSSAERPDNGGGQDRGGESSSSKLIRLQEESSTPSRINNWWLNFK
    SCSLRIRTWCYNICLTLLIFIRTAVGYLQYGLQQLQEAATGLAQALARAAREAWGRLGAIVRSAYRAVIN
    SPRRVRQGLEKVLG
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag , NYVAC-SIV , rMVTT-SIV-gpe
12. Env Gp160
  • Gene Name : Env Gp160
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • VO ID : VO_0010937
  • NCBI Protein GI : 8218033
  • Other Database IDs : CDD:109567
    CDD:144198
    GOA:Q9IBN3
    HSSP: P19549
    InterPro: IPR000328
    InterPro: IPR000777
    UniProtKB/TrEMBL: Q9IBN3
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : ENV (gp160)
  • Protein Length : 849
  • Protein Note : HIV-1 GB8 isolated into the cell line JM and the provirus clone was derived by PCR off extracted high molecular weight DNA
  • DNA Sequence : Show Sequence
    >gi|8218025:6237-8786 Human immunodeficiency virus type 1 proviral genome, isolate GB8, clone 46R
    ATGAAAGCGAAGGGGACCAGGAAGAATTATCAGCACTTGTGGAAATGGGGCATCATGCTCCTTGGGATGT
    TGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAAGAAGC
    AACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGACACAGAAAAACATAATGTTTGGGCCACA
    CATGCCTGTGTACCCACAGACCCCAACCCACAAGAGGTAGTATTGGGAAATGTGACAGAAAATTTTAACA
    TGTGGAAAAATAACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCC
    ATGTGTAAAATTAACCCCACTCTGTGTTACTTTAAATTGCACTGATTTGAGGAATGATACTAATACCGAT
    AATAGTATAATGGAGGGAGGAGAAATGAAAAACTGCTCTTTCAATATCACCACAAGCATAAGGGATAAGA
    TGCAGAAAGAATATGCACTTTTGTATAAACTTGATATAGTATCAATAGGTAGTGATAATACTAGCTATAT
    ATTGACAAAGTGTGACGCCTCAGTCATTACACAGGCCTGTCCAAAGATATCCTTTGAGCCAATTCCCATA
    CATTTTTGTGCCCCGGCTGGTTTTGCGATTCTAAAGTGTAACAATAAGACATTCGATGGAAAAGGACCAT
    GTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTGTCAACTCAACTGCTGTTAAA
    TGGCAGTCTAGCAGAAGAAAAGGTAGTAATTAGATCTGACAATTTCATGGACAATACTAAAACCATAATA
    GTACAGCTGAAAGAAGCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAGGTATATACA
    TAGGACCAGGGAGAAGATTTTATACAACAGGAAGAATAATAGGAGATATAAGACAAGCACATTGTAACAT
    TAGTAAAGAAAAATGGAATAATACTTTACACCAGATAGTTATAGAATTGAGGAAACAATTTAGGAATAAA
    ACAATAGTCTTTAATCAATCCTCAGGAGGGGACCCAGAAATTGTAATGCACAGTTTTAATTGTGGAGGGG
    AATTTTTCTACTGTAAGACAGCACAACTGTTTAATAGTACTTGGAATAGTACTGGAAATGGTACTATAAA
    GTCAAATACCACTGAAATTATCACACTCCCATGTAGAATAAAACAAATTGTAAACATGTGGCAGGAAGTA
    GGAAAAGCAATGTATGCCCCTCCCATCACAGGACAAATTAGATGTGCATCACATATTACAGGGCTACTAT
    TAACAAGAGATGGAGGTAGGGAGAACAATACCAACGAGACCGAGACCTTCAGACCTGGAGGAGGAGATAT
    GAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCC
    ACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATGATAGGAGCTATGTTCCTTG
    GGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCACTGACGCTGACGGTACAGGCCAGACTATT
    ATTGTCTGGTATAGTGCAACAGCAAAATAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCGA
    CTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAGTCCTGGCTGTGGAAAGATACCTAAAGGATCAAC
    AGCTCCTAGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTACTGTGCCTTGGAATGTTAGTTG
    GAGTAATAAATCTCTGGATAAGATTTGGAATAACATGACCTGGATGGAGTGGGAAAGAGAAATTGACAAT
    TACACAAACACAATATACACCTTAATTGAAGAATCGCAGAACCAACAAGAAAAGAATGAACAAGAATTAT
    TGGAATTGGATAAGTGGGCAAATTTGTGGAATTGGTTTGACATAACAAACTGGCTGTGGTATATAAAAAT
    ATTCATAATGATAATAGGAGGCTTAATAGGTTTAAGAATAATTTTTGCTGTAATTTCTATAGTGAATAGA
    GTTAGGCGGGGATACTCACCATTATCATTGCAGACCCACCTCCCAACCCCAAGGGGACCCGACAGGCCCG
    AAGGAATCGAAGAAGAAGGTGGAGAGCAAGACAGAGACAGATCCATCAGATTGGTGAATGGATTCTTAGC
    GCTTTTCTGGGACGACCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGATTGAGAGACTTACTCTTGATT
    GTGACGAGGATTGTGGGACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAGTATTGGTGGAATCTCCTGC
    AGTATTGGATCCAGGAACTAAAGAATAGTGCTATTAGCTTGCTTAATACCACAGCTATAGCAGTAGCTGA
    GGGGACAGATAGGGTTATAGAAGTAGTACAAAGAGCTTATAGAGCTATTCTCCACATACCTACAAGAATA
    AGACAGGGCTTAGAAAGGGCTTTGCAATAA
  • Protein Sequence : Show Sequence
    >gi|8218033|emb|CAB92793.1| ENV (gp160) [Human immunodeficiency virus 1]
    MKAKGTRKNYQHLWKWGIMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEKHNVWAT
    HACVPTDPNPQEVVLGNVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNDTNTD
    NSIMEGGEMKNCSFNITTSIRDKMQKEYALLYKLDIVSIGSDNTSYILTKCDASVITQACPKISFEPIPI
    HFCAPAGFAILKCNNKTFDGKGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEKVVIRSDNFMDNTKTII
    VQLKEAVEINCTRPNNNTRKGIYIGPGRRFYTTGRIIGDIRQAHCNISKEKWNNTLHQIVIELRKQFRNK
    TIVFNQSSGGDPEIVMHSFNCGGEFFYCKTAQLFNSTWNSTGNGTIKSNTTEIITLPCRIKQIVNMWQEV
    GKAMYAPPITGQIRCASHITGLLLTRDGGRENNTNETETFRPGGGDMRDNWRSELYKYKVVKIEPLGVAP
    TKAKRRVVQREKRAVGMIGAMFLGFLGAAGSTMGAASLTLTVQARLLLSGIVQQQNNLLRAIEAQQHLLR
    LTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTTVPWNVSWSNKSLDKIWNNMTWMEWEREIDN
    YTNTIYTLIEESQNQQEKNEQELLELDKWANLWNWFDITNWLWYIKIFIMIIGGLIGLRIIFAVISIVNR
    VRRGYSPLSLQTHLPTPRGPDRPEGIEEEGGEQDRDRSIRLVNGFLALFWDDLRSLCLFSYHRLRDLLLI
    VTRIVGLLGRRGWEALKYWWNLLQYWIQELKNSAISLLNTTAIAVAEGTDRVIEVVQRAYRAILHIPTRI
    RQGLERALQ
  • Molecule Role : Protective antigen
  • Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes , HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein
13. env MN isolate
  • Gene Name : env MN isolate
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 MN
  • NCBI Protein GI : 3342812
  • Other Database IDs : CDD:109567
    CDD:197369
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope glycoprotein
  • Protein Length : 857
  • Protein Note : MN neutralization phenotype variant clone
  • Protein Sequence : Show Sequence
    >gi|3342812|gb|AAC31819.1| envelope glycoprotein [Human immunodeficiency virus 1]
    MRVKGIRRNYQHWWGWGTMLLGLLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEAHNVWAT
    HACVPTDPNPQEVELVNVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNTTNTN
    NSTDNNNSNSEGTIKGGEMKNCSFNITTSIGDKVQKEYALLYKLDIESIDNDSTSYRLISCNTSVITQAC
    PKISFEPIPIHYCAPAGFAILKCNDKKFSGKGSCKNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSE
    DFTDNAKTIIVHLKESVQINCTRPNYNKRKRIHIGPGRAFYTTKNIKGTIRQAHCIISRAKWNDTLRQIV
    SKLKEQFKNKTIVFNPSSGGDPEIVMHSFNCGGEFFYCNTSPLFNSTWNGNNTWNNTTGSNNNITLQCKI
    KQIINMWQKVGKAMYAPPIEGQIRCSSNITGLLLTRDGGIDTDTNDTEIFRPGGGDMRDNWRSELYKYKV
    VTIEPLGVAPTKAKRRVVQREKRAAIGALFLGFLGAAGSTMGAASVTLTVQARPLLSGIVQQQNNLLRAI
    ESQQHMLQLTVWGIKQLQARVLAVERYLKDQQLLGFWGCSGKLICTTTVPWNASWSNKSLDDIWNNMTWM
    QWEREIDNYTSLIYSLLEKSQTQQEKNEQELLELDKWASLWNWFDITNWLWYIKIFIMIVGGLVGLRIVF
    AVLSIVNRVRQGYSPLSLQTRPPVPRGPDRPEGIEEEGGERDRDTSGRLVHGFLAIIWVDLRSLFLLSYH
    HLRDLLLIAARIVELLGRRGWEVLKYWWNLLQYWSQELKSSAVSLLNAAAIAVAEGTDRVIEVLQRAGRA
    ILHIPTRIRQGLERALL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine pCMN160
14. Envelope polyprotein from HXB2
  • Gene Name : Envelope polyprotein from HXB2
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 1906385
  • Other Database IDs : CDD:109567
    CDD:197369
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Length : 856
  • Protein Note : HTLV-III/LAV
  • Protein Sequence : Show Sequence
    >gi|1906385|gb|AAB50262.1| envelope polyprotein [Human immunodeficiency virus 1]
    MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWA
    THACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNT
    NSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSF
    EPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDN
    AKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
    EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRI
    KQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVK
    IEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIE
    AQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWME
    WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA
    VLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHR
    LRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAI
    RHIPRRIRQGLERILL
  • Molecule Role : Protective antigen
15. gag from clade A
  • Gene Name : gag from clade A
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 1537051
  • Other Database IDs : CDD:109591
    CDD:201337
    CDD:199156
    CDD:149684
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : gag
  • Protein Length : 503
  • Protein Note : Blood from an asymptomatic young Thai man was transported from Chiang Mai to the USA where PBMCs were separated and co-cultivated with PHA-stimulated donor PBMCs. DNA from p24 antigen-positive culture was used to amplify the proviral DNA. The complete genomic sequence of the provirus was determined by the compilation of three clones containing different parts of the viral genome. Once the sequence of the provirus was determined the genome was permuted to the organizational structure of the viral genomic RNA; CM240 is an example of a Thai E virus, which is a mosaic of a clade A virus and a clade E virus
  • Protein Sequence : Show Sequence
    >gi|1537051|gb|AAC55459.1| gag [Human immunodeficiency virus 1]
    MGARASVLSGGKLDAWEKIRLRPGGRKKYRLKHLVWASRELERFALNPSFLETAEGCQQIIEQLQSTLKT
    GLEELKSLFNTVATLWCVHQRIEVKDTKEALDKIEEVQNKSQRKTQQAAAGTGSSSKVSQNYPIVQNAQG
    QMAHQPLSPRTLNAWVKVVEEKGFNPEVIPMFSALSEGATPQDLNMMLNIVGGHQAAMQMLKETINEEPA
    EWDRVHPVHAGPIPPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGDIYKRWIILGLNKIVRMYSPV
    SILDIRQGPKEPFRDYVDRFYKTLRAEQATQEVKNWMTETLLVQNANPDCKSILKALGTGATLEEMMTAC
    QGVGGPSHKARVLAEAMSHAQHATIMMQRGNFKGQKRIKCFNCGREGHLARNCRAPRKQGCWKCGKEGHQ
    MKDCTERQANFLGKIWPSNKGRPGNFPQSRPEPTAPPAENWGMGEEITGEEITSLPKQEQKDKEHPPPLV
    SLKSLFGNDPLSQ
  • Molecule Role : Protective antigen
16. Gag from HIV 1
  • Gene Name : Gag from HIV 1
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • VO ID : VO_0011263
  • NCBI Gene ID : 155030
  • NCBI Protein GI : 9629360
  • Locus Tag : HIV1gp2
  • Genbank Accession : AF033819
  • Protein Accession : NP_057850
  • Taxonomy ID : 11676
  • Gene Starting Position : 335
  • Gene Ending Position : 1837
  • Gene Strand (Orientation) : +
  • Protein Name : Pr55(Gag)
  • Protein pI : 9.42
  • Protein Weight : 53447.94
  • Protein Length : 500
  • DNA Sequence : Show Sequence
    >gi|9629357:335-1837 Human immunodeficiency virus 1, complete genome
    GATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGAAAAAATTCGGTTAAGGCCA
    GGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTA
    ATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGAC
    AGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAG
    ATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCACAGC
    AAGCAGCAGCTGACACAGGACACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGG
    GCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGTAGAAGAGAAGGCT
    TTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGAAGGAGCCACCCCACAAGATTTAAACACCA
    TGCTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGC
    AGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGA
    AGTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATCC
    CAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCCCTAC
    CAGCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTATAAAACT
    CTAAGAGCCGAGCAAGCTTCACAGGAGGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGA
    ACCCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGACAGCATG
    TCAGGGAGTAGGAGGACCCGGCCATAAGGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTCA
    GCTACCATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGATTGTTAAGTGTTTCAATTGTGGCA
    AAGAAGGGCACACAGCCAGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGG
    ACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGA
    AGGCCAGGGAATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGG
    TAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAACTTCCCTCAG
    GTCACTCTTTGGCAACGACCCCTCGTCACAATA
  • Protein Sequence : Show Sequence
    >gi|9629360|ref|NP_057850.1| Pr55(Gag) [Human immunodeficiency virus 1]
    MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT
    GSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNIQG
    QMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA
    EWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPT
    SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTAC
    QGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGCWKCGKEG
    HQMKDCTERQANFLGKIWPSYKGRPGNFLQSRPEPTAPPEESFRSGVETTTPPQKQEPIDKELYPLTSLR
    SLFGNDPSSQ
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice (Bråve et al., 2007).
  • Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes , HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag , HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) , HIV recombinant vector vaccine MVA-gag encoding gag , L. T -HIV-1 Gag
17. gag from HIV 2
  • Gene Name : gag from HIV 2
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 2
  • NCBI Protein GI : 1845205
  • Other Database IDs : CDD:109591
    CDD:201337
    CDD:189387
  • Taxonomy ID : 11709
  • Gene Strand (Orientation) : ?
  • Protein Name : gag polyprotein
  • Protein Length : 521
  • Protein Note : similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542
  • Protein Sequence : Show Sequence
    >gi|1845205|gb|AAB47780.1| gag polyprotein [Human immunodeficiency virus 2]
    MGARNSVLRGKKADELEKIRLRPGGKKKYRLKHIVWAANELDRFRLAENLLESKEGCQKILTVLDPLVPT
    GSENLKSLFNTVCVIWCLHAEEKVKDTEEAKKLVQRHLVAETGTAEKMPNTSRPTAPPSGKGGNFPVQQA
    GGNYVHVPLSPRTLNAWVKLVEEKKFGAEVVPGFQALSEGCTPYDINQMLNCVGDQQAAMQIIREIINEE
    AADWDAQHPIPGPLPAGQLRDPRGSDIAGTTSTVDEQIQWMYRQQNPVPVGNIYRRWIQIGLQKCVRMYN
    PTNVLDVKQGPKESFQSYVDRFYKSLRAEQADPAVKNWMTQTLLVQNANPDCKLVLKGLGMNPTLEEMLT
    ACQGVGGPGQKARLMAEALKEALTPPPIPFAAAQQRRTIRCWNCGKEGHSAKQCRAPRRQGCWKCGKPGH
    IMANCPDRQAGFLGMGSRGKKPRNFPVAQAPQGLIPTAPPADPAADLLEKYLQQGRKQREQRERPYKEVT
    EDLLHLEQGETPRREATEDLLHLNSLFGKDQ
  • Molecule Role : Protective antigen
  • Related Vaccine(s): ALVAC-HIV-2 , ALVAC-HIV-2- env/gag/pol , HIV-2 DNA vaccine
18. gag from HIV subtype B
  • Gene Name : gag from HIV subtype B
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 5081475
  • Other Database IDs : CDD:109591
    CDD:201337
    CDD:199156
    CDD:149684
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : gag
  • Protein Length : 508
  • Protein Note : isolated from patient SC49 PBMC; infection was aquired in Sydney, Australia 1998; this patient registered low levels of viral RNA in plasma by RT-PCR (Amplicor 1.0) and low levels of P24 (gag) antigen by monoclonal ELISA despite symptomatic seroconversion; HIV RNA quantitation by an alternative method (bDNA, Chiron 3.0) on the same sample yielded a level of >500,000 copies/ml; subtyping in envelope and P17 gag by sequencing and phylogenetic analysis revealed subtype B; the entire gag gene was then sequenced to search for mutations to account for the failure of detection methods directed to this genomic area subtype: B
  • Protein Sequence : Show Sequence
    >gi|5081475|gb|AAD39400.1|AF128998_1 gag [Human immunodeficiency virus 1]
    MGARASVLSGGKLDKWEKIRLRPGGKKTYQLKHIVWASRELERFAVNPGLLETGGGCKQILVQLQPSLQT
    GSEELKSLYNAVATLYCVHQGIEVRDTKEALDKIEEEQNKSKKKAQQAAADTGNSSQVSQNYPIVQNLQG
    QMVHQAISPRTLNAWVKVIEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA
    EWDRLHPAHAGPNAPGQMREPRGSDIAGTTSTLQEQIGWMTSNPPVPVGEIYKRWIILGLNKIVRMYSPV
    SILDIRQGPKEPFRDYVDRFYKTLRAEQASQDVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTAC
    QGVGGPSHKARILAEAMSQVTSPANIMMQRGNFRNQRKTIKCFNCGKEGHLARHCRAPRKKGCWKCGREG
    HQMKDCTERQANFLGKIWPSHKGRPGNFLQSRPEPTAPPEESFRFGEETTTPPQKQEPLPSQKQETIDKD
    LYPLASLKSLFGNDPSLQ
  • Molecule Role : Protective antigen
19. gag from HIV-1 vector pNL4-3
  • Gene Name : gag from HIV-1 vector pNL4-3
  • Sequence Strain (Species/Organism) : HIV-1 vector pNL4-3
  • NCBI Protein GI : 12831136
  • Other Database IDs : CDD:109591
    CDD:201337
    CDD:189387
    CDD:149684
  • Taxonomy ID : 151458
  • Gene Strand (Orientation) : ?
  • Protein Name : gag polyprotein
  • Protein Length : 500
  • Protein Note : gag gene protein p17 (matrix protein); pfam00540
  • Protein Sequence : Show Sequence
    >gi|12831136|gb|AAK08483.1|AF324493_2 gag polyprotein [HIV-1 vector pNL4-3]
    MGARASVLSGGELDKWEKIRLRPGGKKQYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT
    GSEELRSLYNTIAVLYCVHQRIDVKDTKEALDKIEEEQNKSKKKAQQAAADTGNNSQVSQNYPIVQNLQG
    QMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA
    EWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTHNPPIPVGEIYKRWIILGLNKIVRMYSPT
    SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPGATLEEMMTAC
    QGVGGPGHKARVLAEAMSQVTNPATIMIQKGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCWKCGKEG
    HQMKDCTERQANFLGKIWPSHKGRPGNFLQSRPEPTAPPEESFRFGEETTTPSQKQEPIDKELYPLASLR
    SLFGSDPSSQ
  • Molecule Role : Protective antigen
  • Related Vaccine(s): SHIV DNA vaccine encoding env and gag , SHIV(Ba-L) DNA vaccine encoding env and gag
20. gag from HXB2
  • Gene Name : gag from HXB2
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 HXB2
  • NCBI Protein GI : 328450
  • Other Database IDs : CDD:109591
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : gag protein
  • Protein Length : 132
  • Protein Note : gag gene protein p17 (matrix protein); pfam00540
  • Protein Sequence : Show Sequence
    >gi|328450|gb|AAA44995.1| gag protein, partial [Human immunodeficiency virus 1]
    MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT
    GSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNY
  • Molecule Role : Protective antigen
  • Related Vaccine(s): CVB4/p24(73(3))
21. gag from SHIV-89.6
  • Gene Name : gag from SHIV-89.6
  • Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
  • NCBI Protein GI : 2828037
  • Other Database IDs : CDD:109591
    CDD:201337
    CDD:189387
    CDD:199156
  • Taxonomy ID : 57667
  • Gene Strand (Orientation) : ?
  • Protein Name : gag
  • Protein Length : 510
  • Protein Note : gag gene protein p17 (matrix protein); pfam00540
  • Protein Sequence : Show Sequence
    >gi|2828037|gb|AAB99958.1| gag [Simian-Human immunodeficiency virus]
    MGVRNSVLSGKKADELEKIRLRPNGKKKYMLKHVVWAANELDRFGLAESLLENKEGCQKILSVLAPLVPT
    GSENLKSLYNTVCVIWCIHAEEKVKHTEEAKQIVQRHLVVETGTTETMPKTSRPTAPSSGRGGNYPVQQI
    GGNYVHLPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEE
    AADWDLQHPQPAPQQGQLREPSGSDIAGTTSSVDEQIQWMYRQQNPIPVGNIYRRWIQLGLQKCVRMYNP
    TNILDVKQGPKEPFQSYVDRFYKSLRAEQTDAAVKNWMTQTLLIQNANPDCKLVLKGLGVNPTLEEMLTA
    CQGVGGPGQKARLMAEALKEALAPVPIPFAAAQQRGPRKPIKCWNCGKEGHSARQCRAPRRQGCWKCGKM
    DHVMAKCPDRQAGFLGLGPWGKKPRNFPMAQVHQGLMPTAPPEDPAVDLLKNYMQLGKQQREKQRESREK
    PYKEVTEDLLHLNSLFGGDQ
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) , rBCG-SIVgag and rDIsSIVgag Prime-boost SHIV vaccine
22. Gag protein from SIV-mnd 2
  • Gene Name : Gag protein from SIV-mnd 2
  • Sequence Strain (Species/Organism) : SIV-mnd 2
  • VO ID : VO_0010949
  • NCBI Gene ID : 956108
  • NCBI Protein GI : 27311167
  • Taxonomy ID : 159122
  • Gene Strand (Orientation) : ?
  • DNA Sequence : Show Sequence
    >gi|27311166:737-2290 Simian immunodeficiency virus 2, complete genome
    ATGGGCGCGAGCGCGTCAGGTCTTAGGGGAGAAAAATTGGACGAGCTGGAAAAGATTAGGTTACGGCCCT
    CCGGAAAAAAGAAATACCAGCTGAAACACATAATATGGGTAAGCAAGGAACTAGACAGATTTGGCCTTCA
    TGAAAAGCTGTTAGAAAGTAAGGAAGGATGCGAGAAAATTCTTAGCGTACTCTTTCCACTAGTTCCTACA
    GGGTCAGAAAATTTAATCTCGCTGTACAACACCTGCTGCTGCGTATGGTGCGTACATGCGAAAGAGAAAG
    TAACAGATACAGAGGAAGCGAAAGAGAAAGTAAAACAAAAGCTCCATCTAGTGGCCGAAAAGGAAAATGC
    AGCATCAGAAAAAGAACAAAGAGCAATAGTGACACCTAGTGGCCGCTCAAAAAATTACCCAATACAGATA
    ATAAATCAGACCCCAGTCCATCAGGGAATTTCACCGCGCACGCTGAATGCGTGGGTAAAATGCATAGAAG
    AGAAGAAGTTTAGCCCAGAAATAGTGCCCATGTTCATAGCCTTGTCTGAAGGGTGCCTCCCCTATGATCT
    CAATGGCATGCTCAATGCTATTGGAGACCATCAGGGAGCGCTTCAAATAGTGAAGGATGTCATCAATGAG
    GAAGCTGCAGACTGGAACTTGAGACACCCACAAGTGGGTCCTATGCCCCAAGGTGTCTTGAGAAACCCAA
    CGGGCAGTGATATTGCTGGAACAACAAGCTCCATAGAAGAGCAGATAGAATGGACTACAAGGGAGCAAGA
    TGCAGTAAATGTGGGAGGAATATATAAACAATGGATAGTTTTAGGGCTTCAGAAGTGTGTAAGCATGTAT
    AATCCAGTAAACATCCTGGACATAAAGCAAGGACCAAAGGAGCCGTTCAAGGACTATGTGGACAGGTTTT
    ACAAAGCTCTGCGGGCGGAGCGGACTGATCCACAAGTCAAAACCTGGATGACACAAACTTTGCTCATCCA
    GAATGCTAACCCAGATTGTAAATCCATCCTTAAAGGGCTAGGCATGAATCCCTCTTTAGAAGAGATGCCG
    CTAGCCTGCCAAGGGGTAGGAGGCCCTAAATATAAAGCACAAATGATGGCAGAGGCTATGAAGGAAGCCC
    AGTCAGCTGTAATGATGCAGAATTCGGGAGGGCCACCGCGGGGCCCCCCGAGACAACCTCCTAGAAACAT
    CAGATGCCCTAACTGTGGAAAATTTGGTCATGGGCTGAGGGACTGTATAAGCCCTCGAAAAAAGGGATGC
    TTCAAGTGTGGAGATCTAGGACACATAATGAGAAATTGCCCAAAGATGGTGAATTTTTTAGGGAATACCC
    CCTGGGGCAGTGGCAAACCCAGGAACTTCCCGGCGATGCCATTGACCCCAACGGCCCCTCCAATGCCAGG
    GATGGAAGACCCAGCAGAGAGAATGCTGTTAGATTACATGAAGAAAGGGCAACAGCAGAAAGCGGAAAGC
    AAACAGGAAAAGAAAGAGAGGGGTCCATACGAGGCAGCTTACAACTCCCTCAGTTCTCTCTTTGGAACAG
    ACCAACTACAGTAG
  • Protein Sequence : Show Sequence
    >gi|27311167|ref|NP_758886.1| gag protein [Simian immunodeficiency virus SIV-mnd 2]
    MGASASGLRGEKLDELEKIRLRPSGKKKYQLKHIIWVSKELDRFGLHEKLLESKEGCEKILSVLFPLVPT
    GSENLISLYNTCCCVWCVHAKEKVTDTEEAKEKVKQKLHLVAEKENAASEKEQRAIVTPSGRSKNYPIQI
    INQTPVHQGISPRTLNAWVKCIEEKKFSPEIVPMFIALSEGCLPYDLNGMLNAIGDHQGALQIVKDVINE
    EAADWNLRHPQVGPMPQGVLRNPTGSDIAGTTSSIEEQIEWTTREQDAVNVGGIYKQWIVLGLQKCVSMY
    NPVNILDIKQGPKEPFKDYVDRFYKALRAERTDPQVKTWMTQTLLIQNANPDCKSILKGLGMNPSLEEMP
    LACQGVGGPKYKAQMMAEAMKEAQSAVMMQNSGGPPRGPPRQPPRNIRCPNCGKFGHGLRDCISPRKKGC
    FKCGDLGHIMRNCPKMVNFLGNTPWGSGKPRNFPAMPLTPTAPPMPGMEDPAERMLLDYMKKGQQQKAES
    KQEKKERGPYEAAYNSLSSLFGTDQLQ
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : A novel primate lentivirus was identified in Mandrillus sphinx. One of the newly isolated SIV strains was intravenously inoculated into two rhesus macaques and resulted in chronic infection. These SIVs do not cluster with SIVmndGB1, the former representative strain of SIVmnd, but form a new, independent lineage. These results indicate that these SIVmnds are a novel type of SIVmnd and have infected Cameroonian mandrills for a long time. To date, M. sphinx is the only primate species other than humans that is naturally infected with two different types of SIV (Takehisa et al., 2001).
  • Related Vaccine(s): Adenoviral vector Ad5 expressing SIV gag protein , DNA and poxvirus priming-boosting SHIV vaccine , HIV DNA and adenoviral vector Ad5 expressing SIV gag protein , HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag , HIV DNA vaccine pHIS-SHIV-B , HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost
23. gag-pol
  • Gene Name : gag-pol
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Gene ID : 155348
  • NCBI Protein GI : 28872819
  • Locus Tag : HIV1gp1
  • Genbank Accession : AF033819
  • Protein Accession : NP_057849
  • Taxonomy ID : 11676
  • Gene Starting Position : 335
  • Gene Ending Position : 4641
  • Gene Strand (Orientation) : +
  • Protein Name : Gag-Pol
  • Protein pI : 9.02
  • Protein Weight : 152515.27
  • Protein Length : 1435
  • Protein Note : Pr160
  • DNA Sequence : Show Sequence
    >gi|9629357:335-4641 Human immunodeficiency virus 1, complete genome
    GATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGAAAAAATTCGGTTAAGGCCA
    GGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTA
    ATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGAC
    AGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAG
    ATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCACAGC
    AAGCAGCAGCTGACACAGGACACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGG
    GCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGTAGAAGAGAAGGCT
    TTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGAAGGAGCCACCCCACAAGATTTAAACACCA
    TGCTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGC
    AGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGA
    AGTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATCC
    CAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCCCTAC
    CAGCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTATAAAACT
    CTAAGAGCCGAGCAAGCTTCACAGGAGGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGA
    ACCCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGACAGCATG
    TCAGGGAGTAGGAGGACCCGGCCATAAGGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTCA
    GCTACCATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGATTGTTAAGTGTTTCAATTGTGGCA
    AAGAAGGGCACACAGCCAGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGG
    ACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGA
    AGGCCAGGGAATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGG
    TAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAACTTCCCTCAG
    GTCACTCTTTGGCAACGACCCCTCGTCACAATAAAGATAGGGGGGCAACTAAAGGAAGCTCTATTAGATA
    CAGGAGCAGATGATACAGTATTAGAAGAAATGAGTTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGG
    AATTGGAGGTTTTATCAAAGTAAGACAGTATGATCAGATACTCATAGAAATCTGTGGACATAAAGCTATA
    GGTACAGTATTAGTAGGACCTACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTGGTTGCA
    CTTTAAATTTTCCCATTAGCCCTATTGAGACTGTACCAGTAAAATTAAAGCCAGGAATGGATGGCCCAAA
    AGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAGTAGAAATTTGTACAGAGATGGAAAAG
    GAAGGGAAAATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAAG
    ACAGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACTTAATAAGAGAACTCAAGACTTCTGGGAAGT
    TCAATTAGGAATACCACATCCCGCAGGGTTAAAAAAGAAAAAATCAGTAACAGTACTGGATGTGGGTGAT
    GCATATTTTTCAGTTCCCTTAGATGAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGTATAAACA
    ATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCACAGGGATGGAAAGGATCACCAGCAATATT
    CCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACAAAATCCAGACATAGTTATCTATCAATAC
    ATGGATGATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAACAAAAATAGAGGAGCTGAGAC
    AACATCTGTTGAGGTGGGGACTTACCACACCAGACAAAAAACATCAGAAAGAACCTCCATTCCTTTGGAT
    GGGTTATGAACTCCATCCTGATAAATGGACAGTACAGCCTATAGTGCTGCCAGAAAAAGACAGCTGGACT
    GTCAATGACATACAGAAGTTAGTGGGGAAATTGAATTGGGCAAGTCAGATTTACCCAGGGATTAAAGTAA
    GGCAATTATGTAAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACCACTAACAGAAGAAGCAGA
    GCTAGAACTGGCAGAAAACAGAGAGATTCTAAAAGAACCAGTACATGGAGTGTATTATGACCCATCAAAA
    GACTTAATAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGGACATATCAAATTTATCAAGAGCCATTTA
    AAAATCTGAAAACAGGAAAATATGCAAGAATGAGGGGTGCCCACACTAATGATGTAAAACAATTAACAGA
    GGCAGTGCAAAAAATAACCACAGAAAGCATAGTAATATGGGGAAAGACTCCTAAATTTAAACTGCCCATA
    CAAAAGGAAACATGGGAAACATGGTGGACAGAGTATTGGCAAGCCACCTGGATTCCTGAGTGGGAGTTTG
    TTAATACCCCTCCCTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACCCATAGTAGGAGCAGAAACCTT
    CTATGTAGATGGGGCAGCTAACAGGGAGACTAAATTAGGAAAAGCAGGATATGTTACTAATAGAGGAAGA
    CAAAAAGTTGTCACCCTAACTGACACAACAAATCAGAAGACTGAGTTACAAGCAATTTATCTAGCTTTGC
    AGGATTCGGGATTAGAAGTAAACATAGTAACAGACTCACAATATGCATTAGGAATCATTCAAGCACAACC
    AGATCAAAGTGAATCAGAGTTAGTCAATCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTATCTG
    GCATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGTGCTGGAATCA
    GGAAAGTACTATTTTTAGATGGAATAGATAAGGCCCAAGATGAACATGAGAAATATCACAGTAATTGGAG
    AGCAATGGCTAGTGATTTTAACCTGCCACCTGTAGTAGCAAAAGAAATAGTAGCCAGCTGTGATAAATGT
    CAGCTAAAAGGAGAAGCCATGCATGGACAAGTAGACTGTAGTCCAGGAATATGGCAACTAGATTGTACAC
    ATTTAGAAGGAAAAGTTATCCTGGTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTTATTCC
    AGCAGAAACAGGGCAGGAAACAGCATATTTTCTTTTAAAATTAGCAGGAAGATGGCCAGTAAAAACAATA
    CATACTGACAATGGCAGCAATTTCACCGGTGCTACGGTTAGGGCCGCCTGTTGGTGGGCGGGAATCAAGC
    AGGAATTTGGAATTCCCTACAATCCCCAAAGTCAAGGAGTAGTAGAATCTATGAATAAAGAATTAAAGAA
    AATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGCAGTATTCATCCAC
    AATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAG
    ACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTACAGGGACAG
    CAGAAATCCACTTTGGAAAGGACCAGCAAAGCTCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGAT
    AATAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAGATCATTAGGGATTATGGAAAACAGATGGCAG
    GTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTA
  • Protein Sequence : Show Sequence
    >gi|28872819|ref|NP_057849.4| Gag-Pol [Human immunodeficiency virus 1]
    MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT
    GSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNIQG
    QMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA
    EWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPT
    SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTAC
    QGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGCWKCGKEG
    HQMKDCTERQANFLREDLAFLQGKAREFSSEQTRANSPTRRELQVWGRDNNSPSEAGADRQGTVSFNFPQ
    VTLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAI
    GTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEK
    EGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGD
    AYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQY
    MDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWT
    VNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSK
    DLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPI
    QKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNRGR
    QKVVTLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDQSESELVNQIIEQLIKKEKVYL
    AWVPAHKGIGGNEQVDKLVSAGIRKVLFLDGIDKAQDEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKC
    QLKGEAMHGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTI
    HTDNGSNFTGATVRAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIH
    NFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKGPAKLLWKGEGAVVIQD
    NSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine pCMN160 , NYVAC-HIV-1 , NYVAC-HIV-2
24. gag-pol SIV
  • Gene Name : gag-pol SIV
  • Sequence Strain (Species/Organism) : Simian immunodeficiency virus
  • NCBI Gene ID : 1490009
  • NCBI Protein GI : 22535297
  • Locus Tag : SIVgp1
  • Genbank Accession : M66437
  • Protein Accession : NP_687035
  • Taxonomy ID : 11723
  • Gene Starting Position : 896
  • Gene Ending Position : 5313
  • Gene Strand (Orientation) : +
  • Protein Name : Gag-Pol
  • Protein pI : 8.66
  • Protein Weight : 157171.22
  • Protein Length : 1472
  • DNA Sequence : Show Sequence
    >gi|9627204:896-5313 Simian immunodeficiency virus, complete genome
    AATGGGCGGGGGTCACTCAGCACTGTCAGGGAGAAGCCTCGACACGTTCGAGAAGATTAGGCTACGTCCG
    AACGGGAAAAAGAAGTACCAAATTAAACATTTAATATGGGCAGGAAAAGAAATGGAACGATTTGGGTTAC
    ATGAGAAACTTTTAGAAACAAAAGAAGGCTGTCAAAAAATCATAGAAGTTTTAACCCCGTTGGAACCGAC
    AGGCTCCGAGGGGCTAAAAGCTCTGTTTAATTTGTGCTGCGTCATTTGGTGCATTCACGCAGAACAGAAA
    GTGAAAGACACAGAGGAAGCTGTAGTAACAGTTAAGCAACACTACCATCTAGTGGACAAAAATGAGAAAG
    CAGCTAAAAAGAAAAATGAGACAACAGCGCCACCTGGTGGCGAATCAAGAAATTACCCAGTAGTAAATCA
    GAATAATGCCTGGGTACACCAGCCTTTGTCTCCGCGCACGTTAAATGCGTGGGTCAAATGCGTGGAGGAA
    AAAAGGTGGGGAGCAGAAGTAGTCCCCATGTTCCAAGCACTCTCAGAGGGATGTCTCTCCTATGATGTAA
    ATCAGATGCTCAATGTAATAGGAGACCATCAGGGGGCATTACAAATTCTTAAGGAAGTCATTAATGAAGA
    AGCAGCAGAGTGGGACAGGACACACAGACCACCAGCTGGCCCGTTACCAGCAGGGCAGCTAAGAGACCCG
    ACAGGGTCAGATATAGCAGGAACTACCAGCTCAATTCAGGAACAAATAGAGTGGACCTTCAATGCCAATC
    CAAGAATAGACGTAGGGGCACAATACAGAAAATGGGTTATTTTGGGCTTACAAAAGGTAGTGCAGATGTA
    CAATCCCCAAAAGGTCCTAGACATTCGACAGGGACCTAAAGAACCCTTCCAGGACTATGTAGACAGATTC
    TATAAAGCCCTGAGAGCAGAACAAGCACCACAGGATGTTAAAAATTGGATGACACAAACTTTGCTTATCC
    AGAATGCCAATCCGGATTGTAAATTGATTCTGAAAGGATTGGGAATGAATCCAACCTTGGAGGAAATGCT
    AATAGCTTGCCAGGGAGTAGGAGGGCCACAACATAAGGCTAAGCTAATGGTAGAAATGATGAGTAATGGA
    CAGAATATGGTCCAAGTGGGACCTCAGAAAAAGGGCCCCCGAGGGCCGCTAAAATGCTTTAATTGTGGCA
    AATTTGGACATATGCAAAGGGAATGCAAGGCACCAAGACAGATCAAATGCTTTAAGTGCGGCAAAATTGG
    CCATATGGCAAAAGACTGCAAGAATGGACAGGCAAATTTTTTAGGGTATGGCCATTGGGGAGGAGCGAAA
    CCAAGAAATTTTGTGCAATACAGAGGAGACACAGTTGGTCTGGAACCAACAGCCCCCCCAATGGAAACAG
    CTTACGATCCAGCAAAGAAGCTCCTCCAGCAGTATGCAGAGAAGGGACAGCGCCTGAGAGAGGAGAGAGA
    ACAGACAAGGAAACAGAAGGAGAAAGAAGTGGAGGATGTTTCCTTGAGCTCCCTCTTTGGAGGAGACCAA
    TGAAACGAGTCATCATAGAAGGAACGCCAGTGCAAGCCTTGTTAGATACAGGAGCAGATGACACTATAAT
    TCAAGAAAAGGACTTGCACTTTCCCCCACATAAACCATGGCGTTCCAAGGTAGTAGGAGGTATAGGAGGA
    GGGATTCATGTCAAAGAATATCAGGGGGTACAAGTACAATTGGAGGATAAAATCATCACCGGCTCAATTC
    TAATAGGAAGTACACCAATCAATATTATAGGAAGAAATATTTTAGCTCAGGCAGGCATGAAATTAGTTAT
    GGGAGTTCTATCTAGTCAGATTGAGGAAACAAAAGTACAACTAAAAGAAGGGAAAGATGGACCTAAATTG
    AAACAATGGCCCTTATCAAGAGAAAAAATTGAAGCTTTAACAGAAATATGCAAACAAATGGAAGAGGAGG
    GAAAATTATCTAGGATAGGAGGAGAAAATCCTTATAATACACCAGTGTTTGCCATAAAGAAAAAGGATAA
    AACACAATGGAGAATGCTTGTAGATTTCAGGGAACTAAACAAAGCTACTCAAGACTTTTTTGAGGTTCAG
    CTGGGAATTCCTCACCCAGCGGGCCTTCAGAAAAAGAAGCAAATCACAGTAATAGACATAGGGGATGCCT
    ATTATTCAATACCATTATGCAAGGAATTCAGAAAATATACAGCATTTACCATCCCCTCAGTAAATAATAC
    AGGGCCAGGGATAAGGTATCAGTTCAATTGTCTGCCTCAGGGATGGAAAGGATCTCCTACAATTTTCCAG
    AATACGGCAGCAAACATTTTAGAGGAGATCAAAAGGCACACTCCTGGGTTAGAAATTGTCCAATACATGG
    ACGATTTGTGGTTGGCGTCAGACCATGATGAGACTAGACATAATCAACAGGTAGACATAGTAAGAAAGAT
    GCTGCTAGAAAAAGGTCTAGAAACCCCAGACAAGAAAGTCCAAAGAGAACCGCCATGGGAATGGATGGGG
    TATAAATTGCATCCGAATAAATGGACCATTAACAAAATAGAATTACCCCCCTTAGAAGGAGAATGGACAG
    TAAACAAAATACAGAAGGTAGTAGGAGTTCTAAATTGGGCAAGTCAAATTTATCCAGGAATTAAAACCAA
    ACATACCTGTGCCATGTTGAGAGGGAAAAAGAACCTCCTAGAAGAAATAGTATGGACAGAAGAGGCAGAG
    GCAGAATATAAGAACAATCAAGGGATAGTGCAGGAAACACAAGAAGGAACATACTATGACCCTCTCAAAG
    AATTAATAGCAACAGTTCAAAAGCAAGGAGAAGGGCAATGGACATACCAATTCACCCAAGAAGGGGCAGT
    ATTAAAGGTGGGAAGATATGCCAAGCAAAGAGAAACTCATACTAATGATCTAAGGACTCTAGCACACCTT
    GTCCAAAAAATCTGTAAGGAAGCACTTACCATTTGGGGAAGACTTCCACGAGTACAACTCCCAGTAGACA
    AGAAAACATGGGATATGTGGTGGCAGGACTATTGGCAAGTATCCTGGATACCAGAATGGGAGTTTGTTAG
    CACACCACTCCTAGTAAAACTGTGGTATTCCTTAGTAAAAGAACCAATCAAAGGAGAAGATGTTTATTAT
    GTGGATGGGGCAGCATCCAAAGTGACCAAATTAGGTAAGGCAGGATATCTGTCAGAGAGAGGAAAAAGTA
    GAATTAGGGAATTAGAAAACACCACTAACCAACAAGCAGAATTAACAGCAGTTAAGATGGCATTGGAGGA
    CAGTGGAGAAAATGTAAATATAGTCACAGATTCTCAATATGTAATGAACATCTTGACAGCATGTCCACAG
    GAAAGTAACTCACCCTTAGTGGAACAGATAATACAAGCCCTAATGAAAAAGAGGCAGGTCTACTTACAAT
    GGGTACCAGCTCATAAGGGGATAGGAGGCAATACAGAAATAGATAAATTAGTAAGCAAAGGAATAAGACA
    GATCCTCTTCTTAGATAGAATAGAAGAAGCACAAGATGACCATGCAAAGTACCATAACAATTGGAGAAGT
    ATGGTACAGGAATTTGGATTACCTAATATAGTAGCAAAAGAGATAGTAGCGGCATGTCCCAAATGCCAAA
    TAAGAGGAGAACCTAAGCATGGACAGGTAGACGCCTCCATTGAAACTTGGCAGATGGACTGCACCCATTT
    AGAAGGAAAAGTTATAATAGTAGCAGTACATGTAGCCAGTGGATTCATAGAAGCAGAGGTGATCCCAAGA
    GAAACTGGGAAGGAGACAGCACACTTTCTGCTGAAACTGTTAGCAAGATGGCCAGTGAAACATCTACACA
    CTGATAATGGCCCAAACTTTACCTCTCAGAATGTGGCAGCGGTGTGCTGGTGGGGTAATATAGAGCACAC
    CACTGGAATACCTTATAACCCACAGTCACAGGGTAGTGTAGAAAGCATGAACAGACAGCTCAAGGAAATC
    ATCTCTCAAATAAGAGATGATTGTGAGAGATTGGAGACAGCAGTGCAAATGGCTACGCATATCCACAATT
    TTAAAAGAAAGGGAGGAATAGGGGGTATCTCTAGTGCAGAAAGATTGGTTAATATGCTAACAACACAACT
    AGAACTAAATACTCTACAAAACCAAATCCAAAAAATTTTGAATTTTAAGGTCTACTACAGAGAAGGTAGA
    GATCCAGTGTGGAAAGGACCAGCGCGACTCATCTGGAAAGGAGAAGGCGCGGTGGTAATTAAAGAGGGGG
    AAGACATCAAGGTAGTCCCCAGGAGAAAGGCTAAGATTATCAAAGATTATGGAGAGAGAAAAACAATGGA
    TAGTGAGGGTAGTATGGAGGGTGTCAGAGAGGCAAATAAGCAGATGGAGGGGGATAGTGACTTACAAGAT
    CAGGAATA
  • Protein Sequence : Show Sequence
    >gi|22535297|ref|NP_687035.1| Gag-Pol [Simian immunodeficiency virus]
    MGGGHSALSGRSLDTFEKIRLRPNGKKKYQIKHLIWAGKEMERFGLHEKLLETKEGCQKIIEVLTPLEPT
    GSEGLKALFNLCCVIWCIHAEQKVKDTEEAVVTVKQHYHLVDKNEKAAKKKNETTAPPGGESRNYPVVNQ
    NNAWVHQPLSPRTLNAWVKCVEEKRWGAEVVPMFQALSEGCLSYDVNQMLNVIGDHQGALQILKEVINEE
    AAEWDRTHRPPAGPLPAGQLRDPTGSDIAGTTSSIQEQIEWTFNANPRIDVGAQYRKWVILGLQKVVQMY
    NPQKVLDIRQGPKEPFQDYVDRFYKALRAEQAPQDVKNWMTQTLLIQNANPDCKLILKGLGMNPTLEEML
    IACQGVGGPQHKAKLMVEMMSNGQNMVQVGPQKKGPRGPLKCFNCGKFGHMQRECKAPRQIKCFKCGKIG
    HMAKDCKNGQANFFRVWPLGRSETKKFCAIQRRHSWSGTNSPPNGNSLRSSKEAPPAVCREGTAPERGER
    TDKETEGERSGGCFLELPLWRRPMKRVIIEGTPVQALLDTGADDTIIQEKDLHFPPHKPWRSKVVGGIGG
    GIHVKEYQGVQVQLEDKIITGSILIGSTPINIIGRNILAQAGMKLVMGVLSSQIEETKVQLKEGKDGPKL
    KQWPLSREKIEALTEICKQMEEEGKLSRIGGENPYNTPVFAIKKKDKTQWRMLVDFRELNKATQDFFEVQ
    LGIPHPAGLQKKKQITVIDIGDAYYSIPLCKEFRKYTAFTIPSVNNTGPGIRYQFNCLPQGWKGSPTIFQ
    NTAANILEEIKRHTPGLEIVQYMDDLWLASDHDETRHNQQVDIVRKMLLEKGLETPDKKVQREPPWEWMG
    YKLHPNKWTINKIELPPLEGEWTVNKIQKVVGVLNWASQIYPGIKTKHTCAMLRGKKNLLEEIVWTEEAE
    AEYKNNQGIVQETQEGTYYDPLKELIATVQKQGEGQWTYQFTQEGAVLKVGRYAKQRETHTNDLRTLAHL
    VQKICKEALTIWGRLPRVQLPVDKKTWDMWWQDYWQVSWIPEWEFVSTPLLVKLWYSLVKEPIKGEDVYY
    VDGAASKVTKLGKAGYLSERGKSRIRELENTTNQQAELTAVKMALEDSGENVNIVTDSQYVMNILTACPQ
    ESNSPLVEQIIQALMKKRQVYLQWVPAHKGIGGNTEIDKLVSKGIRQILFLDRIEEAQDDHAKYHNNWRS
    MVQEFGLPNIVAKEIVAACPKCQIRGEPKHGQVDASIETWQMDCTHLEGKVIIVAVHVASGFIEAEVIPR
    ETGKETAHFLLKLLARWPVKHLHTDNGPNFTSQNVAAVCWWGNIEHTTGIPYNPQSQGSVESMNRQLKEI
    ISQIRDDCERLETAVQMATHIHNFKRKGGIGGISSAERLVNMLTTQLELNTLQNQIQKILNFKVYYREGR
    DPVWKGPARLIWKGEGAVVIKEGEDIKVVPRRKAKIIKDYGERKTMDSEGSMEGVREANKQMEGDSDLQD
    QE
  • Molecule Role : Protective antigen
  • Related Vaccine(s): NYVAC-SIV
25. gp120
  • Gene Name : gp120
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 2326505
  • Other Database IDs : CDD:109567
    GOA:O40515
    InterPro: IPR000777
    UniProtKB/TrEMBL: O40515
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Length : 109
  • Protein Note : Envelope glycoprotein GP120; pfam00516
  • Protein Sequence : Show Sequence
    >gi|2326505|emb|CAA74764.1| gp120 [Human immunodeficiency virus 1]
    NGSLAEGEVVIRSENFTDNAKTIIVQLNESVVINCTRPNNNTRKNIHLGRGRSVYATEKIIGNVKQAHCN
    ISRAKWNDTLKQIVEKLREQFGKNKTIVFNQSSGGDPEI
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine VlJns-tPA-gp120
26. gp120
  • Gene Name : gp120
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 7769646
  • Other Database IDs : CDD:109567
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : gp120
  • Protein Length : 138
  • Protein Note : isolated from a 37 year old injecting drug user; HIV-1 RNA was extracted from plasma; RNA was reverse transcribed and the gp120 region was amplified using nested PCR; sequence was obtained bi-directionally from cloned DNA
  • Protein Sequence : Show Sequence
    >gi|7769646|gb|AAF69493.1|AF236860_1 gp120 [Human immunodeficiency virus 1]
    VPVWKDAETTLFCASDAKAHETEVHNVWATHACVPTDPNPQEIQLKNVTENFNMWKNNMVEQMQEDVISL
    WDQSLKPCVKLTPLCVTLNCTDATLTNSTYITNVSKIIGDITEEVRNCSFNMTTELRDKKQKVHALFL
  • Molecule Role : Protective antigen
27. gp120 from MN
  • Gene Name : gp120 from MN
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 1129018
  • Other Database IDs : CDD:109567
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope glycoprotein gp120
  • Protein Length : 90
  • Protein Note : Envelope glycoprotein GP120; pfam00516
  • Protein Sequence : Show Sequence
    >gi|1129018|gb|AAC37905.1| envelope glycoprotein gp120, partial [Human immunodeficiency virus 1]
    VVIRSENFTNNAKTIIVHLNKSVEIDCIRPNNNTRRSIHIGPGRAFYGTDIIGDIRQAHCNISRKEWNDT
    LTKIVSKLKEQFKNKTIVFN
  • Molecule Role : Protective antigen
28. gp120 Indian subtype C
  • Gene Name : gp120 Indian subtype C
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 169641099
  • Other Database IDs : CDD:109567
    CDD:197369
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope glycoprotein
  • Protein Length : 799
  • Protein Note : subtype: C
  • Protein Sequence : Show Sequence
    >gi|169641099|gb|ACA61283.1| envelope glycoprotein, partial [Human immunodeficiency virus 1]
    VPVWKEAKTTLFCASDAKAYETEVHNVWATHACVPTDPNPQEMLMGNVTKNFNMWKNDMVEQMHEDVISL
    WDQSLKPCVKLTPLCVTLECREVNSTNRNVTVDAKEEIKNCSFNATTEIRDKQKKVHALFYKLDIVPLDN
    KTSSNHTNYRLINCNTSAITQACPKINFDPIPIHYCAPAGFAILKCNNDTFNGTGPCTNVSTVQCTHGIK
    PVVSTQLLLNGSLAEKEIIIRSANLTDNAKTIIVHLNQSVEIVCTRPNNNTRDSIRIGPGQTFYATGDII
    GDIRQAHCNISEAAWNKTLYEVSKKLEEHYNKTIKFNASSGGDLEITTHSFNCRGEFFYCNTSKLFNGTY
    MNMNGTNSSSDSIITIPCRIKQFINMWQEVGRAMYAPPIAGNITCKSNITGLLLVRDGGPGNGTNNTETF
    RPGGGDMRDNWRSELYKYKVVEIKPLGVAPTEAKRRVVERQKRAVGLGAMFLGFLGAAGSTMGAASMTLT
    VQARQLLSGIVQQQSNLLRAIEAQQHLLQLTVWGIKQLQARVLAIERYLREQQLLGLWGCSEKLICPTTV
    PWNDSWSNKSLDIIWGNMTWMEWDKEISNYTQTIFNLLEDSQIQQEKNEKDLLELDSWKNLWNWFNISNW
    LWYIKIFIMIVGGLIGLRIIFAVLSVVNRVRQGYSPLSFQTLTPHPREPDRLRGIEEEGGEQDKGRSIRL
    VNGFLALAWDDLRSLCLFLYHRLRDFISVTARAVDILGRRGWEALKYLKSIVQYWLLELKKSAISLLDTI
    AIAVAEGTDRIIELIQRVFRAIINRPTRI
  • Molecule Role : Protective antigen
29. gp41
  • Gene Name : gp41
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 1490266
  • Other Database IDs : CDD:197369
    GOA:Q76270
    InterPro: IPR000328
    PDB: 1I5X
    PDB: 1I5Y
    PDB: 1QR8
    PDB: 1QR9
    UniProtKB/TrEMBL: Q76270
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : GP41
  • Protein Length : 124
  • Protein Note : heptad repeat 1-heptad repeat 2 region (ectodomain) of the gp41 subunit of human immunodeficiency virus (HIV-1), and related domains; cd09909
  • Protein Sequence : Show Sequence
    >gi|1490266|emb|CAA58216.1| GP41 [Human immunodeficiency virus 1]
    FLGFLGAAGSTMGAASITLTVQARTLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLQ
    DQQLLGIWGCSGKHICTTTVPWNSSWSNKSLEEIWQNMTWMEWEREIDNYTGLI
  • Molecule Role : Protective antigen
30. HIV complete genome
  • Gene Name : HIV complete genome
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Nucleotide GI : 388332048
  • NCBI Protein GI : 388332049
  • Protein Accession : AFK29870.1
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : gag protein
  • Protein Note : subtype: B
  • DNA Sequence : Show Sequence
    >gi|388332048|gb|JN860769.1| HIV-1 isolate MERLBDTRC10 from Thailand, complete genome
    GATGGGTGCGAGAGCGTCAGTATTAAGCGGCGGAAAATTAGATCAATGGGAAAAAATTCGGTTAAGACCA
    GGAGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAAAGATTTGCAGTTA
    ATCCTGGCCTTTTAGAAACAGCAGAAGGCTGTAGACAAATACTGGGACAGCTACAGCCATCCCTTCAGAC
    AGGGTCAGAAGAACTTAAATCATTATTTAATACAGTGGCAACCCTCTATTGTGTGCATCAAAGGATAGAG
    ATAAAAGACACCAAAGAAGCTCTAGACAGGATAGAGGAAGAACAAAATAAAAGTAAGCAAAAAGCACAGC
    CAGCGGCAGCTGACACAGGAAACAACAGCCAGGTCAGCCAAAATTACCCTATAGTACAGAACCTGCAGGG
    GCAAATGGTACATCAGCCCATATCACCTAGAACTCTAAATGCATGGGTGAAAGTAGTAGAAGAGAAGGCT
    TTCAGCCCAGAAGTAATACCCATGTTTTCAGCYTTATCAGAAGGAGCCACCCCACAAGATTTAAACACCA
    TGCTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACTATAAATGAAGAAGCTGC
    AGAATGGGATAGAGTGCATCCAGTACATGCAGGGCCTATTGCACCAGGCCAGATGAGGGAACCAAGGGGA
    AGTGACATAGCAGGAACCACTAGCACCCTTCAGGAACAAATAGCATGGATGACAAATAATCCACCTATCC
    CAGTAGGAGACATCTATAAAAGATGGATAATCCTGGGGCTAAATAAAATAGTAAGAATGTACAGCCCTAC
    TAGCATTCTGGACATAAAACAAGGACCAAAAGAGCCCTTTAGAGATTATGTAGATCGGTTCTATAGAACC
    CTAAGAGCCGAGCAAGCTTCACAGGATGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATTCGA
    ACCCAGATTGTAAAACTATTTTAAAAGCATTGGGACCAGCAGCTACACTAGAAGAAATGATGACAGCATG
    TCAAGGAGTGGGGGGACCCAGCCATAAAGCAAGAGTCTTGGCTGAAGCAATGAGCCAAGCAACAAATTCA
    GCTGCTGCCATAATGATGCAGAGAAACAATTTTAAGCAGAGAGGCAATTTTAAGGGCCAAAGGAGAGTCG
    TTAAATGTTTCAACTGTGGCAAGGAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGAAAAAAGGGTTG
    TTGGAAATGTGGACAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAA
    ATCTGGCCCTCCCACAAGGGAAGGCCAGGAAACTTTCTTCAGAACAGACCAGAGCCAACAGCCCCTCCAG
    AAGAGAGCTTCAGGTTTGGGGAAGAGACAACAACTCCCCCTCAGAAACAGGAACCAATAGACAAGGAACT
    ATATCCCTTAGCTTCCCTCAGATCACTCTTTGGCAACGACCCCTTGTCGCAATAAAGATAGGGGGGCAGT
    TAAGGGAAGCTCTATTAGACACAGGAGCAGATGATACAGTATTAGAAGAAATGAATTTACCAGGAAAATG
    GAAACCAAAAATGATAGGGGGAATTGGAGGTTTTATCAAAGTAAGGCAATATGAGCAAATACCTATAGAA
    ATCTGTGGACATAAAGCTATAGGTACAGTATTAATAGGACCTACACCTGTAAACATAATTGGAAGAAATT
    TGTTGACTCAGCTTGGTTGCACTCTAAATTTTCCCATTAGTCCTATTGAAACTGTACCAGTAAAATTAAA
    GCCAGGAATGGATGGCCCAAAAGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAGTAGAA
    ATTTGTACAGAAATGGAAAAGGAAGGAAAGATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAA
    TATTTGCCATAAAGAAAAAAGACAGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACTCAATAAGAG
    AACTCAAGACTTCTGGGAAGTTCAATTAGGAATACCACATCCTGCAGGGTTAAAACAGAAAAAATCAGTA
    ACAGTACTGGATGTGGGTGATGCATACTTCTCAGTTCCTTTGGATAAAGAATTCAGGAAGTATACTGCAT
    TTACCATACCTAGTGTAAACAATGAGACACCAGGGGTTAGATATCAGTACAATGTGCTTCCACAGGGATG
    GAAAGGATCACCAGCAATATTTCAAAGTAGCATGACAAGAATTTTAGAGCCTTTTAGAAAACAAAATCCA
    GACATAGTTATCTATCAATACATGGATGATCTGTATGTAGGGTCTGACTTAGAAATAGAGCAGCATAGAA
    CAAAAATAGAGGAGCTGAGACAACATCTGTTGAGGTGGGGATTTACCACACCAGACAAAAAACATCAGAA
    GGAACCTCCATTCCTTTGGATGGGTTATGAACTCCATCCTGATAAATGGACAGTACAGCCTATAAGGTTG
    CCAGAAAAAGACAGCTGGACTGTCAATGATATACAAAAGTTAGTGGGAAAATTGAATTGGGCAAGCCAGA
    TTTATCCAGGGATTAAAATAAAGCAATTATGTAAACTCCTTAGGGGAACCAAAGCACTAACAGAAATAGT
    ATCACTAACAGAAGAAGCAGAGTTAGAACTAGCAGAAAACAGGGAGATTCTAAGAGAACCAGTACATGGA
    GTGTATTATGACCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGGACATATC
    AAATTTATCAAGAGCCATTTAAAAACCTGAAAACAGGAAAGTACGCAAGAATGAGGGGCACCCATACTAA
    TGATGTAAAACAATTAACCGAGGCAGTACAAAAAATAGCCACAGAAAGCATAGTAATATGGGGAAAGACC
    CCCAAATTTAAACTACCCATACAAAAAGAAGCATGGGAAGCATGGTGGACAGATTATTGGCAAGCCACCT
    GGATCCCTGAATGGGAGTTTGTCAATACCCCTCCTTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACC
    CATAGAAGGAGCAGAAACTTTCTATGTAGATGGGGCAGCTAATAGGGAGACTAAAATAGGAAAAGCAGGA
    TATGTTACTAACAAAGGAAGACAAAAAGTTGTCACCCTACCTGACACAACAAATCAGAAGACTGAGTTAC
    AAGCAATTAATCTAGCTTTACAAGATTCTGGATTAGAAGTAAACATAGTAACAGACTCACAATATGCATT
    AGGAATCATTCAAGCACAACCAGATAAGAGTGAATCAGAGTTAGTCAGTCAAATAATAGAGCAGTTAATA
    AAAAAGGAAAAAGTCTACCTGGCATGGGTGCCAGCACACAAAGGAATTGGAGGAAATGAACAAATAGATA
    AATTAGTTAGTGCTGGAATCAGGAAAGTACTATTTTTAGATGGAATAGATAAGGCCCAAGAAGAACATGA
    GAAATATCACAATAACTGGAGAGCAATGGCTAGTGATTTTAACCTGCCACCTATAGTAGCAAAAGAAATA
    GTAGCCAGCTGTGATAAATGTCAGCTAAAAGGAGAAGCCATGCATGGACAAGTAGACTGTAGTCCAGGAA
    TATGGCAACTAGACTGTACCCATTTAGAAGGAAAAATTATCCTGGTGGCAGTACATGTGGCCAGTGGCTA
    TATAGAAGCAGAAGTTATTCCAGCAGAAACAGGACAGGAAACAGCATACTTTCTCTTAAAGTTAGCAGGA
    AGATGGCCAGTAAAAACAATACATACAGACAATGGCAGCAATTTCACCAGTAATACGGTTAAGGCCGCCT
    GTTGGTGGGCGGGGATCAAGCAGGAATTTGGCATTCCCTACAATCCCCAAAGCCAAGGAGTAGTAGAATC
    TATGAATAAAGAATTAAAGAAAATTATAGAACAGGTAAGAGATCAAGCTGAACATCTTAAGACAGCAGTA
    CAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAA
    TAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACATATTACAAAAATGCAAAATTT
    TCGGGTTTATTACAGGGACAACAGAGATCCACTTTGGAAAGGACCAGCAAAGCTCCTTTGGAAAGGTGAA
    GGGGCAGTAGTAATACAAGAAAATAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAGATCATTAGGG
    ATTATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAACACCTGGAAAA
    GTTTGGTAAAATACCATATGCATGTTTCAAAGAAAGCTAGGGGATGGTTTTATAGACATCACTATGAAAG
    CACTCACCCTAGAATAAGTTCAGAAGTACACATCCCACTAGGGGATGCTGAATTGGTAGTAATAACATAT
    TGGGGTCTAAATACAGGAGAAAGAGAGTGGCATTTAGGTCAAGGAGCCTCCATAGAATGGAGAAAAAAGA
    GGTACAGCACACAAGTAGACCCTAATGTAGCAGACCAACTAATTCATCTGTATTACTTTGATTGTTTTTC
    AGAATCTGCTATAAGAAAGGCCATATTAGGAAGTAGAGTTAGACCTAGGTGTGAATATCAAGCAGGACAT
    AACAAGGTAGGATCTCTACAGTACTTGGCACTAACAGCATTACTAACACCAAAAAAGATAAAGCCACCTT
    TGCCTAGTGTTAGGAAACTGACAGAGGATAGATGGAACAAGCCCCGGAAGACCAAGGGCCACAGAGGGAG
    CCAAACAACGAATGGACATTAGAGCTTTTAGAGGAACTGAAGAGTGAAGCAGTTAGACACTTCCCTAGGC
    CATGGCTCCATAGCTTAGGACAATATATCTATAGAACTTATGGAGATACTTGGACGGGAGTGGAAGCTCT
    AATAAGAATGCTGCAACAACTGCTGTTTATTCATTTCAGAATTGGGTGTCAACATAGCAGAATAGGCATT
    ACTCCAACGAGAAGAGCAAGAAATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGT
    CAGCCTAGGACTACTTGTACCAATTGTTATTGTAAAAAGTGCTGCTTTCATTGCCAAGTTTGCTTCATAA
    AAAAAGGCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAGGACCTCCTCAAGACAGTCA
    GACTCATCAAGCTTCTCTATCAAAGCAGTAAGTAGTAAATGTGATGCAAGCTTTATACATTTTAGCAATA
    GTAGCTTTAGTAATAGCAGCAATAATAGCAATAGTTGTATGGACCATAGTAATTATAGAATATAGGAAAA
    TATTAAGACAGAAAAAAATAGATAGATTAATTGATAGAATAAGAGAAAGAGCAGAAGACAGTGGCAATGA
    AAGCGAAGGGGATCAGGAAGAATTATCAGCACTTGTGGTGGAAATGGGGCACGATGCTCCTTGGGATGTT
    GATGATCTGTAGTGCAACAAAACAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAAGATGCA
    TCCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGCACATAATGTTTGGGCCACGC
    ATGCCTGTGTACCCACAGACCCTAACCCACAAGAAATAGCATTGGGAAATGTGACAGAAAAGTTTAACAT
    GTGGGAAAATAACATGGTAGATCAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCA
    TGTGTAAGATTAACCCCACTCTGTGTCACTTTAAATTGCACTGATGTGTGGAGAAATACTACTAATACTA
    CTAGTGGTGGGGAGGAAGTGATGGAGAGCGGAGAAATAAAAAACTGCTCTTTCAATATCACCACAAGCAC
    AAAAGATAAGAAGAACACATATGCACTTTTTTATAAACTTGATGTAACACCAATGGATAATGAAGTATCA
    AGAAATAATATTACAAATGATACCAATTATAGTAGGTATAGGTTGTTAAATTGTAACACCTCAGTCATTA
    CACAGGCCTGTCCAAAGGTATCCTTTGAACCAATTCCTATACATTATTGCACCCCGGCTGGTTTTGCGAT
    TATACAGTGTAATGATAAGAAGTTCAATGGAACAGGACCATGTAAAAATGTCAGCACAGTACAATGTACA
    CATGGAATTAGACCAGTAGTGTCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAGGAGATAGTAA
    TTAGATCTAAAAATTTTACAAACAATGCTAACACCATAATAGTACAGCTGAATAAATCTGTAACAATTGA
    TTGTATAAGACCCAACAACAATACAAGGAAAAGTATACATATGGGGCCAGGGAAAGCATTTTATACAACA
    GGAGACATAATAGGAGATATAAGAAAAGCACATTGCAGCATTAATAGAACAGATTGGGAAAACACTTTAA
    AACAGGTAGCTAACAAATTAATGGAACAATTTGGGAATAAAACAATAGTCTTTAAGAACTCCTCAGGAGG
    GGACCCAGAAATTACAACACACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATACATCAGCACTG
    TTTAATCATACGTTTAATAATACTGAAGGCGAAAATATAACTGAAAGCATAAATACAACAATTATCAAGC
    TCCCATGCAGAATAAAACAAATTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCAT
    CAGTGGACAAATTAGCTGTTCATCAAATATTACAGGAATACTATTAACAAGAGATGGTGGTGGTAATAAT
    ACGGGAAATGAGACCTTCAGACCTGGGGGAGGAAATATGAAAGACAATTGGAGAAGTGAATTATATAAAT
    ATAAAGTAGTAAAAATTGAGCCATTAGGAATAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGA
    AAAAAGAGCAGTGGGAGTGATAGGAGCTATGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC
    GCAGCGTCACTGACGCTGACGGTACAGGCCAGACAATTGTTGTCTGGTATAGTGCAACAGCAGAACAATT
    TGCTGAGAGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGC
    AAGAGTCCTGGCTGTGGAGAGATACCTAAAGGACCAACAGCTCCTAGGGATTTGGGGTTGCTCTGGAAAA
    CTCATTTGCACCACTGCTGTACCTTGGAATGATAGTTGGAGTAATAAATCTCTGACTGAGATTTGGAATA
    ACATGACCTGGATGGAGTGGGAAAGAGAAATTAACAATTATACAGGCATAATATACTCCTTAATTGAGGA
    ATCGCAGAACCAGCGGGAAAAGAATGAACTAGAATTATTGGAATTGGATAAGTGGGCAAGTTTGTGGAAT
    TGGTTTGACATAACAAAATGGCTGTGGTATATAAAAATATTCATAATGATAGTAGGAGGCTTGGTAGGTT
    TAAGAATAGTTTTTGCTGTACTTTCTATAGTAAATAGAGTTAGGCAGGGATACTCACCATTGTCATTACA
    GACCCGCTTCCCAGCCCCGAGGGGACCCGGAGGGCCCGAAGGAATCGAAGAAGAAGGTGGAGAGAGAGAC
    AGAGACAGATCCGGGACATTAGTGAACGGATTCTTGACACTTATCTGGGACGACCTCCAGAACCTGTGCC
    TCTTCAGTTACCGCCGATTGAGAGACTTACTCTTGATTGTAGTGAGGATTGTGGAACTTCTGGGACGCAG
    GGGGTGGGAGGCCCTCAAGTATTGGTGGAACCTCCTGCAGTATTGGGGTCAGGAACTAAAGAATAGTGCT
    GTTAGCTTGCTCAATGTCACAGCCATAGCAGTAGCTGAGGGGACAGATAGGGTTATAGAAGTAGTACAAA
    GAGCCTATAGAGCTATTATCCACATACCTAGAAGAATAAGACAGGGCTTAGAAAGGACTTTAGTATAAAA
    TAAAAATAAGACAGGGCTTAGAAAGGACTTTAGTATAAAATGGGTGGCAAGTGGTCAAAAAGTAGTCTGG
    TTGGATGGCCTGCTATAAGGGAAAGAATGAAACGAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATC
    TCGAGACCTGGAAAGACATGGAGCAATCACAAATAACAATACACCAGCTAATAATGCTGATTGTGCCTGG
    CTGGAAGCACAAGAAGAGGAGGAGGAGGTGGGTTTTCCAGTCAAACCCCAGGTACCTTTAAGGCCAATGA
    CTTACAAGGGAGCTCTGGATCTGAGCCACTTTTTAAGAGAAAAGGGGGGACTGGAAGGGTTAGTTTACTC
    CCAGAAAAGACAAGACATTCTTGATCTGTGGATCTATCACACACAAGGCTTCTTCCCTGACTGGCAGAAC
    TACACACCAGGGCCAGGGACCAGATTTCCACTGACCTTTGGATGGTGCTTCAAGCTAGTACCAGTAGAGC
    CAGAGGAGGTAGAAAAGGCCAATGAAGGGGAGAATAACTGCTTGTTGCATCCTATGAGCCAACATGGAAT
    GGAAGACCCGGAGAGAGAAGTGTTAAAGTGGAAGTTTGACAGCAGCCTAGCATATCATCACAGGGCCCGA
    GAGCTGCATCCGGAGTTCTACAAAGACTGCTGACACCGAGCTTTCTACAAGGGACTTTCCGCTGGGGACT
    TTCCAGGGGAGGTGTGGCCTGGGCGGGACCGGGGAGTGGCGAG
  • Molecule Role : Other
31. Nef
  • Gene Name : Nef
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • VO ID : VO_0011261
  • NCBI Gene ID : 156110
  • NCBI Protein GI : 28872818
  • Locus Tag : HIV1gp9
  • Genbank Accession : AF033819
  • Protein Accession : NP_057857
  • Taxonomy ID : 11676
  • Gene Starting Position : 8342
  • Gene Ending Position : 8962
  • Gene Strand (Orientation) : +
  • Protein Name : Nef
  • Protein pI : 6.42
  • Protein Weight : 22179.3
  • Protein Length : 206
  • Protein Note : This particular nucleotide sequence has a premature stop codon in place of a well-conserved tryptophan codon at position 8712-8714 that truncates the HIV1 Nef protein sequence to a 123 amino acids-long N-terminal portion (not shown).
  • DNA Sequence : Show Sequence
    >gi|9629357:8342-8962 Human immunodeficiency virus 1, complete genome
    GATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTACTGTAAGGGAAAGAATGAGACGAGCT
    GAGCCAGCAGCAGATAGGGTGGGAGCAGCATCTCGAGACCTGGAAAAACATGGAGCAATCACAAGTAGCA
    ATACAGCAGCTACCAATGCTGCTTGTGCCTGGCTAGAAGCACAAGAGGAGGAGGAGGTGGGTTTTCCAGT
    CACACCTCAGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAA
    AAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATATCCTTGATCTGTGGATCTACCACA
    CACAAGGCTACTTCCCTGATTAGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGACCTTTGG
    ATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGATAGAAGAGGCCAATAAAGGAGAGAACACCAGC
    TTGTTACACCCTGTGAGCCTGCATGGGATGGATGACCCGGAGAGAGAAGTGTTAGAGTGGAGGTTTGACA
    GCCGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCTG
  • Protein Sequence : Show Sequence
    >gi|28872818|ref|NP_057857.2| Nef [Human immunodeficiency virus 1]
    MGGKWSKSSVIGWPTVRERMRRAEPAADRVGAASRDLEKHGAITSSNTAATNAACAWLEAQEEEEVGFPV
    TPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQGYFPDWQNYTPGPGVRYPLTFG
    WCYKLVPVEPDKIEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Study compared the handling of overlapping 24-mer peptides from HIV Nef either mixed or covalently linked in tandem in one protein. With adjuvant, overlapping peptides were capable of protecting Balb/c mice against lethal viral challenge with 3 × 108 plaque forming units of vv-nef, whereas the intact protein was less protective (Zhang et al., 2009).
  • Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes
32. nef from HIV 2
  • Gene Name : nef from HIV 2
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 2
  • NCBI Protein GI : 1845210
  • Other Database IDs : CDD:109523
  • Taxonomy ID : 11709
  • Gene Strand (Orientation) : ?
  • Protein Name : nef protein
  • Protein Length : 257
  • Protein Note : similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542
  • Protein Sequence : Show Sequence
    >gi|1845210|gb|AAB47785.1| nef protein [Human immunodeficiency virus 2]
    MGASGSKKLSKQSQGLRERLLRARGGGYVRQCSASGGESSQSQGGSGREQKSPSCEGQQYRQGDYMNTPW
    RTPAMEGQKESYKQQNMDDVDSDDNDQVGVSVTSRVPLRPMTYKLAVDMSHFIKEKGGLEGMFYSRDRHR
    ILDLYLEKEEGVIPDWQNYTHGPGVRYPMCFGWLWKLVPVNMSQEAEDDETNCLMHPAQTSRYDDIHGET
    LVWRFNSMLAYEYKAFTLYPEEFGHKSGLPEKEWKAKLKARGIPYSE
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV-2 DNA vaccine
33. nef from subtype B
  • Gene Name : nef from subtype B
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 108860393
  • Other Database IDs : CDD:109523
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : Nef
  • Protein Length : 207
  • Protein Note : Vector:p04JPDR6075B-50; subtype B
  • Protein Sequence : Show Sequence
    >gi|108860393|dbj|BAE95916.1| Nef [Human immunodeficiency virus 1]
    MGGKWSKFSGWPAVRERIRRTEPAADPPADGVGAASRDLGAHGAITSSNTAATNADCAWLEAQEEEEVGF
    PVRPQVPLRPMTYKGAVDLSHFLKEKGGLEGLIYSQKRKDILDLWVYHTQGYFPDWHNYTPGPGTRFPLT
    FGWCFKLVPVDQEQVEKANEGENNALLHPMHLHGMDDPEREVLQWKFDSRLAFRHVAREMHPDFYKD
  • Molecule Role : Other
34. Nef SIV
  • Gene Name : Nef SIV
  • Sequence Strain (Species/Organism) : Simian immunodeficiency virus
  • NCBI Gene ID : 1490008
  • NCBI Protein GI : 9627209
  • Locus Tag : SIVgp7
  • Genbank Accession : M66437
  • Protein Accession : NP_054373
  • Taxonomy ID : 11723
  • Gene Starting Position : 8599
  • Gene Ending Position : 9270
  • Gene Strand (Orientation) : ?
  • Protein Name : nef protein
  • Protein pI : 6.4
  • Protein Weight : 24504.09
  • Protein Length : 223
  • DNA Sequence : Show Sequence
    >gi|9627204:8599-9270 Simian immunodeficiency virus, complete genome
    TATGGGCTCCAGCAACTCCAAGAGGCAGCAACAGGGCTTGCTCAAGCTCTGGCGAGGGCTGCGAGGGAAG
    CCTGGGGCAGACTGGGTGCTATTGTCCGATCCGCTTATCGGGCAGTCATCAACAGTCCAAGAAGAGTGCG
    GCAAGGCCTTGAAAAAGTCCTGGGGTAAAGGTAAAATGACTCCAGACGGCCGCCGCCTGCAAGAAGGAGA
    CACCTTTGATGAGTGGGATGATGATGAAGAAGAAGTAGGCTTCCCTGTGCAACCTCGAGTCCCCTTAAGA
    CAGATGACCTATAAATTAGCAGTGGACTTTTCCCACTTTTTAAAATCAAAGGGGGGACTGGATGGGATAT
    ATTACTCTGAAAGAAGAGAAAAGATCCTGAATTTGTATGCCTTGAACGAGTGGGGAATAATAGATGATTG
    GCAAGCTTACTCACCAGGCCCGGGGATAAGGTACCCGAGAGTCTTTGGCTTCTGCTTTAAGCTAGTCCCA
    GTGGACCTGCATGAGGAGGCACGCAACTGTGAGAGACACTGTCTGATGCATCCAGCACAGATGGGGGAAG
    ATCCTGATGGAATAGATCATGGAGAAGTCTTGGTCTGGAAGTTTGACCCGAAGTTGGCGGTGGAGTACCG
    CCCGGACATGTTTAAGGACATGCACGAACATGCAAAGCGCTA
  • Protein Sequence : Show Sequence
    >gi|9627209|ref|NP_054373.1| nef protein [Simian immunodeficiency virus]
    MGSSNSKRQQQGLLKLWRGLRGKPGADWVLLSDPLIGQSSTVQEECGKALKKSWGKGKMTPDGRRLQEGD
    TFDEWDDDEEEVGFPVQPRVPLRQMTYKLAVDFSHFLKSKGGLDGIYYSERREKILNLYALNEWGIIDDW
    QAYSPGPGIRYPRVFGFCFKLVPVDLHEEARNCERHCLMHPAQMGEDPDGIDHGEVLVWKFDPKLAVEYR
    PDMFKDMHEHAKR
  • Molecule Role : Other
  • Related Vaccine(s): HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost
35. pol from HIV 1
  • Gene Name : pol from HIV 1
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 7021456
  • Other Database IDs : CDD:133149
    CDD:73152
    CDD:200982
    CDD:115473
    CDD:203523
    CDD:209893
    CDD:187690
    CDD:202092
    CDD:207376
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : pol
  • Protein Length : 846
  • Protein Note : long-term nonprogressor
  • Protein Sequence : Show Sequence
    >gi|7021456|gb|AAF35355.1| pol [Human immunodeficiency virus 1]
    FFREDLAFPQGKAREFPSEQTRAISPARRELQVWGRDNNSLSEAGANRQGTVSFSFPQITLWQRPLVAIK
    IGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQVAIEICGHKAIGTVLIGPTPVNI
    IGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENP
    YNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFR
    KYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEI
    GQHRIKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLN
    WASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQG
    QWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKVAIESIVIWGKTPKFKLPIQKETWEAWWTEY
    WQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKVVPLTDTTNQ
    KTELQAIHLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKEKVYLAWVPAHKGIGGN
    EQVDKLVSAGIRKVLFLDGIDKAQEEHEKYHSNWRAMAGDFNLPPVVAKEIVACCDKCQLKGEAMHGQVD
    CSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGSNFTSNT
    VKAACW
  • Molecule Role : Protective antigen
  • Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes , HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
36. pol from SHIV-89.6
  • Gene Name : pol from SHIV-89.6
  • Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
  • NCBI Protein GI : 2828038
  • Other Database IDs : CDD:133149
    CDD:207741
    CDD:200982
    CDD:73150
    CDD:115473
    CDD:203523
    CDD:200979
    CDD:187690
    CDD:202092
    CDD:201381
    CDD:144223
  • Taxonomy ID : 57667
  • Gene Strand (Orientation) : ?
  • Protein Name : pol
  • Protein Length : 1059
  • Protein Note : Retropepsins, pepsin-like aspartate proteases; cd05482
  • Protein Sequence : Show Sequence
    >gi|2828038|gb|AAB99959.1| pol [Simian-Human immunodeficiency virus]
    LELWERGTLCKAMQSPKKTGMLEMWKNGPCYGQMPRQTGGFFRPWSMGKEAPQFPHGSSASGADANCSPR
    GPSCGSAKELHAVGQAAERKAERKQREALQGGDRGFAAPQFSLWRRPVVTAHIEGQPVEVLLDTGADDSI
    VTGIELGPHYTPKIVGGIGGFINTKEYKNVEIEVLGKRIKGTIMTGDTPINIFGRNLLTALGMSLNFPIA
    KVEPVKVALKPGKDGPKLKQWPLSKEKIVALREICEKMEKDGQLEEAPPTNPYNTPTFAIKKKDKNKWRM
    LIDFRELNRVTQDFTEVQLGIPHPAGLAKRKRITVLDIGDAYFSIPLDEEFRQYTAFTLPSVNNAEPGKR
    YIYKVLPQGWKGSPAIFQYTMRHVLEPFRKANPDVTLVQYMDDILIASDRTDLEHDRVVLQSKELLNSIG
    FSTPEEKFQKDPPFQWMGYELWPTKWKLQKIELPQRETWTVNDIQKLVGVLNWAAQIYPGIKTKHLCRLI
    RGKMTLTEEVQWTEMAEAEYEENKIILSQEQEGCYYQEGKPLEATVIKSQDNQWSYKIHQEDKILKVGKF
    AKIKNTHTNGVRLLAHVIQKIGKEAIVIWGQVPKFHLPVEKDVWEQWWTDYWQVTWIPEWDFISTPPLVR
    LVFNLVKDPIEGEETYYTDGSCNKQSKEGKAGYITDRGKDKVKVLEQTTNQQAELEAFLMALTDSGPKAN
    IIVDSQYVMGIITGCPTESESRLVNQIIEEMIKKSEIYVAWVPAHKGIGGNQEIDHLVSQGIRQVLFLEK
    IEPAQEEHDKYHSNVKELVFKFGLPRIVARQIVDTCDKCHQKGEAIHGQANSDLGTWQMDCTHLEGKIII
    VAVHVASGFIEAEVIPQETGRQTALFLLKLAGRWPITHLHTDNGANFASQEVKMVAWWAGIEHTFGVPYN
    PQSQGVVEAMNHHLKNQIDRIREQANSVETIVLMAVHCMNFKRRGGIGDMTPAERLINMITTEQEIQFQQ
    SKNSKFKNFRVYYREGRDQLWKGPGELLWKGEGAVILKVGTDIKVVPRRKAKIIKDYGGGKEVDSSSHME
    DTGEAREVA
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
37. pol from subtype B
  • Gene Name : pol from subtype B
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 108860386
  • Other Database IDs : CDD:133149
    CDD:73152
    CDD:200982
    CDD:115473
    CDD:203523
    CDD:209893
    CDD:187690
    CDD:202092
    CDD:207376
    CDD:144223
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : Pol
  • Protein Length : 1003
  • Protein Note : Vector:p04JPDR6075B-50; subtype B
  • Protein Sequence : Show Sequence
    >gi|108860386|dbj|BAE95909.1| Pol [Human immunodeficiency virus 1]
    FFRENLAFQQGEAREFPSEQTRANSPTRRELQVWGEDNNSLSEAGADRRGTISFSFPQITLWQRPLVTVK
    IGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQVPIEICEHKVIGTVLIGPTPVNI
    IGRNLLTQLGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENP
    YNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFR
    KYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEI
    GQHREKVEDLRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLN
    WASQIYPGIRIKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGYG
    QWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGKIPKFKLPIQKETWEAWWLEY
    WQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRDTKLGKAGYVTDRGRQKVVTLTDTTNQ
    KTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKEKIYLAWVPAHKGIGGN
    EQVDKLVSNGIRKVLFLDGIDKAQEEHEKYHSNWRAMVSDFNLPPVVAKEIVANCDKCQLKGEAMHGQVD
    CSPGIWQLDCTHLEGKIILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGGNFISTA
    VKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGYS
    AGERIIDIIATDIQTKELQNQITKISKFRVYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSEIKVVPRRKA
    KIIKDYGKQMAGGDCVASGQDED
  • Molecule Role : Other
38. Pol SIV
  • Gene Name : Pol SIV
  • Sequence Strain (Species/Organism) : Simian immunodeficiency virus SIV-mnd 2
  • NCBI Gene ID : 956107
  • NCBI Protein GI : 27311168
  • Locus Tag : Siv2gp2
  • Genbank Accession : AF367411
  • Protein Accession : NP_758887
  • Taxonomy ID : 159122
  • Gene Starting Position : 2049
  • Gene Ending Position : 5081
  • Gene Strand (Orientation) : +
  • Protein Name : pol protein
  • Protein pI : 7.91
  • Protein Weight : 106929.88
  • Protein Length : 1010
  • DNA Sequence : Show Sequence
    >gi|27311166:2049-5081 Simian immunodeficiency virus SIV-mnd 2, complete genome
    ATTTTTTAGGGAATACCCCCTGGGGCAGTGGCAAACCCAGGAACTTCCCGGCGATGCCATTGACCCCAAC
    GGCCCCTCCAATGCCAGGGATGGAAGACCCAGCAGAGAGAATGCTGTTAGATTACATGAAGAAAGGGCAA
    CAGCAGAAAGCGGAAAGCAAACAGGAAAAGAAAGAGAGGGGTCCATACGAGGCAGCTTACAACTCCCTCA
    GTTCTCTCTTTGGAACAGACCAACTACAGTAGTAGAGATAGAAGGGCAAAAAGTGGAGGCCTTACTGGAC
    ACAGGAGCTGATGATACAGTAATCAAAGATCTAGATTTAAAAGGTAATTGGAAACCACAGATTATTGGAG
    GAATTGGAGGATCAATCAATGTAAAACAGTTTTTCAATTGTAAAGTAACAATAGCAGGCAAAACTACACA
    CGCTTCAGTCCTAGTGGGCCCCACACCTGTAAATATTGTAGGTAGAAATGTGCTGAAGAAATTAGGATGT
    ACACTAAATTTTCCAGTTAGTAAAGTAGAAACAGTAAAGGTAACACTAAAACCAGGAACTGACGGACCTA
    AAATAAAACAATGGCCATTGTCTAAGGAAAAGATTTTAGCCTTACAAGAAATATGTAGTCAAATGGAGAA
    GGAAGGCCAGATCTCTAAGATAGGTCCAGAAAATCCTTACAACACACCGGTGTTTTGCATCAAAAAGAAA
    GATGGAACCAGCTGGAGAAAATTGGTAGATTTTAGACAGTTAAACAAAGTAACTCAGGACTTCTTTGAGG
    TGCAGTTGGGAATCCCACACCCTGGAGGTCTCAAACAATGTGAGCAAATTACAGTACTGGACATAGGGGA
    TGCCTATTTCTCATGTCCTTTGGATGAGGACTTTAGAAAGTACACTGCATTCACCATTCCATCGGTGAAT
    AATCAGGGCCCAGGAATCAGGTACCAGTATAATGTCCTACCACAGGGATGGAAGGGCTCCCCAGCCATTT
    TCCAGGCAACAGCAGATAAAATCTTACAGCCCTTCAGAGAGAGACATCCAGATGTAGTGATCTATCAATA
    TATGGATGATCTCTTTGTTGGGAGTGATAGAGTTGCCCCAGAACACAGCAGAATGATTCAAGAGTTAAGA
    GACCACCTCTTGTTTTGGGGGCTCGAGACCCCAGACAAGAAGTTTCAAAAGGAACCACCCTTTGAGTGGA
    TGGGATACATACTGCACCCTAAGAAATGGACAGTGCAGAAAGTACAGCTTCCAGAGAAAGAAGAATGGAC
    AGTAAATGACATCCAAAAGTTGGTAGGGAAACTTAATTGGGCAAGTCAGATTTATTCCGGAATTAAAACA
    AAAGAGCTCTGTAGACTAATTAGAGGGGCAAAACCCCTAGATGAAAAAGTAGAATGGACTAGAGAAGCAG
    AATTAGAATATGAAGAAAACAAACTCATAGTGCAGGAGGAAGTGCATGGAGTATACTATCAACCAGAGAA
    GCCTTTAATGGCAAAGGTTCAAAAATTGACACAAGGGCAATGGAGTTACCAAATAGAGCAGGAGGATAAT
    AAGCCGCTGAAGGTAGGGAAATATGCCAGAACAAAGAATGCTCATACAAATGAGCTTAGAGTGCTTGCAG
    GACTAGTACAGAAGATTGCAAAAGAAGCTTTAGTGATCTGGGGAAAACTCCCTAAGTTTTATCTGCCAAT
    AGAAAGAGAAGTCTGGGACCAGTGGTGGCCAGAATATTGGCAAGCCACATGGATTCCCGAATGGGAATTT
    GTATCCACTCCACACCTTATCGGGTTGTGGTATAACCTGTTGAGAGAACCTGTGCCAGGAGAAGATGTGT
    ATTATGTGGATGGAGCAGCTAACAGAAACTCCAAAGAAGGGAAAGCAGGATATGTAACAGCTAGAAATAA
    ATCCAGAGTAATAGCCCTAGAGAATACCACAAACCAAAAAGCAGAATTGGAGGCAATAAAAATGGCATTA
    CAAGACTCAGGACCAAAAGTAAATATAGTGACAGATTCACAGTATGCTATGGGTATCCTATCGGCAGCAC
    CCGACCAATCAGACAACCCCATAGTAAGAGAAATTATAGAACTCATGATCCACAAGGAAGCAGTATACCT
    AGCTTGGGTACCAGCACACAAAGGCATAGGAGGGAATGAGCAAGTAGATAAACTAGTGAGCAGAGGAGTA
    AGGCAAGTACTGTTTTTAGAAGGCATAGATAAAGCACAAGAAGAGCATGATAAATATCACAATAATTGGA
    GGGCATTAGCACAAGACTTCTGTATACCAAACATAGTGGCAAAAGAAATAGTAGCCCAGTGTCCAAAGTG
    TCAAACAAAAGGAGAGCCAATACATGGCCAGGTAGATACATCCCCAGGAACCTGGCAAATGGACTGCACA
    CATATGGAAGGAAAAGTAATCATAGCAGCAGTCCATGTAGCAAGTAGGTATCTAGAAGCAGAAGTAATAC
    CCACAGAAACAGGAAAAGAAACAGCACACTTCCTGTTAAAATTAGCAGGTAGATGGCCAGTAAAACATCT
    ACACACAGATAATGGCCCTAATTTCACCAGTGAAAAAGTAGCCACAGTCTGTTGGTGGGCTCAAATAGAG
    CACACTACAGGAATTCCCTACAATCCTCAGAGTCAAGGAGTAATAGAGGCAAAAAACCATCATCTCAAAC
    AAATCATAGGGCAAGTTAGAGACCAAGCAGAGAAACTAGAAACAGCAGTTCAAATGGCAGTATTAATTCA
    CAATTTTAAAAGAAAAGGGGGGATAGGGGAATACAGTCCAGGAGAAAGAATAGTAGACATTATAGCAACA
    GACCTCCTAACAACTAAATTACAACACAATATTCAAAAAATTCAAAATTTTCGGGTTTATTACAGAGAAG
    GAAGGGACCAACAGTGGAAAGGACCAGCAGAACTCATTTGGAAAGGAGAAGGAGCGGTGGTAATCAAAGA
    GGGGACAGACTTGAAGGTAGTACCAAGGAGAAAAGCAAAAATCATCAGAGATTATGGAAAAACAGTGGAT
    AGTGATCCCAACGTGGAAGCTTG
  • Protein Sequence : Show Sequence
    >gi|27311168|ref|NP_758887.1| pol protein [Simian immunodeficiency virus SIV-mnd 2]
    FFREYPLGQWQTQELPGDAIDPNGPSNARDGRPSRENAVRLHEERATAESGKQTGKEREGSIRGSLQLPQ
    FSLWNRPTTVVEIEGQKVEALLDTGADDTVIKDLDLKGNWKPQIIGGIGGSINVKQFFNCKVTIAGKTTH
    ASVLVGPTPVNIVGRNVLKKLGCTLNFPVSKVETVKVTLKPGTDGPKIKQWPLSKEKILALQEICSQMEK
    EGQISKIGPENPYNTPVFCIKKKDGTSWRKLVDFRQLNKVTQDFFEVQLGIPHPGGLKQCEQITVLDIGD
    AYFSCPLDEDFRKYTAFTIPSVNNQGPGIRYQYNVLPQGWKGSPAIFQATADKILQPFRERHPDVVIYQY
    MDDLFVGSDRVAPEHSRMIQELRDHLLFWGLETPDKKFQKEPPFEWMGYILHPKKWTVQKVQLPEKEEWT
    VNDIQKLVGKLNWASQIYSGIKTKELCRLIRGAKPLDEKVEWTREAELEYEENKLIVQEEVHGVYYQPEK
    PLMAKVQKLTQGQWSYQIEQEDNKPLKVGKYARTKNAHTNELRVLAGLVQKIAKEALVIWGKLPKFYLPI
    EREVWDQWWPEYWQATWIPEWEFVSTPHLIGLWYNLLREPVPGEDVYYVDGAANRNSKEGKAGYVTARNK
    SRVIALENTTNQKAELEAIKMALQDSGPKVNIVTDSQYAMGILSAAPDQSDNPIVREIIELMIHKEAVYL
    AWVPAHKGIGGNEQVDKLVSRGVRQVLFLEGIDKAQEEHDKYHNNWRALAQDFCIPNIVAKEIVAQCPKC
    QTKGEPIHGQVDTSPGTWQMDCTHMEGKVIIAAVHVASRYLEAEVIPTETGKETAHFLLKLAGRWPVKHL
    HTDNGPNFTSEKVATVCWWAQIEHTTGIPYNPQSQGVIEAKNHHLKQIIGQVRDQAEKLETAVQMAVLIH
    NFKRKGGIGEYSPGERIVDIIATDLLTTKLQHNIQKIQNFRVYYREGRDQQWKGPAELIWKGEGAVVIKE
    GTDLKVVPRRKAKIIRDYGKTVDSDPNVEA
  • Molecule Role : Other
  • Related Vaccine(s): HIV DNA vaccine pHIS-SHIV-B , HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost , rMVTT-SIV-gpe
39. Polymerase protein
  • Gene Name : Polymerase protein
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 6715123
  • Other Database IDs : CDD:133149
    CDD:207741
    CDD:200982
    CDD:73150
    CDD:115473
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : polymerase
  • Protein Length : 420
  • Protein Note : Retropepsins, pepsin-like aspartate proteases; cd05482
  • Protein Sequence : Show Sequence
    >gi|6715123|gb|AAF26291.1| polymerase [Human immunodeficiency virus 1]
    PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYDQILIEICGKK
    AIGTVLVGPTPVNIIGRNMLTQIGCTLNLPISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEM
    EEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDV
    GDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIDIY
    QYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDS
    WTVNDIQKLVGKLNWASQIYPGIKIKQLCKLLRGAKALTDIVPLTEEAELELEENREILKTPVHGVYYDP
  • Molecule Role : Other
40. pro
  • Gene Name : pro
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Protein GI : 19911446
  • Other Database IDs : CDD:133149
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : protease
  • Protein Length : 99
  • Protein Note : HIV-1; subtype C; synonym: Human immunodeficiency virus type 1
  • Protein Sequence : Show Sequence
    >gi|19911446|dbj|BAB88039.1| protease [Human immunodeficiency virus 1]
    PQITLWQRPLVTIKVEGQVKEALLDTGADDTVLEDMNLPGRWKPKMIGGIGGFIKVRQYDQITLEICGKK
    AIGTVLVGPTPVNIIGRNMLTQLGCTLNF
  • Molecule Role : Other
41. rev from HIV 1
  • Gene Name : rev from HIV 1
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Gene ID : 155908
  • NCBI Protein GI : 9629359
  • Locus Tag : HIV1gp6
  • Genbank Accession : AF033819
  • Protein Accession : NP_057854
  • Taxonomy ID : 11676
  • Gene Starting Position : 5515
  • Gene Ending Position : 8198
  • Gene Strand (Orientation) : +
  • Protein Name : Rev
  • Protein pI : 9.36
  • Protein Weight : 12578.23
  • Protein Length : 116
  • DNA Sequence : Show Sequence
    >gi|9629357:5515-8198 Human immunodeficiency virus 1, complete genome
    TATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCTCTAT
    CAAAGCAGTAAGTAGTACATGTAATGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGCAAT
    AATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATA
    GACAGGTTAATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAG
    CACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTAGTGCTACAG
    AAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGC
    ATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGAC
    CCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAACATGTGGAAAAATGACATGGTAG
    AACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACT
    CTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTAGCGGGAGAATGATA
    ATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACAAGCATAAGAGGTAAGGTGCAGAAAG
    AATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATGATACTACCAGCTATAAGTTGACAAG
    TTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATTGT
    GCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTCAATGGAACAGGACCATGTACAAATG
    TCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAACTCAACTGCTGTTAAATGGCAGTCT
    AGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAATGCTAAAACCATAATAGTACAGCTG
    AACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAAGAATCCGTATCCAGAGAG
    GACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGAGACAAGCACATTGTAACATTAGTAG
    AGCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAGAGAACAATTTGGAAATAATAAAACA
    ATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTGGAGGGGAAT
    TTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGTTTAATAGTACTTGGAGTACTGAAGGGTC
    AAATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAATAAAACAAATTATAAACATGTGGCAG
    AAAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATTAGATGTTCATCAAATATTACAGGGC
    TGCTATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGATCTTCAGACCTGGAGGAGGAGATAT
    GAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCC
    ACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGT
    TCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGCTGACGGTACAGGCCAGACAATTATT
    GTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTC
    ACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGC
    TCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAG
    TAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTAC
    ACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGG
    AATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATT
    CATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTT
    AGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAG
    GAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCCTTGGCACT
    TATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTGATTGTA
    ACGAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATATTGGTGGAATCTCCTACAGT
    ATTGGAGTCAGGAACTAAAGAATA
  • Protein Sequence : Show Sequence
    >gi|9629359|ref|NP_057854.1| Rev [Human immunodeficiency virus 1]
    MAGRSGDSDEELIRTVRLIKLLYQSNPPPNPEGTRQARRNRRRRWRERQRQIHSISERILGTYLGRSAEP
    VPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE
  • Molecule Role : Protective antigen
  • Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes , HIV DNA vaccine pHIS-SHIV-B , HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) , HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein , HIV recombinant vector vaccine MVA.HIVA encoding env and rev
42. rev from SHIV-89.6
  • Gene Name : rev from SHIV-89.6
  • Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
  • NCBI Protein GI : 2828043
  • Other Database IDs : CDD:189539
  • Taxonomy ID : 57667
  • Gene Strand (Orientation) : ?
  • Protein Name : rev
  • Protein Length : 116
  • Protein Note : REV protein (anti-repression trans-activator protein); pfam00424
  • Protein Sequence : Show Sequence
    >gi|2828043|gb|AAB99964.1| rev [Simian-Human immunodeficiency virus]
    MAGRSGDSDEELIRTVRLIKLLYQSNPPPSLEGTRQARRNRRRRWRERQRQIRSISERILGTYLGRSAEP
    VPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
43. rev MN isolate
  • Gene Name : rev MN isolate
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 MN
  • NCBI Protein GI : 3511264
  • Other Database IDs : CDD:189539
  • Taxonomy ID : 11676
  • Gene Strand (Orientation) : ?
  • Protein Name : rev protein
  • Protein Length : 116
  • Protein Note : neutralization phenotype variant molecular clone
  • Protein Sequence : Show Sequence
    >gi|3511264|gb|AAC33786.1| rev protein [Human immunodeficiency virus 1]
    MAGRNGDSDEELLKTVRLIKFLHQSNPPPSSEGTRQARRNRRRRWRERQRHIRSISAWILSNYLGRPAEP
    VPPQLPPLERLTLDCSEDCGTSGTQGVGSPQILVESPTVLESGTKE
  • Molecule Role : Other
  • Related Vaccine(s): HIV DNA vaccine pCMN160
44. Tat
  • Gene Name : Tat
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • VO ID : VO_0011262
  • NCBI Gene ID : 155871
  • NCBI Protein GI : 9629358
  • Locus Tag : HIV1gp5
  • Genbank Accession : AF033819
  • Protein Accession : NP_057853
  • Taxonomy ID : 11676
  • Gene Starting Position : 5376
  • Gene Ending Position : 7969
  • Gene Strand (Orientation) : +
  • Protein Name : Tat
  • Protein pI : 10.43
  • Protein Weight : 9638.3
  • Protein Length : 86
  • Protein Note : the length of Tat varies depending on virus strain or clade
  • DNA Sequence : Show Sequence
    >gi|9629357:5376-7969 Human immunodeficiency virus 1, complete genome
    AATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCTTGTACC
    AATTGCTATTGTAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTTCATAACAAAAGCCTTAGGCATCTCCT
    ATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCTCTATC
    AAAGCAGTAAGTAGTACATGTAATGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGCAATA
    ATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATAG
    ACAGGTTAATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAGC
    ACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTAGTGCTACAGA
    AAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGCA
    TCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGACC
    CCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAACATGTGGAAAAATGACATGGTAGA
    ACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACTC
    TGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTAGCGGGAGAATGATAA
    TGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACAAGCATAAGAGGTAAGGTGCAGAAAGA
    ATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATGATACTACCAGCTATAAGTTGACAAGT
    TGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATTGTG
    CCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTCAATGGAACAGGACCATGTACAAATGT
    CAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAACTCAACTGCTGTTAAATGGCAGTCTA
    GCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAATGCTAAAACCATAATAGTACAGCTGA
    ACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAAGAATCCGTATCCAGAGAGG
    ACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGAGACAAGCACATTGTAACATTAGTAGA
    GCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAGAGAACAATTTGGAAATAATAAAACAA
    TAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTGGAGGGGAATT
    TTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGTTTAATAGTACTTGGAGTACTGAAGGGTCA
    AATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAATAAAACAAATTATAAACATGTGGCAGA
    AAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATTAGATGTTCATCAAATATTACAGGGCT
    GCTATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGATCTTCAGACCTGGAGGAGGAGATATG
    AGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA
    CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTT
    CTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGCTGACGGTACAGGCCAGACAATTATTG
    TCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCA
    CAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCT
    CCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGT
    AATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA
    CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGA
    ATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATTC
    ATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTA
    GGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGG
    AATA
  • Protein Sequence : Show Sequence
    >gi|9629358|ref|NP_057853.1| Tat [Human immunodeficiency virus 1]
    MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLS
    KQPTSQPRGDPTGPKE
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice (Bråve et al., 2007).
  • Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes , HIV DNA vaccine pHIS-SHIV-B , HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
45. tat from HIV 2
  • Gene Name : tat from HIV 2
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 2
  • NCBI Protein GI : 1845211
  • Other Database IDs : CDD:201292
  • Taxonomy ID : 11709
  • Gene Strand (Orientation) : ?
  • Protein Name : tat protein
  • Protein Length : 130
  • Protein Note : similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542
  • Protein Sequence : Show Sequence
    >gi|1845211|gb|AAB47786.1| tat protein [Human immunodeficiency virus 2]
    METPLKAPESSLKSYNEPSPCTSEWEVAAQELAKQGEELLAQLHRPLEACTNPCYCKKCSFHCQLCFLKK
    GLGIWYVRKGGRRRTPKRTKTHPPSTPDKSISIQTGDSRPTKKQKETPETPVATTSGLGR
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV-2 DNA vaccine
46. tat from SHIV-89.6
  • Gene Name : tat from SHIV-89.6
  • Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
  • NCBI Protein GI : 2828042
  • Other Database IDs : CDD:201292
  • Taxonomy ID : 57667
  • Gene Strand (Orientation) : ?
  • Protein Name : tat
  • Protein Length : 101
  • Protein Note : Transactivating regulatory protein (Tat); pfam00539
  • Protein Sequence : Show Sequence
    >gi|2828042|gb|AAB99963.1| tat [Simian-Human immunodeficiency virus]
    MEPVDPRLEPWKHPGSKPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLS
    KQPSSQPRGDPTGPKEQKKKVERETETDPVH
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
47. vif
  • Gene Name : vif
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Gene ID : 155459
  • NCBI Protein GI : 9629361
  • Locus Tag : HIV1gp3
  • Genbank Accession : AF033819
  • Protein Accession : NP_057851
  • Taxonomy ID : 11676
  • Gene Starting Position : 4586
  • Gene Ending Position : 5164
  • Gene Strand (Orientation) : +
  • Protein Name : Vif
  • Protein pI : 10.39
  • Protein Weight : 21322.07
  • Protein Length : 192
  • DNA Sequence : Show Sequence
    >gi|9629357:4586-5164 Human immunodeficiency virus 1, complete genome
    TATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAGAACATGGAAAAGT
    TTAGTAAAACACCATATGTATGTTTCAGGGAAAGCTAGGGGATGGTTTTATAGACATCACTATGAAAGCC
    CTCATCCAAGAATAAGTTCAGAAGTACACATCCCACTAGGGGATGCTAGATTGGTAATAACAACATATTG
    GGGTCTGCATACAGGAGAAAGAGACTGGCATTTGGGTCAGGGAGTCTCCATAGAATGGAGGAAAAAGAGA
    TATAGCACACAAGTAGACCCTGAACTAGCAGACCAACTAATTCATCTGTATTACTTTGACTGTTTTTCAG
    ACTCTGCTATAAGAAAGGCCTTATTAGGACACATAGTTAGCCCTAGGTGTGAATATCAAGCAGGACATAA
    CAAGGTAGGATCTCTACAATACTTGGCACTAGCAGCATTAATAACACCAAAAAAGATAAAGCCACCTTTG
    CCTAGTGTTACGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCC
    ACACAATGAATGGACACTA
  • Protein Sequence : Show Sequence
    >gi|9629361|ref|NP_057851.1| Vif [Human immunodeficiency virus 1]
    MENRWQVMIVWQVDRMRIRTWKSLVKHHMYVSGKARGWFYRHHYESPHPRISSEVHIPLGDARLVITTYW
    GLHTGERDWHLGQGVSIEWRKKRYSTQVDPELADQLIHLYYFDCFSDSAIRKALLGHIVSPRCEYQAGHN
    KVGSLQYLALAALITPKKIKPPLPSVTKLTEDRWNKPQKTKGHRGSHTMNGH
  • Molecule Role : Other
  • Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
48. vif from SHIV-89.6
  • Gene Name : vif from SHIV-89.6
  • Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
  • NCBI Protein GI : 2828039
  • Other Database IDs : CDD:109609
  • Taxonomy ID : 57667
  • Gene Strand (Orientation) : ?
  • Protein Name : vif
  • Protein Length : 214
  • Protein Note : Retroviral Vif (Viral infectivity) protein; pfam00559
  • Protein Sequence : Show Sequence
    >gi|2828039|gb|AAB99960.1| vif [Simian-Human immunodeficiency virus]
    MEEEKRWIAVPTWRIPERLERWHSLIKYLKYKTKDLQKVCYVPHFKVGWAWWTCSRVIFPLQEGSHLEVQ
    GYWHLTPEKGWLSTYAVRITWYSKNFWTDVTPNYADILLHSTYFPCFTAGEVRRAIRGEQLLSCCRFPRA
    HKYQVPSLQYLALKVVSDVRSQGENPTWKQWRRDNRRGLRMAKQNSRGDKQRGGKPPTKGANFPGLAKVL
    GILA
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
49. vpr
  • Gene Name : vpr
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Gene ID : 155807
  • NCBI Protein GI : 28872817
  • Locus Tag : HIV1gp4
  • Genbank Accession : AF033819
  • Protein Accession : NP_057852
  • Taxonomy ID : 11676
  • Gene Starting Position : 5104
  • Gene Ending Position : 5395
  • Gene Strand (Orientation) : +
  • Protein Name : Vpr
  • Protein pI : 8.54
  • Protein Weight : 11024.76
  • Protein Length : 96
  • Protein Note : An artificial frameshift eliminating the orf-disrupting nucleotide at position 5320 is introduced to obtain the typical HIV-1 Vpr protein sequence. For this particular HIV-1 strain, HXB2, only a short (78 amino acid long) variant of the Vpr sequence can be obtained by translation of nucleotides 5105 through 5341 without the frameshift
  • DNA Sequence : Show Sequence
    >gi|9629357:5104-5395 Human immunodeficiency virus 1, complete genome
    GATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCCACACAATGAATGGACACTAGAGCTTTTA
    GAGGAGCTTAAGAATGAAGCTGTTAGACATTTTCCTAGGATTTGGCTCCATGGCTTAGGGCAACATATCT
    ATGAAACTTATGGGGATACTTGGGCAGGAGTGGAAGCCATAATAAGAATTCTGCAACAACTGCTGTTTAT
    CCATTTTCAGAATTGGGTGTCGACATAGCAGAATAGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGC
    CAGTAGATCCTA
  • Protein Sequence : Show Sequence
    >gi|28872817|ref|NP_057852.2| Vpr [Human immunodeficiency virus 1]
    MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETYGDTWAGVEAIIRILQQLLFI
    HFRIGCRHSRIGVTRQRRARNGASRS
  • Molecule Role : Other
  • Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
50. vpr from SHIV-89.6
  • Gene Name : vpr from SHIV-89.6
  • Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
  • NCBI Protein GI : 2828041
  • Other Database IDs : CDD:109573
  • Taxonomy ID : 57667
  • Gene Strand (Orientation) : ?
  • Protein Name : vpr
  • Protein Length : 101
  • Protein Note : VPR/VPX protein; pfam00522
  • Protein Sequence : Show Sequence
    >gi|2828041|gb|AAB99962.1| vpr [Simian-Human immunodeficiency virus]
    MEERPPENEGPQREPWDEWVVEVLEELKEEALKHFDPRLLTALGNHIYNRHGDTLEGAGELIRILQRALF
    MHFRGGCIHSRIGQPGGGNPLSAIPPSRSML
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
51. vpu
  • Gene Name : vpu
  • Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
  • NCBI Gene ID : 155945
  • NCBI Protein GI : 9629366
  • Locus Tag : HIV1gp7
  • Genbank Accession : AF033819
  • Protein Accession : NP_057855
  • Taxonomy ID : 11676
  • Gene Starting Position : 5607
  • Gene Ending Position : 5855
  • Gene Strand (Orientation) : +
  • Protein Name : Vpu
  • Protein pI : 4.43
  • Protein Weight : 8250.01
  • Protein Length : 82
  • Protein Note : Vpu and gp160 are translated from different reading frames of the same bicistronic mRNA
  • DNA Sequence : Show Sequence
    >gi|9629357:5607-5855 Human immunodeficiency virus 1, complete genome
    AATGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGCAATAATAATAGCAATAGTTGTGTGG
    TCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATAGACAGGTTAATTGATAGACTAA
    TAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAGCACTTGTGGAGATGGGGGTGGA
    GATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTA
  • Protein Sequence : Show Sequence
    >gi|9629366|ref|NP_057855.1| Vpu [Human immunodeficiency virus 1]
    MQPIPIVAIVALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEISALVEMGVE
    MGHHAPWDVDDL
  • Molecule Role : Other
  • Related Vaccine(s): HIV DNA vaccine pHIS-SHIV-B , HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
52. vpu from SHIV-89.6
  • Gene Name : vpu from SHIV-89.6
  • Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
  • NCBI Protein GI : 2828044
  • Other Database IDs : CDD:109608
  • Taxonomy ID : 57667
  • Gene Strand (Orientation) : ?
  • Protein Name : vpu
  • Protein Length : 81
  • Protein Note : Vpu protein; pfam00558
  • Protein Sequence : Show Sequence
    >gi|2828044|gb|AAB99965.1| vpu [Simian-Human immunodeficiency virus]
    MQPIQIAIVALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEISALVEMGVEM
    GHHAPWDVDDL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
1. ANXI
  • Gene Name : ANXI
  • Sequence Strain (Species/Organism) : Ovis aries
  • NCBI Gene ID : 100302599
  • Taxonomy ID : 9940
  • Gene Strand (Orientation) : ?
  • Protein Name : annexin I
  • Molecule Role : Vaximmutor
2. human IFNG
  • Gene Name : human IFNG
  • Sequence Strain (Species/Organism) : Homo sapiens
  • NCBI Gene ID : 3458
  • NCBI Protein GI : 56786138
  • Genbank Accession : AC007458
  • Protein Accession : NP_000610
  • Taxonomy ID : 9606
  • Chromosome No : 12
  • Gene Starting Position : 68548549
  • Gene Ending Position : 68553520
  • Gene Strand (Orientation) : -
  • Protein Name : interferon, gamma
  • Protein pI : 10.01
  • Protein Weight : 18454.87
  • Protein Length : 166
  • Protein Note : Also known as IFG; IFI
  • DNA Sequence : Show Sequence
    >gi|224589803:68548549-68553520 Homo sapiens chromosome 12, GRCh37.p5 Primary Assembly
    AGTTGTGAACTTACACTTTATTCATATATATTAGATATTGATAATTTTAACAAATGAGTTACTTTCCATT
    TGGGTACAGTCACAGTTGTCAACAATATTTGGAAGCACCAGGCATGAAATCTCCTGAGATGCTATGTTTT
    CATCAGGGTCACCTGACACATTCAAGTTCTGTCTGACATGCCATTAAAGCACTGGCTCAGATTGCAGGCA
    TATTTTCAAACCGGCAGTAACTGGATAGTATCACTTCACTTATAAGTGTTCATTGTATCATCAAGTGAAA
    TAAACACACAACCCATGGGATCTTGCTTAGGTTGGCTGCCTAGTTGGCCCCTGAGATAAAGCCTTGTAAT
    CACATAGCCTTGCCTAATTAGTCAGAAAACAAAGGATTAAGTGAGACAGTCACAGGATATAGGAATTATA
    AATAATACATATATTAATAGATATTCATTTTCATTACACAAAAGTTGCTATTATAAATACTTATTTGATT
    GATGAGTCTAAAAATATATTCCCCATATAAATAATGTTAAATATTAATAAATAGATTTAGATTTAAAATT
    CAAATATTGCAGGCAGGACAACCATTACTGGGATGCTCTTCGACCTCGAAACAGCATCTGACTCCTTTTT
    CGCTTCCCTGTTTTAGCTGCTGGCGACAGTTCAGCCATCACTTGGATGAGTTCATGTATTGCTTTGCGTT
    GGACATTCAAGTCAGTTACCTATCGGGAAAGAAAAGAGCAAAATTAATTTCAGGCATATAAGCCATCAGG
    ATATTCTGCTAATGTCATGATGGTCAGTGAAAATAAAAGTATTCCTTTAAAAAATGGACCGTATTACCTT
    AATATACAATATTTACTTCTTCAGCAGTTGAAGCTAAAAATTACAATTACATTTCTAGTTGTGCTATAAT
    GTGGTGGAGTCCATCACATATCTTTAAATCTACTTCTATAGAATTCTTGAAATTATATAGTGAAAAGACT
    CCTGGTTGTGGAGTCAGCATAAAAAGGTGGGTTTGAATCTCATGCATGCAATAATTCTGACCTTGAGCCA
    GCTACTTAACCTCTCTGAACTTCTATTTTCTCATCTAAAGGAGGATGAGACTGTTTCTATGACCTCTCTA
    TCATCAATCTACCAATTATATCACTTTATACTTCAGTCTTTCCTGTATGCATCAAATGAGTAACTATAGG
    TCAATGATTCTCACTGTTGTGCATAGCAGATTAATCCGGAAACCTGTCAAAGACCTCAGAGATCCAGGTG
    CATGAAGTGGAAGGACTGTGCCCTGTGCATTCACTAAGCTCCCCAGGTGATTCTGACATCCACCTAAGTT
    TGAGAACCACTGATCTAGGTTAGGTACCCTAGAAAACACCAAATCCAAAACGAGTGAAAACTGTAATTTT
    TAATTTCTCCCAGATTAGGTCAGTCTCTCAATTTCCATAATAGATTTTAAAATAAACACCCCCAATCATA
    TTTATATATGGCTTACTGATATATAAAGTTTAAAATTAAGAATTGCAACAACTTTTCCAGTACCCTGCCT
    TCTAGGCAAGCAAATTGAACTACTTGCATCTCCTCACTCTAACCAATAGGGCCATTTAGATGATGCTTCA
    TAAAATGTGGACCATTTACCTTCCTCTTGGCTCTGCCATTACATTTTTTCTAATCTTGGGAACACTATGG
    CTACTCACCACATTTCTGAGGATGGCTGGGGGATTACAGCTAAAGACTAATTGTCAAAGGGCATAACATG
    CATAAAATAGCTTAGCAACTGAGCCAAAGAGAATAATAATTAATAGAGCTCACTCAAGATTGCCCATCAA
    GAAACAGGAGGTTTGTAGCTTCCAGAAGGAAGAAACCACAGATTTTTTTTCATTTTTTTAAGGCCCAGTT
    CCTGCAGAGTAGAAAAAATTTTCGACAAGCTGTGTGTTTGCAAGTGACAGATTTTACTTTCCAATGTTCA
    AATCATCACCAAGAAACTAAGAGACTTATCCAGGACTGAACAGTAAGCCAGGGGCACCACTGGATTAGAA
    ACAAGTGCTGAGTGTCTAGTTTATAACCAAAGGAGACCTGTTGCCATGTCTCTCCTTTCTGTTTCTGGGG
    GCTTACATGAGAGGAGTGAGAGGCAGGCCCAGCAATAGTGAAAGCTGAGCACATATCCTAAGAACACAAA
    TGCTAGCTTGAAGACCCTGGTCCCTCTCATTTGAGCCCATTTATATCAAAGTCAACCCCAAAGGAATCTA
    GAGGCCTTTGTCTTCTAGAAAACATTTTGAAAAACATGATTTGTCTTTATGCCTCAACGTTATCTTTCTG
    TTTATAGAAGCCATAACTTAAAGATACAAGTTCATGAGGTAAGACTTAGGAGTCTAAGGAGTTCTCCAGC
    TGAGATATTCTGAAAGTTGATAGAGAGTTGATAGAACAATCTTTTCATAAGGTATAAATTCTATCTATTT
    TTCCCTAAAAACAAACAAACAGCAACCATTCTTGCTTCTAATTGGGCAGTACAATCTGATAGGTTGGCTA
    GAGACTTGCAGTGGGGTGTCCCTGGTACCTATTCAAAGACTGTAGCTTTCTTCTATCTCATTCTCATTTT
    CTATTCTTTGCATTGTAGAGTTTTGGAGCAAAGAAGGTCATCAAACTTATACAGTGAGCCTAACAGTTTC
    CTTTTAAGATGAGGAAACTGAGCCCCAGCCAGCCATGTGATTCATCACAGTTCCTTGGTGGCTGAGTTGG
    GAGGAGAACACACATCTTCTCAGCTCCTCCCACTGCTCTTTCCATTAAGACAGACAGCCTCTCATTCAAA
    GTAAGAGAATTTCCATCATATGAGCAAGGGACAATGAGAGAACTGCTTCTCAGTACTCCCCGCTTCTTCC
    TCACCTACTTCCTCTTCACTGGATTTGTCAACTCACCTGTCTTTACGCAATAGTTACAATGCCAGCATTT
    CTCTACATTACATACTTCAGCGATTCTCTTACTGGCTTTGCAAAGTCACCCAAACACGAATGGAAATAGT
    AAGGTAGAGTTTCAGCCATGAGTTGAGTTCATAGCTTTAGCAACTGTTAAATAGCTAATGTCTACTTTCT
    GGAGAATAAATGCTTTGCAAGACCCTCGGCAATGAAACCAAAGAAAGAATTTAAATAGCCTCACCGAATA
    ATTAGTCAGCTTTTCGAAGTCATCTCGTTTCTTTTTGTTGCTATTGAAAAACTTGACATTCATGTCTTCC
    TTGATGGTCTCCACACTCTTTTGGATGCTCTGGTCATCTTTAAAGTTTTTAAAAAGTTTGAAGTAAAAGG
    AGACAATTTGGCTCTGCATTATTTTTCTGTCACTCTCCTTGGAAGGAAAGAGCACAAACAGAGGATGATG
    TGAATTTATCCATCAGAAAGCAAGCAACAGGAAAATTAGCCAAATGGGAATATTCAGCTTACCTCTTTCC
    AATTCTTCAAAATGCCTAAGAAAAGAGTTCCATTATCCGCTACATCTGAATGACCTGCATTCTAAAAAAA
    AAAAAAGAAAAAATTGGTTTACAATTAGCCCATAAATTGCCTTAAAAATATATTTCAAGTTTCATTGAAC
    TCAGATGTGACAATATTCACTGATTTCCTTTTCAACTCTTCTGCTTAGTTCTAACAATAAGTATTCCCAA
    AAGGCTTATGTGAGATATAGACAAAGACTATTATGTTCTTTTAGCTTTTTTATTTCCCAATATAACCATT
    AAATTGCAATGTCACAAATGAGCTCAACAAAGCTGATACTCCAAAGGTCCCAAAAACTATAGTAAGCTAA
    AGAAAGTATTTTCAAGCTAGGCTAAAAAATACAAAAACAAAAAACAGCAAAGCCACCCCACTATAAAATA
    CTGCCCCCCAATGGTACAGGTTTCTATTACATCTACTGTGCCTTCCTGTAGGGTATTATTATACGAGCTT
    TAAAAGATAGTTCCAAACATGTGCGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGATTTGATTTTGTGTT
    GTAAGAATAAAATCAATTGTGAATGTCTGAATATTATTATGACAGCTATAATTATAACAGCTAAGTTTTA
    AACAAATAATGAAATATTTAAAATGTAAAAACTTTTCATTAACCATCAATAAAATTTTAAAAGAAACTCA
    AAAAATTCACTTAAAATTTTTAAACATTCCTTAGCCAGAATCATAATTCTTCCAAAATCCCAGTGAGCAA
    CGAAGTTCCGGAATACTTCACAAGTAATATAGATAGAGAAGCAGAATGTTGAAATCACTTTTTGGAGAAA
    ATCACCTATCAGTTATTTTTTTAAGCCAAAGCTTTAAGGACCTTTTTGACTTTAATTTGTAAACATTTCC
    TATTACCTTTTTAATGCTAATCTTGACCTTAGAGTCTGAGAAGTCAAAAACTAATAACCAATCATTTTTT
    TCAATCTGCATACTCCTTGACTATCACAACTGAATGAGTTCCCACCACAAAATTATTAACATCATTATGC
    TTCATACCCATATTATGCCCATCTTTTGGAAAATTCATAAATCCCTTTTAAGTCTCTATACAAACTGAGC
    AGAAGGTTAAAACAATATCTAGATTATTTAGTCAAGGAACTCATCTAGTCAATAATTAACAAAATAACAC
    CAAATCTCAAAATGACTGCCTACAAGAGATGACAGCCTATCAGAGATGCTACAGCAAGTCGATATTCAGT
    CATTTTCAACCACAAACAAGTACTATTAAAAAGTCATACTTACAAAATATTTCTTAAGGTTTTCTGCTTC
    TTTTACATATGGGTCCTGGCAGTAACAGCCAAGAGAACCCAAAACGATGCAGAGCTGAAAAGCCAAGATA
    TAACTTGTATATTTCATCGTTTCCGAGAGAATTAAGCCAAAGAAGTTGAAATCAGTAGTTCTTGTATCAA
    GCTGATCAGGTCCAAAGGACTTAACTGATCTTTCTCTTCTAATAGCTGATCTTCAGATGATCAGAACAAT
    GT
  • Protein Sequence : Show Sequence
    >gi|56786138|ref|NP_000610.2| interferon gamma precursor [Homo sapiens]
    MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQS
    QIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVM
    AELSPAAKTGKRKRSQMLFRGRRASQ
  • Molecule Role : Vaximmutor
3. IFNG
  • Gene Name : IFNG
  • Sequence Strain (Species/Organism) : Macaca mulatta
  • NCBI Gene ID : 574282
  • NCBI Protein GI : 74136365
  • Locus Tag : EGK_03901
  • Genbank Accession : CM001263
  • Protein Accession : NP_001028077
  • Taxonomy ID : 9544
  • Chromosome No : 11
  • Gene Starting Position : 65143979
  • Gene Ending Position : 65148219
  • Gene Strand (Orientation) : -
  • Protein Name : interferon-gamma
  • Protein pI : 9.92
  • Protein Weight : 18339.63
  • Protein Length : 165
  • Protein Note : Also known as IFN-gamma
  • DNA Sequence : Show Sequence
    >gi|109156580:65143979-65148219 Macaca mulatta chromosome 11, Mmul_051212, whole genome shotgun sequence
    ATTATTGGGATGCTCTTCGACCTCGAAACATCTGACTCCTTTTTCGCTTCCCTATTTTAGCTGCTGGCGA
    CAGTTCAGCCATCACTTGGATGAGTTCATGTACTGCTTTGCGTTGGACATTTGAGTCAGTTACCTATTGG
    GAAAGAAAAGAGCAAAATTAATTTCAGGCATATAAGCCATCAGGATATTCAGTTAATGGCATGATGGTCA
    GTGAAAATAAAACTATTCCTTTAAAAAAATGGACCATATTACCTTAATATACAATATTTACTTCTTCAGC
    AGTTGAGGCTAAAAATTACAATTACATTACTAGTTGTGCAATGATGTGGTGGAGTCCGTCACATATCTTT
    AAATCTACTCCCATAGAATTCTTGAAATCATATAGTGAAAAGACCCCTGGTGTGGAGTCAATGTAAAAAG
    GTGGATCTGAATCTCATGCGTGCAATAATTCTGACCTTGAGCCAGCTACTTAACCTTTTGGAACCTCTAT
    TTTCTCATCTAAAGGAAGAGAAGACTGTTTCTATGACCTCTCTATCATCAATCTACCAATTATATCACTT
    TATACTTTAGTCTCTCCTGTATGTATCAAACGAGTAACTATAGGTCAATGATTCTCACTGTTGTGCATAG
    CAGATTAACCTGGAAACCTAATAAAGACCTCAGAGATCCAGGGGCACGAATTGGAAGGACTGTGCCCTGT
    GCATTCACTAAGCTCCCCAGGTGATTCTGACATCCACCTAAGTTTGAGAACCACTGATCTAGGTTAGGTA
    CCCTAGAAAACATCAAATCCAAAACAAGTGAAAACTGTAATTTTTAATTTCTCCCAGATTAGATCAGTCT
    CTCAATTTCCATAATAGGTTTTAAAATAACCACCAATCATATTTATATATGGCTTACTGATATATAAAGT
    TTAAAATTAGGAATTGCAACAACTTTTTCAGTACCCTACCTTCTAGGCCAGCAAATTGAACTACTTGCAT
    TTCCTCACTCTAACTAATAGGGCCATTTAGGTGATTTCATTCTTCCTAAAATGTGGACCATTTACTTTCC
    TCTTGACTCTGCCATTATATTTTTTCTAATCTTGGGAACACTATGGCTACCTCGCCACATTTCTGAGGAT
    GGCTGGGGGATTACAGGCTACAGAGCTAATTATGAAAGGGCATAACATACCTCAGCTTAGCAACTGAGCC
    AAAGAGAACAATAATTAATAGAGCTCACTCAAGATTGCCCATCAAGAAACAGGAGGTTTGTAGCTTCCAG
    AAGGAAGAAACCCACAGATTTTTTTTTCACTTTTTTAAGGCCCAGTTCCTGCGGAGTAGAAAAAGTTTTC
    TACAAGCTGTGTGTTTGCAAGTGACAGATTTTACTTTCCAGTGTTCAAATCATCACCAAGAAACTAAGAG
    ACTTATCCAGGACGGAACAGTAAGCCAGGGGCACCACTGGGTTGGTGGCAAGTGCTGAGTGTCTAGTTTC
    TAACCAAAGGAGACCTGTTGCCATGTCCCTCCTTTCAGTTTCTGGGGGTTCACATGAGAGGAGTGAGAGG
    CAGGCCCGGCAATAGTGAAAGCTGAGCACAAATCCTAAGAGCACAAATGCCAGCTTGAGCTCTCATTTGA
    GCCCATTTATATCAAAGCCAATCCCAAAGGAATCTAGAGGTCTTTGTCTTCTAGATAAAATTTTGAAAAA
    CGTGTTTTGTCTTTATGCCTCAATGTTATCTTTCTGTTTATAGAAGGCATAATTTAAAGATAATTTAAAG
    ATACAAGTTCATGAGGTATGACTTAGGAGTCTAAGGAGTTCTCCAGCTGAGATATTCTGAAAGTTGATAG
    AGACTTGATAGAACAATGTTTTCATAAGCTATAAATTCTACCTATTTTTCCCTAAAAACAAACAGCAACC
    ATTCTTGCTTCTAATTAGGCAGTACAATCTGATAGGTTGGCTAGAGAATTGCAGTGGGGTGCACTGGTAC
    CTACTCAAAGGCTGTAGCTTTCTTCTATCTCATTCTCATTTTCTATTCTTGGCATTGTAGAGTTTTGGAG
    CAAAGAATGTCATCAAACTTATGCAGTGAACCTAACAGTTTCCTTTTAAGATGAGGGCACTGAGCCCCAG
    CCAGCCATGTGATTCATCACAGTTCCCTGGTGGCTGAGATGGGAGGAGAACACACATCTTCTCAGCTCCT
    CCCACTGCTCTTTCCATTAAGACAGACAGCCTCTCATTCAAAGTAAGAGAATTTCCATCATATGAGCAAA
    GGACAATGAGAGAATTGCTTCTCAGTACTCCCCACTACTTCCTCACCTACTTCCTCTTCATTGGATTTGT
    CAATTCACCTGTCTTTACACAATAGTTACAATGCCAGCACTTTTCCTACATTACATACTTCAGTGATTCC
    CATACTGGCTTTGCAAAGTCATCCAAACACAAATAGAATTAGTAAGAGTTTCAGCTACGGGTTGAGTTCA
    TAGCTTTAGCAACTGTTAAATAGCTAATGTCTACTTTCTGGAGAACAAATGCTTTGCAAGACCTTCCGCA
    ATGAAACCAAAGAAAGAATTTAAAGAGCCTTACCGAATAATTGGTCAGCTTTTCAAAGTCATCCCGTTTC
    TTTTTGTTGCTATTGAAAAACTTGACATTAATGTCTTCCTTGATGGTCTCCACACTCTTTTGGATCCTCT
    GGTCATCTTTGAAGTTTTTAAAAAGTTTGAAGTAAAAGGAGACAATTTGGCTCTGCATTATTTTTCTGTC
    ACTCTCCTTGGAAGGAAAGAACACAAACAGAGGATGATGTGTATTTATCCATCAGAAAGCAAGCAACAGG
    AAAATTAGCCAAATGGGAATATTCAGCTTACCTCTTTCCAATTCCTCAAGATGTCTAAGAAAAGAGTTCC
    ATTATCTGCTACATCTGGATCACCTGCATTCTGGGGGAAAAAAAAGGGTTTACAATTAGCCCATAAATTG
    TCTTAAAAATATATTTCAAGTTTCATTAAACTCAGATGTGACAATATTCACTGATTTCCTTTTCAATTCT
    TCTGCTTAGTTCTAACAATAAGTGTTCACAAAATGTTTATGTGAGATATAGCCAAAGACTACTATGCTCT
    TTTAGCTTTTTTATTTTCCAACATAACCATTAAATTGCAATGTCACAAAGGAGTTAAACAAAGCTGATGA
    TACTCCAAGGGTCTCAAAAACTATAGTAGGCTAAAGAAAGTATTTTCAAGCTAGGCTAAAAAATACAGAA
    CAAAAAACAGCAAAGCCACCCCACTATAAAATACTGCCCCCCAATGGCACAGGTTTCTATTACATCTACT
    ATGCCTTCCTGTAGGGTATTATGTCAACTTTAAAAGATAGTTCCAAACGTGTGCGTGCGTGTGTGTGTGT
    GTGTGTGTGTGTGGTCTGATTTTGTGTTGTAGGAATAAAATTAATTGTGAATGTCTGAATATTAGTATGA
    CAGCTATAATTATAACTAAGTTTTAAATAAATAATGAAATATTTAAAATGTAAAAACTTTTCATTAACCA
    TCAATAAAATTTTAAAAGAAACTCAAAAAACTCACTTAAAATTTTTAAACATTCCATAGCCAGAATCATA
    ATTCCTACAAAATCCCAGTGAGCAACTAAGTTCAGGAGTAATTCACAAGGAATATAGATAGAGCAGCAGA
    ATGTTGAAATAACTTTTTGGAGAAAATCACCTATCAGTGATTTTTTTTAAGCCAAAACTTTAAGGACCTT
    TTTTACTTTAATTTGTAAACGTTTCCTATTAACTTTTGAATGCTAATCTTGACCTTAGAGTCTGAGAAGT
    CAAAAACTAATAGCCAATCATTTTTTTCAATATGCATACTCCTTGACTTATCACATCTGAATGAGTTCTC
    ACCACAAAATTATTAACATCATTATGCTTCATATCCATATTATGCCCATCTTTGGGAAGATTCATAAATC
    CCTTTTAAGTCTCTATACAAACTGAGCAGAAGGTTAAAACAATATCTAGATTATGTAGTCAAGAAACTCA
    TCCAGTCAATAATTAACAAAATAAAACCAGATCTCAAAATGACTGCGTACGAGAGGACAGTCTATCAGAG
    ATGCTACAGCAAGTCAATATTCAGACATTTTCAACCACAAAAAAGTACTATTAAAAAGCCATACTTACAA
    AATATTTCTTAAGGTTTTCTGCTTCTTTTACATATGGGTCCTGGCAGTAACAGCCAAGAGAACCCAAAAC
    AATGCAGAGCTGAAAAGCCAAGATATAACTTGTGTATTTCA
  • Protein Sequence : Show Sequence
    >gi|74136365|ref|NP_001028077.1| interferon gamma precursor [Macaca mulatta]
    MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGDPDVADNGTLFLDILRNWKEESDRKIMQS
    QIVSFYFKLFKNFKDDQRIQKSVETIKEDINVKFFNSNKKKRDDFEKLTNYSVTDSNVQRKAVHELIQVM
    AELSPAAKIGKRKRSQMFRGRRASQ
  • Molecule Role : Vaximmutor
  • Related Vaccine(s): DNA and poxvirus priming-boosting SHIV vaccine , HIV DNA and adenoviral vector Ad5 expressing SIV gag protein
4. Ifng (Interferon gamma)
  • Gene Name : Ifng (Interferon gamma)
  • Sequence Strain (Species/Organism) : Mouse
  • NCBI Gene ID : 15978
  • NCBI Protein GI : 33468859
  • Genbank Accession : NM_008337
  • Protein Accession : NP_032363.1
  • Other Database IDs : MGI:107656; UniProt: P01580
  • Taxonomy ID : 10090
  • Gene Strand (Orientation) : ?
  • DNA Sequence : Show Sequence
    >gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA
    ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA
    GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA
    GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT
    AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC
    AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT
    GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC
    AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC
    GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA
    AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG
    AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC
    AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT
    TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC
    TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT
    ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG
    GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC
    AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC
    TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA
    AGTATACCTTTGCAACC
  • Protein Sequence : Show Sequence
    >gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus]
    MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI
    ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ
    LLPESSLRKRKRSRC
  • Molecule Role Annotation : IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria.
  • Additional Molecule Role : Vaximmutor
  • Additional Molecule Role Annotation : The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes (Wang et al., 2009).
  • Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes , HIV DNA vaccine VlJns-tPA-gp120 , HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein
5. IFNG from Macaca nemestrina
6. IgA
  • Gene Name : IgA
7. IgA Fc fragment
  • Gene Name : IgA Fc fragment
  • Sequence Strain (Species/Organism) : Macaca mulatta
  • NCBI Gene ID : 664734
  • NCBI Protein GI : 90265825
  • Protein Accession : NP_001035039
  • Taxonomy ID : 9544
  • Chromosome No : 19
  • Gene Starting Position : 60887587
  • Gene Ending Position : 60904465
  • Gene Strand (Orientation) : +
  • Protein Name : Fc fragment of IgA, receptor for
  • Protein pI : 7.75
  • Protein Weight : 30407.11
  • Protein Length : 287
  • Protein Note : Also known as CD89
  • DNA Sequence : Show Sequence
    >gi|109156886:60887587-60904465 Macaca mulatta chromosome 19, Mmul_051212, whole genome shotgun sequence
    GATGGACCCCAAAGAGACCACCCTCCTGTGTCTCGGTGAGTTTCAGAGTAAAAGTGGGTTAGAGGGGAAA
    ACAGGGAAATCCCAAAATAATCCGGGTGTCTCTTGACAGTATGACTAGGAGATTTTAGTGGCTGCCAAGG
    AGATTCTGACCTCCTTAGTGGAAAGGCAGTCTTTATCAATATGTCTATAACTTTGTCTCTGCCCAAGTCC
    AACCTAGCTTGTGGGACTCAAGGGTTAATATTTTTATTAAACCTATAGTGTGTTATCTGGGATTAATGAT
    GGTTCCAAGGTTCCCATCAAAGACAGACTTAGGGGCTGGAATCTGAAAGGTAAAAATAAAGAATGAGCCT
    CAAAACTGTGATTGTTGTGGAATGAAAAAATATGATTGAACCCCATATAGAAATATGGTTACTAGTATTT
    TGTTGAAGATTTTTGCATTTATGTTCAACAAAGACGTTATCCCGAAGTTTTCTGGTTTTGTTGCGTCTCT
    GCCACGTTTTGTTATCAGGATGATGCTGGCCTCATAGAATGAGTTGGGGAGGAGTCCCTCCTCCTGGATT
    TTTTCAATAGTTTCAGTAGGAATAATACTAGTTCTTCTTGGCCAGGTGCAGTGGCTCACGCCTATAATCC
    CAGCACTTTGGGAGGCCAAGGCAGGTGGAACACACGGTCAGGAGATCACATCCTGCCTAACACAGTGAAA
    CCCCGTCTACTAAAAATACAAAAAAATTAGCCAGATGTGGTGGCGGGCACCTGTAGTCCCAGCTACTCGG
    GAGGCTGAGGCAGGAGAATGGCATGAACCTGGGAGGCAGAGCTTGCAGTGAGCTGAGATCGCACCACTGC
    ACTTCAGCCTGGGCGACAGAGCGAGACTCTGTCTCAAAAAAAAAAAAATACTAGCTCTTCTTTATATATC
    TAGTGGGACTGAGCTGTGTCTCCATCTGGTACTGGTCTTTTCCTGGTCTATCATTACAGAGGGTGATTTG
    TCATAAAGATTGGAAATGGAAGCTTGATTTTTCATAAATCTCTCTCTTCCAGTGCTCTGTCTGGGCCAGA
    GGATTCAGGCACAGGAAGGTAAGTGTCCTGTAAATCTCTCCCAGCCCCTTTAGACTCTCTTGGAAGCTCA
    GGATAAAGAAATTGAGGAATAGCCTGAAGTACAGATTCTTATTTTAGTCCCCATTCCAGTTGTTTCTGCT
    GTGCTTCTCTTGCATAATTTCTATCACACTTTGTTATAGCCAAATCCTTCAGACTCATTAATGCTCAGAC
    CTGGATTTATAGTTAGTCCTTGCCTGTGTTAGACTGCCCATGAAGGATCTGTAATCTACTGAATGCTCAA
    AACTGCAAGAATGAGGAAATCAGGAGTCATTTGCCCAACATCCTTCCTTATGCTTTGTTTTAGCAACCTA
    CTTCCTCCTGTCACTTCATTTAAAGGGATACTGCCATAGTCTAATCCTACTGAACATTCTACTATTCTAT
    AGTACTACTGCAGTACTAAGCATGCAGTAGTCTTAAGAGTACTACTGAATATTCTGCCACCCCAACTACT
    ACTGCCTTAGCCTCCTAATGGGTGTAAGCCCCATGTCCATCCATGTCTGCTCTCTTCCAGCTCCTTCTAT
    AGCCTGAATTATTTGTGTGTTGAACAATATTCATTCTTCCTATCCATGAGCATGGAATGTTTTTCCATCT
    GTTTGTGTCATCTATGATTTCTTTGAGCAGCGTTTTGTAGTTCTCCTTGCAGATATCTTCCACCTCCCTG
    GTTAGCTGTATTCCTAGGTATTTTATTCTTTTTGTGGTAATTGTGAATGGATTCTGTTCTTGATTTGGCT
    CTTAGCTGAGACGTTTTTGGTGCATAGGAATGCTACTGATTTTTGTATATTGATTTTGTGTCCTGGAACT
    TTGTCAGAGTCGTTTATCAGATTAAGAAGTGTTTGGGCAGAGATTGTGGTTTTCTAGGTATAGAATCACA
    TCATCTGCAAACAGGGATGGTTTGACTTCCTTTCTTCCTATTTGGATGCCTTTCATTTCTTTCTCGCCTG
    ATTGCTTTGGCTAGGACTTCCAGTACTATGTTGAATAGAAGTAGTGACAGAGGGTATCCATGTCTTGTGT
    CAGTTTTCAAGGGGAATACTCCCAGCTTTTGCCCATTCAATATTATGTAGGCTGTGAGTTTGTCATAGAT
    CTTCCTTATTATTTTGAAGTACGTTTCTTCAATGCCTAGTTTGTCGAGGTTTTTTAGCATAAAGGGATGT
    TGGATTTTATCAAAAGCTCTATTGAGATGATTATATGTGTGTGGCCGGGGGATTGTTCTATGAATCACAT
    TTAAGATTTGTGTATATTGAATCAACCTTGCATCCCAGAAATAAAGCCTACCTCATGGTGGTGGACTGGC
    TTTCTGATGTGCTGCTGGATTGTTTGCTAGTATTTTCTTGAGGATTTTTGCATTTATGTTCAACAAGGAT
    ATTGTCCTGAAGTTTTCTGGTTTTGTTGTGTCTCTGCCATGTTTTTGCATCTATGCGGGTCTCATAGAAT
    GACTTGGGGAGGCATTCCTCTTCCTGAATTTTCTGGAAAGCTTCAGTAGATATAGTACCAGCTCTTCTCT
    ATGTATCTGATGGGATTCAGCAGTGAGTTTGTCTGGTACTGGCCTTTTTCTTCTTTTGAAGAGGCCTTTT
    TATTACTGATTCAATTTTGGAGTTCATTATTGGTCTGGTTCATGGAATCAGTTTGTTCTTGGTTCAATCT
    CAGAAGGATGTATGTGTCCAGGAATCTCTCCATTTATTCTGGATTTTCTAGTTTGTGTGCACAGAGGTGT
    TCCTAATATTCTCTGATGATTGTATTTCTGTGGGGTCAGTGGTAATATCCCCTTTGTTGTTTCTAATTGT
    GTTTATCTGGATCATCTCTCTTTTCTTCTTAATTAGTCTAACTAGTCACCTGTCTTACTAATTTTTTTCA
    AAAATCCAACTCCTGGATTTGCTGATCTTCTGAATGGTTTTTTGCATCTCAATCTCCTTCTGTTCAGCTC
    TGGTTTTGGTTATTTCTCGTTTTCTACGAGCTTTGGGGTTGATTTCCTCTTGGTTCTCTCAGTTCCTCTC
    GTTGTGATGTTAGGTTGTTAATTTGAACTTTTTCTAACTTTTTGACGTGGGAGTTTAGTACTATAAACTT
    CCCCCTTAACACTGCCTTAGTTGTGTCCCAGAGATTCTGCTGTATTTACCCACAAATTCCAGAACAGACT
    GTTTAATTTCCATGCATTGTACAGTTTTGAGTGGTTTTCTTAGTATCTATTCCTATTTTTATTCCACTGT
    GCTCTGAGAATGTGCCTGGTATGATTTCACTATTCTGGATTTGTTAAGGATTGTTGTATGTCTGATTGCA
    TGATTGACTTTAGAGTATGTGCCACGGGGCAATGAAAACAATGTAGATTCTGTTGTTTTGGGGGTGGAGA
    GTTCTGTAGATGTCCATCAGGTCCCTTTGGTCCAGTGCTGAGTTCAGGTCCTGAATATCTTTGTTTGCCT
    CAGTGATCTAACACTGTTGACGAGATGTTAAAGTCCCCCCCTATTATTGTGTGGTTGTCTAAGTCTCTTT
    GTTGGTCTCTCAGAACACGCTTTATGAATCTGGGTGCTTCTGTGTTAGATGCATGATATTTAGGATAGTT
    AGGTCTTCATGTTCTGTCTTTATTTTTTTCTTTTTCTTTTCCTTTTTTTTTTTTTTTTTTTTTTTTTTTT
    TGAGATGGAGTCTCACTCTGTTGCCCAGGCTAGAGTGCAGTGGTGCAATCTCGGCTCACTGCAAGCTTCA
    CCTCCCGGGTTCACGCCATTCTCCTGCTTCAGCCTCCCGAGTAGCAGGGACTACAGGTGCCTGCCACCAC
    GCCCGGCTAGTTTTCCAACATGGAAAACTATGTTTTCCATATTGCTTGCTTTCTCCCCATCTCTTTCGGG
    GACCCCAATGGGTTGCCTATTTGGTCTCTTTACATAATCCCATGTTTCTTAGAGGTTTCAAATTTCATTC
    ATTCTTTTGTATTCTTTTGTCTTCATTTTTGTCTGACTGAATTAGTTCAGAGAGCCAGTATTCATGCTCT
    GAGATTCCTTCCTCGTTTTGCTTTATTCTGCCGTTAATACTTGTGATTGCATTATGAAATCTTGCAGTGT
    GTTTTTCAGCTCTATCAGATCCGTTCGGTTCTTTCAAAATGACCGTTTCTTAGATTAGCCCCTGTGTCAT
    TTTATCGTAATCTTTCGATTCCTCGCATTGGGTTTCAACTTTCTCCTGAATTTGATGACCTTGATTTCTA
    CTCATATTCTGAATTCTATTTCTGTCATTTCAGCCACTTCCTCCTGGTAAAGAGCCCTTGCTGGGAAGCT
    CATGTGGGAATTTGGAGGAAGGAAGACACTTGCTTTTTGAGTCTTGTGCTAATTCTTTCTCATCCGTGTG
    GGCTAATGTTCTTTTAAGTGTGGTGCAATTGGAGTGTTTTTCTTTTTTCTTTTAACTGTGGTGTAATTTG
    AGTACAGTCAGTAGACTTCTTTTCTGGGTGGTTTCAGAGGGCTGGGGCTTCGCACAGGGTCTTTACTGAT
    AGCTAAATTCTTGTCCTTGGTATAACGGGGGGTATATTAGCAAGCATTTTTGGTGTTGAAGTTTGGGCTG
    CAATCCAGTAAGTGATGCTTAAGCATAATGGCCAGTAGGTCATTCCTCATGACGGCCGCTGTGCTCCCTC
    TCATGCTCTGAATGTGTGGGCTCCTCTCCCACTCAAGCACTGGCTGCAGATCTGGGCTCCGCACTCCCAG
    GCTGCCCATCACAGCGCTGGGGTGAGCTCAGGTTTTATGTTCCCTCCGTGGCTTGGGGGCAGCAGGGGAA
    GGGACCTCAGCAGTGGCTGTGGCAGATGGCCTTTCACTTGTCCCTTGGGACTCCACCCCAGAGAGATGTG
    GAACCACTATCAGTAGTGTGATGAGCCAAGAGTGGGGCGACTGCGCTGTGGGCCCAAGCTAGGGGCCCTG
    CCTAGTGATGAGCAGCGGGGACAGGTGGGTCACAGGGGTGACAGACTGGCCTCTTCTCCTTAGGGCAGCT
    TGCGGGAGGTGTGGTTAAGGCACTCAGAGTCTTTGCTCCTTCCCCAGTCTGAGGGCAGCAAGGCCAGGAC
    CACCGCAGTGGCAGCCGCAGAGGGGCTGTGAGTTGCCTCTGGGAGCTCCGCCACAGAGAAATGCAGACCC
    ACAGCTCCCAGGCACGCTCCGCAGAGGGTGGGGCTGCTGTGCTGCGGGCTCAGGCTGGGGTTTGGTGAAG
    AGCAGGGGGCTGAGGGCTCGCAGGGAGAGGAGACTGAGCTCCTCTCTTACGGTGACTGTGGTGTGCTAGA
    GGCATGAATGAAGGCTGGGGCTCGGCGGCTCACACCTGTCATCCCAGCACTTTGGGAGGCCGAGGCGGGC
    GGATCACGAGGTCAGGAGATCGAGGCCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACA
    AAAAACTAAGCCGGGCGTGGTGGCAGGTGCTTGTAGTCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCTACAAA
    TGCTCAGTAAAAAAAATACTAATAATAAAATAAAATAAAATAAAGCATGAATGAAGCTCCTAGGCTCCTT
    GTTCTTCCTCAGACCACAGGCAGCAGGGGCAGAATCCTTGCCATGGCGGTGGCAGAGGGGCCGTCAGTTG
    CCTCTGGGAGCCATTCCCCAGGGAAACACGGAGCCACCACCAGTGAGGATGCTGAGGGTAGGGCAGCTGC
    TCTGCAGTCCCAAGCTGGGGGCTCTGCCTGGTAAAGTGGGGGTGGGGGCTCACGGGGAAGAGAGACTAGA
    CTCCTCTCTGTCTGATGGCTGTGGCATAATGACCAGTCCCCAACACGTGAAAAAGAATTGTGGGAACTCA
    GAAACCCAGTTTGTCCCCACCATGGACTCCTTGCACTGCGTTTCAAATTTCTCCTCAATCTCCATGAGCT
    TCCCAGCCATCCAGATTCTGAATTCTATGTCCCTCGTTTCATTCATCTCAATCTAGCTAAGAACCAGATT
    TCCAGGGGACTATCGAGTTGCCAGAGTTCTTGTGTTCCTTTTATTTTTTCCTTTTGTGTGACAAGAGTCT
    TACTCTGTTACCCAGGCTGGGGTGCGGTGGCGTGATCTCAGCTCACGGCTGCAACTTTCACCTCCCAGGT
    TCAAGCTATTCTCCTGTCTCAGCCTCCCAAGTAGCTGGGATTACAGCTGCGTGCCACCACACACAGCTAA
    TTTTTGTATGTTTAGTAGAACCCAGGTTTTGTCAGGTTGGTCAGGCTGGTCTTGAACTCTTGACCTCCGG
    TGATCCGCCCGCCTGGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACCGTGCCCGGCCTTGGTGT
    CGATTCTTTCTCTTGTGTGAGGGCTGGTGTTCCTTTAACTGTGATGTCAGTTGAATACAGTCACTTAGCT
    TCATTTCTGGGTGTTTTCAGATGCCAGGACTCTGCACGGAATCTTTATTTGTGGCTGGATTTTTCACTTC
    GTTGTCTACTGGCAAAATATTTCAGTCTTGTATTTTGACGTGTGATCCAGTAGGTGGCACTTAAAAGGGG
    CTGGCCAGCATACAGGATCTTAGCCACAAGGCTGTTTTGTAGTTTTGTTTCGTTTTTTGTTTTGTTTTTT
    GACACAGGGTCTTGCTCTGTCACCCAGGCTGGAGCGCAGTGGCACAGTCTCGGCTCACTGCAGCCTCCAT
    CTATCAGGCTAAGTGATCCTCCTGCCTCAGCCTCCTAAGTAGCTGGGACTACAAGCACATACCACCATAC
    CAAGAAAATGTTTGTAATTTTTTTTTTTTTTTTTTTTTAGAGATGGGGTTTCACCATGTCTGCCAGGCTG
    GTCTCAAACTCCTGGGTTTAAGTGATCTGCCTCCCTTGGCCCCCCAACTCTTGTATTTTGACAAAGTTAG
    CAGTAGTGCTCTGTGGTTGTGGGGAGGGGTGACTTCCTCACCTGGTCCATTCCTGGGCCTTGGAGGAGCC
    TCCTACAATCACTAGCTCTGCACCCACCGTTTCCTTTGTTAGGATTGTTCTGCCCACGGGGTTCCTTCAG
    GCAGTGCATGGTGGGAAGACAGGCTGTATCCTTCCCCAGCCAGCCTACGGAGGGAGGACCACCCCACTCC
    TCTGCAGACTGATGAAATCACGTGTTTCATTCTTCTGAGTGTTCTGAGAATGAGGGCTCCTCACCGCTCA
    GTCGCCACCCAAGCTGGTGAGTCCTTCTCAGCAAGGGCGGTTGGAACCACCTGATCTGCCATCTCAGTGC
    TTCCCAGGGGAACCCAGAGCTGCTGGGGCATGGCAGCTCATGCCTGTAATCTCAGTACTTTGGGAGGCCA
    AGGCGGGCAGATCACGAAGTCAGGAGATCGAGACCATCCTGGATAACATGGTGGAACCACATTTCTACTA
    AAAATACAAAAATTATCCAGGCATGTGGCGGGCACCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGA
    GAATTGCTTGAACCCGGGAGGCGGAGTTTGCAGTGGGTCGAGATTGCGCCACTGCACTGCAGCCTGGGCG
    ACAGAGCGAGACTCTGTCTCGAAAAATAATAACAAAAAAAAATAAAGATGGCAACCACAGACACTGGAGA
    CGACTAGACGGGGAGGAAGAGAGGGGCTTGAAAAACTAACTGCCTACTGGGTACTACGCTCAGCACCTGG
    GTGACAGGATCCACCGTACCCCAAACCTCAGCATCATAAATTATTTACATGTTTATTTTTATTTATTTAT
    TTATTTTAATTGAGACAGAGTCTCACTCTGTGGCCCAGGCTGGAGTGCCATGGCGGGATCTCAGCTCACT
    GCAAGCTCCGCCTCCTGGGTTCACGCCACTCTCCTGACTCATCCTCCCAAGTAGCTGGGACTACAGTCGC
    CCACCCCCACGCCTGGCTAATTTTTTGTATTTTTAGTAGAGACGAGGTTTCACCATGTTAGCCAAGATGG
    TCTCGATCTCCTGACCTCGTGTTCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCA
    CCACACCTGGCCTAAATTTTTCTTTAAATAAAGAATGACAGGTTCTTCATACCCTAATTTTCTTCCAGGG
    AACTTTTCCACGCCTTTCATATCTACCAGGTCAAGTCCTGTGGTTCCCTGGGGTGGGTCTGTGAGAATCC
    AGTGCCAGGCCATTCCTGACGCTTACCTGATCTGGCTGATGATGCTAAAAAACTCCACGTACGAGAAGAG
    AGACGAAAAACTGGGGTTTTGGAATGATACTACGCCTGAGTTCGTCATTGACCACATGGACGCGAACAAA
    GCAGGGCGCTATCAGTGCCGATATAGGATAGGGTTCTCCAGGTTCCGGTACAGTGACACCCTGGAGCTAG
    TGGTGACAGGTAAGGAAACATCCAGGGTCCACAGCCCTGGTGTGATTTTTTTTCTTATTTTTAATAGAGT
    ATTTTTCGATAAGTTTTAGATTTACAGAAAAAAGAAAAATTGAGATGACTGCTTCACAGAGTTCTCAGCT
    ATCTGGCCACTTCCCCCAGAGTTAACATCTGACATTACTATGGCACATTTCTTTTTTTTTTTTTTTTTTA
    ATTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCACTCTGTCGCCCAGGCTGGAGTGCAGTGGCCGGATCT
    CAGCTCACTGCAAGCTCCGCCTCCCGGGTTTACACCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGAC
    TACAGGTGCCCGCCACCTCGCCTGGCTAGTTTTTTGTATTTTTTAGTAGAGACGGGGTTTCACCGTGTTA
    GCCAGGATGGTCTCGATCTCCTGACCTCGTGATCCGCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAG
    GCGTGAGCCACCGCGCCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCACACACAC
    ACACACACACACACAGAGGTTACACACACACACACACACACACAGAGGTTACACACACACACACACACAG
    AGGTTACACACACACACAAACACACACACACAGAGGTTACACACACACACACACACACACAGAGGTTACA
    CACACACACACACACACACAGAGGTTACACACACACACACACACACAGAGGTTACACACACACACAAACA
    CACACAGAGGTTACACACACACACACACACAGAGGTTACACACACACACACACACAGAGGTTACACAAAC
    ACACACACACACAGAGGTTACACACACACACACACAAACACACACACACACACACACACACACACAGGTT
    TCACTTTGCATTCAGGTGTCATGTATCTTTAGCTTTCTCCCGGCTCTCACAGCTTCTCCGATGTTGCTGG
    TTTTCCATGGCCTTGTCAGTTTTGAGAGTAGAAGTCCATCACTTTCATTGGCCGGGCGCGGTGGCTCAAG
    CCTGTAATCCCAGCACTTTGGGAGGCCGAGACGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGG
    CTAACACGGTGAAACCCCGTCTCTACTAAAAAATACAAAAAAACTAGCCGGGCGAGGTGGCGGGCGCCTG
    TAGTCCCAGCTACTCGGGAGTCTGAGGCAGGAGAATGGCGGGAACCCCGGAGGCGGAGCTTGCAGTGAGC
    TGAGATCCGGCCACTACACTCCAGCCTGGGCGGCAGAGCCAGACTCCGTCTCAAAAAAAAAAAAAAAAGT
    CCATCACTTTCAAGGGTACTCCCACTATTGGAAATTGTCCGATGTGTTGCTCATGACTAGACTGAGTTAT
    GGGTTGTTGAAGACCACAGAAGCAAAGTGCCGTTTCATCTCCTCATAGCAAAGGTTTAAACTGTCCATGG
    GAATATGACTGTTGATGCTGAACTGGCTGTTGTTGAAAGCCTGGCTGAAGTAGTGACTGTGACCAGGCAC
    CGAGGCTCACGCCTGTAATCCCAGCGCTTTGAGAGGCCGGGCGCAGTGGCTCACGCCTGTAATCCCAGCA
    CTTTGGGAGGCCGGGCGCAGTAATCCCAGCGCTTTGAGAGGCCAAGACAGGCGGATCACTTAAGCCCAGG
    AGACCAGCCGAGGCAACATAGTAAGACCCCATCTGTACAAAAAAAACAAAAAATTAGCTGGGCATGGTGG
    CACCCACCTGTAGTCTCAGCTACTTGAGAGGCTGAGATGGTAGGATCACTTGAGCCTGGGAGGTCGAGGC
    TGCAGTGAGCCGCGATTATGCCACTGCCCTCAGCCTGGGCGACGGAGTGAGACCCTCTCTAAAATAAATA
    AATAAATAAAATTTTAAAAAGAAAAAAGAGGCTGGGCACTGTGGTTCACGCCTGTAATCCCAGCACTTTG
    GGAGGCTGAGGCGGGTGGATCACCTGAGGTCAGAGATTCAAGACCAGCCTGACCAACATGGTGAAACCTC
    GTCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGGAGGTGCCTGTAATCCCAGCTACTCAGGAGG
    CTGAGGCAGGAGAATCACTTGAACCTCGGAGGTGGAGGTTGTGGTGAGCCAAGATTGTGCCACTGCACTG
    CAGCCTCGGTGACAGATCGAGACTCCATCTCAAAACACAATAATAGGCCGGGTGCGGTGGCTCACGCCTG
    TAATCCCAGCACTTTGGGAGGCCAAGATGGGCAGATCACTTGAGGTCAGGAGTTCGAGACCAGCCTGACC
    AACATGGAGAAACCCCATCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGTGCACACCTGTAATC
    CCAGCTTCTCAGGAGGCTGAGGCAGGAGAATCACTTGAACCCAGGAGGCAGAGGTTGTAGTGAGCCGAGA
    TCACACAATTGCTCTCCAGCTTGGGCAACAAGAGCAAAGCTCCGTCTCAAAAAATATATATAATAATAGC
    AATAATCAGAAGAAGAAAAAAATAAAGGAGAAAAGGTCTTGCTAACAGCTCACTCTTCTCTCTCTTAGGC
    TTGTATGGCAAACCTTCCCTCTCTGTGGATCGGGGTCCAGTGTTGATGCCGGGAGAGAATATTTCCGTCA
    CGTGCAGCTCAGCACACATCCCATTTGATAGATTTTCACTGGCCAAGGAGGGAGAACTTTCTCTGCCACA
    GCACCAAAGTGGGGAACACCCGGCCAACTTCTCTCTGGGTCCTGTGGACCTCAATGTCTCAGGGAGCTAC
    AGGTGCTACGGCTGGTACAACAGGAGCCCCTACCTGTGGTCCTTCCCCAGTAATGCCCTGGAGCTTGTGG
    TCACAGGTAGGTACCTCCCCATCCAGCCCTGTGTCCGGGTTGGCTGTCCAGGCCCTTGTCACTGGGCAGG
    AATATGAATATGAAGAGGTGCACTGAGAATAATGTGAAGAGAGGCAAAGACTCACCCACTCCAGGACAGT
    GGAGAAAGAAAGTCTTCCCATCACACTTTCCACCTTCACTTCCTCGCTAGAGTTCTCCAGACAGTGTTCA
    TTGAAAACTTGTGGTCTATGGAGAAAAGAAGGACTGACTCATTTTATTTTATTTTATTTTCTGTGATGGA
    GTCTTGTTCTGTCGCCAAGGCTGGAGTGCAGTGGCGCGATCTCGGCTCACTGCAAGCTTCGCCTCCCGGG
    TTCAAGCAGTTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACCATGCAGAGTTTCACCATGTTGTTCAGG
    CTGGTCTCGATCTCATGACCTTGTGATCCACCCACCTCAGCTTCCCAAAGTGCTGGAATTACAGGCGTGA
    GCCACCGTGCCCAGTCAAAAAAGGCTAACTTAGAGTCACAGGTTTATGGGCTATGTTGAGACAGTAGATA
    CCAGGCTCAACCTTGTCTACCACACCTCTCCTTTCCAGTTGCAGCTGGAAATCCTCGAACTCACCAACCG
    TACTGGAATTTACCATGAGTAATCAAATGGTCATTCATGGTGACCATTTAGTGACCAAATAGTGAGTGAG
    GGGTCAAATAGTGACATATTTGGTGACCAAATAGTGAGTGAGAGGTCATAGGAAAGACTTTTAAAACCTC
    TATCATGAGCCCCATTTTTATTTTATTCATTTATTTATTTTGAGACAGAATCTCGTTCTGTCGCCCAGGC
    TGGAGTGCAGTGGCACAATCTCTGTTCACACTGCAACCTCCACCTCCCAGGTTGAAGCAATTCTCGTGCG
    TCGGCCTCCTAAGTAACTGGGACCACAGGCGTGCACCACCGCACCAGGCTACTTTTTGTATTTTTAGTAG
    AGATGGGGTTTTGCCATGTCGCCCAGGCTAGTCTCAAACTCCTGGCCTCAAGTGATCTGTCTGCCTCAGC
    CTCACAACGTGCTGGGATTACAGGCGTGAGCCACCACGCCTGGTGGTGAAGACTCTAAAGGCTCTTCTCA
    GACCAGCCTTTGTCCTGAGGGTCACATGCCCGTGTCCAGTTACCTCTCCAGCATCTTTTCAGGAGTTCCA
    CGGACTCGCCCCTTCATTATCCAGGGTTGAGCTACAGATATTCTGATTAGGATTCCACCTAGTTCTGGTG
    GTGGTGTAGAGATATGATTAGATATTTAGTGAAATCACCAAGTGAGGAGAGAATGAAAAGAAAACACAAC
    TTGCCTGGCCGGGTGTGGTGGCGTGAGCCTGTGGTCCCAGCTACGCAGGAGGCTGAGGCAGGAGAATCGC
    TTGAACCCAGGAGGCGTTGGTTGCACTGAGCCAAGATTGCGCCATTGCACTCCAGCCTGGGTGACAGAAT
    GAGACTCCATCTCAAGAAAAAAAAAAAAAAACATGGCTGGGCACGGTGGCTCACGCCTGTAATCCCAGCA
    CATTGGGAGGCTGAGACGGGCGGATCACTTGAGGTCGGGAGTTCGAGACCAGCCTGGCCAACATGGTGAA
    ACCCCATCTCTACTAAAAATACAAAAATTAGCCAGGCATGGTGGCGGGCGCCTGTAATCCCAGCTACTTG
    GGAGGCTGAGGCAGGAGAATCGTTTGACCAAGGAGGTGGAGGTAGTAGTGAGCCGAGATCGCGCCACTGC
    ACTCCAGCCTGGGCGACAGAACAAGACTCCGTCTCCAAAAAAAAAAAAAAAACAACCTGCCCGTAATCAC
    TCCCTTCCCAGTTTATGGAACTTCCCTGCCTGTGGACACAGTCCTGCTGACTGATCAATGTGGTGCTTGC
    AAAGTGTGAGCCCATCGAGGAGATGCCTGAGGGAGTCACATTTTGGCAAGCGAATAGGGAAATGGGCTCC
    CGTTTCAGGGCTCTGGGGTTGGGATGGAATGGAACACACCCGCCAACCATTCATCTCCCCGAATTGTGTC
    TCCAGACTCCATAAACCGAGATTACACGACGCAGAACTTGATCCGCATGGCCATGGCAGGACTGGTCCTC
    GTGGCTCTCTTGGCCATACTGGTTGAAAATTGGCACAGCCATAAGGCGCTGAACAAGGAAGCCTCGGCAG
    ATGTGGCTGAACCGAGCTGGAGCCACCAGATGTGTCAGCCAGGATGGACCTTTGCACGAACACCAAGTGT
    CTGCAAGTA
  • Protein Sequence : Show Sequence
    >gi|90265825|ref|NP_001035039.1| immunoglobulin alpha Fc receptor precursor [Macaca mulatta]
    MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLIWLMMLKNSTYEK
    RDEKLGFWNDTTPEFVIDHMDANKAGRYRCRYRIGFSRFRYSDTLELVVTGLYGKPSLSVDRGPVLMPGE
    NISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSLGPVDLNVSGSYRCYGWYNRSPYLWSFPSNA
    LELVVTDSINRDYTTQNLIRMAMAGLVLVALLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFA
    RTPSVCK
  • Molecule Role : Vaximmutor
  • Related Vaccine(s): HIV-1 gp120 with mCT E112K
8. IgG
  • Gene Name : IgG
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 16059
  • Genbank Accession : AF010213
  • Taxonomy ID : 10090
  • Chromosome No : 12
  • Gene Starting Position : 881411
  • Gene Ending Position : 914690
  • Gene Strand (Orientation) : +
  • Protein Name : immunoglobulin heavy chain (V7183 family)
  • Protein Note : Also known as IgG; IgH; VI24H; VH7183; B9-scFv; IgVH1(VSG)
  • DNA Sequence : Show Sequence
    >gi|94393741:881411-914690 Mus musculus strain 129/SvJ chromosome 12 unlocalized genomic contig, MGSCv37 alternate locus group 129/SvJ
    CATGGACTTTGGGCTCAGCTGTGTTTTCCTTGTCCTCATTTTAAGAGGTAATTTGTAGAAATAAGATCCT
    GCCAGTATTGTGTACAGGAGAAATAGAAAAATTTTTCTTTCCTCTATTTTGTTTTGTTTTGTTAGTGACA
    GTTTACAAATAAGCATTCTCTGTTGTGAGGTGCCCAGTGTGAGGTGAAGATGGTGGAGTCTGTGGGAGGC
    TTAGTGCAGCCTGTAGGGTCATTGAAACCCTCCTGTGCAGCCTCTGGATTCATTCTCACTGACTACTGAA
    TGACCTGGATCCTTCAGGCTTCAAAGAAAAGGATGGAGAGGGTGACAATAAAATTTTTCCCACTCACACC
    CACTTGCTGGCCCTGGCGTTCCCCTGTAATGAGGCACATAAAGTTTGCAAAACCAAGGGGCCTCTCTTCT
    CAATGATGGCTGACTAGGACATCTTCTGATACATATGCAGCTAGAGACATGAGCTCCCGGGATACTGGTT
    ACTTCATATTGTTGTTCCCCCACAACAGTTGCAGACCCTTTTATTTCTGTGGGTACTTTCACTAGCTCCT
    CCATTGGGGGCCCTGTGTTCCATCCAATAGCTGACTGTGAGCATCCACTTCTGTAGTTGCTAGGCCCCGG
    CATAGCCTCACAAGAGACAGCTATATCAGGGTCCTTTCAGCAAAATCTTGCTGGTGTATGCAATGGTGTC
    AGAGTTTGGAGTCTGATTATGGGATGGATCCCCAGGTATGGCAAACTCTAGATGGTCCATCCTTTCCCAA
    CAATAATTTTTAATGGTGGAGATAGCACCTACTATCCAGACACAATGAAGGGCCAATTCACTATCTCTAG
    AGATGATGCCAAAAACACACTTTACCTGAAAATAAACAGTCTGAGGTCTGAGTACACAGCCATGTATACA
    TATATTCCTAAGCTTGAGTAAGTGGACTTAAACTGATTCCATCACAACTTGCATGAGATGGATATTCCCC
    AGTGTTAAGACCTGTCACCATCACTGTCAATCAGAAGACAAAGTTTATGCACAACAAAACAAAAAAACCA
    AAAGCAGAGGCCTCCAATTACAAGTAATAGACCCAGACCCACAGTCTCTGAAAACTGACTGTACAGTTGG
    ATCCAGTCTTTTACTTCTTTTCCCTGGATTTTATATTACTGAGGAAATGAGGAAAGCTCTACAATATCTG
    TTCTCCATAGTGCTCAACACCTCCAAGCACAGGTTACCCATATTCATGCCTGCCTTCTGCTACACTTCTT
    GTCTTGTAGACTACTTCAACCTATTTTGTACTCCAGTTAATGAAACTCAAGTCTAGCAGCCTGTCACTGT
    TTATTCTAAAGTATTATGAACAGGTGACCTCCCATCCTTCCCCAACGCAATAATCATATTTAGGAATTTG
    AGGTTTTATGAGATATGATCTCAGGGTAGAGAGAGAAAGCAAACTACATAGAAATATAGACTGACATAAA
    TCAAGACTTGCATAAGCTAGTCCCCAAGTTCCATGTCCCTAAGTGGCAAGGACTATCTTCTGAGCCTAAT
    GAGATGAGATCCAAATCAAACCTCCTGGGTCTTTTTAGATAAACATGTGAGATCAATAGACTAAATGCTT
    TGGCTGGGCTTCCTTGCAATCCAATTCCCAAACAAAAATGGATCTGGCTCCACAGACACCACAAGAATAG
    TCTTAAATAGTTCTTTAAGTAGAATGTCTGATCACTACGAGCCCAATTCCATCCTAAATACTCTTCTGGA
    TTATACATAAATAAAAATTGAACATAGGGCATGGGGCACTGATCTCCCTGTGCTACATGAATGGGGGCTC
    ATTTACTAAATGTTCCCATTTTTCTTTCTAGCGCTGCACAGTGCAAATCCTACAACTTCCTGTTTATCTA
    CAATGTGAACTCCAAACAGTACAAGAAAAAACGTTCCTTATGTTCCTCTCCAGGTTCTCCAACAAGCACA
    GAGCAACCTTCTGTCACCAGGACGGAAAACTGGAAACCTTGCTCACTGCTTCCTTTTATTCCCTCGGGAA
    CCTCCCCCAATGCAAAGCAGCCCTCAGGCAGAGGATAAAAGCTCACACAAAGACGAGAAGCCCCATCCTC
    TTCTCATAGAGCATCCATCAGAGCATGGCTGTCCTGGGGCTGCTTCTCTGCCTGGTGACTTTCCCAAGCT
    GTAAGTGTTTCAGGGTTTCAGAAGAGGGACTAAGACATGTCAGCTAGAAGATGTGTGACTAATGGTGATG
    TTGCTTGTCCCCAGGTGTCCTGTCCCAGGTGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCA
    CAGAGCCTGTCCATCACATGCACCGTCTCAGGGTTCTCATTAACTAGCTATGGTGTACACTGGGTTCGCC
    AGCCTCCAGGAAAGGGTCTGGAGTGGCTGGTAGTGATATGGAGTGATGGAAGCACAACCTATAATTCAGC
    TCTCAAATCCAGACTGAGCATCAGCAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTC
    CAAACTGATGACACAGCCATGTACTACTGTGCCAGAAACACAGTGTGGGAAGTCCAATGTGAGCCTGCAC
    AAATACTTCTCTGCAGGGATGATCACAACCAGCAGGGGGCGCTGATGACCCAAAGGGACTTCCCAGGATC
    TCTTCTGGAATCTAGGGAGTTCTGGCCTGTGTCTATCAGCATGTGTTTCAATGTTAGAGTTGTGAGTTTT
    CCTTCCAGCAACAGAGATATTTTAGAGCCCACTTTTCATGGTCATTCTACTAAATTTGTTCACATAGTGG
    AAAGATTTGTTAAATGATTCTATAGTCTAATAGGGTCAAACAAAAACAAATAATTGAGTTCATATCTACC
    AAAAAAAAAAAAATTCCCTCAAAGTGGACAACTGTGTAGGTGAGGAAAACCAGGGGGATTTGGGAATAGA
    TTATTTCTCTCCCGACTGTGGTGTTAGTCACCTTTCAGCCATTTACTGTATTTAATTCATGTTTAAAGTT
    AATTGTATTCATCTTCCCTAACATGAAGTTTTCAAACACATGTCCACAATTTAATGATGACACAGTTATC
    ATTGTGAATGATAACTCATAAGATCTCTCTCCATATATGAAACACACGATATTCTGTTATTAGCTATAGC
    CAACAAAGTTACATATCATTATTATTACTGAAATAATTCTTCCCATCTAACTGAATAGTTTTCTCACTCG
    ACACTGCCTATGCTGCGATCAGCCTGCTCTAATTTTACCTTTGCTCAGAGCACTGCTTTCTGTTTCATTT
    GATAAGATGGTGCCTGGTTGTCACTGAAAATGTGTCCTCCAGTTTCACAGTGATTAATGTGATTTTCAGT
    ACATTGAGAACAGAGCCACAGCAAAAATGAGATGGAATGTCATCATTTTTACGCCAGGTGCTGCAGAAAT
    AGCTAGGTGGTTAAGAGAGAATATTGAACTTTGAGGGGTTCAGATTAAATTCCTGATACCCACAATGTGC
    ACCTCATAACCACATGTACATATAGAAAACTCAGTATAAATGTGGCCTCCGTGAGCACCACACTACTCCC
    ACAAACACATATACACATAATTAAAAGTAAAGATTTTAGAAAAATGGCTAATCTAATGATAGGAAGTAGT
    CAAAAAGAGAGTTCTTTTGTCATGTACATATGTGTAGCAGACTTAAATGTTAAACATTCAAGAATACATT
    CCTCGATCCACATTAAAATTTTGCAAAGAGTAGCACAGACGGTGGCAATTGCTAAACTTATATCTAGAAA
    CACAATTATGTGTGGTGATATTTAATTACACATTTATACCAGGACATATGACAATATGGAAACCAAACAT
    GTTGTATCCACATGCTCTAAGGAAAACTAAATGGAGTGTGATAAAACCAAAGAAAATGTGAATATGAAAT
    ATTTTTCCAACTCTGCATCTTAAAACGGTTTCTTTCATGTGTCATATCTGCTATGAGGACTTTCTTCTGC
    CCATGTCCAACTCCAGAGCATGCCACAGCAGGAAGACCTACAGGTATTACTTCTCTGCACCCAGGAAAAC
    CACCTCTGTCCTGACCCTGCAGCTCTCAGAAGAGCCCAGACCTTCATTCTCAGGCCCTCATCCAGTAATC
    AGCACTGAATACAGAGCACTCACCATGGACTTTGGGCTCAGCTTGGTTTTCCTTGTCCTTATTTTAAAAG
    GTAATTCATAGAGATAAGATTCTATCTGTTTTGTGTACATGAGAAACAGAAAAATTGTATTGTTTCTCTA
    TTTTGTTTTGTTTTGTTAGTGACAGTTTCTGACTCAAGATTCTCTGTTTGAAGGTACCCAGTGTGAGGTG
    AAGCTGGTGAAGTCTAAGGGGAGGCATAGTGCAGCCTAGAAGGTCCATGATACTCTACTGTGCAGCCTCG
    GATTCACTGTAAGTGACGACTGGTTTGTCCGTGTTTGCCAGGCTCCAAAGAAGGGGCTGCAGTGGGGGAT
    GGGAATAATTTTTCATGGTTGTGGTAGCCCCTCTTATGCAGACACCTTGAAGAAGTGGGTTGGACGTAAC
    ATATTCAGAATCAATATTTAAAGATTCTAATCCTTGAAGATATCACTTTTGACCAAGTATATATGAACCA
    TGTTACTGAGGTTTATGGAGGTTTGAGTATGTTAGGTCCATGGATAGGGAAAATATTAGGGGATTTTAGG
    AGTAACTGAGGCTTGTTGTAGGAAGGACATCACTGTAGGGGTAGGCTCCGTGTTCCTATCTTCAAGCTCT
    ACCCAGTGCAGAATAGAGCCCTCTTCTGCCGGCAAGTGGAAAGAGTTTCTCTTCCTGGCTGCCTTCAATC
    CAAGTTGTAGAATATCAAATCTCCTAACACTATGACTGCGAGCATGCTGACATGCGTCCCACCATAAAAA
    TAGACTGAACCTCTGAAGCTTTAAGCCAGCCTCTAGTAACTGTATTCTTTAATAAGACTGAACTTGGCTA
    TGGTGTCTTTTCACAGTAAAATGGAAACATAGACAAGGTTCTAACTCTCTGTACTAGAGGACCATCTCTA
    TGTCCTTGGTGTTGTATGTAAATTATTGAACAAATACTATAGACAAGTTGTATGGCCAAAAGTCCATCCC
    CTTCAACAATCTACTATCTGGAACCATATAGATTAGATTCCTTTCCTGCACTCATTTCCCTTACTTGCTG
    AGACATTTTGAAGACATGCTCAGAATCCCTGAACTTCCTGCTGAAAAAAAAATACCCCTCCAATTTGAAG
    ACAGTTCTCTTCCAAAATTCATCATAAATACTGATCCACATGTCCAGGCATATCATGTAGTTTTAAAAAA
    CAAACCAATCAATGCTAAAGTGGGTAAGTGCCTACATCATTGGTTTATGTCTGTTCATAACCTGGTATAT
    AGCTAGAGACCAGGACTGCATGTTTCTCCTAGGCCACACCTCTCCCACAAATGCTGGCTCTGCCTCTCCA
    GAATTCCAAGATCATGGATCTCTGGGTCCCCAAGGAACAATAAGTGTGCACTCTTGCCAGCCTGTACACT
    ACTGCACTAGCTTCTCCCCCTGGAGCTTGGTCATTGCTCAATCTTCCCTTTCCAAAGCCTGGCCAAATTC
    CTCCTACCTTTTGTTCTTTCAGTCAGGCCACCTAAGTCATCTTGAATGAAAAACAACACAAAATCTGAAC
    TTAAAATCAACAAATAATACAAGTGCTGCGCACAAAATCAATCATTCTAAACTCATCAACTATTTTATGA
    TGGAAATCTTCCAACATACAAGCTACCACCAGGTCTAAGAATTACTCATCTACATGTTGCTTCCTCTCAC
    TCACAGCCTAACCATAAAAGGGCTGTTTCTTCCTCCCATGTCCCCTCTTTTGCCTTCAGAAGCAGAAGCT
    CCACCTCCTCCTCTTTGCCCAGCAATTGGCTTCTTGTCGTCTTTATTATCATATTAATTACTTAGGGGAA
    AATCCCGTGTAGTGGCTATTCCTGGTTGTCAACTTGACAATATTTGGAATGAACTACAATCCGGAATTGG
    AAGGCTCACCAGTGACCCTTATCTGGAGGCTTGGAGATCCTTATCTGGATCTTGGTTTGAAGATCTTGAG
    CCATAGGGGCTATGGATTCCAGAAGATTGAATCTCCGAGTTTAAGGAACACACCTTTAATCTGGGCTACG
    CCTTTCATCTGGGATTAAAGGTGTGGCGGAACACACCTTTAATCTGGACTACACCTTCTGCTGGAGACAA
    TATAAGGACATTGAAAGAAGGGAGTCTAGCTCTTGCTCTTGCTCCTTCGCCTGCTTGCTGCGTGAGACTG
    AGTAACTGCTAGATCCTTGGACTTCCATTCACAGCTGCGACTGAACAATTGTTGGGAATTGGGCTGCCGA
    CTCTAAGTCATCAATAAATTCCTTTACTATCTAGAGACTATCCATAGTTCTGTGACTCTAGAGAACCCTG
    ACTAATACAGAAGTTGGTACCAGGAGTGGTTCTAGAGTAACAGAAGTACAAGGATGAATCTTTTAAAATA
    CTGGAATTGGCTTGTTGATCCACCAGCACTTTCAACTATTGAAACCTCTCCAGATTCTCTCCCTCCTGGG
    AGCTCAGAGAATTTTGAAGACCCATGGTTGAAACTATATTCCGAACTTAAAGAAGCAAATGCCCTTGATT
    TTCTTAATGAATTAGGTGATTCAGTGCACAAAGCTTTCTACAAGATGGGGAAAAAATTGGAAAATGATTT
    TACTGGCTGGCTGCTCTTAGTATCTGTGGAAAAAATGATGAATGAAAGGAAGGAGTTGTGTGATAAAATC
    GAAAGGCTCCAGACACAAGTAAACGATCTAAAAGTTGCTAAGTGTGTCCTTGAGGAGAATCTTCTCTCTT
    GTAGCAATAGAGCTCAAGTTGCAGAAAATCAAACAGAAACTCTCATTGTAAGGTTGGCTGAACTACAGCG
    AAAATTCAAGTCTCAGCCTCAGAGTGTGTCAACAGTTAAAGTAAGGGCTCTAATTGGCAAAGAATGGGAT
    CCTACAACATGGGACGGGGATGTGTGGGAAGACCATGTTGAAGCTGAGAATTTTGAATCTTCAGATTCTC
    AAGGGTTTGCCCCACCTGAGGAAGTAGTACCCTCAGCCCCACCCCTTGAAATAATGCCTTCCCCACATGA
    GGAAATTAATTTTGCAGAGTCTGATAAACCAGCAATGATTTTCACTACTGATGTTTCTCAAGGCCCACCA
    ATAGTTTCTTCTAGACCTGTAACCAGACTCAAAGCAAAACAGGCTCCTAGAGGGGAGGTAGAAAGTGTAG
    TCCATGAGGAAATTCGCTACACTACTAAGGAGCTTAATGAGTTTGCTAATTCATTCAAGCAGAAACCTGG
    TGAATATGTGTGGGAATGGATTTTAAGGGTGTGGGATAAGGGTGGAAGGAACATAAGACTAGAGCAGGCT
    GAGTTTATTGACATGGGTCCTCTGAGTAGAGATTCTAGGTTTAATACGGAAGCTCGCATAATTAAAAAAG
    GTGTCAAAAGTTTGTTTGAATGGTTGGCTGAGGTGTTTATCAAAAGATGGCCTACTGGAAATGACTTGGA
    GATGCCTGATATTCCGTGGCTTAGTGTTGATGAAGGGATTTTAAGACTTAGGGAAATTGCAATGCTAGAG
    TGGATATATTGTGTAAAGCATAATTGTCCACAATGGGAAGGTCCAGAAGATATGCCTTTCACTAGCTCTA
    TAAGACGCAAATTGGTGAGAGGGGCACCAGCACATTTGAAGGGTTTTGTTCTTTCCCTTTTCCTTGTACC
    AGATCTTAGCATTGGAGATGCTTCTGCTCAATTAGATGAATTAAATTCACTGGGTTTAGTTGGATTCCGA
    GGTAACAAGGGCCAGGTGGCAGCATTGAATCGCCGGAGACAAGGTGATTCTAGTTATTATAATGGACAGC
    GTAGACAAAAGAATGTTTATAATAACATACCCAGCAATGGTCAGCACAGGAGAGGTGAAATTTATAATGG
    CATGACTCGGTTGGACCTTTGGTACTGGCTAACCAATCATGGTGTTTCCAGGAATGAAATACATAGGAAG
    CCTACTGCATATTTGTTTGATCTGTATAAGCAGAAAAATTCTCAAACAAATGAAAGAAAGGCTACATTAG
    ATCATGGTAAACAGCAATCTCGGCCAGTGAATCAATTTCCAGACTTGAGACAGTTTGCAGATCCAGAACC
    CCTTGAATGAAGGGGTGGCCAGGTTCCGCTGAGGAAGGATCTTGATAAGACACCCAAAGGTTTTGCTGTT
    ACCCTTTCTCCAGTTCTTCCCCAGAGGGACCTAAGGCCTTTTACAAGGGTAACTGTACACTGGGGAAAAG
    GAAATAATCAGACTTTTCAGGGTCTGCTGGATACTGGTTCTGAGTTGACACTGATTCCAGGGGATCCCAA
    GAAACATTGTGGCCCTCCAGTTAAAGTAGAGGCTTATGGAGGGCAGGTGATTAATGGAGTTTTGACTGAT
    GTCCGACTCACAATAGGTCCAGTAGGTCCCCAGACACATCCTGTGGTGATTTCCCCAGTTCCAGAATGTA
    TAATTGGGATAGATATACTCAGAAATTGGCAGAATTCTCATATTGGTTCCCTGAACTGTAGAGTGAGGGC
    TATTATGGTTGGAAAGGCCAAATGGAAACCTTTAGAGTTGCCTCTGCCAAAGAAAATAGTGAATCAAAAA
    CAGTATCGTATTCCTGGAGGCATTGCAGAAATTACTGCCACTATCAAGGACTTGAAAGATGCAGGGGTGG
    TGGTTCCCACCACATCTCCGTTTAACTCTCCTATCTGGCCAGTGCAGAAAACAGATGGATCATGGAGAAT
    GACAGTTGATTATCGAAAACTAAATCAGGTAGTAACTCCAATTGCAGCTGCTGTACCAGATGTAGTTTCA
    TTACTTGAGCAAATTAACACATCTCCTGGCACCTGGTATGCGGCTATTGATCTGGCAAATGCCTTCTTCT
    CAGTACCTGTCCATAAGGACCACCAGAAGCAATTTGCTTTCAGTTGGCAAGGCCAACAGTATACTTTCAC
    AGTTTTGCCTCAAGGATATATTAACTCTCCTGCCCTGTGTCATAATTTAGTTAGAAGGGATCTTGATCGT
    TTGGATCTTCCACAAAATATCACATTGGTGCACTATATTGATGACATTATGCTGATTGGACCAAGTGAGC
    AGGAAGTAGCAACCACTTTGGACTCATTGGTAACACATATGCGTATCAGAGGATGGGAAATAAATCCAAC
    CAAAATTCAAGGACCATCTACCTCAGTGAAATTCTTAGGAGTCCAGTGGTGTGGAGCATGCAGAGATATT
    CCTTCTAAGGTGAAAGATAAGTTATTGCACCTGGCCCCTCCTACAACCAAGAAAGAAGCACAACGTTTAG
    TGGGTCTATTTGGATTCTGGAGACAACACATCCCTCACTTGGGTGTGTTACTTAGGCCTATTTACCAAGT
    GACTCGGAAAGCTGCTAGCTTTGTGTGGGGCCTGGAACAGGAGAAGGCCCTTCAACAGGTCCAGGCTGCT
    GTGCAGGCTGCACTACCACTTGGACCATATGACCCAGCAGACCCGATGGTACTTGAGGTGTCTGTGGCTG
    ATAGAGATGCTGTTTGGAGCCTCTGGCAGGCCCCTGTAGGTGAATCACAGAAAAGACCTTTGGGATTTTG
    GAGCAAAGCTCTACCATCATCTGCAGACAACTATTCTCCCTTTGAAAAACAGCTCTTGGCCTGCTATTGG
    GCCTTAGTGGAAACTGAACGTTTGACAATAGGACACCAAGTTACTATGCGACCTGAACTACCCATCATGA
    GCTGGGTACTATCAGACCCTGCAAGTCATAAAGTGGGACGCGCACAGCAGCAGTCTGTTATCAAATGGAA
    GTGGTATATACGTGATCGGGCCAGAGCAGGTCCTGAAGGCACAAGCAAGTTACATGAAGAAGTTGCTCAA
    ATGCCTATGGTTTCTACTCCTGTTACACTGCCATCTGCTGCCAAACATGTGCCTATAGCCTCATGGGGTG
    TTCCCTATGATCGACTGACCGAAGAGGAAAAGACTAGAGCCTGGTTTACTGATGGCTCTGCACGTTATGC
    AGGCACCACCCAGAAGTGGACAGACAGCTGCAGCATTACAACCCCTTTCTGGGACAACCCTGAAAGACAC
    AGGTGAAGGGAAATCTTCACAGTGGGCAGAACTTCGGGCAGTACACATGGTATTACAGTTTGTTTGCAAG
    AAGAAATGGCCAGATGTACGATTATTCACTGACTCATGGGCTGTAGCCAATGGATTGGCTGGATGGTCAG
    GGACTTGGAAAGATCACAATTGGAAAATTGGTGAGAAAGACATCTGGGGAAGAAGTATGTGGATAGATCT
    CTCCAAATGGGCAAAGGATGTGAAGATATTTGTGTCCCATGTAAATGCTCACCAAAAGGTGACTTCAGCT
    GAGGAGGAGTTCAATAATCAAGTGGATAAGATGACCCGTTCTGTGGACAGTCAGCCTCTCTCCCCAGCCA
    TCCCTGTCATTGCTCAATGGGCACATGAACAAAGTGGCCATGGTGGTCGAGATGGAGGTTATGCTTGGGC
    TCAGCAACACGGGCTTCCACTCACCAAGGCTGACCTGGCTACAGCTGCTGCTGATTGCCAGATCTGCCAA
    CAGCAGAAACCAACACTGAGTCCCAGATATGGCACCATTCCTCGAGGTGACCAGCCAGCAACCTGGTGGC
    AGGTTGACTACATTGGACCACTTCCTTCGTGGAAAGGACAGCGTTTTGTTCTTACTGGAGTAGATACTTA
    TTCTGGTTATGGATTTGCCTTTCCTGTACGTAATGCCTCTGCTAAAACCACCATTAACGGACTGACAGAA
    TGCCTTATCTATCGTCATGGTATTCCACACAGTATTGCTTCTGACCAAGGAACTCATTTCACAGCCAGAG
    AAGTACGACAGTGGGCCCACGATCATGGAATTCACTGGTCTTACCACATTCCCCATCATCCTGAAGCAGC
    TGGTCTGATAGAAAGATGGAATGGCCTTCTGAAGACGCAGTTACAGCGCCAATTAGGTGGTAACAGCTTG
    GAAGGCTGGGGTAGAGTTCTTCAGAAGGCAGTATATGCTTTGAATCAGCGCTCGATATATAGTACAGTTT
    CACCCATAGCCAGGATTCATGGGTCCAGGAATCAAGGGGTGGAAAAAGGAATAGTTCCACTTACTATCAC
    TCCTAGTGACCCTCTAGGAAAATTTTTGCTTCCTGTCCCCATAACTCTAGGTTCTGCTGGCTTAGAAGTT
    TTGGCTCCAGAGAGGGGAGTGCTCCTACCAGGAGCTACAACAAACATTCCATTGAACTGGAAGCTCAGAC
    TTCCCCCTGGTCATTTTGGGCTTCTAATGCCCTTAAACCAACAGGCTAAAAAAGGAGTAACAGTGTTAGG
    AGGGGTGATAGATCCAGATTACCATGGGGAAATTGGATTACCTCTTCACAATGGTGGTAAGCAAGATTAT
    GTCTGGAGTGTAGGAGATCCCTTAGGGCGTCTCTTAGTACTACCATGTCCTGTGATTAAAGTCAATGGGA
    AACTACAACAGCCTAATCCAAGCAGGATGACAAAGGACACAGACCCATCAGGAATGAAGGTATGGGTCAA
    TCCTCCAGGAAAAGAGCCAAGACCTGCTGAGGTGCTGACTGAAGGAGAAGGAAATATAGAATGGGTAGTA
    GAGGAAGGTAGTTATAAATACCAATTAAGGCCACGTAACCAGTTGCAGAAACGAGGATTATAAAGTAATA
    TGAATGCCCATTGTAAATTTACTAATGCGTTTGCGATTGTACGAGGGATAGTTATATCATGTTAGGCGTA
    TTTACAAACTTGTTATTGTTTTATGTGAACATGAGATATTATTTGTGTCAAGTTGACAAGGGGTGGATTG
    TAGTGGCTATTCCTGGTTGTCAACTTGACAATATTTGGAATGAACTACAATCCGGAATTGGAAGGCTCAC
    CAGTGACCCTTATCTGGAGGCTTGGAGATCCTTATCTGGATCTTGGTTTGAAGATCTTGAGCCATAGTGG
    CTATGGATTCCAGAAGATTGAATCTCCGAGTTTAAGGAACACACCTTTAATCTGGGCTACGCCTTTCATC
    TGGGATTAAAGGTGTGGCGGAACACACCTTTAATCTGGACTACACCTTCTGCTGGAGACAATATAAGGAC
    ATTGAAAGAAGGGAGTCTAGCTCTTGCTCTTGCTCCTTCGCCTGCTTGCTGCGTGAGACTGAGTAACTAC
    TAGATCCTTGGACTTCCATTCACAGCTGCGACTGAACAATTGTTGGGAATTGGGCTGCCGACTCTAAGTC
    ATCAATAAATTCCTTTACTATCTAGAGACTATCCATAGTTCTGTGACTCTAGAGAACCCTGACTAATACA
    TCCCTACATACAGGAAACTTGATGTATAAGTAAAGAAAATAGTAAATCTAAAAATTTCCTTATCAAATAC
    ATGCAAGAAATCCAAAATACCATGAAAAGACCTGATCTAAAAATAGTAGGAACTGAAGGTGAAGTGTCCC
    AGCTCTGAAAACTAGAAAATGTTTTCAATATTTTTCCTAACAGTGAAGACATGGATCTAATGAGGCCACC
    TCTTATAGCCATGCAAGACTGACAGTGGAGGGATAAGGACACCAATCCACCCACAAAACTTTTGACCCTA
    AATCAGTTTTATCTAAAAGCAATGCAGGGGCACAAATGGAGCAGAGACTGGAGGAATGGTCAAACAATAA
    CCTGTCATATCTGAGACCCACCTAATTGGCATACACCAGTCACTGACATTATTAATAATGTTCCATTATG
    CTTACAGGCATTTCTCTAGCATTACTATTCTTGGAGAGACTTCACACAGCATCTTATTGAAACAGATGCA
    GACACCCAGAACCAAACATTGGATGGAGATTGGGATCCTTAAAGAAGAGTTGGGAGGATAATTGAGAGAC
    CTCAAAGGAATAGCAACCCCATAGAAAGACACGAACAGGGTCAGTAAACCTGGACCCATGGGGTATCTCA
    GAGACTGATCACCAACCAAAAATCACAGAGGGCCTGGATTGATTCCCCTGGCACACATGTAGCAGAGGTC
    TGCCTTGTCCTTCAGTAGGTGAAGATGAGCCTAAGGCTTCAGAGACTTGATATATCAGCATACAGCAACA
    CCCAAGTGTGTCCCACTATCTCAGAGGTGAAGGGGTGGAGATGGGCAGAAGGGTCCTGATAGGGGACAAC
    TGCAAAGAGGCAATATTTGGGACAGAAAGAAAGGAAGAGAGAGGAAGATAAAGAGAGAGATGAAGGAAGG
    AAACAAACAAACCAAGATGAAGAGAGAGAAAAGGGGGAAAATAGCCTTGAATGGTTCAGGGATTCAAAGG
    GACATACCTAAGCATGGTAAAACAATGCACATAATGGCAGCAAGTAGCTAACACTGAATTAAATAGAAAG
    ACACATAAAGCAGTTCTACTAAAGTAAGAGACAGAGTTGCCCAATCTCACCCTATTTATTCAATAATAAT
    GTACTTGAAGTTCTAGCTAGGGCTGTAAGACAACTCAAGGAGATCGGAGGATACAAATTAGAAAGAAAAA
    TTCAAAGAATTGTAATTGGTAGATGATAGGATAATATACATAAATGACCTCAAAATTCTTCCAGAGAACT
    CTGAAAGCTGATAAATACCTTCAGCAAAGTGGCTAGAAACAAAATTACTTCATAGAATTCAGGAGCTATC
    CTTTATAGAAAAGTTAAAGTGGCTGAGAAAGAAATTAGGAAAATCACATTCTTTGCAATAACCAAAAATA
    ATATGAATTAGCTTGGTGTGACTCTAATCTTGCAAGTGAAAGATGTGTGTGACAAGAGCTTCAGGACCCT
    GAAGAAAGAAATCAAAGAACTCAAAGATGCAAAGTACTCTAATGCTCATGGATAGGCAGAATTAACATAA
    TGAAAATGCCAAATTTAACAATTCAATCTACAGATTCAGTGGAATTCCCATTAAATATCCAACCCAATTT
    ATTACATTCTTGAAAAAGCAAATCTCAACTTCATATAGAAAAACAAGAAATTGAGGGTAGCTAACAAAAT
    CCTGAACAATGAAAACACTTCAGGAGAATTCACCATCCCCTACCTCAAGCTGTATTTTAGAGCAATAGTT
    ATTAAAACTGCATGGTATTTGTATAGAAACAGATATGATGATCAATGTAATTGAATTGAATACACTGACA
    TAAAACCACACTGTTATGGACACTTGATTTTTGACAAAGAACCCAATAATCATAATAAAAATCATAATAA
    GAATGCATCCCCCAACAAATGGTCCTGATCTAAATGCAAATAGATTCATATCTATCATCCTGCACGAAAT
    TCAAATCAAAGTGAATTGCAGACTTCGACCTAATACTGGATTAACTAAATCTAAATGAACAAAAAGTAGA
    GAATAGTTTTGAACTCATTGATGCAGGATTCAATTTCCTGAACAGAACCACAATGGCTCAGGCTCTAGGA
    TCATAAATTGGTAGATAGGATCTCATGAAACTGAAAAACTTCTGTAAGGCAAAGGCAATAAAACAAAATG
    GCAACCTACAGATTGGAAAAAAAATAATCTTCAGTATCCCTAAATCCCATTGAAGGCCAATATGCAAAGT
    ATATAAAGAACTCAAGATGTTATCCTCCACAAAACCAAATAAATCAATTAAAAATGAACTACAGAGCTAA
    CAAGAGAATTCTCAACAGAGGAATCACCAATGACTGAGAATCACTTAAAGAAACATTCAATATTTGTAGT
    CACCAGAGAATTGCAAATCAAAACTACCCTGAGATTCTACTTTATACCAATCATAATGGTCAAGATAAAA
    ATTCAAATGACAGCGCATGTTGGTGAGGATGTGTATACTTTTGCATTGCTGGTGAGGAAAACAATCTGGC
    AGCTCCTCAGAAAATTGTAAATAATTCTACCTGAAGATCCAGCCATACCACTCCTGTGCATATACATAAA
    ATGTGCTCCACCATACCACTAGGAGATATGTGCCACTATGCCCATAGCAGCCTTATTTGTTAATAGCCAA
    AAGATGGATACAACCCTGATGTGCCTCAAACAAAGATTGTATATAGAAAATATGGGTTCCCTTACACAAT
    GGTATTCTACTCAGCAATTAAAACGTGAGAACATCATAAAGTTTTCAGGCAAACTGATCAAATGAAAAAG
    TATAATCTTGAGTGAGGTAACAGAACCAAAATGACCTGCATGGGATGTACTCACTGGTAAGTGAATATTA
    GACTAAAAGTATAGAATATCAATGATGAAAGCCACAGACCATAAAGAGTTTAATAAGATGGAAAGCTCAA
    GTACGGATTCTTCAATCCAATATAGAAAGAGGGACAAAATAATCAGGGGAGGCAGAGGGAGAGAGAGACA
    TTTGGTGGAAATGGGAGAAGAAGGGAGAAAGGCAGAAAGGATCAGGCGTTGGGGAACACTGGAAAGCAGC
    CCAGGGGTCCTGGTAAATGGATTAAATATTCAGCTGAATGGAGGTGGGAGGCAGGGGGAAGCTCTGCAAA
    GTCCAAGAGACCTGGGATGTGAGAGGCTCCCCAGATGATAATCTTAGCCTTCATGCCTAACAGTTGTAGA
    TAAACCCTGAAGAGATCACTTCCAATAGATGCAGAGGGCCCTAAGTGGTTGGATGGAGTCCCCCAACTTA
    CCTCAAAATTGTCAATACTCATAGAAATTAGGACAATGAAAATCAAAACACCCTGAGATTGTATCTTATG
    TCTGTCACAATGGTTAAGACCAAAACCTCAAGTGATGGCTTGTGCTGGCAAAGATTCAGAATAGTAAAAG
    TCTCCCCATGGCTTGTGGGAATGCAAACTCTTACAACCTCTTTGGAAGTATATTTGATTGTTACCTGGTA
    TAAAATGGCAAAAAAAAAAAATGGTTGAAGGGGGACTAAAAAAGGAAGAAAGGGGAGAACTATGGGATGC
    GAAACAAGAAAGTTTGTTGCAAAAGAAATATGTTTCCACTGCAAACCCTGAGTCTCAGACAGAAGGGGAC
    CTGGAATTCTTCAGATACAAAGAATCTCTAAACCCTGAGGACATTCTATCACAAATAAGTAAAATTCAGA
    AAATTCTGAGTGCTCCCATCACGGAGATGAATCTGCTATGAACAGCTCATAGGTGTGACCCTCTACAAAA
    GCCATATTATTGAAAAGCCACATTGTGCCCAGACTTTGGAAAGACTGAGCTCATATCCTGAAATACAGTT
    ATGTGTGGTTCTATTTAATTACACATTTACACTAAGAAAACATGGCAGTATGGGAATGAAGCTTGTTCTG
    TACACATTAACAGAGGGAAACTAAACAAAGTATGGTGAATCCCTAACCAAAAGTAAAAAAAAAAAAAGAA
    AGAAAAGAAAATAAAAGTGAAACTACAATATGTTTCAAATGCTGTAACTGAAATCTGGTTTTTTGATGCT
    TATATCTGGTATCATCAGTGACTTCAGATTTAGTCCAACTCCAGAGCATGGTATAGCAGAAAGACATGCA
    AATAAGCCTTCTCTCTGCCCATGAAAAACACCTCGGCCCTGACCCTGCAGCTCTGACAGAGGAGGCCAGT
    CCTGGATTCGATTCCCAGTTCCTCACATTCAGTGATCAGCACTGAACACGGACCCCTCACCATGAACTTG
    GGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTAATTTATTGAGAAGAGATGACATCTGTTGTA
    TGCTCATGAGACAGAAAAATTGTTTGTTTTGTTAGTGACAGTTTTCCAACCAGTATTCTCTGTTTGCAGG
    TGTCCAGTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCTGAAACTC
    TCCTGTGCAACCTCTGGATTCACTTTCAGTGACTATTACATGTATTGGGTTCGCCAGACTCCAGAGAAGA
    GGCTGGAGTGGGTCGCATACATTAGTAATGGTGGTGGTAGCACCTATTATCCAGACACTGTAAAGGGCCG
    ATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCCGTCTGAAGTCTGAGGAC
    ACAGCCATGTATTACTGTGCAAGACACACAATGAGGAAATGTTACTGTGAGCTCAAACTAAAACCTCCTG
    CAGAGCACCCAGGACCAGCAGGGGGCGCAGAGAGCACATGGAGTTCTGATTCACAGAAGAGTTACAGCCT
    GTACAATTAGACCCAATCTTCAACAAACCGTCAAAATATTCGATCCAAAATTGTTCCTGTCTAAAAGTAA
    TTCAAGGACAAAATGGACCAGAGACTGAAGAAATGGCTGACCTGTGACCCTCCCAACTTTGGATCTATCT
    CATAGGCAGGTACCAAACCTTGACATTTGTCACTGACACTGTATTGTGCTTGCAGACAGGAGCATAGCAT
    GGCTGACCTCTAAGAGGCTCTGCAAGCACCTGAATGAGACAGATGTAAATAGAGTGTACAACTGGATTAA
    GTTTGAAGACTGCAATGGAAGAGTTAGAGGAAGGAATGAAAAATCTGAAGGGGATCACAACCCCAGAAGA
    AGACCAACAGTGCCAATTAAACTGGATGCCTGGGAACTCCCAGAGACTAAGCCACAAACCAAGAATCATG
    CAGGCTGGTCTGAGAATCCTGGCACCCAAGTCTCAAGGAACTGCCTTTTCTTGGCTCAGATGGGAGAAGA
    TGAGCCTAAAGCTTTAGACTTGACGCCCCAGGGATGGGCAATACAAAGTTGAGTTTCTTGGGAAAGTGAA
    GAGGATGGTGGGAGGAGGAATAAATCTGGGAAGTGGGACTGGTTGGGGACAACATATTGGTCCTAAATTT
    ATGAAATAATTATCTAATTGATAAAAAGAGTCCTTGGGGTAATGGAGGGCTAGACTCCTCTGTGCCTAGT
    TTGTAACTCTACAGGGATCCTCTTTAAAAGAATAGGGTGCACATAGAGTATATGTGTGTGACACTAATAC
    AGGGGTAAGTGTTTCTGTAAGAACTTTATGAATAAACTTTATTAAAACATCAAAAAGTATAGGTTGTAGC
    AACCCTTGACCTGTACGAATGTTTATAAAACTTTCTATTTTCCTTAATTATATCTGTTTTGCATTTGTTT
    ATTTATTTATTTACTTACTTACTTATTTATGATTTCACTGTGTCTTTCTGTAGTCCTGTATGTGTTTATT
    TGTCTCTTTATTGCTCTGTTTCTGTTTCTTTCTCTCTGTCTAGTATTGTATCTCTCTGTGTCTCTATGTC
    GCCGATTGTGTCTGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCATATTGAAA
    TGAGATCTCTTCTTCTATCAGTGTACATAATGACTTTGAAATAAAGTCCATCACTGGGCTTGGATATCAC
    TATCTTGTTAGAATGGTTGCCCAAAGTGTTCCAACCATCACACTGTTTCTACATATAATAGATGGGTTTA
    TTGATTTACTACCAAAACTACCCCATCTTAAGTTATGGATATTAAACACAGATCCTCATGGTGTGTTAAG
    AACTTGAAGCACAGAGCTATATGTACAGCCCACTAAAAATGACTTAAATATAAGATAAACTCTGGCTTGA
    ACAAAACACAGAGCATCACACGAGGCAGAAGTGAATCTCTATGAGGACCAGGATCACATCCCAAAGAACC
    AAAGAACACTTGAGACTGTGGAACCCTAGAGTCAGGGCTGACACTCAGTAAGATTTACTTCATAGAGCAT
    GATGTGGGATTCAAGAAGAAATCAGGCAGGGCCTGTGACCCATGAACCAGATGACTTCCAGTCTCTCCAT
    CATCCTCACACAAACCATAGGCAACAGCTCAGCACTGACTCACCTGTGATGCTGGTGACAAAATGTGTGC
    AAAGCCTCAGAACTGAGACGTGAGGCCAATGTTGCTACCGACACTCAGTGAGCTTCAATTTGCTGCAAAC
    TGCTCCAAAACAACTCAAAGGGTAACTTCTTCTTTTTCTATTTGTACTTGTGATGCCTTGGTAGATATAG
    TTCCCCAATAATTTAATAGGACAAATCATTTTTCCTTTTAACACATTAATCCCCTTTCCTTCCCCCAAGA
    TTCTAAAATTTTTCTTTAACACTGATGTCTGAGAGATATGGCATAATAGATGTTTGTCTTATTCTGAGTT
    GTTCCTTATCAAAAGAAATCAGCTGTGGCACTTTGAACCTAAATATAACAATATTTCACAAAGGCATTCT
    GGGAATATATAGATGGTATTGCTACAAAAGAATAGGAGGATCTATGGCCATACCACCCTTAATGAACCAG
    ATACTATCTAAAAGATTAGGACAGCTGGGCATGTTGGCACAGGCCTTTAATCCCAGCACTAAGGAGGCAG
    AGGCAGGCAGATTTCTGATTCGAGGCCAGACTGGACTACAAAGTGAGTTCCAAGACAACCAGGGCTATAC
    AGAGAAACCCTGTCTCGAAAAAACAAAACAAAACAAAACAAGAGTAGGAGGGTATTAGATGCGAGGTGAT
    GATGGCCATTCAATCAAACCAGAATGTGACCTGAGAAAAGGTCTAAGTTTGTCAGCTTGTCCTGGAGATG
    TGTTGCCTCTGATAAATGCAGAGCTGGAACTGCAATACATTGGATTCCTGTGAGTTACGGAGAAATAAAA
    GGAATAGCCTCTGTTTCCTTTGGTTCATCAAGTTGGCAGTGAGCTAGAAGATGATACTGGGAACCATCAC
    ATGTACTTCTACAGAGTTATTCTACATTCTACAAGTCAGTCTTGCTTGCTTTCGTTTCTGTGAGGAGCTA
    AATACAGAATGTTTTCAATGTCTCATAATGTTCTGTGCACACCCATGGGTGCCTAGCCAAGGATAGAAAC
    TTGTATCTGATAAGGAAAGAGGATGCTGCAGTGGCCACACTCTGAGATCACCTCCTGCCAAATTATACTA
    GAGTGTTTTACATAGTCTTGAAAACACTAGGTCAAATATGTTGTCATCCAGATATGAAAACTCTGTGCAA
    CAATTCAGAAATACAGTGGTCAGGACAACTGGTATGTAACACTTTAGTTCCAGCCCACATTAATCTCACA
    TCTTTTCTGTGGTTTCAATAAAGAGCACACATGTTTGGAACACCATCTCCACTTTGTATGCTTATCCTTA
    TGCATCAAACTTTTCCTGTAATTTCCTACCCCGCACAGGTTCCTGTCTTGATCTCTTTTTCTAATGAACA
    GCAATACAGAAGTGTTGGCCAAATGAACACTTTCACCCCAAGTTGCTTTGCCATTGTGTTTCATCACAGC
    ATTAGTAACTCCCAGTAAGGCTACTGGTTACCCTGCATCTTCTATGTAGATCTTTTGATGAAGTTCCAGG
    CTTGGGGTCTTTATCTGACTGTTATCCTGGTTAATTCATGTCCACCAATAGAATATTGTTCTCATTTTCA
    ATATCATATGAAGTTACCTGTTTATAGGATCTTCCTAAAGCAGAAAACTATATAAAATGTCTGCTTACTT
    TAAGAAAAGTATGTGTCCTTGGAGGTAAATGGAGGAAAGGGTGGAGGATGTTGAGTAATGGAAGACTGGC
    TAATACAGGAAGGTCACAGAATTGAATGATTTTAAAAATTTTAACTCCTCATCAATGAGGTACTTCAAGT
    TGAGGCAGGAGTCCTTGATGCACAGGTGACCCAAAGGCCCCAGCCTCTGTTTCTTGGTCTGCTCCAGTCT
    CCCGGCTCAGCACAGTTCACTGAGTGACAATCTTTAAGATAGTCTTTCAGGATACAGTTATCACAGTTTT
    CAAACTCTCTTCATTGAAACAATATAATGAGTCAGAGTCCAGTGTGCCATTAATAGGCCCTATGCAATAG
    GATTTTACTTCATCTGTGGAAAGAAACCACCATGGCCTCATCAAGGCCTCATTTGATGATTAGTGTAGAA
    AGCGTCCCCAGAGCTTTGCTGGGATGAAAACCCTGGCAAGATGTTTAGGGCACTCTCCATCTGACAGGAC
    AATTCTATCAAGGGTTGCTTCCATATAGAGAGAAATCTCCACATCTGCAGTATTTCCCGATTTATCAACA
    GTTCTTTACCCCGTGTCATATGCATAAAATCTTTTCTCTGTAGAATTTTCAGTACTAAAAACTAACAAGG
    ATGTTGGTCCTGATATCAGACATAATAAATAAATAAACATCAAATTATACCCTAAACATGTGGAGATGGT
    TTTCTGTTATGAATTTATTGGCTCTCTAAAAAGTGTTAATTAAGCCAGGCGTGATGGCACATGCCTTTAA
    TCCCAGCACTTGTGAGGCAGAGGCAGGCGAATTTCTGAGTTTGAGGCCAAACTGATCTACAGAGTGATTT
    CCAGGACAGCCAGGGTTACACAAAAAAACCCTGTCTCCAAAAAGTAACAAAAAGAAAGTGTTAATTAACA
    TCTACACTTTAAGATAATTTGGTGGCAAAGGTTAATAGTCTGAAATACTAGATATGAAAGTATGACACCT
    AAATTGCATGCAGAGAATAAAGCTGAATTCCAATGAGATTCATGCCTTGTGAATCCATTCCAATCTGATC
    TCAATCTTCAAACATGTTTGTGCATAATTTACATCTTAATCAGTTGCTGGAAATTAAAAGGACATAAGCT
    AAACTTAAAACTCTTTCTATTTAATGTGTCAGAATAGAATATGTGCACTGAAGTTTTCATGTGCATAGGA
    TATCATTGTTACAATGATGGTTCAAATACGCACCAGTAGCACAGGTGATGCTTGACATGAAAAAAACTGT
    GACCAGAGCCCAGACGTTGATGTTGGCTGAAAGAGCCTAGTGTCTCACATTTGATCAAGCAAAGTGTTAT
    TCAGAGAAGCAGTGCCAGATTTGGGATCCTTCTTAATGGATCAAGAACATGAGGAAGATTTGGAAGCCAG
    ATTGATGAGATTACTAGAATCCTGGATCTGAACACACAACACACAATAGTAAGTTGAACTTTTCCACGCA
    ATGCTAAAGATAAAGCATCCAGTATCATGTTATACAGGACCAAGGTGAGGATCAGTCTGTGGGTGAAGTA
    CAATGAACTGGAAATTGTTTGGATTTTAAATGTTGGTTTTTAAATTATATATAAAATATATATATATATA
    TATATATATACATATATATATATATATATATATATATATATATATCGGAACCAACATTTAAAATTTGGAT
    TTTAAATGTTGGTTTTTAAATTATATATAAATTATATATATATATATATATATATATATATATATATATA
    TATATATATATATATCGGAACCAACATTTAAATTCCTAATTCTTAAGGACTTCACTTTTGACCAAAAATA
    TTTGAAATGGGTTATTTAGGTCTGTGGTGGTTTGAATATGCATAGCCTATAGGAAGTGGAAGTATGGCCA
    TTTTGTAGTATGTGTAGCCTTGATGGAGGAAGTACATCACTATATGGTGTTGTGAGAGTTGAGATCCTAT
    GTTCAAGTTCTGCCAAAAACAGAAGAGAGTCCCCTCCTGGATATTTGAAACAGATGCAGAGGCCCAAAGC
    CAAACATTGGGTATATCTCAGGGTTTCTTATGGAAAAGTTGGCTGAAGGATTGAAGGCCTTAAAGGGGAT
    AGGAACTTCACAGGAAAACCAACAGATTCATCTAACCTAGACTCTAGGGGTCTTTCAAAGGTTGAGTCAC
    CATACAAAAAGGACACAATGGCTAGACCTAGGTCCCTGATACATATGTAGCAAATGTGCAGCTTAGACTC
    CATGTGGATTCCCCAACGACTAGAGCAGGTATTGTCCCTGAAGTTATTGCTTGTCTGTAGAATACATTTC
    CCAACATAATTGTCTTGTCTGGCCTCAGTAGGAGAGTATGTTCCAATCCTGGAGAGACTTGATATGCCAG
    GATTGAGAGATTAAGGGTCTCCCACCATCTCAAAGTTCATGGGTATGACAGGGGAGGGGCAGTGCAGGTT
    TTCCCCATCTCTGATTTCCAGCATTTGCACCCCCAATATTGAGGGGGAGGTCTAGCAATTGGAGGGGGGA
    CAAACAGTATGAGAAAGCTAACTTTAGTGGTGTTGTCACAGTGTGGGGTATTGTGGGTGGGAGTGGAGAT
    GAATCCTCCTCCTCCTCAGGAGGCTGTAGCAGGTGCTTGCCCTCTTTTGGGACAGTAGAGCTGTGGTCAG
    TACTGGCCTGTTCCTGACAAATTTATTCTGTGCTGTGACCATTTATTCAAGGGAGGAAGATTTAAGACTT
    GCTATGATAACCTGACGAATCTGGACAAACAAGAGACAGGAGGTAACACCTGAGTTACTCTTTTGCTTGC
    TAGTACAGAAGAGCACTATAATCCACAAATTGGGGTCCCACATATTCTTGAGTGGGATCCAAGGTGCCAT
    AATTTCAGCCACATTCCAAAGTCCCTCAAGGTCTGACAGTTTAGTCTTTAGGCTTCTCCTAACCAAATCA
    TATTTGGAGTTCTTTAACATAAAAGGGTAGTTTCCCCATATCACTGCCAGCAAAACAGGTTGAATTTGGA
    CAGACAAGCAAAACTATCACAAACAAGACAGACTATGTGTGCGATCCAAATGTCTTGTGATTAGAGGGGA
    AGTTCTGCAGCTTATTAGGCTGTGTCCTTATGCCCACAAATGTCTTCAGATAGGAAAGGGCCATTGGGTG
    CCAATCCTTAGTTCTTCTGTTTCCTGGGCTGTCAGTTTTTATGTGGAGAAGACATGAACCAAATGCAAAG
    TCATGTATCCTACAAGAACTGACATACACAGACAAACAAGGAATAACAATGAGCTCTCTCATTCACCTAA
    GGGGGTCTTATAACATAGAACAGAAAGGGGCCAACTTAGCAAGAATTGACCAAAAGGTGGTCACCTAGAC
    CACACCACAATGCAGGAAGGATATCAATGAAGGAAGAACAAAGGAAAGGCCAAATCAAGTTTGTTGGCAC
    ATGACATAAAACAGTGCTCAAAAAACAATAGATGCGAGCAAAATGAAGCATTGGAATCATATCGGGGTAC
    ATAGGGGTCACTCTTACCCCTGTTCAAGTGCCAGATGTTGTTTTAGCCTTAGGCTCCCTGAGTTTGTCTT
    TAGGGGAAATGGGTAAGAATACACAAAAATAATGTCACAGAATCTTAGAGGCAGATGAGAAGTCAAAGCA
    GACTCATTTATTGCTATAGAAAAGAATGCCTTTATACCTTCTGTCCATAACACCTCTGCCCATATATGCT
    CATCTCTGTGAGGCAATGGACTACCTGCAGACAGGCTGGTATCCAGTCAAGCTGAGGTCTGAACCACAAT
    GGTCGTAACTCACCTAAAGGACGTGGTAGGCATGACGCGATAGGCGTTCCCTCATGCTCCTGGAACTCCG
    GCCCCTGCCTAAGGTACCACCTCCCACAGCCCCCACAAGAGAAGCATGGTCAGTAGTCATGTAAGCAATG
    GCCCAAGCTTCTGACCTTCAGCCTAAACTCCTCCCCAGTTACCTAGCAACAGTGAAGACCATAAAATGGG
    ATGTTAGGCCCCCACCTCACTCTCTTACTCCTTTGTTCCTTTACCTCTCACTTCTCTCAATTCTCTCTCC
    TCTTCCCTTTCTTTGTCTTCTTCTTTCCTTGTCTCTCTGTCTTTCTCTTTCTCTCTAGCCTTCTCTGCCT
    CTCTCTCTCTCTCTGTCTCTCTGTCTCTCTCTTCTCTCTTTCCCTTGAATTTCTTTTTTTCTTTTTTCTT
    TTTTTGATGAGCACAGTATAAATAGTTTATTGCATTGTTTCTGAATGTGGCTGTATTCTCTATTGTTCTC
    TTTCTTATTTTTTTTCTTTTTTTGGTTGTTTTTGTTTTTATAGTCTCGCACAGAATTCTACATCTACCAA
    ATCCCCATTGTGTACTTTAGTTTTGTCTTGTATTCAAAGGTTCTTTCAGAAAGAATCTTAAAGATGAAAT
    TTGCCTTCCAACTTTTCAAAAATACATATAAAGATAGATGTTACATAGTTCACGGAATAGACACATATAC
    GGAGATGCAGCAATATCTCCTTTGTGCCTCTTGTATATTCATGTTATTTCCTCAACTAAAAATACATAGC
    CACAAAGACATACAATGAGCACTCCACTTAGGAAAATATGGCCATATTTTTTTACATTTTTATGATTTTA
    TGATTAGGTATATTCTTCATTTACATTTCCAATGCTACCCCAAAAGTCCCCCAACCCTTCCCTCACTCCC
    CTTCCCCACTCCCACTTGTTGGCCCTGGAGTTCCCCTGTACTGAGGCATATAAAGTTTGCAAGACCAATG
    GGCCTCTCTTTCCACTGATGGCCCACAAGGTCATCTTCTGATACATATGCAGCTAGATACATATACATAC
    ACGAGCTCCAGGGGGTACTGGTTAGTTCATATTGTTGTTCCACCTATAGGGTTGCAGATCCCTTCAGCTC
    CTTGGGTACTTTCTCTAGCTCCTCCATTGAGGGCCCTGTGATCCATCCAATAGCTGACTGTGAGCATCCA
    CTTCTGTGTTTGCTAGGCCCCATTATAGCCTTGCAAGACAGCTATATCAGGGTCCTTTCAGCAAAATCTT
    GCTAGTGTGTGCAATGGTGTCAGCATTTGGGGGCTGATTATGGCATGGATCCCCGGATATGGCAGTCTCT
    AGATGGTCCATCCTTTCATCTCAGCTCCAATCTTTGTCTCTGTAACTCTTTCCATGGGTGTTTTGTTCCC
    AATTCTAAGAAGGAGCAAAGTGTCCACACATTTGTATTCATTACTCTTGAGTTTCATGTGTTTCCCTTGC
    ATTTCTATAATAAACCATAAGGAGTCTCTGCTCTACCAAGACCCGCTGCACACTCTGGTCAGTGTTGGGA
    ACTTTTCCCCTATTCCCTCTCTCCTATAACTCCGGGGCTACAGGGTGTCTCCTTTGGGTCCCGGTTGGGA
    GCTGTCTCTTCTCAACCCCCTGACTCATGGGTCAGAGGCCTAAATCTCCACCCAAGGCTGTGTGAAAAGC
    ACCGGGTGGTCTCCCCATATCTCCCTGTCCAGAGCACAGGAACTCTGGCCGGACATGGCATATTTTTCCT
    CCCCAACTTCTTCCCCGGCCTCCTCAGGGCTGTCCCTTCATTTTGTTCCCCACACATCTCCACATGGCTG
    CCACCATCCAATTGGCTGCTGAGGTCACACACTCTGTCTTTGTTCTTCTCTGAGTCTCATGCAGGTTTTG
    TGTTAGTAAATGCAAAAGTGCCTGCTGTGCATGCATGAACCATTACAGGCTGCTAGGCAGAACATGCTGA
    CTTGCTCCTGGATTATAAATCCATCACTGTGATAGCAGGACATATCCAGAAGACATTATTTAACAACACT
    CCTCTTCGTGCTCAACCTCTCATGGTCTTTCTACCTCCTCTTTCTTAGTGTTCTCTGAGCCTACATGAAA
    TGTGAACAAACCTGAAAAAAATCTCTGTGTCAAATACATAGTGTGGATTGGGAAGGAAAAACCCTGCACT
    TGTGTGTGGGCAGGGAAATGCTGGTGCTTTAACAGGACAAGTGCGGTGTGGCTAGAGAAAGTGATGAGAA
    GAAGGGAAGCATGAGAACTGGGTGGGTGGATCCCATGTCTACTGAAAATGCTATGTTGATGTCAAGATAT
    TGTGTCTTGTTACAAAAATTCATTGAGTACCTAGGTTATTCTCAGTATATAAAAGGGGAGGAATGAAACT
    AGAATTAAACACACACACACACACACACACACACACACACAAACACACACACACGAGTAGAGAAAAGAAA
    TAGTCATGAGTTGCCTAGTGAATGAAGAGCGGAAAATGGTGCAGTTAATAGGGATCATAGAAAGAACTGG
    GGGATGCACACGAATGGGTTTCCTGTAATTATGTCTTCATAGTAATCTCTGCTCAATAATCAGACAGTGA
    CAATGTATGCCTCATTTACAAGCCCTGATGGCCTCTCAGAGGAAAGCATCTCTCTGAAATGAATAAAGTT
    CAGAAATGTCCTAAGTGTCCCTGTCACAGGAAAGCAGTGTTGGTAACGTTTCCAGGAAGCTCAGTCTTTG
    TCAAATATCCACAACAAGAAGAAGCCATGTCTAGACAGACAACAGACTGGGAAAGACTGAGCTCATGTAT
    GGAAACACAACTATGTGTCATGCTTTTATTTTCACATTATACTGAGGGGATATGACATTATAGAAACACA
    GTTTGTTCTTTGCATATGCTGAGAGAGGAACTAGATGAAGTGTGCTAATTCTTAGCAATAAAAAGATATA
    CAAAGTGGTACTTTACTGTTTCAATTTTTGTAACTGGCATCATTGTCTTTGATATTTTATATCTTCCTTG
    AGCACTGCCTTCTCTCAAGTGTCCAACTTCAGAGTATGCTATAGCAGGAAGACTACCAAATAAGATTAAT
    TTTTTTGTACCCATGAAAAAATTATGTGCCCTGACCCCTGTTCTCTGAAAGAGGAGCCAAGTTCTGGATT
    CCCAGATCCTCATATTCATTGATCAGCAGTGAACACAGATCATTCACCATGGACATGGGGCTCATCTGGA
    TTCTCCTTATTGTTTTTAAAAAAGGATTTCATTGGGAAAAGCTGCCTCATATTTCTATGACCAGGAGAGG
    AAGATACAGCTAGAGACACAAGCCCCACCATGTAAAATCTGTATGGTACTCTCGTTTTCATTTTACAACA
    TTTTGCTTTTGCATTGCAAAGGAGCAATAAGGGTTCAGCAATCAGCACTGTAACTGTACTTTTAAAATTT
    CCACCTCTACCCTCTGTGTCCTCTATCTAGTGATAGAAAGTGAAATAAGCACATAAAGCATGGGACAAGA
    AGAACACACAGAGGAGCAGAGACTGGCTACAAGTGGCAGCCAGCATGGAGCTGGACAGAATTTAAAAAGA
    TAAAGAGAAATGTCATGGCATGAAGCAGTGACTTTTTCTGTTCACAATGCCTGCAAAAACTTTATGGAGC
    CTACTACTGCTGAGATATGCAGGTTTGGTTCCAGAGAGGATTTTCTGTTTTATTTAATTTGCTTTTAAAT
    TTTTCTTCTTTGTATAGTCTGTATTTTTAAAAAGGGGTTGAATGAATACCTAAGCAGTTGGAAAATTTGT
    GAGTAGAAACCGAGGGCCTGAGAAACAAATAAATCAAAATTTTGAAATGGCAAAAGAAAGGGTTCATTCT
    ATTTTCTCTTTTCAGAAAAGGTTGCAAAGTTGGATGTGCAAATGGAGATGTTATGGGTGGACTTGGAACA
    TCTTGGGAAGGAAGGAACCCAGGAAAAGAAAGAATGAAATGGCTCAGCCTCAATGACTGAGCAAGAGAGT
    TAGAGTCACCCACAGGAGAAAAGAAGAAAATAAACAGCACTGGGGTGAATTTGGGTCAGAGAAAACCTTA
    AAATGCCAGAGGACAATGTGATGAAAGAGACCATTTGAAAGAAAGGGTTAACCTCATTCCATCAGTCATG
    CCAGAGTTAGAGAATGGGCAGTCTGGAGTTACAAGATCACGATTAGCCTTCCCAGTATGTATACAGCATA
    TTCCTGATAATGAGATGAAGCAAAGTTTGACAAGGTAAGATTGTATCCTATAGTAATATATAGATCAAAG
    GCATGTTGCAGTAAATCTCCAACAGAAATAAGCCCGGGCAATGAAAACACAACTCAATTAATATGAATAC
    GTGCTGTGCACCTAGACTGGGCAGATCTACCACTCCACTACCATATGAGAGATCCCTTATAACTTGTGGT
    TTCTCCAGGCCAGCTGCTTCTGCTCTACTTTCCTTCCTCCTCCTCCTATGTCATCCTCTCCCTCACTCTT
    TCTCTCCCAAAACTTTCAGCTGCACCTTCCCCTCTTCATCCCCCAATCAGTGGCTCTAGCCTTTATTTAT
    AAATTAAGGTAGGAAGAAGGTTTATAGGAAATTACCTGAGTGTTGACGTGTTGATAACCCCACACAAGAG
    AACAAAATTAATATCAAATATGATTAGCTCCAGGGTTATATGCAACAAAGGCATGATAAAGTGGTCATGA
    TTTCATATGAGATGTACTGGACTCATGTGAAAAAACGTTTAAATACATGGGCTTACTCAAAATATAGACT
    CATACCCCCAAGATGGGAAGAGACTGGTAACATTTGTACTGGAGGCTGGTCTGCTGTGGCAGCCATTAAC
    ACAGTGGAGGGAAGAGCCTCAAAGAGTGAAATAGAGGAAGGGGAACAAATACAGTAAACCACCAGTTACT
    ACTTAAAGGGCAGTGTTCTGATGTCCTAGGGAGGGCACTCCAAAATACCAATGGCCTTATCCTTAAATTT
    ATTGTTTAATGAGCCTACACTGATCTCAGTGGCCCACTACTAAGGAGAAATGACAGGCACTTGAACAGCT
    GATATGAGAACAGCTGGAGGCACAGTATACAGAAGAGTTTACAAGCCTATGGAACTCCCCTGTATTTTTT
    TATGATGAGGAAATCTGAAAAATGTAAAATGTTGAAAGATTTAAGAGCAGTTATTAGAGTAGATCAACCA
    ATGAGTCTCTTGCAGCCTGGAATTCTTTTATCTTGTTTGTAACAACAATCAGGCTCCATAAATTATAAAC
    TATAAAAATTTACTTTATAAATTATAAATATATATATATGTGTGTCTGTAGATAGATAGATAGATAAATA
    GATAGATAGATAGATAGATAGATAGATAGATATATGGATTTGATGGTTGCAGCAAATTCTAATTGGTTCC
    AACAACCCTACTCACATAATACATTCATACAGGTTTGATAGATGGAGCTAAGTTTTAAATAAATTATTTT
    TCTCCCATGGCTTATATATACACCACCAAAATTCTCAAAAATTAAAATGTGATTGTGTTGTATTTTTCTT
    TTACTGAATGACTATAAAAAGTTACAACATTCTCCATAAATTTACATGAAAAAATATTATGTAGTGCAGG
    TAAAGAAAACAAATTGACCCAAGAATGGTGTATATTCATTACTAAGCAACTTTTTAGATTCACAAAGTGT
    GGGTAAACAAGGTAATTTTTTCAATCAGTTTTTTTTAACTGGCAGGCAGCAATTCAGAGTTACAATGAGA
    AGATTAATAATTTTATTGTGTATTTTAAAATAAATCTTACAAAAATATTAATAGAATCACAAATTTATAC
    CTTTGTATAAAAACAATCAGTCATTTCTACTTTAAGAAACAGAACTCACATCTACTCATCAATCATTTTA
    TTAAGTCATATTACAAAGCTGAGTGCTAACATGGGTATAAGAAAACCATAACCTTATTCACCAGCCCAGC
    GTCAAAAAGAAAAAAACCAGTCATATCAGCTGCTGCTTCAAGAGTTCTTGTTCCTTGACATTAACAAAAT
    CCCTAGCTTAACTATTAAATTTTTTTTCAAAACTTCTAATTGATCCCTTAGATAAATGTTTGTGCTAACC
    ATCGGGACACATCCCATGAGTTCTGAAGCAGTGTGTTGTTCTTCATGCATGGCCCTTTTGTAGAGCTGTG
    AGTGTAGGGGAAGAGGGGGGAGAGAGAGCCCGTGTCCAGCCAGAGATCCTGTGCTCTGGGCAGGCAGACA
    CGGGAGGACAACGGAACACTTTTCACTCGGCCTTTGGTGGGCATCTGGCTGTGTGAAGTTACTGACCCCA
    CATGGTGGGGGATGGACAAGGGGCAGCCCCTGGTACCAGGAGCCCCAGGGCTACACTCTCGGCCCCAGAT
    ATACAAGAAGAGGGCAGAGGGAGAGAGGCTCCCACACAGGCGAGAGTCCTTAGTCTGGTCTGTGGCTGGA
    GCAGGGGAATTCCTTCTGATTGGAGATTAGGCACAGCTGATTAGGGGAAAGCCTACCCCATCATCCAAGC
    ACAATGGACTTTGAGGAACAGAGCCAGTCTAAGCTTTTATAGCTTTATGGTAGAAAGGCAGGGAGAAAGG
    AGAGAATGTGGAGAGAGACAGAGAGAGACTGGCCATGGCCAAGAGGAGGGAAGGGGGAAGAGAGAGAAAC
    AGGAAAAGCTAGAAAGTAAGATAAGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGCAAAGTG
    GGGCCAAGCAGCCCCTTTTCTAGTGAGCTTGTCATCTCACAGTTGCTAGGTAACTGGGGAGGAGTTTAGT
    CTGAAGGTCAGAAGCTTGGGACCTTGTGTATGTGACTACTAACCACAGCTTCTCCTGTCGGGACTGTGGG
    AGCAGTAACTTTGACAGGAGACAGGGATCCAGGAGACATGAGGGAACACCTTCTGTCCCACATAGGTGGA
    ATCGGTTGTACCAGGGTTCAGAACTCAACTCCACTGGAGACCAGCCTATGTGTGCATAGCCCATTGCCCT
    ACAGCCTTTGACATTCTACAGAGTTCTGAGACTGGTAGAGATACAAAATAGCTAGGATTACACAGAGAAA
    CACTGGCTTGACAATAAAACTTCCAAAACAAATATAAATGAATAAATACACAAATTGGAGCAAGTGAACT
    TGCACTAAATCCATCAAAACTTGCACAGGATGGCTGTCTCCATAATGTTCAGATCTACTTCTATTAATGT
    CATTAAGAAGACAAAGATTATGCACAAAAAGAAACAAAACAAGAAACCCAAAAGGTAAAGGCTCCAATTG
    TAAGTAATAGACCCACAGTCTCTGAGGCCTGACTGTGCAGGTCCTCACCTTTGGTAATCAGCACTGAATG
    CAGACCACTCCTCATGGACTTTGGGCTCAGGTTTGTTTTCCTTGTCCTTATTTTAAAAGGTAATTCATAG
    AAATGAGATCCTGCCAGTATTGTGTACATGAGAAATAGAAAAATTGGTTTTCTTTGCTCTATTTTGTTTT
    GTTTGGTTAATGACAGTTTCCAAATCAGCATTCTTTGCTTTGAGGTGCCCAGTGTGAGGTGAAGCTGGTA
    GGGTCAGGGCAGCCTGGAGGGTCCCTGAAACACTCCTGTGCAGCCTCTGTAGTCACTGTGAGTGACTACT
    GAATGACCTGGGTCCTTCAGGCTCTAAAGAAGGGGCTGGAGAGGGTGGAAATAATTTTTAATGGTGGAGG
    TAGCACCTATTATCCAGACACCATGAAGGGCTGATTCACCATCTACAGAGATGATGCCAGAAACACACTT
    TACCTGAAAATAAACAGTCTGAGGTCTGAGTACACAGCCATGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
    TGTGTGTGTGTGTGTGTGTGTGTGAGTGTGTATTCATATATATATATATAGTGTGTATGTATATTCATAT
    ATATATGTATATTCATAAGGTTGAGTAAATGGACTTAAACTGATTCCATCACAACTTCCATGGGATGGAT
    ATTTCCCAGTGTTAAGACCTGTCAACATCACTGTCATTCAGGAGACAATGATTATGCACAACAAAACAAG
    AAACCCAAAAGCAGAGGACTCCAATTACAATAGACCCAGACCCACAGTCTCTGAAGATTGACTGTACAGT
    TCAACCCAGCCCTGTACTTCTCTTCCCTAGAATTTACATTACTGAGTAACTGAGGAAAGCTCTACAATAT
    CTGTTCTCTATAGTGGTCAACACCTCCAAACACAGGTTACCCATATTCATGCCTGCCTTCTGCTACACTT
    CTTGCCATAATGTAGACTACTTCAGCCTATTTTGTACTCCAGTTAACGAAACTCAAGACTAGCTGCATGT
    TAGTCCTTATTCTGAAATATTATGAACAGGTGACCTCCCATCATTCACCAATGCAATAATCATATTTAGG
    AATATGAGGTTTTATGAGATATAAGCACAAGGGAGAGAAAGTAAGAAAACTACATAGATATATAGACTGA
    CATAAATCAAGACTTGCATGAGCTAGTGCCCAAGTACCATGTCCCTAAGTGGCAAGGAGTATCTTTTGAG
    CCTAGTGAGATGAGGTACAAATCGGACTCTTACATCTTTTTAGATAAACATGTGAGATCAATGGACTAAA
    GGCGTGAGCTGGGCTTCCTTGCAATCCATTTTCCATACAAGATAACAATAGATCTGGCTCCACAGACACG
    ATGAGAATAGTCTTAATTAGTTCTTTAAGTAGAATGACTGATCACTAAGAGCCCAATTCCATACTAAATA
    CTCTTCTGGATTATGCACAGATAAAAATTGCACATAGGGCATGGGGCACTGATCTCCCTGCACTACATGA
    ATGGGGGCTCATTTACTAAATGTTCCCATGTTTCTTCCTAGTGCTGCACAGAGCAAATCCTACAACTTCC
    TGCTTGTCTACAATGTAAACTCCAGACAGTACCAGAAAATCATTCCTTATGTTCCTCTCCAGGTGCTTCA
    ACAAGCACAGTGCAAATTTCTGTCACCCTG
  • Molecule Role : Vaximmutor
  • Additional Molecule Role : Vaximmutor
9. IgG Fc fragment
  • Gene Name : IgG Fc fragment
  • Sequence Strain (Species/Organism) : Macaca mulatta
  • NCBI Gene ID : 718859
  • NCBI Protein GI : 383873191
  • Locus Tag : EGK_10892
  • Genbank Accession : CM001271
  • Protein Accession : NP_001244449
  • Taxonomy ID : 9544
  • Chromosome No : 19
  • Gene Starting Position : 55776057
  • Gene Ending Position : 55793029
  • Gene Strand (Orientation) : +
  • Protein Name : 3
  • Protein pI : 6.71
  • Protein Weight : 38189.56
  • Protein Length : 365
  • DNA Sequence : Show Sequence
    >gi|109156886:55776057-55793029 Macaca mulatta chromosome 19, Mmul_051212, whole genome shotgun sequence
    AGAAGGATATTAAAGAGCACCTGCAGGACCTTTCTAACGGGATGTCGGGGGAAGGGCTTGAAGGAGGATC
    TAGGGAGGCTTCCATAAGATTTTGATTAACATCCAGCGCTAGGGAAGGTCACAGGGATACAAAAGGGTAG
    GAGGAGGATCCAGAGACCTGCATGTTGTGGACTTCGAAGGCATCCGGTTCCTTTCCCAGCTTTGTCAAGA
    ATTCCCTGGGCGGCGGACACCCTCATAATAAAAAAAACGGGAACCACAGGGAAGGGGAATAGAAGAACCA
    CAAGCGTTTTGAGAAACATACATAGGCTGGGCCTAGGGCCTGGGGTGTGCCCTGCAACTGGGGGGGGTGG
    GGCTGGATGTTCTTGGAGTCAGGGAGCAGCAGCCTCCCACAGGATGTGAGAGAGGAACTGGGGTCTCCAG
    TCACGGGAGCCAGGAGCCGGCCAGGGCCGCAGGCAGGAAGGGAGCGAGGCTGAAGGGAACGTGAGCCGAC
    CAGGCCCCGATTGAGGGAGGAGGGAAGGGCCTGGACCCCTGGGCCTGAGGGAGGAGGGGCTGGGGGTCTG
    GACAGTGCGTCTGAGGGAGGAGGGGCTGGGGGGGTCTCGACACTGGTTCTGAGGGAGGAGGGGCTGGGGG
    CCTGGACGCCTGGGACGGAGGGAGGAGGCACTGGGGGTCTGGACACTGGGTCCGAGGGAGGAGGGGCTGG
    GGGCCCGGACTCCTGGGTCCGAGGGAGGAAGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGGG
    CTGGTGGCCCGGACTCCTGGGTCCGAGGGAGGAAGGGTTGGGGGCCCGGACTCCTGGGTCAGAGGGTGGA
    GGGGCTGGTGGCCCGGACTCCTGGGTCCGAGGGAGGAAGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGG
    TAGAGGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGGGCTGGCGGCCCGGACTCCTGGGTCCG
    AGGGAGGAAGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGGGCTGGTGGCCCGGACTCCTGGG
    TCCGAGGGAGGAGGAGCTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGAGCTGGGGGCCCGGACTCC
    TCGGTCGGAGGGTGGAGGGGCTGGGGGCCCGGACTTCTCGGTCGGAGGGTGGAGGGGCTGGGGGCCCGGA
    CTCCTCGGTCGGAGGGTGGAGGGGCTGGGGGCCCGGACTTCTCGGTCGGAGGGTGGAGGGGTTGGGGGCC
    CGGACTCCTGGGTCCGAGGGAGGAGGGGCTGGGGCCTGAGGGGGACGGAAGGGGCGTGGCCGAGCTCGGG
    GCCGGGACTCTCAGCCTATCAAGTTTCTGTAATTAATTAACTAACTGAGATCCAGTTCAGGGGTGAAAGT
    TCTTCAGGTAGGAGGAGGGCATTGTTGTCAGTCTGGACCGAGCCCGCAGAGCCCCTCCTCGGCGTCCTGG
    TCCCGGCCCCTGCCCCGGTACCCCGGGAGGAAGGGCGGGGCCGGGGGTTTTTCGGGAGGAGTCACGTGCC
    CCCTCCCGCCCCAGGTCGTCCTCTCAGCATGAGGGTCCCGCGGCCTCAGCCCTGGGCGCTGGGGCTCCTG
    CTCTTTCTCCTGCCCGGGAGCCTGGGCGCAGGTGAGGGCCGCTGCGGGCCGGGGCCCTGCTGCAGGCGGG
    CGGTGGGAGGCGGCCCCAGGCAGGCAGGGGCGAAGCCAGCGGGACCCGAGTTCCCCGCGAGTCCCGGGCG
    CTGCCTTCTCCGCTCAGTTCACTTTCTCAGCGTCTCCTGCTGGGCCTGAGGCTGAGAACCACCTGTCGCT
    TCTGTGTCTCTGTTTCCCTCTCTCTCTCTCTGGGTCTCTGTCCTCTCTCTCTCTCTGGGTCTCTGTCCTC
    TCTCTCTCTCTGGGTCTCTGTCTCTGTCTCCCTCTCTCTCTCTGGGTCTCTGTCCCCTCCCTCTGAATCT
    TCCCTCTCCATAATAGATTCTTCTCCCTCCCTGGATATCTGTCCCACTGCAATCTAGTTCCCCGCCCATG
    TTCTCCCTTCAGCTCTGTCTCTGTCTGCAGAAAGTCACCTCTCCCTCCTGTACCACCTCACCGCGGTGTC
    CTCGCCTGCCCCGGGGACGCCTGCCTTCTGGGTGTCCGGCTGGCTGGGCCCGCAGCAGTACCTGAGCTAC
    GACAGCCTGAGGGGCCAGGCGGAGCCCTGTGGAGCTTGGGTCTGGGAAAACCAAGTGTCCTGGTATTGGG
    AGAAAGAGACCACAGATCTGAGGATCAAGGAGAAGCTCTTTCTGGAAGCTTTCAAAGCTTTGGGGGGAAA
    AGGTGAGATTCGAATCCGGAGGGGCAAGGGGCTGGGTCCATGCTCCTGGGCCCCACTTACATGTGTGTGG
    GCGCCCCAGGCCCCTACACTCTGCAGGGCCTGCTGGGCTGTGAACTGAGCCCTGACAACACCTCGGTGCC
    CACCGCCAAGTTCGCCCTGAACGGCGAGGAGTTCATGAATTTCGACCTCAAGCAGGGCACCTGGGGTGGG
    GACTGGCCCGAGGCCCTGGCTATCAGTCAGCGGTGGCAGCAGCAGGACAAGGCGGCCAACAAGGAGCTCA
    CCTTCCTGCTATTCTCTTGCCCACACCGGCTGCGGGAGCACCTGGAGAGGGGCCGTGGAAACCTGGAGTG
    GAAGGGTGAGCCGGATCTGCAGCCACAGGCTGTTCTGTCCTCTCTGCCATCACGCCCACCTGCCTCAGTT
    CCCCTGTCAGGACCCTCAGTCAGCCTCCCACTGCAGCCCACGCTCTGCCCCCATTCCTCAGGGGTTTTTC
    TACATTCAGCCCTCCCATGGCTCCCCAGCGCCCCCCAAGACAAACTCTTGGCTTCCTTGCCTTTTTTTGT
    TGAGACGAAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGTGTGATCTCGGCTCACTGTAACCTCC
    GCCTCCCGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCTAGTAACTGGATTACAGGCATGCATCACCAT
    GCCTGGCTAATTTTGTATTTTTAGTAGAGGCGGGGTTTCTTCATGCTGGTCAGGCTGGTCTCAAATTCCC
    AACCGCAGGTGATCCGCCCGTCTCAGCCTCCCAAAGTGCTGGGATTACAAGCGTGAGCCATCGCACCTGG
    CTGTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGACAGATTCTCTGTCACCCCAGGCTGGAGTGTGGT
    GGCACAATCTCAGCTCACTGCAGCCTGAACCTCCCAGGCTCAAGCAATCCTCCCACGTCAGCCTCCCAAG
    TAGCTGCGACCACAGCATCGTCACACCTGGCTGACTTTAATTTTTATAGACACAGTGTCTCACTACGTTG
    CCCAGGCTGGTCTTGAACTCCTAGGCTCAAGCAGTCTTACTGCTTTGGCCTCCTGAATAGCTGAGATTAC
    AGGTGCATACCACCATAACTGGCTAATTTTTTTTTTAGTTTTCCGCACAGTCTGCCTCCCAGGCTAGTGT
    GCAGCAGCGTGATCTCAGCTCGCTGCACACTCTGCCTCCTGGGTTTAAGCGATTCTCCTGCTGCAGCCTC
    ATGAGTAGCTGGCACTACAGGCACATCCACCATCTCTGGCTAATTTTTGTAGTTTTAGTAGAGACAGGGT
    TTCGTCATGTTAGCTAGGCTGGTCTCAAACTCTTGACCTCAAGTGATCCACTCACCTCAGCCTCCCAAAG
    TGGTGGGATTACAGGCGTGAGCCACCGCATTTGACCATAACTGGCTAATTTTTAAAATTTGTTGTAGAGA
    TGGCATCTCGCTGTGCTGCCCAGGCCAGACTCAAACTCCTGGCCTCAAGTGATTCTCCCACTTTGGCCTC
    TCAGGGTGCTGGGATGACAGGTGTGAACCACTGTGCTTGGCCTTCCTTGCCTTAATGCCCTCGTCAGACC
    CACGCAGCAGCACTTGTCTCTACACAGCTGTCAGAGTCTAGGCTCCAGCCACCCAACATGAGCAATCTTC
    TCCCTCTGAGCATTTGTTCATCCAGTTCCCCCGGCCCCTCTCTGTTCCACCCTTCCCCCTCTCTGCATAT
    ACTCCAGCCCTCCTTATTCTTCAAGGTCGGGGCTGGATATCACTTCCTCTGAGAAGCCTTCTCTCAGCTC
    TGTAGGGCAGAGTTCACTGTTTCCTCCCCAGCGGCCCCAGATCCCCATTCATTCAGCTGTTGGCCAAGAG
    CATTTGCACTGCCAGACACCGCTCTGGGACGCCGCTCTGGGCCTTGAGCAAAGAGGGAAGTGACACACGT
    TCACCCTCTGTGGCTTCCAGGCTGCTGGACAAAGATAGATATCGGCTGGGGATTTGCACAGATGTTCATT
    CCAAGTGCCACAAAGGAGAAGTTGAGACTTAACCAGGTAGTTTTTCTTTGATCGTCTTCTTTCTTTTTTA
    AGTAGGGAAAATTTCCTTTTTTTTGAGATGGAGTCTCGCTCTTGTCGCCCAGGCTGGAGTGCAATGGCGC
    AATCTCGGCTCACTGCAACCTCCGCCTCCCAGCTTCAAGTGATTTCTGCCTCAGCCTCCCGAGTTGCTGG
    GACTACAGGCACGTACCACCATACCTGGCTAATTTTTGTATTTTTTTTAGTAGAGACAGGGTTTCACCAT
    GTTGGCCGGGATGGTCTTGATCTCTTGACCTTGTCATCCGCCTGCCTCGGCTTCCCAAAGTGCTGGGATT
    ACAGACATGAGCCACTGTGCCCGGCCTTTTTTTTTTTTTTTTTTTGAGACAGACTTTTGCATTGTTGCCC
    AGGCTGCAGTGCAGTGGCACAGTCTTGGCTCACTGCAACCTCCACCTCCCAGGGTCAAGCAATTCTCCTA
    CCTCAGCCTCCCGAGTAGCTGGGAATACGGGCACGCACCACCCTGCCTGGCTAACTTTTGTATTTTTAGT
    AGAGACGGGTTTCACCATGCTGGCCAGGCTGGTCTCGAACACCTGATCTCGTGATCCGCCCACCTTGGCC
    TCCCAAAGTGCTGGGATTATAGGCGTGAGCCACCACACCTGGCCTAAGTAGGGAAAGTTTCAAACCACAC
    TTAAGTAGACACAATAGTATAAAAAGGACCAGGCATGGTGGCTCATGCCTGTAATCACAGCATTTTGGGA
    GGCCAAGGCAGGTGGATTGCTTCATCCCAGGAGTTCAAGACCAGCCTGGGCAACATAGCAAGACCTCATC
    TCTACTAAAAACTCAAAAAATTAGCCTGGCATGGTGGTATGTGCCTCTAGTCCCAGCCACTGGGGAGGCT
    ATGGTGGGAGGATCACTTGAGCTCAGGAGTTTGAGGCAGTAGTGAACTGTGATTGCAATCCTGCACTCCA
    GCCCAGACTACAGAGCCAGACCCTGTCTCAAAAAGAAAAAAAATATGATGGCCAGACGCGGTGGCTCATG
    CCTGAATTCCAACACTTTGGGAGGCTGAGGTGGGCAGATCACTTAACAGGAGTTTGAGATAAGCCTGGCC
    GACATAGTGAAACCCCATCTCTACTAAAAATACAAAAATTAGCCAGGTGCGGTGGTGGGCGCTTGTAATC
    CCAGCTACCCTCCACTTCAAGTGATCCACCCTCCTTGGCCTCCCAAAGTGCAAGAGTCACGGTGCCCGGC
    CAGAGTGTTTTGTTGATAAGTACTTTAGTATGTAACTCTACTAGGTAAGGGCATGTAAAAAAAATTAATA
    CCAAAACCATTATCACACCTACGATCAATTAACTGTAACTCCTTAATGGCATCAGATGTCTAGTTTTTGT
    TCACATTTTCCTGACTGTAAATTTTTTTTTTTTTTTTTTGAGACAGTCTCTTTCTCTGTCACCCAGGCTG
    GAGTGCAGTGGCCGGATCTCAGCTCACTGCAAGCTCCGCCTCCCAGGTTTACGCCATTCTCCTGCCTCGG
    CCTCCTGAGTAGCTGAGACTACAGGCGCCTGTCACCTTGCCCGGCTAGTTTTTTGTATTTTTTTTTTTTT
    TGTTTGTTTGTTTTTTTTGAGACGGAGTCTGGCTCTGTCGCCCAGGCTGGAGTGCAGTGGCCGGATCTCA
    GCTCACTGCAAGCTCTGCCCCCCGGGTTTACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTA
    CAGGCGCCCGCCGCCTCGCCCGGCTAGTTTTTTGTATTTTTTAGTAGAGACGGGGTTTCACCGTGTTCGC
    CAGGATGGTCTCGATCTCCTGACCTAGTGATCCGCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGC
    TTGAGCCACCGCGCCCGGCCGTTTTTTGTATTTTTTTAGTAGAGACGGGGTTTCACCGTGTTAGCCAGGA
    TGGTCTCGATCTCCTGACCTCGTGATCTCCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNGCACACCACCATGCCTGGCTATTTTTTGTATCTTTAATAGAGACAGAGTTTCACCAT
    GTTGGCCAGGCAGGTTTTGAACTCCCGACCCCAGGTGATCCACCTCCCTCGGCCTCCCAAAGTGTTGGGA
    TTACAGGCATGAGCCACCGCGCTCAGCCGTATTTTTGTTTTCTTTTTTTTTTTTTGGAGACGGAGTCTCG
    CTCTCTCGCCCAGGCTGGAGTGCAGGGGTGCCATCTCAGCTCACTGCAACCTCCACCTCCCGGGTTCAAG
    CGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGCGCCTGCCACCACGCCTGGCTAATTTTT
    GTATTTTTAGTAGAGATGGGGTTTCACGTGTTAGCCAGGATGGTCTCGATCTCTTGACTCGTGATCCGCC
    CTCCTCGGCCTCCCAAAGTGCTGGAATTACAGGCATGAGCCACTGTGCCTGGCCATAATTTTTGTATTTT
    TAGTAGAGACAAGGTTTCACCATGTTGGTCAGGCTGGTCTTGAACTCCTGACCTCATGATCCGCCTACCT
    CGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCTACTGTGCCCGGCTGGATTCCAATTTTTTATCAGA
    TAGGTGTTTTGCAAATATTCCTTACACTCTCTAAGTTGTCTTTTCATTGTTTTAACTGTGCCTTTCAGAA
    AGAAAAAGTTTTTAACTTCGATAAAATAGTTTATTCTTTTTTTTTTTTTTTTTTAAATCATGGGTTATGC
    TTTTGGTGTCTTATTTCAGAAGTAAGCACTAAACCCAAAATCAGCTAGATCTTCTCCTGTGTATTTTACG
    AGTTTTAAAGTTTTGCATTTTATAGTTAGGTCTGTGATTCATTTTGAGGTAATTTGAGTTACTTGTGATC
    TTGAGTGTCTTTTGATTTACAGGTTTCCCATTTTCTTTTTTTTTTTTCCCCTCGTAATTGTGGTTTGAAG
    AAAGTCCGTTTATGTCCTATTGAGTTTCCCTCAGACTGGATTTTACCCTTTGCATCCTCTGATGTTGCTG
    GACATAGTCCTCCTTCTCTTCTTTAAAGGAGCAGCTCGATCTGCAAGCTTGATCAGATTCTGGTTCAGTT
    TTTATGGCAAGAAAAGTTTCGGCCGGGCGCCTGTAATCCCAGCACTTTGGGAGGCCGAGACGGGTGGATC
    ACAAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAAAATACAAAA
    ATTAGCTGGGCGAGGTGGCGGGCGCCTGTAGTCCCAGCTATACTGGAGGCTGAGGCAGGAGAATGGCTTG
    AACCCAGGAGGCGGAGCTTGCAGTGAGTGGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGGGCGAG
    ACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAACTTTCTGGGTAGTTGGTGGTTATGTCTGTGTG
    CATAGGCTGCAAATATCTGCTCGCTTCTGTGCTGTTCTGCGGACCACTGGATTCGGGTGTTACAAAGTTC
    TCTGTCAGGTTTTCTCCTGATGCTTTTAGCGGACAGCCATGGCCACTGCCTTAATCTTTTTTATTTATTT
    ATTTATTTATTTTTGAGATGGAGTCTTGCTCTGTCGCCCAGGTTGGAGTGCAGTGGTGTGATCTCGGCTC
    ACTGCAACCTCTGCCTTCCAGGTTCAGGCGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGG
    CGCATGCCACTATGCCCGGCTAATTTTTGTATTTTTTTGGTAGAGATGGGGTTTCACCATGTTGGTCAGG
    CTGGTCTTAAACTCCTGACCTTGTGATCCACCTGCCTCGGCCTCCCAAAATGCTGGGATTACAGGCATCA
    GGCATGAGCCAGCGCGCCTGGCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGAGGGAGTCTGC
    CTCTGTCACCAGGCTGGAGTGCAGTGGGCATGATCTCGGTTGACTGCAACCTCCACCCCTCAGGTTCAAG
    TGATCCTCCTGCCTCAGCCTCCTTAGTCGCTGGAATTACAGGTGCACACTACCACACCCAGCTACTTTTT
    GTATTTTTAGTAGAGACGGGGTTTCACCATGTTGGCCAGGATGGATTTCTTTTTTTTTAGAGAGATGGAG
    TTTCACTCTTATTGCCCAGGCTGTAATACAATGGCATGAACTCGGCTCACTGCAACCTCTGCCTCCTAGA
    TTCAAGTAATCCTCCTGCCTCAGCCTCCAGGGTAGCTGGGACTACAGGCATGCGCCACCATGCACAGCTA
    ATTTTTATATTTTTAGTAGAGACGGGGTTTCACCATGTTGGCGAAGCTGGTCTTGAACTCCTGACATCAG
    GTGATCCGCCTGCCTCAGCCTCGCAGAGTGCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNCACCGCGCCAGCCTTTTTCTTTTTTTTTTTTTTTAGACAGAGTCTTGCTCTGTC
    GCCCGGGCTGGAATGCAATGGTGCAACCTCTGCCCACTGCAACCTTCGCATTCCGAGTTCAAGTGGTTCT
    CCTGTCTCAGCCTCCTGAGTAACTGGGACTATAGGCGCCTGCCATCATGCCCAGCTAATTTTATGTATTT
    TTAGTAGAGATGGGGTTTCACCATATTGGCTAAGCTGGTCTTGAACTCCTCACCTTGTGACCCACCCGCC
    TCAGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACTGTGCCTGGCCCCAAGTTTATAAATTTTAAT
    TTATAAAGCTCAATTTTATCTTTGATTCTGTAGCTTTGTTGTGTATTCTCTTTAAGGAATCTTTCCTCCG
    AGAAAGGTATTCACCTATGTCTTCTAGAAGCTTAGTTGATGAATAGCTTCCACATTTAGTGATACCATTG
    ATTTTGAGTTAATTGCCTGTTATGATGAGGGTAGGAGTTGAGGTTCATATGTCCAGCCAGCATCATTTGT
    TGCTAGACCATCATCCCCTCTCCCTCACTGGACTGCAGGGGAGTGTGTTTTGTGTGTAAGGTGTGGATCT
    GCTTCTGACCCTCTCCTATTCTGCTGATTATTGGACTTAGTGTCAGTACCTCACTCTTGATTTGATGTAG
    CTTTTTTTTTTTTTTTTCTTTTTTGAGATGGAGTCGCACTCTGTCGCCCAGGCTGGAGAGTAGTGGTGTG
    ATCTCGGCTTACTGCAAGCTCCGACTCCCGCGTTCACGCCATTCTCCTGCCTCAGCCTCCCAAGTAGCTG
    GTACTACAGGCGCCCGCCACCACACCCGGCTCATTTTTTTGTATTTTTAGTAGAGATGGAGTTTCACTGT
    GTTAGCCAGGATGGTCTTGATCTCCTGACCTCCTGATCCGCCCACCTTGGCCTCCCAAAATGCTGGGATT
    CCAGGTGTGAGCTACTGCACCCATCCTGAATCTATTTTTATGAGAGACATTGGCCTTAAGTTCTCTTTCT
    TATAATGTCCTTTGTTGTCAAGATGATGCTGACCTCATAAAATATGCTGGGAGAGTGTTTCCTCTGTTTT
    ATTGCCTGAAGAGTTTGCGTAGGAGTAGAATCATTTCTACATTGGAAGAATTCACTAATTGATGTCTTCC
    GGACCTGGAATTTTAGTTTTCGGAAAGTTTTTTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTATGT
    CGCCCAGGGGGGGGGGCAGTGGCCGGATCTCAGCTCACTGCAAGCTCCGCCTCCCGGGTTTTTACCCCAT
    TCTCCTGCCTCAGCCTCCCGAGTAGCCGGGACTACAGGTGCCCACCACCTCCCCTGGCTAGTTTTTTGTA
    TTTTTTAGTAAAAACAGAGTTTCACTGTGTTAGCCAGGATGGTCTCGAACTCCTGACCTCGTGATCCGCC
    CGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGCTTGAACCACCGCGCCCGGCCAGTTTTCGGAAAGTTT
    TAAACTATGGATTAAACATTTTATTTATTTATTTTTTTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNCAGCTACTCGGGAGGCTGAGGCCGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCTG
    AGATCCGGCCACTGCACTCCAGCCTGGGTGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAATA
    CTTACAGGACTGCTGACATTTTAAATTTCCTCTTGTGTCAGTTTAGAAGGTTGTATTTATCAAGAATGTG
    TTCAGTTCATCTAAATTTTCAAATGTGTTAGTATGGAATTTTTCATAATTATCCTCTATCTTTTTTTTTC
    CTTTCCCCAAGACGAAATCTCGCTCTGTCACTCAGGCTGGAGTGCAGTGGCACGATCCCAGCTCACTGCA
    ACCTCTGCCTTCCAGGTTCAAGCGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGGTGCCCA
    GCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCACGTTGGCCAGTCTGGTCTCAAACTCCTGACC
    CCAGGTGATCCACCCACTTTGGCCTCCCAAAGTGTTGGGATTACAGGCGTGAGCCACCATGCCCAGCCCA
    GGGAGGTGACATCTTGAGGGGACACCTTCAGGGTGGATAGGTTCAGTCTCTGTCACCTGGGAAGCGCCTC
    CTCTTTTACCACCACATTATCCGGGGTTAGCACATTGCAAACATGGAGGCCTCTTTCTGTCATTACCCAG
    CCCTGGCCCTGGGAGTGGTGGGCTCGGGGCTTAGACCTGTCTGCCTGGTTTCCTGCAGAGCCCCCCTCCA
    TGCGCCTGAAGGCCCGACCCGGCAACCCTGGCTTTTCCGTGCTTACCTGCAGCGCCTTCTCCTTCTACCC
    TCCGGAACTGCAACTGCGGTTCCTGCGGAATGGGATGGCCGCTGGCACCGGACAGGGCGACTTCGGCCCC
    AACAGTGACGGCTCCTTCCACGCCTCGTCGTCACTAACAGTCAAAAGTGGCGATGAGCACCACTACTGCT
    GCATCGTGCAGCACGCGGGGCTGGCGCAGCCCCTCAGGGTGGAGCTGGGTGAGGCCCCGCCCGGTGGTGA
    TGCTCCTGGTTTCCCGTTGCCTTGTCTCACTGCTGCGCCGGTCCTTCCTGAGTCTGACCTTCCTCCCCGC
    TGCTGCCATCTCCTTGAATCTGACTGCCTTGTGCCTCGCGCCTTTCAGTGCCCCCAAAGCCTGATGCCTT
    GTCCTTCCCAAGGCCGACTGCCTTCCGTCCTGCTGCTTCTGGCCTCACTGAGTCTGAAGAGCTGTTAACC
    ACCATGGCCAGTCCTCCCTGAGTCTGACCGTCTTCCATCCTGCTGCTGCTGCGGCTGCAGGTCTTCCTGG
    AATCTGACCATTCGTTGTCTGCTATGCCCGTCCTCACCAAGACTGACCACTTGCTGCCTTGCTACTGCTG
    GGGCCCATGAGGCTGACTTCCCACTGCTCTGCCTGCCTCTCCCCGCTGCGCCGGGACAGCCCCACCCTGC
    CGCTGCTGGTCCATTGCCAGTGTGACCACGGCGGCCGCTCGTGCTGTGGCTGGTTCTTACATCCAGCCTG
    GGGGCACCCTGCCGAGATCGCCCGCCTGGCCTTGCCTCTGTCCATCAGACACTTGGTGCTGGGATCTCCA
    AGGCTGGGAGGGACTGGGACCCCCCACTGCTGTGTCCTGACTGGGTGGGGGTGGACGGGCTGCTCCACAT
    CTCACAGCGTTCTCTGGCTGCAGAAACTCCAGCCAAGTCCTCGGTGCTCGTGGTGGGAATCGTCATCGGT
    GTCTTGCTACTCACGGCAGCGGCTGTAGGAGGAGCTCTGTTGTGGAGAAGGATGAGGAGTGGGCTGCCAG
    GTGTGGGCAGCGGGAGGAAGAGCCTTGGAGAGAGGGACAGAGACCCCAAGAGAGGGGCACACAGACCTGG
    GAGGAGAGACCTGGTGTGGGGACAGACCCAAAGAGAGGAGGACAGAGACCAGAGAGAAGTGGAGACAGAA
    ACCCAGAGACGGGGGAACAGAGGCACAGAGAGAGGGGACAGAGGAAGGGGGAGACAGAGACCCCGAGGAG
    GGAGGCAAAGATGTAGAAAGAGGGGGGATGGAAAATTGGGAGAAGGGGAGACAGGCCCAGAAGGAAGGGG
    TTAGAGACTGAGGGAGTGTGTGTGAGACACACACAGAAATGGGGGATGCCAGTCAGACCCAGAGCACCTC
    AGAGATTCTGATGACCTCCCCCTCTCTCTCCACAGCCCCTTGGATCTCCCTCCGTGGAGATGACACCGGG
    TCCCTCCTGCCCACCCCGGGGGAGGCCCAGGATGCTGATTCGAAGGATATAAATGTGATCCCAGCCACTG
    CCTGACCATCTGCCATTCCGACTGCTAAAAGCGAATGTAGTCAGGCCCCTTTCATGCTGTGAGACCTCCT
    GGAACACTGGCATCTCTGAGCCTCCAGAAGGGGTCCTGGGCCCTGTTGTCCTCCCTCTGGAGCCCCGTCC
    TGTGGTCTGCCTCAGTTTCCCCTCCTAATACATATGGCTCTTTTCCACCTCGATAATATAACACGAGTTT
    GGGCCCGAATCAGTGTGTTCTCATCATTTTTCAGGCAGGGGAGGTAAGGGAATAAATCAGGGGACTGAAT
    GGCCGCTGAGGCTCAGATCTCTCCTACAGGTAA
  • Protein Sequence : Show Sequence
    >gi|383873191|ref|NP_001244449.1| Fc fragment of IgG, receptor, transporter, alpha precursor [Macaca mulatta]
    MRVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYDSLRGQAEP
    CGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELSPDNTSVPTAKFALNGEEF
    MNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKAR
    PGNPGFSVLTCSAFSFYPPELQLRFLRNGMAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHA
    GLAQPLRVELETPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGSLLPTPGEA
    QDADSKDINVIPATA
  • Molecule Role : Vaximmutor
  • Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) , HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost , HIV-1 gp120 with mCT E112K
10. IgG2b
  • Gene Name : IgG2b
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 16016
  • Genbank Accession : AC160982
  • Taxonomy ID : 10090
  • Chromosome No : 12
  • Gene Starting Position : 56717
  • Gene Ending Position : 60336
  • Gene Strand (Orientation) : -
  • Protein Name : immunoglobulin heavy constant gamma 2B
  • Protein Note : Also known as IgG2b; Igh-3; gamma2b
  • DNA Sequence : Show Sequence
    >gi|121699722:56717-60336 Mus musculus immunoglobulin heavy chain complex (Igh) on chromosome 12
    CCTAGGCTCCCTGCCCAATCATGTTTCTGTAGTCAGGGGAGATCTTCTGCTTCAGCTCCACCACTGAGGA
    GAAGATCCACTTTACCTGTGGGGAAGTGAGAGTCAGAGACCACACCCATGCTCAGACCCTCCAATCCTGT
    GGGGAAGACAGAGGCCTGTCTCTTCTTCAATTCCTTTCATACAGGTAGGAGACTGGGTATGGGAAGTGGT
    CAAAGTGGAGATATTGTGGGAGTTGAGGTGGAGATGGTATGAGATTAGCTCACAGAGTACCTTGAGTTAT
    GGTGAGGCGAACATCAAGGGGATTGTGTGTTAGACAGCATGAACCTCATTAAGGCTAGTGTGGAATGCAA
    GGAGGTTTGGTCTCATAAGACAGTATGAGGATCACGCAGGACAGCAGTAGAGACAGAAGGGCAGACTGTA
    TGGGACAAAATGTGGAGTCACATAGAGCAATGTGGGATGGCTCAGGGAATGGAGGAAACGGTGTGTGGTA
    CAGAGTGGGGACAGCAAAGTAACATCCTACTACATCAGGGGAGGAGTGAGAGGACATTTTGTGGTCAGTG
    TAGCTATCACAGCAGAGGGTGGGAGACAGTGCCAACCTTGAAGAGTGTGACAGAGGCGCTGTAGCACACG
    CTGAGCAGGAAGAGGCTGATGAAGATGGTGATGGTCGTCCAGAGCCCGTCCAGCTCCCCATCCTTGGCCT
    CAGCACAGATATCATCCAGGTCTAGCCCTGAACAGAGAGGACAGTCAGTGTTTGTCCCAACATGGTTGAT
    GCTGGGAGAGATTCCCTGTGAGGCAGACATGTCTGCATGAAGTCAGAGGAGAGATCTCCAGCCTGACTGG
    GACAGCAGACCCTCCCCGGGGCCTGCTTTCCTTCCTTTCCCTCTGGGACATCAGTCTCAGCTTCCTCCAC
    CTGAGTCCAATAATGCCTTGGATGGACCTCAGAGTGACCTGGATTATTCAAGTGCCCTCTATGCTTGTCT
    CATCTTTCATTCCTTCAGTACAGGAGAAGGTGGAGGGTCAGCAGGGCCTGTGACCCAGGTCAACAGTGGC
    TATACAGCTGGACTGACCCTTTGCTATTCTTCAGTCATCAGCAGAGCCTGTGGCTTTTCTTGCCTGAACT
    TGGGAACATCCCAGTGTGAAGTGATTCAGACCATTATGGCTATGGTTTGAATTATTCATGTGGGGTTGAA
    GCATGACCCCGAGGTACCAGAGATGAATCTGGCTTCAGAGGTCTTGTTTTGAGCGGAGAATGGAGTGTCC
    TCAGAAGAGGAAAGGTGTGTCTGATTGTGATGGCAGAAACGTGGGCATTGAATTTTTGGCCGTGTGTATG
    GTGATACATTGCTGGATGTAGGTGCTGTGCTGGGCACAGAGGAGTTGTCCCAGTGTGTTAAATGCGTTTT
    GTGCTCACGAGCATGAGGATACATGTGCTATATGGACTGGATGGTGTTCAGCAGGGTCAGGATTTAGCAT
    GAGTGTGGCTATCTAATAGTCCCTCCCTTGGGGCATCAAGAGCCATGTGCCTCAGCCCCAGGTGGCACAG
    GCAGGAGTGAGCCATTTGTATGGGTGTGCAGACCTCGTCTGTGAAAAGCTGCCTGAGTTGAGAGTATAGA
    TGACAAAGGTCTATGGAATGCCCCTGGCCATGTGTCACTCCACAATAGACTCAGAAAAACCCCTAAGTAG
    AGAAATGGGGCAGGGGGACAGGAACAGCCTAAGGGAGGTGGGTTTGTGTGCTTATCCATTTGAGGCTTCC
    TAGGATTATCTCTATGTCTGGCAGCTGCTGGTTCATGGGAAGGCAAGGAAAAGGCACTGCCTAAAGCCAA
    GCCCCAACAGTCCAAGGCAGAATGACTCATGACCTCTGAGTCATGCAGTGCAGAAACCTCATTCTCTTCC
    TATAGACAAGGCTGTCCTCCAACCCTGGCCAGACCTATCAGCCCGTGAGCTATGCTCTATACCTTGGAAA
    GAACCAGGACAGTTTTACATGGTACCAGGCTTTGCTGGATGCTTTATTTATACAAGGGATGCATGGATAT
    GGGTGCCAGTGTCTCTTAGGACCTGAGAGCTTTGTGGGTGCTGAGCTCATTTACCCGGAGACCGGGAGAT
    GGTCTTCTTCAGGTAGTAATTTTTCAGACCCTCGTGTCTCACGTTGCATGAGAAGGAATCTGTTTTCTCC
    CACTTGCTTGTTTTTATATCGAGCTTGCTGTATATGAAGTAAGAACCGTCAGAGTCCAGGACTGGTGCGG
    TGTCCTTGTAGTTCTCCTCTGTATGCCCATTGCTGGTCCACTCCACACTGATGTCTCCAGGGTTGAAGCC
    CACGACCAGGCAAGTGAGACTGACATCTTTCCTGGACAACTGCTCTGCTGGTGGCGGCAAGATGTATACT
    TGTGGAGCTCTGACTAGCCCTGTGGGGTTAGAAACATACATAGAGGTCATGGCTGAAGTGGAAGGCTGTC
    CACATAGACATTTATTCTTATGCCCATCCCAGCCCCCATGCAGTTGTCCTGCAGGTCCCACCTTTAATTT
    TTGAGATGGTTCTCTCGATGGGTGATGGGAGGTCTTTGTTGTTGACCTTGCATTTGAACTCCTTGCCACT
    CATCCAGTCCTGGTGCTGGATGGGGAGGGCACTGACCACCCGGATAGTACTGTTGTAATCCTCTCTATGG
    GTTTGTGTCTGAGCTGTGTGTACTTCCACGTTGTTCACAAACCAGCTGATCCGGACGTCTGGGTCATCCT
    CGCTCACATCCACCACCACACACGTGACCTTGGGTGTCAGGGAGATCATGAGTACATCCTTGATATTTGG
    AGGGAAGATGAAGACGGATGGTCCACCCTCGAGGTTAGGAGCTGATGAGAAGAGATGGAAATGGATTTGT
    ACATGGCTTATCCTCCATTACAGGGATTTTTACAGCACTTACCATTCTCCTGGGAGTGGAGCTCTGGTAG
    TGACTTACCTGGGCATTTGTGACACTCCTTGCATGGAGGACAGGGGTTGATTGTTGAAATGGGCCCGCTG
    GGCTCTGCAGAGAGAAGGCTGGATGTTACTGGTTTTTGAAGGAGAGAAGCACCAAACCAGAGAGAGGAAA
    GTTTGTCCCTGGTATGGGCTTAGTCCAGGATGATCCTGGAAATGACAAGCACACCTATCCCAGAGGATCA
    TGTCCTTGAGTGTAGGTGGTCATAGCTAGATGTTCCCAGGAGGGAGGCAGAGACAGTATCTCCCTCTTCC
    CTGGGCTAAGGTCACCTCCTTGGTGATGGATCCCAGCCTGGCTGGTTTAGATAGGCTAATACCTTTGCCT
    CAACTCTGGTGAATCCCTCCTCCCCTGAATGTCCTCTCACCAAGTTTTTTGTCCACCGTGGTGCTGCTGG
    CTGGGTGAGCAACGCTGCAGGTGACGGTCTGACTTGGCCAGGTGCTGGAGGGGACAGTCACTGAGCTGCT
    CATAGTGTAGAGTCCAGACTGCAGGAGAGCTGGGAAGGTGTGCACACTGCTGGACAGGGATCCAGAGTTC
    CAAGTCACAGTCACTGACTCAGGGAAGTAGCCCTTGACCAGGCATCCCAGAGTCACAGAGGAACCAGTTG
    TATCTCCACACCCAGGGGCCAGTGGATAGACTGATGGGGGTGTTGTTTTG
  • Molecule Role : Vaximmutor
11. Ighg1
  • Gene Name : Ighg1
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 16017
  • Genbank Accession : AC160982
  • Molecule Role : Vaximmutor
12. Ighv1-9
  • Gene Name : Ighv1-9
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 668478
  • Genbank Accession : AC073561
  • Taxonomy ID : 10090
  • Chromosome No : 12
  • Gene Starting Position : 114583568
  • Gene Ending Position : 114583861
  • Protein Name : immunoglobulin heavy variable V1-9
  • Protein Note : Also known as Igg2a; Gm16697
  • DNA Sequence : Show Sequence
    >gi|372099098:114583568-114583861 Mus musculus strain C57BL/6J chromosome 12, GRCm38 C57BL/6J
    GTCTTGCACAGTAATAGATGGCAGAGTCCTCAGTTGTCAGGCTGCTGAGTTGCATGTAGGCTGTGTTGGA
    GGATGTATCTGCAGTGAATGTGGCCTTGCCCTTGAACTTCTCATTGTAGTTAGTACTACCACTTCCAGGT
    AAAATCTCTCCAATCCACTCAAGGCCATGTCCAGGCCTCTGCTTTACCCACTCTATCCAGTAGCCAGTGA
    ATGTGTAGCCAGTAGCCTTGCAGGAAAGCTTCACTGAGGCCCCAGGCTTCATCAGCTCAGCTCCAGACTG
    CTGCAGCTGAACCT
  • Molecule Role : Vaximmutor
13. IL-6
  • Gene Name : IL-6
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 16193
  • NCBI Protein GI : 13624311
  • Genbank Accession : AC112933
  • Protein Accession : NP_112445
  • Taxonomy ID : 10090
  • Chromosome No : 5
  • Gene Starting Position : 30013160
  • Gene Ending Position : 30019967
  • Gene Strand (Orientation) : +
  • Protein Name : interleukin 6
  • Protein pI : 7.5
  • Protein Weight : 23291.86
  • Protein Length : 211
  • Protein Note : Also known as Il-6
  • DNA Sequence : Show Sequence
    >gi|372099105:30013160-30019967 Mus musculus strain C57BL/6J chromosome 5, GRCm38 C57BL/6J
    ACCAAGAACGATAGTCAATTCCAGAAACCGCTATGAAGTTCCTCTCTGCAAGTAAGTGAAGGCAGTTCCT
    TGCCCTCTGGCGGAGCTATTGAGACTGTGAGAGAGGAGTGTGAGGCAGAGAGCCAGCATTGTGGGTTGGC
    CAGCAGCCATCAGCTAGCAGCAGGCGCCCAACTGTGCTATCTGCTCACTTGCCGGTTTTCCCTTTTCTCC
    ACGCAGGAGACTTCCATCCAGTTGCCTTCTTGGGACTGATGCTGGTGACAACCACGGCCTTCCCTACTTC
    ACAAGTCCGGAGAGGAGACTTCACAGAGGATACCACTCCCAACAGACCTGTCTATACCACTTCACAAGTC
    GGAGGCTTAATTACACATGTTCTCTGGGAAATCGTGGAAATGAGAAAAGAGGTGGGTAGGCTGTGAAACT
    GATGAAGACCCAGTGTGGGCGTCCATTCATTCTCTTTGCTCTTGAATTAGAAATTCTCTGCTGGGATCTA
    GGGCCCTTAGGATTTGAAGCTAAAGGTCAGACTAGACTGTGTTCTCTCTTTCTCACCTCTTTGCTGGTTT
    TGAGTGGAGGTTGGGAAGGGGTTCCTTTCCTGTCTGGAAGATACAGAATGTGACTGCATTTCTAGAAAAT
    TCACAGTGGGCCATTCTCTGTTCCAATTTAGCTATTGCTTCTTAGGTGGGGATTCCTTTTCCCTCATTAT
    TCCTTTTTCCTTATCTCTTTGCCTTCATTTATCCCTTGAAGTCTACAAGGACCAGAAAGTGCTTTTTGGC
    TGAATGTAGTAAGTTCTGTGTGTGTGAAATCAGGATGCTCTAGGGTCAGCCCAGATAAGATGCATATTGT
    ATAGAGCCCAATAAAGTGCTAACACACACACACACACACACACACACACACAACCTAGATTAGGCTGGGC
    ATGGTGGTGGATGCCTCCCAGCACTTGGGAGGCACACGCAGGAAGATCTCTGTGAGTTAGAGGCCAGCTT
    GGTCTACATATTGAGTTCCAGGATATCCAAGACTACATTGAGAGATCCTTTCTCAAAAAAAAAAAAAAAA
    AAAAAAAAACAACAACAACAAACAAACAAACAAACAAGAAAAAAAAAACCCAACCAACCCTACCTAGATT
    AAAATATCTCCCATCTTTAAATGAAAAGTATTTTGACTCTGCTTGACAGAAAGGAAAAAAAAAATCACAA
    ACAAGATTAATAGCCTAGGTCTGGGTGTGTAGAACCAACTTTGTAATCTTGGGAAAATCCTCAACTATTT
    AGTACTCTTTATCTGCATAATTATGGAGTTACAGATAATGGCACAGACCCTTCCAGATGGAATATTCTGT
    GACTTAAATTTATTTGCCCCAAGATATCATCAAAATTTCTGTCCTTTACCAAGTTCCTACTCTATGCTGG
    GCAGTTTTTATCGTTGAATCCTTGAGACAAATGTATAAGAGGGACATCAATAATTCTTTATTGAAACATA
    GGAAATACTTAGGAGAGTAACAAGCTTAAAGCCAAGGGACTGAGCCTAAGGGTGCATTTTTATTTATTGG
    GCTGCTTAGTAGGGTTCTAAGAAGGTATAGCTTCCCTTTTCTGTGTCCTGGCTATGAAAGAGCATGACTT
    GGCCCTCTAGTGGTGCTTGTTGTAAGAGGTGTTTAAGTGATTGCTCTGGTAATCTTTTGCAGTTGTGCAA
    TGGCAATTCTGATTGTATGAACAACGATGATGCACTTGCAGAAAACAATCTGAAACTTCCAGAGATACAA
    AGAAATGATGGATGCTACCAAACTGGATATAATCAGGTAGAAACTTGTCACGTTTACTTTCAACAATTCT
    TCAAGGTTCTCTCTTGCACGTGATACCTGCATTTGTACAGTCCCAGTCAGGCAACAAAGATGGGGGGATA
    CATCCAATACCACTTGGATGTAACTGGCCTGCAGTAGCTTGAATACAAAAGGAGATTGAGAGGTACCTCA
    GCAGCTGCTAGGGTGAGGGAAAGTTTACCAACCAGTGCTATAAATGTTCACTCAATCTATGTCCATCAGG
    AGCTAAATGTTTAAAGTCTCTATTCTCATCTTGGCTTTGAGGTGTTAGATGATTAAAAAAAAAACATTTT
    TTTTGTCTAAAAAAGTGGAAGAGTAGATATAAAACATGTTATGTAAACGTCATGAGGAAAGTAACTTACA
    GATTTAATTAAAAAGCAGTTTATTTAAACAGGTAAAGGCCCACTATGCTGGGATTCTTCACCACTGTTAA
    ATGTTAGAAGTCATAGCAAGTTTAGCTAGTTCATGAGCCATCTCTTCTCTGGCTGCCCCTGGAAGGATCC
    AGGCCTACACTCCCTACTGAGAACACTCTTCACACCCCTCTCCTTCCAGCCGGTGAGATAGTCTACATCA
    GGTCTCAGGACAAGTCAGACAAGAACAAGAGTACAGGAAGGGCACTGCAGGATAGAAGGGAAGGAGTGAG
    GGTCAGAAGTGGATTCCCACTGCCACACTCTGGGGTAGGGGGTGGGGGGATATTAAGTGGTGCCTCTCTC
    TACTTGTCCAGATAATTCAGGAGGTCAGCTGATGCTGCCTGTTGTCTAATTCTGTAGAAGATACTGAACA
    GCAGGAATCTTTTTTTCAATTTTTTATTAGATATTTTCTTCATTTACATTTCAAATGCTATCCCCACAGT
    CCCCTATACCCTCCCCCCCCTCCCCGCTCCCTTACCCACCAACTCCCACTTCTTGGCCCTGGCATTCCCC
    TGTACTGGGGCATATAAAGTTTGCAAGACCAAGGGGCCTCTATTCCCAATGATGGCTGACTAGGCCATCT
    TCTGCTACATATGCAGCTAGAGATATGAGCTCTGGGGGTACTGGTTAGTTCATATTGTTGTTCCACCTAT
    AGGGTTGCAGACCCCTTCAGCTCCTTGGGTACTTTCTCTAGCTCCTCCATTGGGGGCCCTGTGTTCCATC
    CAATAGAAGACTGTGAGCATCCACTTTTTGCCAGGCATTGGCCTAGCCTCACACGAGACAGCTATATCAG
    GGTCCTTTCAGCAAAATCTTGCTGGTATATGCAATACTGTCTGGGTTTGGTGGCTGATTATGGGATGGAT
    CCCTAGGTGGGGTAGTCTCTGGATCTTCCATCCTTTTGTCTTAGCTCCAAACTTTGTCTCTGTAACTCCT
    TCCATGGGTATTTTGTTCCCCATTCTAAGGAGGAATGAAGTATCCACATGTTGGTCTTCCTTCTTCTTGA
    TTTTCTTGTGTTTTGGAAATTGTACCTTGGGTATTCTAAGTTTCTGGGCTAATATCCACTTATCAGTGAG
    TGCATATCAAGTGACTTCTTTTGTGATTGGGTTACCTCACTAAGGATCATACTCTCCAGATACATCCATT
    TGACCAAGAATTTCATAAATCCATTGTTTTTAATAGCTGAATAGTACTCCATTTGTAAATGTACCACATT
    TTCTGTATCCATTCCTCTGTTGAGGGACATCTGGGTTCTTTCCAGCTTCTGGCTATTATGAATAAGGCTG
    CTATGAACATAGTGGAGCATATGTCCTTATTACCAGTTGGAACATCTTCTGCGTATATGCCCAGAAGAGG
    TATTGCTGGATCTTCCGGTAGTACTATGTCTAATTTTTTGAGGAACAGCCAGACTGATTTCCAGAGTGGT
    TATACAAGCTTGCAATCCCAACAGCAATGGAGGAGTGTTCCTCTTTCTCCACATCCTTACCAGCATCTGC
    TGTCACCTGAATTTTTGATCTTAGCCATTCTGACTGGTGTGAGGTGGAATCTCAGGGTTGTTTTGATTTG
    CATTTCCCTGATGATTAAGGATGTTGAACATTTTTTCAAGTGCTTCTCAGCCATTCAGTATTCCTCAGTT
    GAGAATTCTTTGTTTAGCTTTGTACCCCATTTTTAATGGGGTTATTTGAATTTCTGGAGTTCAGCTTCTT
    GAGCTCTTTGTATATATTGGATATTAGTCCCCTATCAGATTTAGGATTGGTAAAAATCCTTTCCCAATCT
    GTTGGTGGCCTTTTTGTCTTATTGACAGTGTCTTTTCCCTTACAGAAGCTTTGCAATTTTATGAGGTCCC
    ATTTGTCGATTCTCGATTTTACTGTACAAGCCATTGCTGTTCTGTTCAGGAATTTTTCCCCTGTTCCCAT
    ATCTACGAGGGTTTTTTTCCCACTTTCTCCTCTATAAATTTCAGTGTCTCTGGTTTTATGTGGAGTTCTT
    TGATCCACTTAGACTTGAGCTTTGTACAAGGAGATAAGAATGGATCAATTCGGGCTGGAGAGATGGCTCA
    GTGGTTAAGAGCACTGACTGCTCTTTCAGAAGTCCTGAGTTCAAATCCCAGCAACCACATGGTGGTTCAT
    AACCATCTATAATAAGATCTGATGTCCTTTTCTGGTGTGTCTGAAGACAGCTACAGTGTACTTACATGTA
    ATAAATAAATAAAACTAGATTATTTAAAAAAAAAAAAAAAGAATGGATCAATTCACACTCTTCTACATGA
    TAACCACCAGTTGAGCCCGCACCAATTGTTGAAAATGCTCTCTTTTTCCCACTGGATGGTTTTAGCTCCC
    TTGTCAAAGATCAAGTGACCATAAGTGTGTGGGTTCATTTCTGTGTCTTCAATTGTGTTCCATTGATCTA
    CCTGTCTGTTGCTGTATCAATACCATGCAGTTTTTTTTATCACAATTGCTCTGTAGTACAGCTTGAGGTC
    AGGCATGGTGAGTCCACCAGAGGTTCTTTTATTGTTGAGAATAGTTTTTGCTATCCTAGTTTTTTTTTTT
    TTTTTTTTTTGAACAGCAGGAATCTTATTCTCAAATTGAATCTATTCCTAGAAAGAACTGACTTCCTTTT
    CCATTTTACTTATAGGAAATTTGCCTATTGAAAATTTCCTCTGGTCTTCTGGAGTACCATAGCTACCTGG
    AGTACATGAAGAACAACTTAAAAGATAACAAGAAAGACAAAGCCAGAGTCCTTCAGAGAGATACAGAAAC
    TCTAATTCATATCTTCAACCAAGAGGTGAGTGCTTCCCCATCTCTCATGCAGTGTGGGAAAGAGGACACC
    CGGCACCTCAGGGTAGCGGCACTTTTTCCAGACAGCTGCTCAGAAGGGAGAGAGTCTGAACAACAGTTCT
    TGATTATAAGGCCTTGCTTTGTTTTACTTTGGGGTTTTGTTTGAGGTTCTCTTTTGCAAAGAACATCAAT
    ACCTGCTTTAAACTGTATTAATAGAATGTTACTAATTGCGTAAGAGGTATGAAAACTATGACAGCCATAC
    ATAGTCACCCATTATGAGAGCACAGAGACAAAAGTGACTTTAATATTTAATCCTTGGCAAGTGACATTTT
    TGTAACCAGAGTTCTAATGCAGAGAAGTAGCCAAAAGCTAAAATGTCAGGGAAGGAAGGGATCAAGGGCT
    TCTGGCTACCATTAGCCAGAAGAATGGTAGATATGGAGGATTAATGACTCAGAGTGTGGGCGAACAAAGC
    CAGATGCAATAAGAAGGGCCTGGAATGAAACCCTCTTGCTAAGGCTGCTTTTGCCACTTGTAGTTTCTTG
    CCTTAAACCAGAGAGTTTCCCAATTTAATGTGCACAGGAACCACTTAGGGTCTTGTTCCAGCAGGGTCTT
    ACTTAGGAGGTCTAGGAAGGGAACTAAGATTCATTTTTGTAAACAGCTGCTTGTTTATGACCCTGCTATA
    TAGTATTCAGGCTCCTAAGTAGTGGGGCAAGCCTTCCAGTTAGTCTTCCCCATGCCAGTGGGCCCATGGA
    AGGGTGTTTCCAGACTTCTTCATGCTACCACACTAAGAGACTCTCAACAGAGTCTGAATGGAAACCACGA
    AGGAACACATTTGTTTTAGATTCCTCTGTGCCACCTTTACTGATGGGAGCTTCTGTTTTCCAGTAGAATA
    CAGTATGTTAGCATGGATGCTTGGATAACAGACAAATAAGATGGTGGTGCTGACCTCTGGACGCTTACTC
    TCTAGTGGCAGACAGAACAGTAAGGTTAGAATTCTGTTGCTATTAAAAAACTAATAATAATCACCTTGAA
    AAAGAATGGAGTTGTTAGGCATGGGTCTCTCTCGAGTAAGCTTGGAACAAAAGCATCTCCCCTGGCTTGG
    GTGAGTCAAAGCAGATGGACTTAGCTCGTCTCATTCATTCTAAATTAGAACTTCTTCCCACAGCCCAGAA
    CACGCCACAAGAAAAAAAAAATGTGCAATATTTAACCAGTCTTTGTTTTTTCCTCCTTTAGGTAAAAGAT
    TTACATAAAATAGTCCTTCCTACCCCAATTTCCAATGCTCTCCTAACAGATAAGCTGGAGTCACAGAAGG
    AGTGGCTAAGGACCAAGACCATCCAATTCATCTTGAAATCACTTGAAGAATTTCTAAAAGTCACTTTGAG
    ATCTACTCGGCAAACCTAGTGCGTTATGCCTAAGCATATCAGTTTGTGGACATTCCTCACTGTGGTCAGA
    AAATATATCCTGTTGTCAGGTATCTGACTTATGTTGTTCTCTACGAAGAACTGACAATATGAATGTTGGG
    ACACTATTTTAATTATTTTTAATTTATTGATAATTTAAATAAGTAAACTTTAAGTTAATTTATGATTGAT
    ATTTATTATTTTTATGAAGTGTCACTTGAAATGTTATATGTTATAGTTTTGAAATGATAACCTAAAAATC
    TATTTGATATAAATATTCTGTTACCTAGCCAGATGGTTTCTTGGAATGTATAAGTTTACCTCAATGAATT
    GCTAATTTAAATATGTTTTTAAAGAAATCTTTGTGATGTATTTTTATAATGTTTAGACTGTCTTCAAACA
    AATAAATTATATTATATT
  • Protein Sequence : Show Sequence
    >gi|13624311|ref|NP_112445.1| interleukin-6 precursor [Mus musculus]
    MKFLSARDFHPVAFLGLMLVTTTAFPTSQVRRGDFTEDTTPNRPVYTTSQVGGLITHVLWEIVEMRKELC
    NGNSDCMNNDDALAENNLKLPEIQRNDGCYQTGYNQEICLLKISSGLLEYHSYLEYMKNNLKDNKKDKAR
    VLQRDTETLIHIFNQEVKDLHKIVLPTPISNALLTDKLESQKEWLRTKTIQFILKSLEEFLKVTLRSTRQ
    T
  • Molecule Role : Vaximmutor
  • Related Vaccine(s): HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein
14. Il12a
  • Gene Name : Il12a
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 16159
  • NCBI Protein GI : 226874945
  • Genbank Accession : AC121306
  • Protein Accession : NP_001152896
  • Taxonomy ID : 10090
  • Chromosome No : 3
  • Gene Starting Position : 68690643
  • Gene Ending Position : 68698546
  • Gene Strand (Orientation) : +
  • Protein Name : transcript variant 1
  • Protein pI : 8.33
  • Protein Weight : 25111.9
  • Protein Length : 236
  • Protein Note : Also known as p35; Ll12a; Il-12a; IL-12p35; MGC151228; MGC151232
  • DNA Sequence : Show Sequence
    >gi|372099107:68690643-68698546 Mus musculus strain C57BL/6J chromosome 3, GRCm38 C57BL/6J
    CTGCCACCTACTCCCTTGGATCTGAGCTGGACCCTTGCATCTGGCGTCTACACTGCTGCTGAAATCTTCT
    CACCGTGCACATCCAAGGATATCTCTATGGTAAAAGTCCAGAAAGGCTAAAGATGTTGTCCACAATCTCT
    CGGCAATGACCAGATATATCCCCACCAGTATCACAACTTGCAACGCGCTCCGTTCCCATCTGCCCTCTGC
    CTCCCTACTGTGTTGATTCCCATTTCCAAAACTAGCTCAGAATGCATCCCACTGGCAGCCAGGCAATGCC
    TTCTTGCAGATCTGGAGGCTTCAGGAGCCTTTGCTGCCTCTTAGGCTCCTGCAGAGAGATGGCCTTGCTC
    TCTCTGGGCCCTTTTCCCCCAAGATGCTGTGCAGTCGTCTCACTAAATCAAAACTGCCAGAACTGAGTTT
    TAAGCGATATATAGCCACCACATCTATTTTGTTCCTTTATACTTTCAAAGTAGGACAGATTCGCAAAATA
    CATTGAGTCAGACTCAGTGTCCACGATGGAGAGACGAGTGGGTAGCTTGTGCTTCTTTAGAAGGGGCACT
    GGGCAGCGTGTTAGGGCTAGGGGGTAGTGGGGCAGGACAGACCTGTCCCGGGACAAGAGTGGCTACTCGC
    AGGCCGGTTTTGCTTTCGCTCTGAGTGTGGTGGGCGGTGGGACGGTCCCGAATCTCCTCAAACGGGCACT
    CCGAGAGTTAATTCGAAAGCGCCACCAGCCTTGGGGGCGATCGACGCACTTGTCCTTGAGATGTAGAGAC
    AGAGAGAGAAAGCAAGAGACACAGTCCTGGGAAAGTCCTGCCGGCTATCCAGACAATTATAAAAATGTGT
    CTCCCAAGGTCAGCGTTCCAACAGCCTCACCCTCGGCATCCAGCAGCTCCTCTCAGTGCCGGTCCAGCAT
    GTGTCAATCACGCTGTAAGTACCTGAGGGCCGGGACCAGGGTGACTTGATGAGAGGAGAAGGCTTGAGAA
    AGAACAGACAGAAGCCCTGGACCCATTAAGGGAGACTAAAGGGCTGCCAGCAACTGCAGGCCAAGGGAAG
    GAAGAGGGGAAAGATGGTCGTGCTAGATTGCGCTGCACCGAGCATGGTCTCATTATAGAACAACCCTGGG
    GGCTACGGCTATGCCCGTTTCACAGAAGAGAACTAAAGCCCAGCCTTGAAACCAATGTAAGGAAAATGCA
    GGTCTCAGGCAGTCCCCAAACAAGATCTGGGAGGTCTTGCTTCATCTGTCAGCCCCGGGGAAGGGCTTAA
    ATTATGTGTGGAGGGAGGTCAGTACCCAGAATGGATGGAAAAAATTGCCAGAATGGCTGAAGAAAGAGGC
    AGGTCAAAACCAAGTTGACAAGCTCCACCTGCCCTTTGTTTCCCTTCCAGACCTCCTCTTTTTGGCCACC
    CTTGCCCTCCTAAACCACCTCAGTTTGGCCAGGGTCATTCCAGTCTCTGGACCTGCCAGGTGTCTTAGCC
    AGTCCCGAAACCTGCTGAAGACCACAGATGACATGGTGAAGACGGTGAGTTTCTCCTGTCCTTCTGGCTT
    CAAAGTTCCGCTGTTGACATGACTTCTAACCTATCTGGTATCTGCTGGGAAGTTTATGGTATCTGGCAGG
    AACCGTAGAGGGTTTCAAGACTTCTAAATATAATCTAAAGGAAACTGTGTCTCTAGAGAAAGGAAGAATG
    GTAATAAATTGTAACGGCATCGGTTTAGGCTGTGTCTACACAGAGGAAAGTGGGGACTTGCAATGTCCCT
    CCCAGCCTGCCTGCCTGTGTGACACAGTGTCAGGTGCTCCCTGCTTCTGCTTCAGGGCAGGTGGAACAGG
    GAGACAGTCTCTAGGTACACTCTCTGTGCTTCACAAGCCATAGAGATGAATTAGATTGTCTCTCCCCCTG
    CTCACCAGTGTCCAGCACTGTGATGCAGTCCCTTGTCGGATGGACACATGTCAGGGAGGACTCAGACATC
    AGATAGCAAGCAGGTCCAGCCTCCAGTTTTCTGGGGCAAGTGTGATCCAGTTTTAGTCACGGCTCCACTC
    ATTTTTCTCAGGTTTCATGTTTGAATGCAAAATAGCCTTTTCCGTTGTAAAATTGCCACGGTTTCCTCTC
    GCTTTGGGGACAAAGCTACAGCAAAATGCTAATGTGTTTGAGATATCCTGCAGCTGCTAGGGCTGGAGAT
    CCAGTAGAATTCTGGCTTAATTATGAATGGGTCTCCCGGGTTCTATCCCCCAACAGAGCGTGCGTTCATA
    AGCACCTGGGAACAGAGGAGGGAAGGAGGGAAACTCTGTCTTCCTGTTTTGTTTTTAAATCTTTCTTGAG
    GATCTTCTAGCTTGTTGTCTTATGGCTATCCCAACATAAGCTCCGCTCCACAAGCCCTTCTTGGTGAATT
    TTCTTTCTTTCCTTCCCGTCTTGCATAACGTGCTGCTGGCTGTTCCTCCAAGCTCAGTCTTAATTGAGTG
    GGGTTCCCAGGAGGGAGAGATGGCTCTGTGGTTAAGAGAGCTGGCTGCTCTTCCAGAGGTCCAGAGTTTC
    CACACCCTCATGGTGGCTCACAATCATGGTAACTCTGATCATAGGGAACCTGTCGTTTTCTCTGTGCCTC
    TGTGGGCACTGAGCACATGCCACACAGACATCCATGCAGGCAGAACACTCTTGGCCATGAAACCTTAAAA
    TGAAGGAGAAACCTTACGAGAGGTTCCCTAAGGAATCCCTGCAGAAGGGAGAGATTGTTTTCCTAAGATG
    AGGTTTGGTGTGGAGGGGATGAGGTATTCAAAGTTAACTAGCCGCTCCTCACTCCTCTGCTGCCAAATAC
    CAGCACTGGGCTTCGAGACACAATAGAATTCGACCTTGTTTTCGTTTGGGTCACTATTGCTCTCTAGTTG
    AACACGGAATCCACGGGGGCACATTGCTGTCTGTCCTTTGTCACACCCCAGGACCACAGCTGCATGGAAA
    AGTCATCGCAGGCTTCAGTCAGAGAGCTGTTGACTTCCTAATATGTTGTGTAATTCTGTTCAGTGGTGCT
    TTCCAGCACACCAGGGAATAAGAGACAGTCCCCGCGTATGTAAATTAAAGCTCAACTAGTATTTAGGGCT
    TGCAAGTTTGTTACAGCCATCAAGCTGTGACTTTAACAGTTTCCTCTTTAGAAGTTAAACTTGAAAAAAA
    ATAGAGGGAGAGAGAGATTCACAGGGCACAGCTGCTTGGAAAAAGGAAAAGCCACAGGACTCACCAGAAG
    CAAGCAGCACAGTGTGGCACTGATGCTGATGAGTACAGCCTGCTGCACCCCAGTGTTCACATGGTGAAAA
    AAATACCCTGCTGGCGGACAGCCTAGGCAAAGGGGGAGGAGAGTAGGGAGAGCGTGCGGGAGGTTGGGTT
    TCTTAGCTTATGAAGAGCCTGAGTTTCCTACAGGCCAAAGAGATGACGGTTCAGAGTGGCCAGCCTAGGC
    TCTGCTGATCCACTGCGATGCAGGTCTCAGAGGGAACCAGCTGTCTTGCTGAGAGATTCACCTCAGCTTC
    TCCTTATGTTTTTCCCAGGCCAGAGAAAAACTGAAACATTATTCCTGCACTGCTGAAGACATCGATCATG
    AAGACATCACACGGGACCAAACCAGCACATTGAAGACCTGTTTACCACTGGAACTACACAAGGTATGGAG
    GACCCCCACCCAAAAAACAACAACAACAACAACAAAAAACACAATTAAGAGCCGTGCAGCCAACCTCAGC
    TGTCTCCAGATACTTACTTGTAGCTATCAAACGTGAGAGTTTTGAAGAAAAAAAAAAAAGTCAACAACCA
    TACAAATACTTCTACAAGCTGAAGGATATACTCGGTAACTAGGAGGTGGCTATGGTGGTATAGACCTTTA
    ATTCCAGCACTTGATGGATAGAGGAAGGCCGGCTCCTGTTAAGTTAGAGGCCAGTCAGGGATACACAGCA
    AGATTTCATCTTTAAAAAGAAAGGGGGTGGTGTGGCGGGTGAAGCTTACTTATTGAAGTGCTCATGTCAC
    AAGCCTGGGGACCTAAGTTCCCATCCCCAGCACCCATGTAGGAGCTGGGTGTGATGGTTTCACATGCAGA
    GACAGGAGGATACCTGGGCCAGCTAGTCTAGCCGAATCCATGAGCTGCAGGCCCAGTGAGAGAACCTGTA
    TCAGAAAACAAGAAAGTCAGGAGAGCGGCTGAGAAAGACCCCAAAGATCATCCTCCGATTTCCACGAGTA
    CATGCACCTGCACACACGTGCACACAGGAATCCTATACATAGCCACCCAAAAGCAGTTATGATGGTGAAG
    TTTCTTTTACTGGAATGAAAAGTTAGTTTGAGAAAAAAATATCAGAGAGATTTATATTAAGAGTGAATGG
    GTGGGGGGTATGCATGCCTTTAATCTCAGCACTTGATAGGCAGAGGCAGATGGATCTCTGTGAGTTCAAG
    GCCGGCCTGGTCTACAGAGTAAGTTCCAGGACAGCCAGTGCTACAATAGAAACAGGTGATGGTGATGATG
    GTGATGATGGCGGTGATGATGATGATGATGACGAAGACAAACTCCTCGGTTTATGATTTTCTTCTAGAAC
    GAGAGTTGCCTGGCTACTAGAGAGACTTCTTCCACAACAGTAAGTAAGCACTCTAAGGGTTCCTTCCCCA
    TGACGGATTCATAACACTGATGCCTGGTCATTCTTTCTCTAGAGAGGGAGCTGCCTGCCCCCACAGAAGA
    CGTCTTTGATGATGGTAAGCCACATCACTTTTCTGAAATGCAGCAGGGTCCTGTAGTTCCAGCCCATCTC
    AATGATTCCTTGCCCATTGTGTCCTGCGCTCTAGACCCTGTGCCTTGGTAGCATCTATGAGGACTTGAAG
    ATGTACCAGACAGAGTTCCAGGCCATCAACGCAGCACTTCAGAATCACAACCATCAGCAGATCATTCTAG
    ACAAGGGCATGCTGGTGGCCATCGATGAGCTGATGCAGGTAAGCCTTCCTCCTATCAGCCAGCGCTCCTT
    TTCCATGGTGAAGAGAGGTCCTTTATTAGATATGATAAAATCAGCACAGCTTGGGTTGGGAGAGACCTGA
    ACACCCCCACCCCACCCCACACCCTCATCCCCCAACCATGAAAGGCCTTGCAAGGTTACATTTGCTTAGA
    GAGCCTTGAGGGGGCCTCTACAATAAGGGCAAATGCAAGCAGCCTTCTACTTGTTGACTCATGATACAAA
    TCAGGCACTTTTCAAATGCTTCTTCTCATACCATCCCCACAACAAGCAAATAAGGTCTCTACAGAGGAGG
    AAACTGAAGCTTAAGAGGATGAACGAGGGTTCCCTACAAAAGGGTTTTTTGTTGTTTGGTTTGGTTTGGT
    TTGGTTTGGTTTGGTTTGGTTTTTCCGAGACAGGGTTTCTCTGTATAGCCCTGGCTGTCCTGGAACTCAC
    TTTGTAGATCAGGCTGGCCTCGAACTCAGAACTCCACCTGCCTCTGCCTCCCAAGTGCTGGGATTAAAGG
    TGTGCGCCACCATTGCCCAGCTTATTGTTGTTTTAAATACATTCTTTTCTTAAAGGTTCAAGATTAGGAC
    TGGAGAGACAGTCCGATGATTAAGAGGACTTGAGTTTGGCCTGGGGCTCCTATGTAACAAACAGGGTGTG
    GTCCTGAACTGCTCTCTAACTCCAGAGAGTGGAGACAGGAGGCCTATGGAGGCTTTCTTGCTGCAAGTTT
    AGCCATGAAATCTCCAGGTTCAGGGAGAAAGCATGCCTCAAAGAAATAAGATGGAGAGTCACGTGATCTC
    TTCTCTGGCTTCTGCATGGTGTAGGCACAGATATGCACATGTTTGAGTGCATACAATACAGGCAAACATA
    CACGTGTCCTTTTTAAAATGTATAGGATGGACATTCTAGGGGCTGCACACATATTCAAATATTACTAGGG
    GAAGCACTTGGGGCTGGTGTCCAAGTATAATCTATTTTGAACCAAAATGTGACCAAAATGAAAAGTGGTC
    TTACATCTAGGTAATTACAGTGTTAGGTATCCGTGGGAACTTTGCTGTACCACCAGTAACACAAAGCACA
    GGAGTGTGCACACCAGAGACAAGCACCTTGGCAACCAAGGCGTGGGATGAACATATGTTCAGAAGTCACT
    GCCTGGAAAGCAATTGTTTTTCATTTCATACATACTGTCTTGCACAGGGTTTCTATGTCTTAGATAAAAT
    ATCATGACGGAAAGCAAGTTGGGGAGGAAAGGGTTTATTTCATCTTGTAGAGTGTAGTGAGTCTATTACC
    CAGGGAAGTGGAGGCAGAAGCTGATGCTGGAGAGGACTCCTGGTGACTGGAGTGCTCCACATGACTTGCT
    CAGTGTGCTTTGTATAGCACCCAGGACCACCAGGCTAGGGTGAGCTGGTGCCTCCCACATCAACTGTCAA
    TCAAGAAAATCACCAGAGGCTTGCCCACTGGCCAATCTGGCTGGAGGTGTTTTTCTCAATGACCACAGGC
    TTGTGTAGAGTTAACATAAAAGCACCCAGGACATTACATATTGCCAGATGACTCCTTTGAAAGACAGTGA
    AGTTTATGCAGGTCAAACAACCTATCATGTAGAGATTTGTAATGGATATTGCATGAACAAGGCCAGAAGT
    CAGGTGATTTGGATAGTAGGAAGAGGTCTACCAGGGACCAGCCAACTATGCTGACAGGGTTAACTCTTGT
    CAGCCTGTTTGTAAAATAAGATGACTTTAAATAGCCTATGTCTCTCTTGAGATTTTTGTGAGGAGCAAGC
    AAAAATCTTAAACATCACAGAAACCTAAGTTCTTATTCTATGTTATGAAATCAAAGGATCGAGTGGGGAA
    ACACGGTACTGGCTTGTTTATCTACCACAAATAGCGTTTCTATCAGAGATAGGTCTGTTGTTGATAATAA
    GCTCTAATCCATAGATCCTACTTACCCTCCAACTCCCTCCTCTAAAAGAACAGGACTTCTTAACATAATT
    TATAAAAATTAATTAGCTATTGCTGCAGGTGCTACCTCATAGACTCACACCTTCTGAGAGATCAGCTCTA
    ATGACAATTTCTTTCTGGAAAATTTAGGGGTCTTGTCAGAGATCATTAAAAACATAGGTATATGCTCACA
    AAAGAGTATTTCTTCCCTCTTTTCCTGCAGGAACACAGCAGGAGTAGATGTGAAATGGGTCTAGGAGTGT
    GATGAGGGGCTAGGTTGCAGGCCCTGGACTTTGCATTGACTGTCTCCCATTTTGCAGACAAACATTCTAA
    TTTTTAAATTGTGCATATGCTATGCTTGGTGTTTCTTTCTAGTCTCTGAATCATAATGGCGAGACTCTGC
    GCCAGAAACCTCCTGTGGGAGAAGCAGACCCTTACAGAGTGAAAATGAAGCTCTGCATCCTGCTTCACGC
    CTTCAGCACCCGCGTCGTGACCATCAACAGGGTGATGGGCTATCTGAGCTCCGCCTGAAAGGCTCAAGGC
    CCTCTGCCACAGCGCCCTCCTCACACAGATAGGAAACAAAGAAAGATTCATAAGAGTCAGGTGGTCTTGG
    CCTGGTGGGCCTTAAGCTCCTTCAGGAATCTGTTCTCCCATCACATCTCATCTCCCCAAAGGTGGCACAG
    CTACCTCAGCATGGTCCCCTCCATCGCTTCTCTCATATTCACTATACAAGTTGTTTGTAAGTTTTCATCA
    AAATATTGTTAAGGGGCGAAGACGTCCTCCCCTCAATGTGTTAGCAGAAGAGCAAGAACTGATAAGCTAT
    TGTTTTTGTGCCAAAGTGTTTATGAAAACACTCAGTCACCCCTTATTTAAAAATATTTATTGCTATATTT
    TATACTCATGAAAGTACATGAGCCTATTTATATTTATTTATTTTCTATTTATTATAATATTTCTTATCAG
    ATGAATTTGAAACATTTTGAAACATACCTTATTTTGTGGTTCTAATAAAGTAATGTTATCACTT
  • Protein Sequence : Show Sequence
    >gi|226874945|ref|NP_001152896.1| interleukin-12 subunit alpha isoform 1 [Mus musculus]
    MVSVPTASPSASSSSSQCRSSMCQSRYLLFLATLALLNHLSLARVIPVSGPARCLSQSRNLLKTTDDMVK
    TAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLC
    LGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKM
    KLCILLHAFSTRVVTINRVMGYLSSA
  • Molecule Role : Vaximmutor
15. Il2
  • Gene Name : Il2
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 16183
  • NCBI Protein GI : 7110653
  • Locus Tag : DN-144H19.3
  • Genbank Accession : AF195954
  • Protein Accession : NP_032392
  • Taxonomy ID : 10090
  • Chromosome No : 3
  • Gene Starting Position : 37120712
  • Gene Ending Position : 37125953
  • Gene Strand (Orientation) : -
  • Protein Name : interleukin 2
  • Protein pI : 4.63
  • Protein Weight : 18506.61
  • Protein Length : 169
  • Protein Note : Also known as Il-2
  • DNA Sequence : Show Sequence
    >gi|372099107:37120712-37125953 Mus musculus strain C57BL/6J chromosome 3, GRCm38 C57BL/6J
    ATTTTTTTTTAGAGGAGAGCTTTATTTCTTGAAAACACTGATTAACATAGAGTTCACAGGAATAACTGAG
    AAGTTATTTTAGCGCTTACTTTGTGCTGTCCTAAAAATGACAGACATCTGAGCTTATTTATATTTGAATC
    ATCTAAATACTTTTATTAATGAGTCTACCTACACATGATATTTAACAATTCAATATAATAAATAATTTCA
    GATAAATAGTTTAAAACATTTTTGAGCCCTTGGGGCTTACAAAAAGAATCTTTAAAGATCCATATTTATC
    ATCTGAAGACTAGTAGTTACAAAAGATAGTAAACAATACATCCAAAAATAAATTAAAGTTAAATATTTAA
    ATAAATAGAGAGCCTTATGTGTTGTAAGCAGGAGGTACATAGTTATTGAGGGCTTGTTGAGATGATGCTT
    TGACAGAAGGCTATCCATCTCCTCAGAAAGTCCACCACAGTTGCTGACTCATCATCGAATTGGCACTCAA
    ATGTGTTGTCAGAGCCCTAAAAAAGAATATAAAATTGTAGGCTAAGGTAGCTTACTTTGCATATAATTAT
    TCTTCACGGAAGCTTTTAGGCATTTATTTTAACACTGGTTAAATATATTGAACATTCACATTTCTGAAAT
    GATCACAATTATTGGGTTATGTTTTATTATGATATCAAATGGTAAAGCATAAAAAATAAAGCTCTCCAGA
    GTTGATTACCAACGAGCATTTGATGGGAACACTGAACACTTCTGTAGAATTCAGTTGCTTGACCACTTTT
    TCTCTGGTAAGTGTACACAGCTATGCATCAATTTAGGCTTCAGGAATGGAGAAATGATACTTGTTATATG
    TTCTTTGCTAAATCTTAAGAGTCTATTATTCAATTCTTTCCCCCCCAAGTCAGAATGGGAACAACCCAGA
    GTAGGTTAGGACAAGCATCTATTGGGGGAAATTTGGAGAATTTTGTTATAGATATACCTACCCTGATACC
    AGTGTAGATGAATCACAAAGTTTGTACATGTATAAATATTATAAATTTGTTCTGTGGATTAGCTTTTTGA
    AAGCTAACCCTCTTTGCTAAAGGAGATATTTTAATTCTGTTTTTAGGTGACAAGCTGAGAAGGAAATATT
    TTGACAAATTTATGGGATGGCTTTTCCAAATCTGACTAATTCCTTGTAAGTCAAATGAGGCAGATTATTC
    CTTTTAAATAAATACTCCTTTTCAAATAAGCTGCTGTGGTCTTATATACCCTCTTTACATAGCTACTTCA
    ATATTCTAATGTCTTGAATTTTTCATTTTTAAAAATATGTGGCCCTTGAAACATTTTTCTAGTTCTCATG
    TAGCTCTAAAGTTTGTACCATTCATTAGGGGTGAACTTTCTGATGTTGGCCATAGATTTTAGAGCATCCA
    TCTTTGCATACGTAAGTACTCGATTTTAGAGCATCCATCTTAGCATACGTAAGTACTCACACCTTTCAAC
    GTCTAGATGATGTGTATTTCAGCCTGCTTTAAAAACCTCAAATGGAAGCTGGGCAGTGGTGGTGCAGGCC
    TTTAATCCCAGCACTTGGGAGGCAGAGGCAGGCGGATTTCTGAGTTCGAGGCCAGCCTGGTCTACAGAGT
    GAGTTCCAGGACAGCCAGGGCTACACAGAGAAATCCTGTCTCAAAAAAACAAACAAACAAACAAACAAGA
    AACAAACAAACAAAAAAAACAAAAACAAACAAAACAAAACCTCAAATGGAAACAGTGCACTGAAATGTGA
    CTTTGGTTTGGAAAGGACTAGCCCACACCCTCTTGGAGGCTTGCTGCTACTGTCTCACCAGAGTCCATGA
    TTCTTGTGCATTTAAAAACAAAGCTCTGCAGTGGGCTCTCCCCGTCCTGCTCTGTCCATTTTAATGGCTG
    CCATTTTTGGAGAGAAATGTCTGTTTTTCTACCAATACCAGCACAACTTCTCTGGAAAAACTTTTCAGAT
    AATTTTTTCTGATCTGATGAATGTAACACCAGCAAGAGTTGCTTGTTTCTTGTGGAATTCTACTCCGTGC
    TTTCTCTCACATCCAGTTCTATGCTGGTGTGGAGGGAGCAGAGTGTTCATGTTCCCAGTTTCCTTGCAGG
    TGATGGTAGGTGGAAATTCTAGCATCATCCTACAGTGGAAGGATTCACTTGCACAGTGACTTTAAACTTT
    GGCTGACTAAATGCACAGAACCCATCAAAGACCAGAAATGGCAAGCCACTTAAAAATGCATTTCTTCTCT
    ATTTTATTTCCAGATTAGCAAATAAAGCAACACCTTACCTTTAGTTTTACAACAGTTACTCTGATATTGC
    TGATGAAATTCTCAGCATCTTCCAATTGAAAGCTTTTGCTTTGAGTCAAATCCAGAACATGCCGCAGAGG
    TCCAAGTTCATCTTCTAGGCACTGAAGATCTTTCAATTCTGTGGCCTAGAGGAGTAATAAGCTTAACCAT
    CAGCTCAGCTCACCACATACTGAAGAGCCAGAAAGTTAGTCTGCAGTCTCTCTAATCAAGAGAAGGCAGC
    ACATAGCTTTTACCACTCCCTGTCCTCTGTAAAGGGGGACTGAGGTAATCGATGCCATAAATCTAGAAGA
    GCAAGAGCTCACAACCATAAGGGTCACCTTGACTGTTAGGCCACTCTAGTGAGCTCTTCTGGCTTCATTA
    GACTTTGTAAAAAGTCTGTGTTTCTCTACCAATGCATAGCACAAGTTCAGACTATTGTTCCAATCTACAA
    AGAAATCTGCAAGGTTCACATTCTAATATCTAATCGCAGAGTTGAGAATCACAGAAGGGTAAGGGACAGG
    AATCCTTGGATGCCAACTGTCATAGGCCTAAATCTTACAGATTAGGTTATCATGGCCCTGACTGAGGGGT
    GTCAAGATAGCCAGGAAGACACATGTAATATTTTTTAAATTTATACTTCTCTGCAATTACTAAAGATGAG
    TTTTTTAAAAACCCATATGTCAAGCTAGGAAGATGGCTTTTAAGGTAAAGGTACCTGCCACCAAACTTGA
    TGATTTGAGTTCAATTGCAGTGACCCACCCACATTGTGGAAAGAATGGCCCAACTTTCATATTTCGTCTT
    CTGACCTCCACAGTTACACTGTGATACACATGCACCTCCACACATACATACATACATACATACATACATA
    CATACATACATACATACATACATACATAAAATGTAAAATCTATTTGTCCCAATGAAAAAAGTCATAACAT
    TTTGGCAGAACACTTGGGAGAATTTTTCTGATCCATGTATGAAATAATGTTTAAATACATCATGCATACT
    TACATACATATACAGGGAAAAAGGATATTGTCTAGCTCTATAGTACACTATGATTTCCATAAAGTCAGCT
    GCTTTAAGTCTACAGTGAACTGTGTTATCTCCATTTTACCAAGTCTCACAATCAGTGTCTTTCCCACAAC
    CACATGAACGGGGAGCAAGGGTGGCCCGGTCGGTCGGTCGCTCCTTTCATTAACCACAGCCTTTGAATTA
    CATGCTTCTATTGTTTTTAAAATCTTACATACCGAATGCAGGTTAAATGAAAACATCAGCAGAATTTACC
    ACATTACTCTTGTTTTCAATAATTATTTTAAAACTTAGATTTCTAGGAATTTCACCACTCTCTAAATTAA
    CATGATCTCTGTTGTTTCTCTAACAATCCTTAGAGGAAGAGGTTTGACAAGATAACACGTAGTTCCTGAT
    TGGTCTGCTATTGACCTTCCAACTTGTTATGGTGTGTCTTGGGTATTCAGTGTGGAGCTCCTTCCCTCAC
    AGAACTCTCCAGTTTGTTACTGTGGGAGCTGAACATTATGTGACTGTAATTAAGCTGGAAGAGCAACTGG
    GGCCTTTCTTTTTCATCTCCTGTAGAACAGCTAGAGGCAAAGTTCCCCTGACTCAATAGGAATGGGTCAA
    CAGCTGCCTCTTTGTCCCCTTAGATCCCATTTTGCTCTAGGCTTGGATTTACTTGGGACAAGCTCTTTCT
    AGGACCAAAGTTATCCATTCTCTTTTGACTTTCGGGACTAGAGCAAATTTCTACCCTTGCTGGAGTTCTA
    AGAGCTTGTGTAAGCTGTTTTGTATCACACAACATTCTGCCTCCAAAGGAGACCAAAAAACCTTTCAATA
    TTGAGAGATAGTATCATGTAGTAATATTACAGCTCTCTAGTTCCACTAGTTAAAAGAGACTGTATAAATC
    CAAAATTGTTTTATACATCTCGGACTTCTTCTCTAGCACTAATAGTGTGTTTATGTGCTGTTGGCCAGAC
    ACTGTTCTGAAACCTGACAAGTGATAAGCATAGCAATGATCATTTATGTAAGTGGGTGAATGAGCATAGA
    CAACTTCCTGAGGCCATGAGAGCTAGGCCCTAGCAGGGCTGGACTCCACTGCAGATCATTGGCCCTAGAA
    TCTTAACATTGGTTATGCTGCTCCTCAAAAATGCAGTCATAGGAATCATTCTTAAAACAGTAAAGTGTGT
    GTAAAATGAGACCCTCTCAAGTCAATTTTTACATTTAAGAAGCTGAAATAATGCACCTCTCTCAAATATC
    TGTAGGACAAGCATAAAACAGAAATCAACAGTCTTTAAATTATCCCAGCATCAAAATGCAATCATCTTGC
    ATTTTCTTCTCATTCCCTTTCCCAACACATAAATACACAGGAAAAATGTAAAGAAAACCATTTAAAAGAA
    GTACCATTGTCAAGATTTTTTTACAGAGAGATATCAGAGAAACTTATTTTCTTCAGATGAGGTACTATTC
    ATCTGGTCACATGTTATTTACACGTTATACACATGTATGTTACTTTGAATTCATTAGAGCACCAGTTAAA
    CACAGAAACTCACTCACCTGCTTGGGCAAGTAAAATTTGAAGGTGAGCATCCTGGGGAGTTTCAGGTTCC
    TGTAATTCTGAGAAAGCGTAACACATTATTATTAAAGGTTATTAAACACAGCCTTTGGCAAGAAAGCTAA
    AGGTATTGCCTATAGATGGGATGGCTGTGCACTTACCTCCATCCTGCTCAGGAGCTCCTGTAGGTCCATC
    AACAGCTGCTCCAGGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGTGCTTCCGCTGTAGAGC
    TTGAAGTGGAGCTTGAAGTGGGTGCGCTGTTGACAAGGAGCACAAGTGTCAATGTGACACAGGATGCGAG
    CTGCATGCTGTACATGCCTGCAGGACTTGAGGTCACTGTGAGGAGTGATTAGCAAGGGTGAT
  • Protein Sequence : Show Sequence
    >gi|7110653|ref|NP_032392.1| interleukin-2 precursor [Mus musculus]
    MYSMQLASCVTLTLVLLVNSAPTSSSTSSSTAEAQQQQQQQQQQQQHLEQLLMDLQELLSRMENYRNLKL
    PRMLTFKFYLPKQATELKDLQCLEDELGPLRHVLDLTQSKSFQLEDAENFISNIRVTVVKLKGSDNTFEC
    QFDDESATVVDFLRRWIAFCQSIISTSPQ
  • Molecule Role : Vaximmutor
16. IL2
  • Gene Name : IL2
  • Sequence Strain (Species/Organism) : Papio anubis
  • NCBI Gene ID : 100126754
  • NCBI Protein GI : 162951936
  • Protein Accession : NP_001106124
  • Taxonomy ID : 9555
  • Chromosome No : 5
  • Gene Starting Position : 113155265
  • Gene Ending Position : 113159953
  • Gene Strand (Orientation) : -
  • Protein Name : interleukin 2
  • Protein pI : 7.38
  • Protein Weight : 17215.83
  • Protein Length : 154
  • Protein Note : Also known as IL-2
  • DNA Sequence : Show Sequence
    >gi|395728657:113155265-113159953 Papio anubis chromosome 5, Panu_2.0, whole genome shotgun sequence
    ATCAGGTCAGTGTTGAGATGATGCTTTGACAAAAGGTAATCCATCTGTTCAGAAATTCTACAATGGTTGC
    TGTCTCATCAGCATATTCACACATCAGTGTTGTTTCAGATCCCTATAAAAGAAACATGTTAATTTTTTAA
    AGTGCAGAGTAGTTTACCTTATATATAGTATTCCCAATTGAAGTCTTATAGGCCTGTTGCCTTTATTTTC
    AAGCTTACCAAACATATTAATTATTCACATTTTCTTGAAATGATCAAAATGAATGCCAAAATTACATATT
    TTGTTATGATACCAAATGATAGTAACATGGAAGCTGAGATTTTCCTCATTTGTTAATTCAGTCAATGAAC
    ACAAAAATTTTTTCCCTGAATTGGGTGCAAATAAACATTTAAATAAAAACAGATCGAGACAAATATTAAA
    TGCTGGATATGAAATAAACTTGATCGCTTTTCCTCTGAGTATGTACCTATATTTGTTTAAGTTAAATGTA
    TGAATTGATATGCACATTATACTTTTCTAAATCTTGATTAGAGTCTCCTATTTTTCTACTTAAGTGAATC
    TCCTTATATTTTCCCCAAAGCAGAATAGAACTAGCCTAGAGTAAGCGAGGACATGTTTCTGTTTGGGAGA
    AATTTGTGTGAAGAACATCTTCATAAATACTTATACCTACCCCTACCCTATCATAGTATCAATACAGGTG
    AATTTAACAACTTTTGAAAGTTTAAACATTGGAAATTTTGTTCTATGGACTGGCTTTTTAGAAACTAGGC
    TCCTCTGCTGAAAGAAGCGATTTAAACGCTTCCTCTAGTTGATAAGCTAAGGAGGAAATATTTTGATATA
    AAGTAATACTTAAAAGACAGCTTTTCAAATTTGAAGTTATTCCTACCCTGGGAACAAAAAGCAAGTGAGA
    TAGAGTGTTCCCTTTAAATAAGTATTCTCTTTAAATAAACTGTTACAGTGTTCTGTACCCTCTTAAGCAT
    AATTATTTAAATATTGTAATATCTTGGGTTTTTTTATTTTAAAAAGTGTTTGGCTTTTGAAACACAGTTT
    TCAGATTTTTGCATGGTTTTGTCTTAAATTTGTATCAAGAGTTAAGAATGAGTTTCTATTTTAGAGTAAA
    ACTCTTGCCATAGATAAGGAACTGAATCTGTCAGTGTCTAGATGACATGGATCTCAATGTATTTTTTTTA
    ATTCAGCTGAAACAGTCCACTAATAAGTGATTCATTTGGACACAACTGGAGTTACTTTTAGAAATGTCTT
    TCTATTATTGTACTTATGCTGCTTATTTAGGATAGCTATTAACTCATGAATTTTATACCTTAGCAGATGG
    GATATAAAAAGAGAGAAGGGAATGTCTTTTACATCACCTGAGTCCCTTGCATATTTTATGCATCCTGTGC
    ATTTAAAAATACTTGATTCTGAAAGTGGGATTGCCTCTAAAAAGGTTGTTGTTTGTTTAGTCCACTGGCC
    ATTGTAATGGCTCCAGGTTTTTTTTTTTTTTTTAAGACAAATCTCTTATGGGTAGTCCTTCTATCAAATG
    ATAAGGAAACACCATTTGAAAAGGCATTTCAGGTAATCAGTATTGACTATTCCAGTAAATGATCTGAAGG
    AATTGAAAAATATATAATAAAATCTGCCTGCTTTCTGTGAAACTCAATTCAGTACCTTCTCTCACTCCCA
    GTTTTGTGTTAATGTGAAAAGTGATGGAGTTTGGGATGAGGCTTGTCCATTAGTAGATGGTAGGTGCAAA
    CTCTGTAGCTTATACTTCCCAGTTAGTTTATCATCTAACATTAGAAACGATTCATGTTCACAGTGTACTT
    AAAATGTAGGCTAATTACATGCATGGGTACTTTACAAATACCAAAAATGTTATGTCACTTTGAAATGTGG
    TACTTTTCCCCTTCCATTTTTTTTTTTTTTATTTCCAGGAGAGCAAATAAAGTAATGCCTTACCTTTAGT
    TCCAGAACTATTACGTTGATATTGCTGATTAAGTCCTTGGTATCTCTTAAGTGAAAGTTTTTGCTTTGAG
    CTAAATTTAGCACTTCCTCCAGAGGTTTAAGTTCTTCTTCTAGACACTGAAGATGTTTCAATTCTGTGGC
    CTAGAATAATAATTATCATCAGCTCAGTTTCCACAGAGGTCAGAATCAGAAATTAATTTCTAATTTATTT
    TATTTGGAGTAGCAGTATGTAGTTTTTACCATTCTCTCTGTTCTCAGTATCACTGTAAAGATGGACCAGT
    AGAGTTTACATTATAAAACTGGAAAAACTAGGGCTCAAGTACCTATGACTAGCGTTAAGTGATAGTTGAC
    TCACTGGTTTTAGCTTAATTTGGCTTTGCAAAATGTTAGCATTTCTGCATCTAAATGCAAATTACAGATG
    TAGGCTGATTACTTTTCCAGTCTGCATAGAAAATCATTAGAACCAGATCAGTTAGAATGTGGAAATATAA
    AAATCACATTCTATGATTATAATATTTGATAATCTAAGAGTTAAGAATCACAGAATGTTAAGAGACAGAA
    GGAACTCTTGGATGCCATCTATCACAATCCTGACATTTTACACTAGGTAACAATAATCATGTAGTAGTGG
    CTCTCGATATAGCCTGGAGCAAGACACATTTAAGTGTGTCTAAATTTTTACTTTTCTACAATCACTACAT
    TAAGATGCATTTCAAAAATATTTGTCCCAATAAAATAAAAGATTATAGTACTTTGGAAGGACTTTTGAAC
    AGGCCTCCTGGTTCTATATTATATATAATATTTCGTATTTCTATGGTATATTATAATTTAAAAGAATTTT
    CTCCAAAATAAGCCCATTTACATCTCACGTCATCTTTTGAAGTAGGCAGTGAAGGATCATCTCCATTTTT
    AAAATAAGGATGCCAAATCTCAGAATTTGACCACATAAGTAGGTAGAGCCAGAATTAGATTTCAGTTCTT
    TCTCATTATAGCATTAACATAGCATCCTTGGAATCAAATATTTTTATTAGTTTCTAAAATTTTTTGTAAA
    TGTGCAATGAGGGTTAAACAAATGAATAGAGTTTATCATTACTTTTGTTTTCAAACTGTTAGATTTCAGT
    GAATTCTACCACCCCCTAAATTATGCACATAATATCGTCTTTCTAACAATCTTTAGTGGGAAAGGTAGGA
    CAAGACAATACCGATCCCCTGATATGTCCATCTATTGTGCTTTCAATTCGCCACTACAAATTCTACAAAT
    TCTACAAATTCGGGGTTAAGTTTTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
    NNNNTTGCTGGAGTTGCATCACGTGGCTCTGTTTAAACTAGAGTAACATCTGTAAGCTGTCTTCTTTACA
    TCTTTCAGAAGAGTAGTTTGAAGCAGATTTCCCTTGAATTAATAGAATTTGAGTCAATGGGATTGCATCT
    GTGTCCCCTTAAATCCTATTATTTTCTGGGTTTGGATTCACCCTGGCACAAGCCCTTTCTGGCACCAAAT
    TTTGTTCATTCTCTCTTAACTGGCACAGCTACTAGGTAGCTTTGCACACCTAATGTAACCTAGGAACTTG
    GATGATTATGCTTATGCTGTATCTGAATCCAAAAACCACCTAATGAAGCTTTTAATCTTGGGAAATAAGT
    CATATAACATTATAAGTCTCAAGTTCTATTGGTAAAAAGATAAAAATCCAAAATTTCACTTTGTATTTCT
    CAGTAAGAATTTTATCTTTAATACTACTAATAATAGCTAATGCTTATATGGTATTTACCTTATGCCAGAC
    ACGGTTCTGAGTGCTTTACATTTACTTACTAATTCTCACAAAAGTGTATTAAGTATATACAGTTATTCAT
    TTAAGTAGACATGAAACTGAATCACAAAGAGAGCAGGTAATTTGCCAAAGGTCATGAAAGCTGGGACATG
    GCAGAGCTGAGATTTCACTTGAGATATCTGGCCCCAGAGTCTGTGCTATTAGTTAGTGTTATGCTGCCTC
    TTACTTAGGAACCTTTCCTAAAACAAGAAAAGGTTTTTTAAGTTGGGCTTCTTGGAAATAGATTTTGGTA
    TTTTACATACTAAAATGGCATAATCAAATATTTTAGAGTTTTACATTTTTAAATGAAACCATAAGTCAAC
    ATTTTTGTTTAAAATTGTCTTATCAATAAAGTGAGAATATTATTTTTATGTTTTCTTCCCACCCCCACCA
    ATACACAAATATATGTAAAAAATATAGGTAAAACTATTTTAATAGATGCTTCATTATCAAACTTGGGTTT
    TCAAAAAACAGAAATTAAAGTTACTCTTTACCTTAGATAAGCTGCTATTAATCCCATCTGTGCAATTTTT
    CATATTACTTTGAATTTTATTAAAACAAATTGAACATAAAAAATTGTACTTACCTTCTTGGGCATGTAAA
    ACTTAAATGTGAGCATCCTGGTGAGTTTGGGATTCTTGTAATTCTAAGAAAGTATAATACATTGTTAATT
    AAGAAATGATCTCCAGCTAGATTACTAAATGTAATAATTTTAGTAAGAAAGAAATATACTTACATTAATT
    CCATTCAAAATCATCTGTAAATCCAGCAGTAAATGCTCCAGTTGTAGCTGTGTTTTCTTTGTAGAACTTG
    AAGTAGGTGCACTGTTTGTGACAAGTGCAAGACTTAGTGCAATGCAAGACAGGAGTTGCATCCTGTACA
  • Protein Sequence : Show Sequence
    >gi|162951936|ref|NP_001106124.1| interleukin-2 precursor [Papio anubis]
    MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA
    TELKHLQCLEEELRPLEEVLNLAQSKNFHLRDTKDLISNINVIVLELKGSETTLMCEYADETATIVEFLN
    RWITFCQSIISTLT
  • Molecule Role : Protective antigen
17. IL2
  • Gene Name : IL2
  • Sequence Strain (Species/Organism) : Macaca mulatta
  • NCBI Gene ID : 708017
  • NCBI Protein GI : 114052044
  • Genbank Accession : AANU01270753
  • Protein Accession : NP_001040595
  • Taxonomy ID : 9544
  • Chromosome No : 5
  • Gene Starting Position : 114846883
  • Gene Ending Position : 114851612
  • Gene Strand (Orientation) : -
  • Protein Name : interleukin 2
  • Protein pI : 7.38
  • Protein Weight : 17187.82
  • Protein Length : 154
  • Protein Note : Also known as IL-2
  • DNA Sequence : Show Sequence
    >gi|109156895:114846883-114851612 Macaca mulatta chromosome 5, Mmul_051212, whole genome shotgun sequence
    CCTGGTATGTTTTAAGTGGGAAGCACTTAATTATCAGGTCAGTGTTGAGATGATGCTTTGACAAAAGGTA
    ATCCATCTGTTCAGAAATTCTACAATGGTTGCTGTCTCATCAGCATATTCACACATCAGTGTTGTTTCAG
    ATCCCTATAAAAGAAACATGTTAATTTTTTAAAGTACAGAGTAGTTTACCTTATATATAGTTATTCCCAA
    TTGAAGTCTTATAGGCCTATTGCCTTTATTTTCAAGCTTACCAAACATATTAATTATTCACATTTTCTTG
    AAATGATCAAAATGAATGCCAAAATTACATATTTTGTTATGATACCAAATGATAGTAACATGGAAGCTGA
    GATTTTCCTCATTTGTTAATTCAGTCAATGAACACAAAATTTTTTTCCCTGAATTGGGTGCAAATAAACA
    TTTAAATAAAAACAGATCTAGACAAATATTAAATGCTGGATGTGAAATAAACTTGATCGCTTTTCCTCTG
    AATATGTACCTATATTTGTTTAAGTTAAATGTATGAATTGATATGCACATTATACTTCTTTTCTAAATCT
    TGATTAGAGTCTCCTATTTTTCTACTTAAGTGAATCTCCTTATATTTTCCCCAAAGCAGAATAGAACTAG
    CCTAGAGTAAGCGAGGACATGCTTCTGTTTGGGAGAAATTTGTGTGAAGAACATCTTCATAAATACTTAT
    ACCTACCCCTACCCTATCATAGTATCAATACAGGTGAATTTAACAACTTTTGAAAGTTTAAACATTGGAA
    ATTTTGTTCTGTGGACTGGCTTTTTAGAAACTAGGCTCCTCTGCTGAAAGAAGCGATTTAAACGCTTCCT
    CTAGTTGATAAGCTAAGGAGGAAATATTTTGATATAAAGTAATACTTAAAAGACAGCTTTTCAAATTTGA
    AGTTATTCCTACCCTGGGAACAAAAAGCAAGTGAGATAGAGTGTTCCTTTTAAATAAGTATTCTCTTTAA
    ATAAACTGTTACAGTGTTCTGTACCCTCTTAAGCATAATTATTTAAATATTGTAATATCTTGGGGTTTTT
    TTATTGTAAAAAGTGTTTGGCTTTTGAAACACAGTTTTCAGATTTTTGCATGGTTTTGTCTTAAATTTGT
    ATCAAGAGTTAAGAATGAGTTTTCTGATGTTAACTATTTTAGAGTAAAGCTCTTGCCATAGATAAGGAAC
    TGAATCTGTCAGTGTCTAGATGACATTGATCTCAATGTATTTTTTAAATTCAACTGAAACAGTCCACTAA
    TAAGTGATTCATTTGGACACAACTGGAGTTACTTTTAGAAATGTCTTTCTATTATTATACTTATGCTGCT
    TATTTAGGATAGCTATTAACTCATGAATTTTATACCTTAACAGATGGGATATAAAAAGAGAGAAGGGAAT
    GTCTTTTACATCACCTGAGTCCCTTGCATATTTTATGCTTCCTGTGCATTTAAAAATACTTGATTCTGAA
    AGTGGGATTGCCTCTAAAAAGGTTGTTGTTTGTTTAGTCCACTGGCCATTGTAATGGCTCCAGGTTTTTT
    TTTTTAAGACAAATCTCTTATGGGTAGTCCTTCTATCAAATGATAAGGAAACACCATTTGAAAAGCATTT
    CAGGTAATCAGTATTGACTATTCCAGTAAATGATCTGAAGGAATTGAAAAATATATAATAAAATCTGCCT
    GCTTTCTGTGAAACTCAATTCAGTACCTTCTCTCACTCCCAGTTTTGTGTTAATGTGAAAAGTGATGGAG
    TTTGGGATGAGGCTTGTCCATTAGTAGATGGTAGGTGCAAACTCTGTAGCTTATACTTCCCAGTTAGTTT
    ATCATCTAACATTAGAAACGATTCACGTTCACAGTGTACTTAAAATGTAGGCTAATTACATGCATGGGTA
    CGTTACAAATACCAAAAATTTTATGTCACTTTGAAATGTGGTACTTTTCCCCTTCCATTTTTTTTTTTTT
    TATTTCCAGGAGAGCAAATAAAGTAATGCCTTACCTTTAGTTCCAGAACTATTACGTTGATATTGCTGAT
    TAAGTCCTTGGTATCTCTTAAGTGAAAGTTTTTGCTTTGAGCTAAATTTAGCACTTCCTCCAGAGGTTTG
    AGTTCTTCTTCTAGACACTGAAGATGTTTCAATTCTGTGGCCTAGAATAATAATTATCATCAGCTCAGTT
    TCCACAGAGGTCAGAATCAGAAATTAATTTCTAATTTATTTTATTTGGAGTAGCAGTATGTAGTTTTTAC
    CATTCTCTCTGTTCTCAGTATCACTGTAAAGATGGACCAGTAGAGTTTACATTATAAAACTGGAAAAACT
    GGGGCTCAAGTACCTATGACTAGCGTTAAGTGATAGTTGACTCACTGGTTTTGGATTAATTTGGCTTTGC
    AAAATGTTAGCATTTCTGCATCTAAATGCAAATTACAGATGTAGGCTGATTACTTTTCCAGTCTGCATAG
    AAAATCATTAGAACCAGATCAGTTAGAATATGGAAATATAAAAATCACATTCTATGATTATAATATTTGA
    TAATCTAAGAGTTAAGAATCACAGAATGTTAAGAGACAGAAGGAACTATTGGATGCCATCTATCACAATC
    CTGACATTTTACACTAGGTAACAATAATCATGTAGTAGTGGCTCTCGATATAGCCTGGAGCAAGACACAT
    TTAAGTGTGTCTAAATTTTTACTTTTCTACAATCACTACATTAAGATGCATTTCAAAAATATTTGTCCCA
    ATAAAATAAAAGATTATAGTACTTTGGAAGGACTTTTGAACAGGCCTCCTGGTTCTATATTATATATAAT
    ATTTCGTATTTCTATGGTATATTATAATTTAAAAGAATTTTCTCCAAAATAGGCCCATTTACGTCTCACA
    TCATCTTTTGAAGTAGGCAGTGAGGGATCATCTCCATTTTTAAAATAAGGATGCCAAATCTCAGAATTTG
    ACCACATAAGTAGGTAGAGCCAGAATTAGATTTCAGTTCTTTCTCATTATAGCATTAACATAGCATCCTT
    GGAATCAAATATTTTTATTAGTTTCTAAAATTTTTTGTAAATGTGCAATGAGGGTTAAACAAATGAATAG
    AGTTTATCATTACTTTTGTTTTCAAACTGTTAGATTTCAGTGAATTCTACCACCCCCTAAATTATGCACA
    TAATATCGTCTTTCTAACAATCTTTAGTGGGAAAGGTAGGACAAGACAATACCGATCCCCTGATATGTCC
    ATCTATTGTGCTTTCAATTCGCCACTACAAATTCTACAAATTCGGGGTTAAGTTTTTGGCATGAACAATG
    AGGAGAAATTTTCTTCAGGAAACAGCATCTAGTGTCTTTATGTTGCTGGAGTTGCATTACGTGGCTCTGT
    TTAAACTAGAGTAACATCTGTAAGCTGTCTCCTTTACATCTTTCAGAAGAGTAGTTTGAAGCAGATTTCC
    CTTGAATTAATAGAATTTGAGTCAATGGGATTGCATCTGTGTCCCCTTAAATCCTATTATTTTCTGGCCT
    TGGATTCACCCTGGCACAAGCCCTTTCTGGCACCAAATTTTGTTCATTCTCTCTTAACTGGCACAGCTAC
    TAGGTGGCTTTGCATACCTAATGTAACCTAGGAACTTGGATGATTATGCTTATGCTGTATCTGAATCCAA
    AAACCACCTAATGAAGCTTTTAATCTTGGGAAATAAGTCATATAACATTATAAGTCTCAAGTTCTATTGG
    TAAAAAGATAAAAATCCAAAATTTCACTTTGTATTTCTCAGTAAGAATTTTATCTTTAATACTACTAATA
    ATAGCTAATGCTTATATGGTATTTACCTTATGCCAGACACGGTTCTGAGTGCTTTACATTTACTTACTAA
    TTCTCACAAAAGTGTATTAAGTATATACAGTTATTCATTTAAGTAGACATGAAACTGAATCACAAAGAGA
    GCAGGTAATTTGCCAAAGGTCATGAAAGCTAGGACATGGCAGAGCTGAGATTTCACTTGAGATATCTGGC
    CCCAGAGTCTGTGCTATTAGTTAGTGTTATGCTGCCTCTTACTTAGGAACCTTTCCTAAAACAAGAAAAG
    ATTTTTTAAGTTGGGCTTCTTGGAAATAGATTTTGGTATTTTACATACTAAAGTGGCATAATCAAATATT
    TTAGAGTTTTACATTTTTAAATGAAACCATAAGTCAACATTTTTGTTTAAAATTGTCTTATCAATAAAGT
    GAGAATATTATTTTTATGTTTTCTTCCCACCCCCACCAATACACAAATATATGTAAAAAATATAGGTAAA
    ACTATTTTAATAGAGGCTTCATTATCAAACTTGGGTTTTCAAAAAAACAGAAATTAAAGTTACTCTTTAC
    CTTAGATAAGCTGCTATTAATCCCATCTGTGCAATTTTTCATATTACTTTGAATTTTATTAAAACAGAAA
    TTGAACATAAAAAATTGTACTTACCTTCTTGGGCATGTAAAACTTAAATGTGAGCATCCTGGTGAGTTTG
    GGATTCTTGTAATTCTAAGAAAGTATAATACATTGTTAATTAAGAAATGATCTCCAGCTAGATTACTAAA
    TGTAATAATTTTAGTAAGAAAGAAATATACTTACATTAATTCCATTCAAAATCATCTGTAAATCCAGCAG
    TAAATGCTCCAGTTGTAGCTGTGTTTTCTTTGTAGAACTTGAAGTAGGTGCACTGTTTGTGACAAGTGCA
    AGACTTAGTGCAATGCAAGACAGGAGTTGCATCCTGTACA
  • Protein Sequence : Show Sequence
    >gi|114052044|ref|NP_001040595.1| interleukin-2 precursor [Macaca mulatta]
    MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA
    TELKHLQCLEEELKPLEEVLNLAQSKNFHLRDTKDLISNINVIVLELKGSETTLMCEYADETATIVEFLN
    RWITFCQSIISTLT
  • Molecule Role : Protective antigen
18. IL4
  • Gene Name : IL4
  • Sequence Strain (Species/Organism) : Macaca mulatta
  • NCBI Gene ID : 574281
  • NCBI Protein GI : 74136371
  • Locus Tag : EGK_16838
  • Genbank Accession : CM001258
  • Protein Accession : NP_001028076
  • Taxonomy ID : 9544
  • Chromosome No : 6
  • Gene Starting Position : 129082063
  • Gene Ending Position : 129090398
  • Gene Strand (Orientation) : +
  • Protein Name : interleukin 4
  • Protein pI : 9.44
  • Protein Weight : 17265.73
  • Protein Length : 153
  • DNA Sequence : Show Sequence
    >gi|109157119:129082063-129090398 Macaca mulatta chromosome 6, Mmul_051212, whole genome shotgun sequence
    AATGGGTCTCACCTCCCAACTGCTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCGGCAACTTTGCCCAC
    GGACACAACTGCCATATCGCCTTACGGGAGATCATCGAAACTCTGAACAGCCTCACAGAGCAGAAGGTGA
    GTACCTATCTGGCACCATCTCTCCAGATGTTCTGGTGATGCTGTCAGTATTTCTAGGCCATGAAAACGTT
    AACAGTTGCTAGAGAAGTTGGAACTGGTGGTTGGTGGCAGCCCGGGGCACACAGCCAGGCTTCCCCTGTC
    ACTCTTTTTTCTGAGGGTTTGTAGGAAGTTTCCTCAGTTGGAGGGAGTGAGAGATGCTCATCAAGGACTG
    CTCTGTCCAGTTGGAGGTTAACTCTGTCTCTTGCTCTCTCATTTCTGCCTGGACCAAGACTCTGTGCACC
    AAGTTGACCATAACGGACATCCTTGCTGCCTCCAAGGTAAGAAGCCGTCCCACGGTCTGTTTTAGCACAT
    GGGGAGATCCATCCCCAAGTGTCTGAATAAGAAACTTGTCTAATGGAAAACAAGCGGGCCCAAATTAACT
    CTAAGGTGTTAGATGTTTTCAAAGAACGAGAAGTCTGATTTTTACTCTTAAGTGTGTTTTGGTCTTTCTG
    GTTTCACTTGATTTAGATGTGTAATAGAAAGCTTACATGCTATAGTCCTGACTCAGATCCTGGTCAAAGA
    AAAGCCCTCTTGGGTTTTACTTAGCTTTGGCATAGTGCCTGGAACGTAGGAGGCACTCAATAAATGCCTG
    TTGAATGGGAGAATTTTTCTGGCCCATACATTTCTGAAAAACCAAATACTCTCACAGAAACAGATATTGA
    GATGACAGGTTGAGGGAGCTTTCATTTTGTCTAAGAGACTTCCTATGGCAACAGAAAAGGTATCACCAGA
    GCCCCTCCTCTTCCACAGCCTGGCCACCTAACAGCCCTCTGGGTTCCAGGGCTGGCGGTCCAGGGCTCCT
    CAGCTTGCTCTGGCGGGTCGAATTCCCGTCCAGCTCGGTCCGGAACCATCCTGCTGGGCAGCGTCCAGCA
    CATCCCTGCTTCCGGTTGCCTGGGCACCTCGCCTCTCTGCCTCCTGTGCTGCCTCACCCCCACCCCTCTA
    TCTGTAGTGGGAGGAGATAGATTTGACAGCTGATAGTGCATTTTCTCTGACAAACACATGACTACAGCCG
    TATCAATAGTTTTGTGCATTTCAGTTCCTGTTTTCATGGAAACACACAGCTGAGAATGAAAGCCCCAAAG
    CCTCAATTTCACAGTGGTCTCCTAACTACTGCTTTCCATGCGAACTAGGGGGATGATTTGGCCAGCAGTG
    AAGCCCTGTGTGTTGGGCAGGGTCACGCCCTGGCACCCAGGCCATAGAACAGGGCCCATCCTGCTTCATG
    AGGGAAACTGCTCTTCGGGCCTTTATCTGGACTATCTCATTCATTAAACGTTATCCCAGGAGTTCAATAC
    AGGATGAGATTCCTGAAGGGTAAATCCACACTTTGTTTTTTTTTTCTTTTGAGATAGGGTCTTGCTCTGT
    CACCCAGGCTAGAGTGCAGTGGTGCGATTTCAGCTCACAGCAGCCTCCACCTCCCAGGCTCAAGCTAACC
    TCCCACCTCAGCCTCCCAAGTAACTGGGATGACAGGTCTGCGCCACCACGCCTGGCTAACTTTTGTATTT
    TTGTTGTAAAGATGGGGTCTTGCCATTTCATTTTGCCCAGGCTTGTCTTGAACTTCTGAGCTCAAGCAAT
    CCATCCACCTCGGCCTCCCAAAGTGCTGGGATTAGCCACTGCACCTGGACAACAGTTTGTGTGTGTGTGT
    GTGTGTGTGTGTGTGTGTATACACAAAATTTCTAAGTCCTTCCAACCGAGATGGCTCCTACTAGAAGCCA
    AGAGTCCACCGGGTTGAGCACTGGGTCTCTGGAGGCCTGTGGCACTGCTGAGAAGGCTCTAACAAAGCCA
    AGGGAAGGGCCACCTCACTAGAAGTCAGGCCTGGAGGAAGGGTGAGGGTTGAGGGCCTGGAGGTGAGACT
    GCCTATGGTTTTAGACCCCGCTCTGCCACTGACAGCTGTGTGGCTGGCCTTCGGCACATCTTCACACCTC
    TCTGCACCTCAGTTTCCACGTGTGAAGATACGAAAGTGATTCTGAAGGTGATTGCAAGGTTGATTGGAAT
    CCAGTTCTTGAGTTAGTGGAAAGGGTTATTGTGAGATGATATAACCCTGATTAAAAGCAAGGACACGTTG
    CAGAGAAGCGATGATTCTAAGAAGGAGGTGCCCAGGTTGGAAAGGATCAAACCCTCCAGGATGCTGAGCC
    TGGGGCTATCCATCTGGGCTGTTTCTGGAAGACCTCCAGGCGCAGGCGAGGACACCACTGCCCTCCCGTC
    CTTAACTCCCCTCTTCACTCAGTCCTCACTCACCTCCCTCTCACACACACAGACATCTCCTAGAACAATC
    CCCACTGCCTGCCTTTACTCTTACCTGTCTCATTCGCCTTCCCCGAACTTCATCCTCCTGGAGTTCTCAA
    TCTCACTCTTCTACTCTTTTCTTCCCCTTGAAGATTCAGCACTGCTTACTTACATGTTAAGATATTTCAG
    AACAGTGAAATGTTGCTATTTTCAAAAACCTACAAAGGTGGTATGCAGAGGAAAAGGTACTTCTTTGTGT
    TCCCAAAGAAAACATCTTTCCAAAATCCAGCCTATTGATTTTATTTCTTCGGGGGGAACAAGAATTTTAG
    TATCTCTAAGTTGGGTAGCATTCTACTCTTGGCAGTTGCTGGAAAGAAGGCACTGATCTAGGTCCTGGGC
    TTCATAGGTAACACCTGTTGGGGTGTCTATGAAGTCAAGGCTGTCTGAGGAACAGCAAAGTGGGAAGAAG
    CAAGCTGGCTGGTCGATGAAGGGTTTCTTGGGTGGACAAGTAGATGGAGCTATTTCCTACTTACCAAAGA
    GAGCTAAAGTTCATAATTCTACAGAGAGTTCCATAATGAACCTCAAATATCTCTGTTTTTTGAAGGAGTT
    TCTCATATAGAGCACTAGCTGACTACCCTGGGCAGGATGGGAGATAATGAATGCAGTGCCAGTCGGGCTG
    GATTTGTATGGTCCTCAGTGAGGCTGGTCAAGAACCAAGTCAGAACTCTCACAGAGTCACTGCCACAGAA
    GAAATCTCCTAAGTGGCTGTTTCCTGACATTCCCGGGAGGGACAGACCTCCTTCTCAGTCACTCCCTAAG
    CAGTTCTGAACGGTGAGGTCAGCCAGGCTGTCAAAGTGCACTCCCTGAGCCACTGGCAGACACACTCAGC
    AGCCGGAGCTAGACAGGCAGGTAGAAGGAGTCCAGGGTCACAGCAGGGATGGAGTGTCGCCCCCTCGCTG
    CGATACCAGAGCAACTAAAACGTAAAGGCCGCACTAAAGCTGCCCTTAGGATGTATTCTTTTAAAGTTTT
    TCCATTTAATGCAGACTCTTTTCAATTCTTATTTTATCCTTGTTTCCTTTAGAAAGTCCTTTGAAAAATA
    TCTTTAGAGGATTTTTTCCTATACTATGTGGCCATATATGGGTCAAAATTAAGTTTAATTTCCAGGGTCC
    AAGCCAGCATTTCAGAAAAATCTCACCAAGGTTTGTGGGAAAAGAAGCAAAGGCTTTTTGGCCTTCTTGA
    AGCTCACTGTTCCCTCTGCAGCAGCATGCATGTCTGCCCACCTCCAGACACTCAGGTAGCATGTGCTGCC
    CCCCACCAGCCCCTGTGTCCCCTCCACCTCGACTCGCCCACAAAGCACAGAGAGGTCTGTTTCTTGGCTC
    CAAGAGCCCAAAAATACTGACACACTCTTGTATTTCCAACTAGAATCAGGAACCAGGAGTGACTCTCAGT
    CAGTTCATTAAGTAAATGTCTTTCCAACCGCTCTGCCCATGGGATGTCACGCCCCACAGAGGAAAGGGGA
    AGCTTCCGTAGCCTGGGATTCTGGTGCCTCAATCTGGGTCTAGATCTTCCTGAAAAAAAAACGTTAAAAT
    ATGAACTGCATTCCTAGAATGTAGCCTATATAAATAAGAGATGAACACAAAGATTTATATAGTTTACTCA
    CTGCCACTTATTTACAGAAAGAGAAAGCTGCTGTAAATAAGGCAAATTACAATTGTAAAGGGGCCTGACA
    AATGACAGCACCACTATGCAATACGTTTCTATGCAGCTCTCAAACCCATGTTCTCAAATACCACCGAAGG
    GCTTAGGAAATGCTTATAGTATATGCAAAGGGTAAAAAAGTTACAAAACAGTATCAACAGTTGATCCCTA
    TTTTAAAAAGTGTTTTTTAAAGTGTGATGATATTTACCAAAATATTAACAGCAGTAGTTACCTCTGGCTG
    ATGGGATGAGTGAATGTACTTTTGTTGAATATATAATTACCTTTATAGTAAATACACGTTACCTTGATCA
    TCAGAAAAAAAAATGTAACCGTAAGAACTTGAAAGCTGCTTGGACAGTGCTGCTGATAGAAATCCCTGAG
    GATCTTGTCACTGTTCTGATTCAGAGGGTCTGGGTGGGGCAGGGGTGGTCTGAGATTCTGTATTCTAAGA
    AGCTCCCAGTGATGTCCATGATTCTGGTCATGGACCACACTTTTGAGTAGCAAGGGACCAGAGCATGTCG
    GGGGAGAGGCTGGGGATAGCTTTATCTCAACTGGATAAAGGAACTAGGCTCAAGCTAAGAACCCTCTCCA
    AGTTCTGCATCTTTGTTCTTCAGTGAAAAATGAGAGGACAGACCAGTTCAGACCGAGACAAAATCCCTCT
    CCTGGGTTCCCAATGACTTGTCTCCCTGTGTGTCCATTCCCTTCTCTAAGGTTAAGGGCCCCAGGAAGAG
    CCATGTGGCCAGACCCTCACAGTTGCCAGCATTTCAGGGAGATTCTCACTCTGCACCATTTGGGGCCAAA
    AGGCCCCTTACAGAAACTCTGCCCAACGCTCAGCTCAATGGCACCTGCTCCCAGAGCCTCCCCTGATCTC
    CCAGGACACCTTTCCCCAATCTGTACACTTATCTCTTGCTGCCTGGGGTAATGTCTTAGCTCCTCACTTG
    GACCATGTGCTGCTCTCCTCTCCCATGGGGAGGACCAAACGGATAGTGCTGCCCAAAGCAGCAGAGTCCA
    GGCCAAAGGATGTGCCCTCATTTATTCAACAGGCATGCAGGATTTCCAGGGAAAGCTGGATTTTAAAACC
    TTTGGGAACGAGAGCAGAACCTGACTGAGAGCTCATGTGGGCACTGTCCATAGCAGAATAGCTCATGGGG
    TATAGAGATACGGACGCGGAACGTGGGCTGTAGCGATAGATAGTCCTGCATTCTAGTCCCCACTGTGCCC
    TTTCCTTGCGGGGTGGCTTTATTCAGGTACCCTTTCAGCAAAATCCTCCAAGAGAAAAGAAACTGGGGGG
    TTCTGGGGAGAAGGCTGCTGCGTTTGCAATTGGGAGAGGTTGTTGACAGAGGTTTGTGTCTGTGGCAAGC
    AGCCTTCCTTCAGTGGAATACTTGAAGACAGGTCTGTAGTTGAGCAAACTCACCTCCATTTGTCCCTCTG
    GAAAGAAGAAATCAAGAGGAAAAAATCTCTTTCCCATCCTCCAAATGGAGCTGGCACATGGCTATCTATG
    GCATTTGTCTTTCCAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGTTC
    TACAGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTTCACAGGCACAAGCAGC
    TGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGGGCTTGGTAAGCTGCACTGTATT
    CCTAGCAAGCTGGCAGCATGGCTCCTGGTGGACAGCAGCCTCACTTCTAAACACTCCTCCTTAGGAGCTG
    CAGCACCCTTGGTCAACCCATTCATTCATTCACTCATTCACTAAGTATTTGTTGAAGTTCCGTAAGTGCT
    GGGTGCGGTTCTAGGTGCTGAGGACGTGTCACTAAAGACACGCAGGCCAAGTCCCTGTTCTCGTGGGATG
    TTCTAGTGGGAGAGTCAGAAAAACAAACATGTAAAATGATGCCCAGTAGTGATACGTGCTACAAAGAAAA
    ACATAGGAATAAAGAATGTAAGGGTCATGGGGGAGGGGGCTGACTTAGGAGCTGGTGACATTATCTGAGC
    AGATATTTGAATTAAGTGAGGGAGCAGGCCACATGACTAACTGGGGAGAGACCATTCCAGGCAGAAGGAG
    GAGCTATGCAAAGGCCTTAGGATGGAAATGAACTTCCTGTATTTGAAGACCAGTAGGAAGGCCAGTGTGG
    CTGGATCACAGTGAGTGAGGGGGAGTTTCTAGGACAGCAGATCACACAAGGCCTTGAGATTCCACCACGA
    GTATGGCAGGGAACACCTGCAGAGCTCTGGGCAGGGCAAAGACTGTACGATCTGATTTACGTGATTTAAA
    AGGGTCAGTCTGGCTACTGTGTGGTAAATAGGCTGAAAGGGGGAGGCATAGAAGCAAGATGGCCTGTTGG
    GAGGCAGTAAACCAGGCTAGAGATGATGGTGGCATGGACAGGATGGGAACAGTGGATAGATTTGGGATAT
    GACTAAAAATAAAACCAGAAAGATTTGCTGACAGATCAGTTGTAAGGGGTAAGATACAGGGGAGGAAAAG
    ATGACCTCTTCGTTCCTGCCTAAACCCGTCTGGCGATGGTTGGTACCGTTTATAGAGCGATGGAAGACTG
    GGGGCAAGGCAGGGCTGGAGGTTAAGCAGAAGATCAAGAGTTCAATTTTGTACGTTGTACATGTAAGGTG
    GCTGTTGGACAGCCAAGTGAAGATGTTGAGAAGATGGTTAGAAGAGTCTGGAACTTAGAGGAGAGGTCAG
    AACTTGCAGTACAAAAAGGAGAGTCCTTAGATAGATGCTATTGAAAGTCTGAATGACAGAAAGGGAGAGA
    TCAAAGGACTGAGCCTGAGATCAACACATGGAGGTCAGGAGAGGAGGATCCAGTAAAGGCGCCTGAGACT
    CCTCAGACCAGTGAGGCAGGAGAACACTGGAGAGTGGGCGGTATCCCAGGAGGCCAGTGAGGACACTCAC
    GGAGGGAGGGTCGACTGTTTCAAATGTACTGAAAGGTCAGGTCAGGTAAGGACTGAGAAAGGCCCCTGGG
    TTTGACTGATGGAGGTCATGGGTGAGGCTGATGTAAATGGAGAAGCAGGAAGGAAAGTCCAGCTGGAGTG
    GGCTCACCGAGGATGGGGCGGTGAGAGAAGCCAAAGAAGGAACAGTGAGGGCAGAACACTCTTTGAAGGT
    GTTTAGCTATAAGGCTGCAGAGAAACTGAACCATGGCTGCAGGGCGGTTATGGAGTGAGGGAAGCTCTTT
    TAAGGTGGGGTGTATACCCAGCATGCTAATGCACCTGGGGGAACGGTCTGGTGGAGTAGGGAGAACTGAA
    GAGAGGAGAAGGAGGAGGAATCATTAGAGGGCAGAAGTCCTTGTGGCCCAGAGTGGGTGTTATCTAATAT
    CGAGTGGAGGAATTAATTGGCTTTAGAAGAGAACAAGGACATGTATCCCTTCTTTGGGCCTATCACCTTG
    TAGACAATGGGATAGGTCATGGGATAGGAACTTGGCACAACACATGTTCTCTTTTAATTCTCTCCATTAT
    CTTATGAAGCAGGCAAGTAGGCAAACAATTGTCCCGACTTTAAAAATAAACTGAAGCTTTTATAAATTAA
    GTAGTACGTTCTCAGCAATACAATTAATAAATGGTAGAGCTGAGATTCAAACTGAAGCAGTGGCCTGGGG
    GTAGCATCTGGAACCCTTCCCACCTTTAGGGCTGCTGTGCTGCAGTGCTGCTGTTTAATGACAGGAGGGC
    CACATGACTGAATCTCTCTCAGCAGTCCAGGCAGCCATGCAGAAGGCCCAGTAGAGCACGGGCAGGTCTG
    AGCCAGCACCTTCAAGTTCTACCCTCTGAGCAAGCACCTAGCTGTGACACACCTCTCCAGAGACTGCACT
    CCCCGCCGCCCTGCCCACCGCAAAAGCAGATAGGTAATGGTATACAGTAACCATTTCTAGAAGTGTAAGT
    AGTATGCACCCAAAACAGGCAACACCTGCTGGCCTAGTGATAGAGACGACTCCCAGTCAGGCTAGACTGG
    AGGCCTTGGTTTGGTAAGTGTTCAGGTGGCAAGTACCAGAGTAGGCTTGATCAAGTAGACAGGCAGGCAA
    GACAAATGCTTACCAATGCAAGCTAATTAAATGCTTCTTTTGTAGAACTCCTGTCCTGTGAAGGAAGCCA
    GCCAGAGTACGTTGGAAGACTTCTTGGAAAGGCTAAAGACGATCATGAAAGAGAAATATTCAAAGTGTCG
    GAGCTG
  • Protein Sequence : Show Sequence
    >gi|74136371|ref|NP_001028076.1| interleukin-4 precursor [Macaca mulatta]
    MGLTSQLLPPLFFLLACAGNFAHGHNCHIALREIIETLNSLTEQKTLCTKLTITDILAASKNTTEKETFC
    RAATVLRQFYSHHEKDTRCLGATAQQFHRHKQLIRFLKRLDRNLWGLAGLNSCPVKEASQSTLEDFLERL
    KTIMKEKYSKCRS
  • Molecule Role : Vaximmutor
  • Related Vaccine(s): HIV DNA vaccine VlJns-tPA-gp120 , HIV-1 gp120 with mCT E112K
19. Il4 (interleukin 4)
  • Gene Name : Il4 (interleukin 4)
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 16189
  • NCBI Protein GI : 10946584
  • Locus Tag : RP23-188H3.4
  • Genbank Accession : NM_021283.1
  • Protein Accession : NM_021283.1
  • Taxonomy ID : 10090
  • Gene Strand (Orientation) : ?
  • Protein Name : IL-4, Interleukin 4
  • DNA Sequence : Show Sequence
    >gi|10946583|ref|NM_021283.1| Mus musculus interleukin 4 (Il4), mRNA
    GGATCCCCGGGCAGAGCTGGGGGGGGATTTGTTAGCATCTCTTGATAAACTTAATTGTCTCTCGTCACTG
    ACGGCACAGAGCTATTGATGGGTCTCAACCCCCAGCTAGTTGTCATCCTGCTCTTCTTTCTCGAATGTAC
    CAGGAGCCATATCCACGGATGCGACAAAAATCACTTGAGAGAGATCATCGGCATTTTGAACGAGGTCACA
    GGAGAAGGGACGCCATGCACGGAGATGGATGTGCCAAACGTCCTCACAGCAACGAAGAACACCACAGAGA
    GTGAGCTCGTCTGTAGGGCTTCCAAGGTGCTTCGCATATTTTATTTAAAACATGGGAAAACTCCATGCTT
    GAAGAAGAACTCTAGTGTTCTCATGGAGCTGCAGAGACTCTTTCGGGCTTTTCGATGCCTGGATTCATCG
    ATAAGCTGCACCATGAATGAGTCCAAGTCCACATCACTGAAAGACTTCCTGGAAAGCCTAAAGAGCATCA
    TGCAAATGGATTACTCGTAGTACTGAGCCACCATGCTTTAACTTATGAATTTTTAATGGTTTTATTTTAA
    TATTTATATATTTATAATTCATAAAATAAAATATTTGTATAATGT
  • Protein Sequence : Show Sequence
    >gi|10946584|ref|NP_067258.1| interleukin 4 [Mus musculus]
    MGLNPQLVVILLFFLECTRSHIHGCDKNHLREIIGILNEVTGEGTPCTEMDVPNVLTATKNTTESELVCR
    ASKVLRIFYLKHGKTPCLKKNSSVLMELQRLFRAFRCLDSSISCTMNESKSTSLKDFLESLKSIMQMDYS
  • Molecule Role : Vaximmutor
  • Molecule Role Annotation : IL-4 plays an important role in Th2 immune response.
20. Il5
  • Gene Name : Il5
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 16191
  • NCBI Protein GI : 6754336
  • Locus Tag : RP23-239O19.2
  • Genbank Accession : AC084392
  • Protein Accession : NP_034688
  • Taxonomy ID : 10090
  • Chromosome No : 11
  • Gene Starting Position : 53720793
  • Gene Ending Position : 53725102
  • Gene Strand (Orientation) : +
  • Protein Name : interleukin 5
  • Protein pI : 8.9
  • Protein Weight : 14616.09
  • Protein Length : 133
  • Protein Note : Also known as Il-5
  • DNA Sequence : Show Sequence
    >gi|372099099:53720793-53725102 Mus musculus strain C57BL/6J chromosome 11, GRCm38 C57BL/6J
    GCGCTCTTCCTTTGCTGAAGGCCAGCGCTGAAGACTTCAGAGTCATGAGAAGGATGCTTCTGCACTTGAG
    TGTTCTGACTCTCAGCTGTGTCTGGGCCACTGCCATGGAGATTCCCATGAGCACAGTGGTGAAAGAGACC
    TTGACACAGCTGTCCGCTCACCGAGCTCTGTTGACAAGCAATGAGGTAAAGTATAACTTATTCCTTCAGC
    TTTGTTTTTAAGATCAGGACCTTGCTATACCGCTCTGACTGGCCTCAAACTTGCTATGTAGGGTAGGCTG
    TCCTAACCCCTACCAGATCTCCTTACCTATGTCTCCCAAATACTAGGATTACAGACACATTACCTTGCCT
    GACGCTATGGTTCTTCAGAATGCATAAATAGCTGCATTTGGCCTTTAATCCCAGAACTTGGGAGGCAGGG
    TCAGGTGGATCTCTGTGAGTTCAAGGCCAGACTTGTCTACGTGGCCAGTTACAGGACAGCCAGAGCTAAA
    GCAAGACCCTGATTCAAAATAATTTTTTTTCAAAACAAAAAAAAAAAACCCAAACCATTTGTGGCAATTC
    ATTTCTAAACATAAAGATCTGCTTTAAATAGTGCAATTATGGCTTGTTCCCTTGCCTTCTTGCTCCCGTT
    CTGTCCTCTTGTCCCACTCTCTCCCCATTCCACCCCCACCATGTGCTCATGGCCCGCATCTCTACTTCTC
    TACTCTCTTTCTCTCCCTCTCCCCTCCTTCTTCCTTTCCCTCTCTCTCTCCCTCTTCTTCTCCTCCTCTC
    TTTCTCTCTCTCTCCCTCTCTCTCTCTCTTTCTCTCTCTCTCTGCTTTTTTCTATCTCTACTACCCTCTC
    AACTCCCCTCTCCATGCCCTGAATAAGCTCTATTCTATACTAAAAAAAAAAAGTGCAATTATGAATGTGT
    TAGTGTTAATGCACAGGTGATAACCCTATCACCAGCAAGCATTGCATTAAAAAAGGCAACGGACTCTCTT
    TAGGATGACCCTATGATGTTCTTTCCTTTGCAGACGATGAGGCTTCCTGTCCCTACTCATAAAAATGTAA
    GTTATTCTTTACTGCCGTGCTTGCATGAGTAAGTCAGCTTCGCATACTAAGCTATAAGTCATCTGCATCT
    AGCTTTCTGGTGTTGTGTGTGTCTGGGATGGGGACCTCTCTAGGTCTCAAGCTCCTGGGTTCAAGTGATT
    CTCTTGCCTTGATAGAGCAGCTGGGACACAGGCCTGTGCCACCACACCCAGCAGAGCTTTTGATTTCAGT
    TAAACTGTTTGACTTTCTTGGAAAAGAAAATTTATGTAGGTAGATATGAAAGTTTGTGCTTATAAATAAA
    AAGAATATGAGAGTGGCAAATTATGTAATCCCAGTACTTGGGAGCCAAAGGCAGGGGTAGTCTGAGTCTA
    GGGCCAGCTTAGATACATTGCCCTGTATGTATCAAAAGTAAATCCTATAAATAAATAAACAAAAACATTA
    GAGGGCTGGAGATATAAGCTCTGTTGATAGATGGCCTAATATGCTGGGTTGACTCTTAGCACCCCATAAA
    CTAAACATGGAAGTACCTGGCTGTAATCTCATGATGGTGAAATGGAGGCGGGAAGATCATAGGTTCAAGG
    TCATCCTCAGCTACATTTTTGAGCTAGAGGCCAGCCTGGGCTATGAGACACGCAAAAACCACCAGCCAAT
    TAATATTAGGAATGGCTTTGAGCTAGATCTGTTATGTAAGTGGCCAGCTGGAGCTGTCAGTCATACATCT
    CACAGCCTCACAAGATTCTTTGCATGGCGAGAGGTCCTGCTGGGCTCCCTTTGGCTCTGTCCATGGCTCT
    CTTCATCCTAGTGCCTCTCTTTGTTTTCCTTGTCTTATTTCTTACTGCTGAGGATCAAGCCCAGGGCCTT
    CAGTGTGTGAAGTGAGCACTCTACCACTGAATTCCAGAGCCCGCCCACTCTAATGCCTTTCTGAAAGTAT
    TAAGAGTTTAGGGTTATATATTCCTTTTGTTTATTTTATGTGTATGAGCATTTTGCCTGCATATATATAT
    ATATATATATATATATATGTGTGTGTGTGTGTGTGTGTGTGTGTATATATATATGTATGTATGTATGTAT
    GTATGTATGTATGTATATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTCCACGTATGTGTCTATGTG
    TCTGGTGTTCCTGAAGGCTAAAAGAAGGGCATCAGATCACCTGGGGCTGGATATGCAGATGGTTGTGAGC
    CAACCATCTGGATGCTGGGAACTGCATCAAGTGTTCTTAACCACTGAGCCATCTCTCCCGCTCAGAGGGT
    TATATTCTTAGGTAATGATAGAAAGACATAAAAATATCATGAATGCCTTTATTAATAATTTCTAAACAGT
    TTAATGAATATGACTATGTAGTGATATTGTATACATTTCAATATTATCTTATTCTAGCGTAAAGTACATT
    ATTTAACTTTTTCTAAATAGAAGAAAATTCATCAGCCTAAATTTCAAAAGAAAATATTAATATGGGTGTG
    GTACCACTCACCTTTAATCCAGATGGTTGTGAGCCACCACAAGGGTGCTGGTAACTGAACCCAGGTCCTC
    TGGAAGAGGACCCAGTGATCTTAACCACTGAGCCATCTCCCCAGCCCCAATCCTAACTTTGGGTTCATTT
    TTTTGAAATGATCTCATGTAGCACTAGCTGGCCTCAAACTCTATGTATCAGAGGCTGGCCTTCAACTCCT
    GATCCTCTTACCTCAACTTCCTGAATGCTGGCATTACAGATAAGCACCATCACATCTTGTATTGTCTGGG
    GTTTTTTATTGATGCATTTAAATTGCATGTATTTATTGCATATGGCATGATATTTCAAAATATGTGTACG
    TTGTGGGCAGTCTGATCTATTTGCTTCTTGATAATCTTCTTTCAGCACCAGCTATGCATTGGAGAAATCT
    TTCAGGGGCTAGACATACTGAAGAATCAAACTGTCCGTGGGGGTACTGTGGAAATGCTATTCCAAAACCT
    GTCATTAATAAAGAAATACATTGACCGCCAAAAAGTAAGTTCCCCAGGGACCCTGTGAATCCGGCTGCAG
    CTGGTTCTCCAGGAGCCAACCTGACAGTCTGTTCTTTTCACAGGAGAAGTGTGGCGAGGAGAGACGGAGG
    ACGAGGCAGTTCCTGGATTACCTGCAAGAGTTCCTTGGTGTGATGAGTACAGAGTGGGCAATGGAAGGCT
    GAGGCTGAGCTGCTCCATGGTGACAGGACTTCACAATTTAAGTTAAATTGTCAACAGATGCAAAAACCCC
    ACAAAACTGTGCAAATGCAAGGGATACCATATGCTGTTTCCATTTATATTTATGTCCTGTAGTCAGTTAA
    ACCTATCTATGTCCATATATGCAAAGTGTTTAACCTTTTTGTATACGCATAAAAGAAATTCCTGTAGCGC
    AGGCTGGCCTCAAACTGGTAATGTAGCCAAGGATAACCTTGAATTTCTGATCCTCCTGCCTCCTCTTCCT
    GAAGGCTGAGGTTACAGACATGCACCATTGCCACTAGTTCATGAAGTGCTGGAGATGGAACCCAAGGCTT
    TGTGCATGTTACCAACTGAGTTATACTCCCTCCCCCTCATCCTCTTCGTTGCATCAGGGTCTCAAGTATT
    CCAGGCTGACTTTGAACTCAGTGTGTAGCCAAGGGTGACCCTGAACTCTTGGTCCAGATGGACGCAGGAG
    GATCACATACCCAACCTTAGCATCCTTTCTCCTAGCCCCTTTAGATAGATGATACTTAATGACTCTCTTG
    CTGAGGGATGCCACACCGGGGCTTCCTGCTCCTATCTAACTTCAATTTAATACCCACTAGTCAATCTCTC
    CTCAACTCCCTGCTACTCTCCCCAAACTCTAGTAAGCCCACTTCTATTTCTTGGGGAGAGAGAAGGTTGA
    CTTTTCTTATGTCCTATGTATGAATCAGACTGTGCCATGACTGTGCCTCTGTGCCTGGAGCAGCTGGATT
    TTGGAAAAGAAAAGGGACATCTCCTTGCAGTGTGAATGAGAGCCAGCCACATGCTGGGCCTTACTTCTCC
    GTGTAACTGAACTTAAGAAGCAAAGTAAATACCACAACCTTACTACCCCATGCCAACAGAAAGCATAAAA
    TGGTTGGGATGTTATTCAGGTATCAGGGTCACTGGAGAAGCCTCCCCCAGTTTACTCCAGGAAAAACAGA
    TGTATGCTTTTATTTAATTCTGTAAGATGTTCATATTATTTATGATGGATTCAGTAAGTTAATATTTATT
    ACAACGTATATAATATTCTAATAAAGCAGAAGGGACAACT
  • Protein Sequence : Show Sequence
    >gi|6754336|ref|NP_034688.1| interleukin-5 precursor [Mus musculus]
    MRRMLLHLSVLTLSCVWATAMEIPMSTVVKETLTQLSAHRALLTSNETMRLPVPTHKNHQLCIGEIFQGL
    DILKNQTVRGGTVEMLFQNLSLIKKYIDRQKEKCGEERRRTRQFLDYLQEFLGVMSTEWAMEG
21. TNF
  • Gene Name : TNF
  • Sequence Strain (Species/Organism) : Macaca mulatta
  • NCBI Gene ID : 715467
  • NCBI Protein GI : 114051684
  • Locus Tag : EGK_14705
  • Genbank Accession : AB128049
  • Protein Accession : NP_001040614
  • Taxonomy ID : 9544
  • Chromosome No : 4
  • Gene Starting Position : 31210603
  • Gene Ending Position : 31212397
  • Gene Strand (Orientation) : +
  • Protein Name : tumor necrosis factor
  • Protein pI : 6.12
  • Protein Weight : 24042.53
  • Protein Length : 233
  • Protein Note : Also known as TNF-ALPHA
  • DNA Sequence : Show Sequence
    >gi|109156893:31210603-31212397 Macaca mulatta chromosome 4, Mmul_051212, whole genome shotgun sequence
    CATGAGCACGGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAGGAAGACAGCGGGG
    CCCCAGGGCTCCAGGCGGTGCTGGTTCCTCAGCCTCTTCTCCTTCCTGCTCGTGGCAGGCGCCACCACGC
    TCTTCTGTCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGGTGAGTGCCTCGCCAGCCTTCAT
    CCACTCTCCCACCCAAGAGGGGGAGAGAGATGGGATGGGCGAAAGATGTGTGCTGACAGGGAGGGATGGA
    GAGAAAAACAACGTGGAGGAAGACGAGGATGCAGAAAGAGATGTGGCAAGAGATGGAGAACAGAGAGAGA
    AAGATGGAGAGGCAGAATGTCTGGCACATGGAAGGTGCTCACTAAGTGTGTATGGAGTGAATGAATGAAT
    GAATGAACAATCAGATAGTAAATAAGATATGGAGACAGATGTGGGGTGTGAGCAGAGAGATGGGGGAAGA
    AACAAGTGATATGAATAAAGATGGTGAGACAGAGAGTGGGAAATATGGCAGCTAAGGAGAGAGATGAGGG
    AGATAAGGAGAGATGAGGGAGATAAGGAGAGATGAAGATAGGATGTCTGGCACACAGAAGACACTCAGTG
    AAAGAGTTGTTGAATGCATGGAGGGTGAATATACAGATGAATGGAGAGAGAAAACCGGACAACTCAGGGC
    TAAGAGCGCAGGTCAGACAGGCAGCCAGCTGTTCCTCCTTTAAGGGTGATTCCCTTGATGTTAACCATTC
    TCCTTCTCCCCAACAGTTCCCCAAGGACCCCTCTCTAATCAGCCCTCTGGCTCAGGCAGTCAGTAAGTGT
    CTCTAAACCTTTTTCCTAATTCTGGGTTTGGGTTGGGGTGTAGGGTTAGTACTGGTACGAAAGCAGTGGG
    GGAAATTTAAAGTTTTGGTCTTGGGGGAGGGCGGATGGGGTGAAAGTAAGGGGATGGGGGGTATTTTCTA
    GGAAGTTTAAGGGTCTCACCTTTTTCTTTTCTCTCTCCTCTTCAGGATCATCTTCTCGAACCCCAAGTGA
    CAAGCCTGTAGCCCATGTTGTAGGTAAGAGCTCTGATGATGTGTCTTGGAACTTGGAGGGCTAGGATTTG
    GGGGTTGAAGCCCGGCTGAGGGTAGGCAGACCTTGGAGACAGTGTGAGAAGGACTGGCTGAGCTCAAGGG
    AAGGGTGGAGGAACTGCACAGCCCTTAGGGGGATACTCAGAACGTCATGGCCAGGTGGGATGTGGGATGA
    CAGACAGAGGGAACAGGAACCGGATGTGGGGTGGGCAGAGCTCGAGGGCCAGGATGTGGAGAGTGAACCG
    ACATGGCCACACTGACTCCCCTCTCTCTCTCTCCCTCCCTCCAGCAAACCCTCAAGCTGAGGGGCAGCTC
    CAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGACAGATAACCAGCTGGTGG
    TGCCATCAGAAGGCCTGTACCTCATCTACTCCCAGGTCCTCTTCAAGGGCCAAGGCTGCCCCTCCAACCA
    TGTGCTCCTCACCCACACCATCAGCCGCATCGCCGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCC
    ATCAAGAGCCCCTGCCAGAGGGAGACTCCAGAGGGGGCTGAGGCCAAGCCCTGGTACGAGCCCATCTACC
    TAGGAGGGGTCTTTCAGCTGGAGAAGGGTGATCGACTCAGCGCTGAGATCAATCTGCCCGACTATCTCGA
    CTTTGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTG
  • Protein Sequence : Show Sequence
    >gi|114051684|ref|NP_001040614.1| tumor necrosis factor [Macaca mulatta]
    MSTESMIRDVELAEEALPRKTAGPQGSRRCWFLSLFSFLLVAGATTLFCLLHFGVIGPQREEFPKDPSLI
    SPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELTDNQLVVPSEGLYLIYSQVLF
    KGQGCPSNHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSA
    EINLPDYLDFAESGQVYFGIIAL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV DNA vaccine VlJns-tPA-gp120
22. TNF-a from Papio anubis
  • Gene Name : TNF-a from Papio anubis
  • Sequence Strain (Species/Organism) : Papio anubis
  • NCBI Gene ID : 100126739
  • NCBI Protein GI : 162951924
  • Protein Accession : NP_001106118
  • Taxonomy ID : 9555
  • Chromosome No : 4
  • Gene Starting Position : 30899937
  • Gene Ending Position : 30901714
  • Gene Strand (Orientation) : +
  • Protein Name : tumor necrosis factor
  • Protein pI : 6.93
  • Protein Weight : 24148.68
  • Protein Length : 233
  • Protein Note : Also known as TNFa; TNFSF2
  • DNA Sequence : Show Sequence
    >gi|395728658:30899937-30901714 Papio anubis chromosome 4, Panu_2.0, whole genome shotgun sequence
    CATGAGCACGGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAGGAAGACAGCGGGG
    CCCCAGGGCTCCAGGCGGTGCTGGTTCCTCAGCCTCTTCTCCTTCCTGCTCGTGGCAGGCGCCACCACGC
    TCTTCTGTCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGGTGAGTGCCTCGCCAGCCTTCAT
    CCACTCTCCCACCCAAGAGAGGGAGAGAGATGGGATGGGCGAAAGATGTGTGCTGACAGGGAGGGATGGA
    GAGAAAAACAACGTGGAGAAAGACTTGGATGCAGAAAGAGATGTGGCAAGAGATGGAGAAGAGAGAGAGA
    GAAAGATGGAGAGGCAGGATGTCTGGCACATGGAAGGTGCTCACTAACTGTGTATGGAGTGAATGAATGA
    ATGAATGAACAATCAGATAGTAAATAAGATATGGAGACAGATGTGGGGTGTGAGCAGAGAGATGGGGGAA
    GAAACAAGTGATATGAATAAAGATGGTGAGACAGAGAGTGGGAAATATGGCAGCTAAAGAAAGAGATGAG
    GGAGATAAGGAGAGATGAAGATAGGATGTCTGGCACACAGAAGACACTCAGTGAAAGAGTTGTTGAATGC
    ATAGAGGGTGAATACACAGATGAATGGAGAGAGAAAACCGGACAACTCAGGGCTAAGAGCGCAGGCCAGA
    CAGGCAGCCAGCTGTTCCTCCTTTAAGGGTGATTCCCTTGATGTTAACCATTCTCCTTCTCCCCAACAGT
    TCCCCAAGGACCCCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGTAAGTGTCTCCAAACTTTTTTCCT
    AATTCTGGGTTTGGGTTGGGGTGTAGGGTTAGTAGTGGTACGAAAGCAGTGGGGGAAATTTAAAGTTTTG
    GTCTTGGGGGAGGGCAGATGGGGTGAAAGTAAGGGGATGGGGGGTATTTTCTAGGAAGTTTAAGGGTCTC
    ACCTTTTTCTTTTCTCTCTCCTCTTCAGGATCATCTTCTCGAACCCCAAGTGACAAGCCTGTAGCCCATG
    TTGTAGGTAAGAGCTCTGATGACGTGTCTTGGAACTTGGAGGGCTAGGATTTGGGGGTTGAAGCCCGGCT
    GAGGGTAGGCAGACCTTGGAGACAGTGTGAGAAGGACTGGCTGAGCTCAAGGGAAGGGTGGAGGAACTGC
    ACAGCCCTTAGGGGGATACTCAGAACGTCATGGCCAGGTGGGATGTGGGATGACAGACAGAGGGAACAGG
    AACCGGATGTGGGGTGGGCAGAGCTCGAGGGCCAGGATGTGGAGAGTGAACCGACATGGCCACACTGACT
    CCCCTCTCTCTCTCTCCCTCCCTCCAGCAAACCCTCAAGCTGAGGGGCAGCTCCAGTGGCTGAACCGCCG
    GGCCAATGCCCTCCTGGCCAATGGCGTAGAGCTGACAGATAACCAGCTGGTGGTGCCATCAGAAGGCCTG
    TACCTCATCTACTCCCAGGTCCTCTTCAAGGGCCAAGGCTGCCCCTCCAACCATGTGCTCCTCACCCACA
    CCATCAGCCGCATCGCCGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCA
    GAGGGAGACTCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTACCTAGGAGGGGTCTTTCAG
    CTGGAGAAGGGTGATCGACTCAGCGCTGAGATCAATCTGCCCGACTATCTCGACTTTGCCGAGTCTGGGC
    AGGTCTACTTTGGGATCATTGCCCTGTG
  • Protein Sequence : Show Sequence
    >gi|162951924|ref|NP_001106118.1| tumor necrosis factor precursor [Papio anubis]
    MSTESMIRDVELAEEALPRKTAGPQGSRRRWFLRLFSFLLVAGATTLFCLLHFGVIGPQREEFPKDPSLI
    SPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVEPTDNQLVVPSEGLYLIYSQVLF
    KGQGCPSNHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSA
    EINLPDYLDFAESGQVYFGIIAL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): HIV-2 DNA vaccine
23. TNF-alpha
  • Gene Name : TNF-alpha
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 21926
  • NCBI Protein GI : 7305585
  • Genbank Accession : AB039224
  • Protein Accession : NP_038721
  • Taxonomy ID : 10090
  • Chromosome No : 17
  • Gene Starting Position : 35199389
  • Gene Ending Position : 35201995
  • Gene Strand (Orientation) : -
  • Protein Name : tumor necrosis factor
  • Protein pI : 4.75
  • Protein Weight : 24010.47
  • Protein Length : 235
  • Protein Note : Also known as DIF; Tnfa; TNFSF2; Tnfsf1a; TNFalpha; TNF-alpha; MGC151434
  • DNA Sequence : Show Sequence
    >gi|372099093:35199389-35201995 Mus musculus strain C57BL/6J chromosome 17, GRCm38 C57BL/6J
    CTTTATTTCTCTCAATGACCCGTAGGGCGATTACAGTCACGGCTCCCGTGGGGAGCAGAGGTTCAGTGAT
    GTAGCGACAGCCTGGTCACCAAATCAGCGTTATTAAGACAATTGGGTTAGATAAATATTTTGTTTTAAAC
    ATAAGCAAAAGAGGAGGCAACAAGGTAGAGAGGCCAGGTGGGGACAGCTCAGCTCCGTTTTCACAGAAAA
    CATGTCTGTCTGAAGACAGCTTCCCACACTGGGTCCTCCAGGACACCCCGGCCTTCCAAATAAATACATT
    CATAAGCAAATAAATAAATAATAAATAAATAATAAATAATAAGTGCAAATATAAATAGAGGGGGGCTGGC
    TCTGTGAGGAAGGCTGTGCATTGCACCTCAGGGAAGAATCTGGAAAGGTCTGAAGGTAGGAAGGCCTGAG
    ATCTTATCCAGCCTCATTCTGAGACAGAGGCAACCTGACCACTCTCCCTTTGCAGAACTCAGGAATGGAC
    ATTCGAGGCTCCAGTGAATTCGGAAAGCCCATTTGAGTCCTTGATGGTGGTGCATGAGAGGCCCACAGTC
    CAGGTCACTGTCCCAGCATCTTGTGTTTCTGAGTAGTTGTTGAAAGCTCTGAGCACAGAGTTGGACCCTG
    AGCCATAATCCCCTTTCTAAGTTAGAAGGATACAGACTGGGGGCTCTGAGGAGTAGACAATAAAGGGGTC
    AGAGTAAAGGGGTCAGAGTGGGGGCTGGGTAGAGAATGGATGAACACCCATTCCCTTCACAGAGCAATGA
    CTCCAAAGTAGACCTGCCCGGACTCCGCAAAGTCTAAGTACTTGGGCAGATTGACCTCAGCGCTGAGTTG
    GTCCCCCTTCTCCAGCTGGAAGACTCCTCCCAGGTATATGGGCTCATACCAGGGTTTGAGCTCAGCCCCC
    TCAGGGGTGTCCTTGGGGCAGGGGCTCTTGACGGCAGAGAGGAGGTTGACTTTCTCCTGGTATGAGATAG
    CAAATCGGCTGACGGTGTGGGTGAGGAGCACGTAGTCGGGGCAGCCTTGTCCCTTGAAGAGAACCTGGGA
    GTAGACAAGGTACAACCCATCGGCTGGCACCACTAGTTGGTTGTCTTTGAGATCCATGCCGTTGGCCAGG
    AGGGCGTTGGCGCGCTGGCTCAGCCACTCCAGCTGCTCCTCCACTTGGTGGTTTGCTGAGGGGGGGGGGG
    AGGATTGAGTCAGTGTCACCCTCTTAGTTCACACTCCACATCCTGAGCCTCAGCAGCTACCCACACTTCA
    CTTCCGGTTCCTGCACCCTCTGTCTTTCCACATCCCATTGGCTATGAGGTCCCGGGTGGCCCCCTGATGC
    CTTGCTTTTGAGTCACTGCTCTGACTCTCACGTGCTGTCTCTAAGAGCTCTGTCTTTTCTCAGCCTGGCT
    CGACACCCCTCAACCCGCCCCCCAAAATCATGCCCCTTCATTCTCAAGGCACATGTAAAGAAATCTTACC
    TACGACGTGGGCTACAGGCTTGTCACTCGAATTTTGAGAAGATGATCCTGGAGGGGAAGAGACAAAGGCA
    AGGATGAGCCTTTTAGGCTTCCCAGCAAGCATCTATGCACTTAGACCCCTTTCCTCCCAAACCAAAGCTT
    TAAGTTCTCCCCCCACCCCATCTCATCCCATGCCTAACTGCCCTTCCTCCATCTTAAATTAAGAGAGAGG
    TGTGGGAACACTTACTGAGTGTGAGGGTCTGGGCCATAGAACTGATGAGAGGGAGGCCATTTGGGAACTT
    CTGTGTAGGAAAAGGAGGTTAGTTAAGACAGACTCACCCCAAAGGAGAAGCCTCCCGGCTGATTGCCCCG
    CTTACAGTTCCTCTTTGCCCCACCCCACCCCCCAGCTTTGTGTTTTTCTTCTTCATTCATTCATCTGTCC
    AACCCACGGCTTCTTTCTGCGGTGCCCTCTGTGCTTGATCTCCCGTTATCTCCCCTTCATCTTCCTCCTT
    ATCTCTCATGCCTCTCTCATTTCTGTCTCTGAGTTTTATCTCTTGCTTATCCCCTCTTCCCCTGGCCACA
    TCTTTCCAGATCTCTCCACGTGTGAACACACTTGTTCGTTCATTCATCTCTCTGTGCATCCGACGAAGGA
    TGTTTAGTCAGCTGGACGCATGGGTCCGAGGTCCTGACTCTGTCCCCTCCACACTCTCCTCCACCTTGCC
    CTGCCCATTAGCCCACTTCTTTCCCTCACACTGTCCTTCTTGCCCTCCTAACCCGTTTTGCTTGTGAGCG
    AGAATAAGGGTTGCCCAGACACTCACCTCATCCCTTTGGGGACCGATCACCCCGAAGTTCAGTAGACAGA
    AGAGCGTGGTGGCCCCTGCCACAAGCAGGAATGAGAAGAGGCTGAGACATAGGCACCGCCTGGAGTTCTG
    GAAGCCCCCCATCTTTTGGGGGAGTGCCTCTTCTGCCAGTTCCACGTCGCGGATCATGCTTTCTGTGCTC
    ATGGTGTCTTTTCTGGAGGGAGATGTGGCGCCTTGGGCCAGTGAGTGAAAGGGACAGAACCTGCCTGGTT
    GGCTGCTTGCTTTTCTGGGAGCTATTTCCAAGATGTTCTGGAGTTTCTGTTCTCCCTCCTGGCTAGTCCC
    TTGCTGTCCTCGCTGAG
  • Protein Sequence : Show Sequence
    >gi|7305585|ref|NP_038721.1| tumor necrosis factor [Mus musculus]
    MSTESMIRDVELAEEALPQKMGGFQNSRRCLCLSLFSFLLVAGATTLFCLLNFGVIGPQRDEKFPNGLPL
    ISSMAQTLTLRSSSQNSSDKPVAHVVANHQVEEQLEWLSQRANALLANGMDLKDNQLVVPADGLYLVYSQ
    VLFKGQGCPDYVLLTHTVSRFAISYQEKVNLLSAVKSPCPKDTPEGAELKPWYEPIYLGGVFQLEKGDQL
    SAEVNLPKYLDFAESGQVYFGVIAL
  • Molecule Role : Vaximmutor
IV. Vaccine Information
1. Adenoviral vector Ad5 expressing SIV gag protein
a. Vaccine Ontology ID:
VO_0000788
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Antigen
SIVmac239 gag protein (Shiver et al., 2002)
e. Gene Engineering of Gag protein from SIV-mnd 2
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click here.
f. Vector:
Adenoviral vector (Ad5)
g. Preparation
The adenoviral vector was based on a serotype 5 adenovirus that is incompetent to replicate with deletion of the E1 and E3 viral genes, and was propagated subsequently in E1-expressing 293 cells. Recombinant adenovirus expressing the codon-optimized SIV gag gene was then prepared. The recombinant adenovirus (Ad5-SIVgag) was grown in large quantities by multiple rounds of amplification in 293 cells. The virus was purified by caesium chloride gradient centrifugation (Shiver et al., 2002).
h. Immunization Route
Intramuscular injection (i.m.)
i. Monkey Response
  • Host Strain: rhesus monkey (Macaca mulatta)
  • Vaccination Protocol: In this study, 21 rhesus monkeys were divided into 6 groups, including an unimmunized control cohort. Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. In the first study, the two viral vector vaccines were administered, followed by a booster dose; preparations of DNA plasmid vector vaccine were delivered thrice, followed by a booster (Shiver et al., 2002).
  • Immune Response: In general, all of the monkeys developed p11CM-specific cellular immune responses after the initial immunization series. The p11CM (residues 181–189) is an immunodominant SIV gag epitope that is presented by the Mamu-A*01 MHC protein and is capable of binding T-cell receptors in the model monkeys. Administration of the third dose of the Ad5 vector resulted in an additional increase of p11CM-specific CD8+ T cells at the time of virus challenge. After the booster inoculation, these animals exhibited peak levels of p11CM-specific CD8+ T cells (Shiver et al., 2002).
  • Challenge Protocol: At 12 weeks after the final immunization, all monkeys were challenged i.v. with the pathogenic HIV–SIV hybrid virus (SHIV) 89.6P16. The challenge of the control and immunized animals within the context of each of the two independent studies occurred concurrently (Shiver et al., 2002).
  • Efficacy: Each of the animals in both control groups exhibited acute CD4+ T-cell lymphopenia and peak viral loads of viral RNA copies at about 3 weeks after challenge. With the exception of one animal, all of the control monkeys experienced dramatic loss of CD4+ T cells. During the acute phase of the infection, most monkeys immunized with either the DNA or MVA vectors exhibit an acute CD4+ T-cell lymphopenia. By about 70 d after challenge, many of the immunized monkeys exhibit some evidence of a positive immunization benefit, as manifested by control of viremia and recovery of CD4+ T-cell counts. However, the animals immunized with Ad5 vector exhibited the most pronounced attenuation of the infection with a pathogenic HIV–SIV hybrid virus (SHIV) (Shiver et al., 2002).
2. ALVAC-HIV-2
a. Vaccine Ontology ID:
VO_0004727
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Gene Engineering of env from HIV 2
  • Type: Recombinant vector construction
  • Description: Live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
  • Detailed Gene Information: Click here.
f. Gene Engineering of gag from HIV 2
  • Type: Recombinant vector construction
  • Description: Live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
  • Detailed Gene Information: Click here.
g. Preparation
A live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
h. Immunization Route
Intramuscular injection (i.m.)
i. Monkey Response
  • Vaccination Protocol: Five monkeys were immunized either three times with ALVAC HIV-2 alone or twice with ALVAC HIV-2 and once with purified native HIV-2 gp125 (Walther-Jallow et al., 2001).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The monkeys were then challenged with HIV-2 given intravenously and finally with pathogenic SIVsm given intrarectally (Walther-Jallow et al., 2001).
  • Efficacy: After challenge with SIVsm, three of five monkeys were completely protected against SIVsm infection. Vaccination with an ALVAC HIV-2 vaccine followed by exposure to live HIV-2 could induce cross-protection against mucosal infection with SIVsm and seemed to be more efficient than immunization with a live HIV-2 vaccine only (Walther-Jallow et al., 2001).
3. ALVAC-HIV-2- env/gag/pol
a. Vaccine Ontology ID:
VO_0004737
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Gene Engineering of env
  • Type: Recombinant vector construction
  • Description: Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
  • Detailed Gene Information: Click here.
f. Gene Engineering of gag from HIV 2
  • Type: Recombinant vector construction
  • Description: Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
  • Detailed Gene Information: Click here.
g. Preparation
A live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
h. Immunization Route
Intramuscular injection (i.m.)
i. Monkey Response
  • Vaccination Protocol: Six monkeys were first inoculated intravenously with live HIV-2(SBL-6669) (Walther-Jallow et al., 2001).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: 7 to 10 months after vaccination, the monkeys were challenged intrarectally with 10 MID(50) of cell-free simian immunodeficiency virus (SIV) strain SIVsm (Walther-Jallow et al., 2001).
  • Efficacy: Vaccination with an ALVAC HIV-2 vaccine followed by exposure to live HIV-2 could induce cross-protection against mucosal infection with SIVsm and seemed to be more efficient than immunization with a live HIV-2 vaccine only (Walther-Jallow et al., 2001).
4. ALVAC-SIV/gp120
a. Vaccine Ontology ID:
VO_0004638
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Immunization Route
Intramuscular injection (i.m.)
5. CVB4/p24(73(3))
a. Vaccine Ontology ID:
VO_0004719
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
A live coxsackievirus B4 recombinant, CVB4/p24(73(3)), that expresses seventy-three amino acids of the gag p24 sequence (HXB2) (Gu et al., 2010).
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Vaccination Protocol: Immunization was by intraperitoneal (IP) injection or by oral gavage. Mice were immunized with either CVB4/p24(733) or the parental CVB4. PBS-treated mice served as controls (Gu et al., 2010).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Mice immunized with the avirulent CVB4 variant are protected when subsequently challenged with a virulent variant (Gu et al., 2010).
  • Efficacy: Results showed that oral immunization with CVB4/p24(73(3)) induced gag p24-specific immune responses in vector-immune mice (Gu et al., 2010).
6. DNA and poxvirus priming-boosting SHIV vaccine
a. Vaccine Ontology ID:
VO_0000825
b. Type:
DNA vaccine
c. Antigen
SHIV89.6P env and SIVmac239 gag (Santra et al., 2004)
d. Gene Engineering of env from SHIV89.6P
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
e. Gene Engineering of Gag protein from SIV-mnd 2
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Vector:
pV1R plasmid and recombinant fowlpox virus
g. Preparation
The recombinant vaccinia viruses (rVac) expressing SHIV89.6P env and SIVmac239 gag were constructed by inserting these genes in the HindIII M region of TBC-Wy, Therion strain of vaccinia. rFPV viruses expressing these same genes were constructed by inserting the genes in the BamJHI region of POXVAC-TC (Schering-Plough) strain of FPV (Santra et al., 2004).
h. Description
An HIV vaccine should elicit a cytotoxic T lymphocyte (CTL) response, but the characteristics of effective vaccine-induced CTL response remain unclear. The SHIV/rhesus monkey model has been used to in the course of assessing the relative immunogenicity of vaccine regimens that include a cytokine-augmented plasmid DNA prime and a boost with DNA or recombinant pox vectors. This study indicates that the steady-state memory, rather than the peak effector vaccine-elicited CTL responses, may be the critical immune correlate of protection for a CTL-based HIV vaccine (Santra et al., 2004).
i. Monkey Response
  • Host Strain: rhesus monkey (Macaca mulatta)
  • Vaccination Protocol: Nonrecombinant wildtype vaccinia virus was designated VV-WT, wild-type fowlpox virus was designated FPV-WT, and wild-type MVA was designated MVA-WT. These wild-type viruses were used as control vector immunogens (Santra et al., 2004). One group of monkeys were vaccinated by separate i.m. injections of HIV-1. Half the dose was delivered to each quadriceps muscle. Seven of the 28 monkeys were vaccinated by both i.d. and i.m. injections of rFPV expressing HIV-1 89.6P Env and the same virus expressing SIV mac239 Gag. Seven monkeys received rMVA-HIV-189.6P Env and rMVA-SIVmac239 Gag, and another seven monkeys received rVac-HIV-1 89.6P Env and rVac-SIVmac239 Gag administered both i.d. and i.m. Another 28 monkeys received sham plasmid DNA and empty pox vectors (Santra et al., 2004).
  • Persistence: Persistence levels were measured 2 weeks after challenge with results mentioned in Challenge Protocol section (Santra et al., 2004).
  • Immune Response: Recombinant vaccinia virus, MVA, and fowlpox were comparable in their immunogenicity. Magnitude of peak vaccine-elicited CTL responses in pox virus-boosted monkeys is substantially greater than that seen in monkeys immunized with plasmid DNA alone, but magnitudes of recombinant pox boosted CTL responses decayed rapidly and were comparable to those of the DNA-alone vaccinated monkeys by the time of viral challenge. Clinical protection seen in all groups of experimentally vaccinated monkeys is similar, indicating that steady-state memory, rather than peak effector vaccine-elicited T lymphocyte responses, may be the critical immune correlate of protection for a CTL-based HIV vaccine (Santra et al., 2004).
  • Challenge Protocol: Eighteen weeks after the final immunization, all animals were challenged with cell-free SHIV-89.6P i.v. (Santra et al., 2004).
  • Efficacy: Control monkeys developed tetramer-binding CD8 T lymphocyte responses that were maximal 2 weeks after viral challenge and no detectable p41A-specific CD8 T cells. In contrast, all four groups of vaccinated monkeys developed robust secondary p11C-specific CTL responses that were comparable in magnitude. Animals boosted with plasmid DNA had Gag p11C-specific CD8 T cell responses similar in magnitude to that seen in the recombinant pox virus-boosted animals. Magnitudes of the postchallenge IFN ELISPOT responses to both vaccine antigens were comparable in all four experimentally vaccinated groups of monkeys. Therefore, although the pre-challenge peak vaccine-elicited immune responses were greater in the groups of monkeys boosted with recombinant pox vectors, the pre-challenge plateau and post-challenge peak secondary responses were equivalent in magnitude in all four experimental groups of animals (Santra et al., 2004).
  • Host Gene Response of IFNG
    • Gene Response: There was a greater contraction of the vaccine-elicited IFN-γ-secreting T cell responses in the groups of monkeys boosted with recombinant pox vectors than in the group of animals boosted with plasmid DNA. Although the pre-challenge peak vaccine-elicited immune responses were greater in the groups of monkeys boosted with recombinant pox vectors, the pre-challenge plateau and post-challenge peak secondary responses were equivalent in magnitude in all four experimental groups of animals (Santra et al., 2004).
    • Detailed Gene Information: Click here.
7. DNA vaccine expressing multiple HIV epitopes
a. Vaccine Ontology ID:
VO_0000817
b. Type:
DNA vaccine
c. Antigen
The antigens are named MultiHIV-A (based on the subtype A consensus sequence), MultiHIV-B (subtype B consensus sequence), MultiHIV-C, and MultiHIV-FGH (based on ancestral sequence for subtypes F, G, and H). The MultiHIV DNAs encode polypeptides consisting of a fusion of the full-length regulatory proteins Rev, Nef and Tat as well structural proteins p17 and p24 (Malm et al., 2005).
d. Gene Engineering of rev from HIV 1
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
e. Gene Engineering of Nef
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of Tat
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Gene Engineering of Gag from HIV 1
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
h. Gene Engineering of Env Gp160
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
i. Gene Engineering of pol from HIV 1
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
j. Vector:
Auxo-GTU vector system (Malm et al., 2005)
k. Preparation
A vaccine platform was constructed with an HIV-1 subtype B DNA immunogen expressing full-length consensus sequences from HIV-1 rev, nef, tat, and gag with additional cellular epitope clusters from the env and pol regions. Furthermore, this platform has been extended to three additional plasmids expressing the same immunogens but originating from subtypes A or C consensus or FGH ancestral sequences (Malm et al., 2005).
l. Description
A significant limitation for HIV vaccine development is that there are no small animals in which actual productive HIV-1 infection can be established. DNA immunization with candidate vaccines comprising multiple genes of clades A, B, C, F, G, and H create strong cellular responses in BALB/c mice, especially after gene gun immunization (Malm et al., 2005).
m. Mouse Response
  • Host Strain: C57BL/6, BALB/c
  • Vaccination Protocol: C57BL/6 mice were divided into groups g.g. immunized or i.m. inoculated. Mice were bled 2 weeks after the last immunization, and individual blood and spleen samples were collected post-challenge and used fresh in ELISPOT assays (Malm et al., 2005).
    BALB/c were immunized by MultiHIV/MultiClade DNA. Initially the immune response was evaluated after 3 immunizations by g.g. Equal amounts of clade A, B, C, and FGH MultiHIV plasmids were mixed together and coated onto the gold particles to construct the subtype cocktail MultiHIV DNA immunogen (MultiHIVmix). Mice were sacrificed 10 days after the last immunization and individual spleens were collected and the cells preserved at –70°C until used. In a second set of experiments a short-term immunization schedule was used to address three different administration routes; g.g., i.m., and i.d. Mice were immunized 3 times with MultiHIVmix DNA (Malm et al., 2005).
  • Immune Response: Though the immune response detected was quite low, the majority of g.g. immunized animals responded with specific IFN production. Interestingly, the gag specific response in the same gene gun immunized animals was weaker than the envelope responses and also drastically weaker than the responses seen before the experimental challenge (Malm et al., 2005). The CTL response, following i.d. injection, was detected five weeks after the first immunization and persisted up to 12 weeks later. In contrast, i.m. immunization induced detectable IFNy only at week 17 (Malm et al., 2005).
  • Side Effects: no side effects occurred (Malm et al., 2005)
  • Challenge Protocol: C57BL/6 mice transgenic for HLA-A201 were given an experimental challenge after a short-term immunization schedule. Amphotropic murine leukemia virus was used to prepare pseudovirus with HIV-1 isolate. Challenged animals were given i.p. injections of sHIV-1/MuLV infected cells (Malm et al., 2005).
  • Efficacy: The vaccine-induced immunity has in vivo efficacy. Here a mouse model showed that the HIV-1 GTU-MultiHIVmix vaccine induces virus-specific CD8 T cellular immunity and protects against experimental HIV-1 challenge (Malm et al., 2005).
  • Description: The cocktail of MultiHIV protected 19/24 animals against an experimental HIV-1 challenge. This experiment also demonstrates cross-clade protection, as the subtypes A and B viruses used for challenge were derived from different subtypes than the sequences found in the clade A or B specific MultiHIV constructs. Furthermore, it demonstrates that consensus approach used in Multi-HIVmix vaccine is functional and causes protection against naturally occurring isolates. Gene gun immunization was superior to intramuscular immunization in terms of both the T cell immunity induced, as well as higher frequency of protection. Data generated in this work support the hypothesis that DNA representing several HIV-1 subtypes and several genes are immunogenic and protective (Malm et al., 2005).
  • Host Gene Response of Ifng (Interferon gamma)
    • Gene Response: IFN-gamma levels in mice immunized by gene gun or intramuscular delivery with HIV-1 subtype B DNA immunogen showed strong up regulation in response to an H-2d restricted gag peptide (AMQMLKETI) and even stronger up-regulation in response to an env epitope (RGPGRAFVTI) (Malm et al., 2005).
    • Detailed Gene Information: Click here.
8. Gag-VRPs
a. Vaccine Ontology ID:
VO_0000822
b. Antigen
HIV matrix-capsid portion of Gag, envelope gp160, secreted gp140, cloned SIVsm H-4i, SIVsm E660 (Davis et al., 2002)
c. Vector:
VEE replicon particles (VRPs)
d. Preparation
Gag-VRPs is a cocktail vaccine of V3014-packaged VRPs expressing the SIVsm H-4i nonmyristylated matrix-capsid region, full-length gp160, and a secreted form of gp160 (gp140). Structural proteins for packaging of replicon RNA into VRPs are expressed from separate helper RNAs. VRPs expressing either the matrix-capsid portion of Gag, the full-length envelope gp160, or the secreted gp140 of cloned SIVsm H-4i were mixed in a cocktail and used to immunize macaques (Davis et al., 2002).
e. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: VRPs with wild-type glycoprotein spikes were inoculated into the footpads of mice (Davis et al., 2002).
  • Persistence: At 11 months post-boosting with the downstream vector, serum antibody levels against HIV MA/CA were undiminished, and MA/CA specific CTLp were detectable in all mice tested. These findings suggest that VEE vectors can be optimized to elicit strong, balanced and long-lived immune responses to foreign viral proteins (Caley et al., 1999).
  • Immune Response: In BALB/c mice, the two vectors elicited cellular immune responses to MA/CA as determined by bulk CTL assays and precursor frequency analysis, but the humoral response induced by the downstream vector was significantly stronger. These findings suggest that VEE vectors can be optimized to elicit strong, balanced and long-lived immune responses to foreign viral proteins (Caley et al., 1999).
f. Monkey Response
  • Host Strain: rhesus monkey (Macaca mulatta)
  • Vaccination Protocol: A cocktail vaccine of V3014-packaged VRPs expressing the SIVsm H-4i nonmyristylated matrix-capsid region, full-length gp160, and a secreted form of gp160 (gp140) was used to immunize rhesus macaques. Animals were given each VRP subcutaneously in the arm and later were challenged by the intrarectal (IR) route. Control animals received an equivalent dose of HA-VRPs (Davis et al., 2002).
  • Immune Response: Both humoral and cellular immune responses were induced. On the day of challenge, all vaccinated animals had neutralizing antibody to the homologous SIVsm H-4, most had CTL specific for Gag, Env, or both. The animals were followed for a period of 40 weeks postchallenge, and although vaccination did not prevent infection by the high dose IR challenge, several protective effects of vaccination were seen. Peak virus titers in plasma were reduced, and the range of peak titers was much smaller for the controls, suggesting that a clear protective effect against the acute phase of infection was induced in some of the vaccinated animals (Davis et al., 2002).
  • Side Effects: No side effects were encountered (Davis et al., 2002).
  • Challenge Protocol: Animals were given a dose of VRP subcutaneously in the arm and 1 month later were challenged by the intrarectal (IR) route. Control animals received an equivalent dose of HA-VRPs. The challenge virus was the highly virulent swarm SIVsm E660 (Davis et al., 2002).
  • Efficacy: Animals were followed for a period of 40 weeks postchallenge, and although vaccination did not prevent infection by the high dose IR challenge, several protective effects of vaccination were seen. Four of six vaccinated animals, as compared to one of six controls, showed virus loads below 1,700 copies per ml at the “set point” (23 weeks postchallenge). By 41 weeks postchallenge, when the experiment was terminated, there was a significant decrease in the mean plasma virus load in the vaccinated animals compared to that in the controls. Most vaccinated animals showed virus loads below the “set point” (23 weeks postchallenge). By 41 weeks postchallenge, when the experiment was terminated, there was a significant decrease in the mean plasma virus load in the vaccinated animals compared to that in the controls. Finally, the CD4C cells of the vaccinated animals were preserved and even increased postchallenge compared to those of the controls. In fact, in the vaccinated animals, there is a clear correlation between increased CD4C cells and lowered viral load (Davis et al., 2002).
9. gp120 recominant with GMDP adjuvant
a. Vaccine Ontology ID:
VO_0004233
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
Recombinant HIV gp120 derived from CHO cells (Bomford et al., 1992).
e. Adjuvant: GMDP
f. Immunization Route
subcutaneous injection
g. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: Mice were subcutaneously immunized with antigen and adjuvant (Bomford et al., 1992).
  • Immune Response: Mice immunized with gp120 and GMDP in combination with pluronic emulsion resulted in a secondary antibody response (Bomford et al., 1992).
10. gp120 recominant with MDP adjuvant
a. Vaccine Ontology ID:
VO_0004234
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
Recombinant HIV gp120 derived from CHO cells (Bomford et al., 1992).
e. Adjuvant: muramyl dipeptide
f. Immunization Route
subcutaneous injection
g. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: Mice were subcutaneously immunized with antigen and adjuvant (Bomford et al., 1992).
  • Immune Response: Mice immunized with gp120 adjuvanted with MPD plus pleuronic emulsion resulted in a secondary antibody response (Bomford et al., 1992).
11. gp140, Gag and Tat Protein Vaccine with MF59
a. Vaccine Ontology ID:
VO_0004238
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
gp140, Gag and Tat recombinant proteins (Bråve et al., 2007).
e. Adjuvant: MF59
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Host Strain: C57Bl/6
  • Vaccination Protocol: The protein vaccine component consisted of 20 μg ro-gp140 delivered in the right tibialis muscle and 20 μg rGag and 5 μg rTat delivered in the left tibialis muscle. The proteins were formulated in 50% MF59 solution. Mock treatment consisted of MF59 adjuvant alone or empty DNA plasmid alone (Bråve et al., 2007).
  • Challenge Protocol: Briefly, 3 weeks after the final immunization (week 12), the animals were injected intraperitoneally with 1 million syngeneic splenocytes infected with HIV-1/MuLV of subtype B (LAI) (Bråve et al., 2007).
  • Efficacy: 83% of mice were tested negative for HIV-1 after challenge (Bråve et al., 2007).
12. HIV DNA and adenoviral vector Ad5 expressing SIV gag protein
a. Vaccine Ontology ID:
VO_0000786
b. Type:
DNA vaccine
c. Status:
Research
d. Antigen
SIVmac239 gag protein (Shiver et al., 2002)
e. Gene Engineering of Gag protein from SIV-mnd 2
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of Gag protein from SIV-mnd 2
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Adjuvant: CRL1005
h. Vector:
V1R plasmid and adenoviral vector (Ad5)
i. Preparation
The V1R DNA vector expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells (Shiver et al., 2002). The plasmid DNA vector was formulated in a solution containing a nonionic blocked copolymer adjuvant (CRL1005) (Shiver et al., 2002).
The adenoviral vector was based on a serotype 5 adenovirus that is incompetent to replicate with deletion of the E1 and E3 viral genes, and was propagated subsequently in E1-expressing 293 cells. Recombinant adenovirus expressing the codon-optimized SIV gag gene was then prepared. The recombinant adenovirus (Ad5-SIVgag) was grown in large quantities by multiple rounds of amplification in 293 cells. The virus was purified by caesium chloride gradient centrifugation (Shiver et al., 2002).
j. Immunization Route
Intramuscular injection (i.m.)
k. Virulence
No virulence has been reported associated with this vaccine (Shiver et al., 2002).
l. Description
Immunization and viral challenge studies were conducted in rhesus macaques (Macaca mulatta). Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. The plasmid DNA vector was formulated in either PBS solution, a solution containing adjuvant, or a solution containing MPL/alum. All immunized animals were genotyped for the MHC class I Mamu-A*01 allele, allowing analysis of the responses of T cells (CD8+) to the test vaccines (Shiver et al., 2002).
m. Monkey Response
  • Host Strain: rhesus monkey (Macaca mulatta)
  • Vaccination Protocol: This study used 14 monkeys, 3 each in the immunized groups and 8 in the unimmunized control group. Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. The DNA vector priming inoculations were administered, followed by viral vector boost inoculations (Shiver et al., 2002).
  • Immune Response: In general, all of the monkeys developed p11CM-specific cellular immune responses after the initial immunization series. The p11CM (residues 181–189) is an immunodominant SIV gag epitope that is presented by the Mamu-A*01 MHC protein and is capable of binding T-cell receptors in the model monkeys. Administration of the third dose of the Ad5 vector resulted in an additional increase of p11CM-specific CD8+ T cells at the time of virus challenge. After the booster inoculation, these animals exhibited peak levels of p11CM-specific CD8+ T cells (Shiver et al., 2002).
  • Side Effects: None of the vaccinated monkeys have yet exhibited any signs of immunodeficiency or suffered any consistent weight loss (Shiver et al., 2002).
  • Challenge Protocol: At 6 weeks after the final immunization, all monkeys were challenged i.v. with the pathogenic HIV–SIV hybrid virus (SHIV) 89.6P16. The challenge of the control and immunized animals within the context of each of the two independent studies occurred concurrently (Shiver et al., 2002).
  • Efficacy: Each of the animals in both control groups exhibited acute CD4+ T-cell lymphopenia and peak viral loads of viral RNA copies at about 3 weeks after challenge. All of the control monkeys experienced dramatic loss of CD4+ T cells. During the acute phase of the infection, most monkeys immunized with either the DNA or MVA vectors or with the DNA/CRL1005–MVA vector prime–boost combination exhibit an acute CD4+ T-cell lymphopenia. By about 70 d after challenge, many of the immunized monkeys exhibit some evidence of a positive immunization benefit, as manifested by control of viremia and recovery of CD4+ T-cell counts. However, the animals immunized with Ad5 vector exhibited the most pronounced attenuation of the infection with a pathogenic HIV–SIV hybrid virus (SHIV) (Shiver et al., 2002).
  • Host Gene Response of IFNG
    • Gene Response: Levels of interferon-gamma in monkeys stimulated intramuscularly with either the p11CM peptide or a pool of peptides derived from SIV gag were significantly upregulated and correlated well with the tetramer-staining results after the final boost. Intracellular IFN-[gamma]-staining assays confirmed that these responses were primarily mediated by CD8+ T cells (Shiver et al., 2002).
    • Detailed Gene Information: Click here.
13. HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag
a. Vaccine Ontology ID:
VO_0004342
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Human
e. Gene Engineering of env
  • Type: Recombinant vector construction
  • Description: This recombinant vector vaccine expressed env from HIV-1 (Barouch et al., 2012).
  • Detailed Gene Information: Click here.
f. Gene Engineering of Gag from HIV 1
  • Type: DNA vaccine construction
  • Description: This recombinant vector vaccine expressed gag from HIV-1 (Barouch et al., 2012).
  • Detailed Gene Information: Click here.
g. Gene Engineering of env from SIV
  • Type: Recombinant vector construction
  • Description: This recombinant vector vaccine expressed env from SIV (Barouch et al., 2012).
  • Detailed Gene Information: Click here.
h. Gene Engineering of Gag protein from SIV-mnd 2
  • Type: DNA vaccine construction
  • Description: This recombinant vector vaccine expressed gag from SIV (Barouch et al., 2012).
  • Detailed Gene Information: Click here.
i. Immunization Route
Intramuscular injection (i.m.)
j. Macaque Response
  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: After the high-dose vaginal SHIV-162P3 challenge, 7/8 control animals were infected. Similarly, 7/8 animals in the vaccine-only group (group V) were infected. In the microbicide-only group (group M), 4/8 animals were infected. In the combination group (group V+M), only 2/7 animals were infected. The intervention efficacy in group V+M was 67%. In summary, the data supports that vaccines and microbicides used in combination may confer protection against sexual HIV-1 transmission to women by the vaginal route (Barouch et al., 2012).
14. HIV DNA vaccine pCMN160
a. Vaccine Ontology ID:
VO_0004345
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Chimpanzee
e. Antigen
env and rev of HIV-1 strain MN and gag/pol from HIV-1 III8 (Boyer et al., 1997)
f. Gene Engineering of env MN isolate
g. Gene Engineering of rev MN isolate
h. Gene Engineering of gag-pol
  • Type: DNA vaccine construction
  • Description: This DNA vaccine encoded gag/pol from HIV-1 III8 (Boyer et al., 1997).
  • Detailed Gene Information: Click here.
i. Vector:
pCMN160 (Boyer et al., 1997)
j. Immunization Route
Intramuscular injection (i.m.)
k. Chimpanzee Response
  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Animals were challenged with a heterologous chimpanzee titered stock of HIV-1 SF2 virus. Polymerase chain reaction coupled with reverse transcription results indicated infection in the control animal, whereas those animals vaccinated with the DNA constructs were protected from the establishment of infection (Boyer et al., 1997).
15. HIV DNA vaccine pHIS-SHIV-B
a. Vaccine Ontology ID:
VO_0004348
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Monkey
e. Antigen
full-length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the 5′ third of HIV-1AD8 Env (Dale et al., 2004)
f. Gene Engineering of env
  • Type: DNA vaccine construction
  • Description: The DNA vaccine strain, pHIS-SHIV-B, encoded full-length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the 5′ third of HIV-1AD8 Env (Dale et al., 2004).
  • Detailed Gene Information: Click here.
g. Gene Engineering of Gag protein from SIV-mnd 2
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
h. Gene Engineering of Pol SIV
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
i. Gene Engineering of Tat
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
j. Gene Engineering of rev from HIV 1
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
k. Gene Engineering of vpu
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
l. Vector:
pHIS-64 (Dale et al., 2004)
m. Immunization Route
Intramuscular injection (i.m.)
n. Macaque Response
  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: DNA vaccination alone primed for protection almost as effectively as the DNA/fowlpox virus regimen (Dale et al., 2004).
  • Host Gene Response of IFNG from Macaca nemestrina
    • Gene Response: SIV Gag-specific CD8 T cells expressing IFN-γ were dramatically boosted after challenge. Mean Gag-specific CD8 T cells peaked 3 weeks following challenge at 11.7% of all CD8 T cells in these outbred pigtail macaques immunized with the 2DNA/FPV regimen. The other vaccine groups had lower mean postchallenge CD8 T-cell responses, with peak responses at week 2 following challenge numbering 3.8% in the 3DNA group, 1.1% responses in the 1DNA/FPV group, and 2.0% in the 2DNA/FPV-IFN-γ-immunized animals (Dale et al., 2004).
    • Detailed Gene Information: Click here.
16. HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
a. Vaccine Ontology ID:
VO_0004344
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Macaque
e. Gene Engineering of gag from SHIV-89.6
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of pol from SHIV-89.6
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Gene Engineering of env from SHIV-89.6
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
h. Gene Engineering of tat from SHIV-89.6
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
i. Gene Engineering of rev from SHIV-89.6
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
j. Gene Engineering of vif from SHIV-89.6
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
k. Gene Engineering of vpr from SHIV-89.6
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
l. Gene Engineering of vpu from SHIV-89.6
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
m. Vector:
pGA (Robinson et al., 2006)
n. Immunization Route
Intramuscular injection (i.m.)
o. Macaque Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Co-delivery of GM-CSF and vaccine DNAs enhanced the temporal appearance of neutralizing Ab and broadened the specificity of the neutralizing activity to include SHIV-89.6P (Robinson et al., 2006).
  • Efficacy: The GM-CSF-adjuvanted group showed a trend towards better control of the challenge infection and had better control of re-emergent virus (P < 0.01) than the non-adjuvanted group. After 52 weeks, the non-GM-CSF group continued to show some peaks of re-emergent virus whereas the GM-CSF group continued to maintain control below our level of detection (Robinson et al., 2006).
17. HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost
a. Vaccine Ontology ID:
VO_0004349
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Macaque
e. Gene Engineering of Gag protein from SIV-mnd 2
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of Pol SIV
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Gene Engineering of Nef SIV
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
h. Gene Engineering of env from SHIV89.6P
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
i. Vector:
pVR1012 prime, rAd5 boost (Mascola et al., 2005)
j. Immunization Route
Intramuscular injection (i.m.)
k. Macaque Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: DNA priming-rAd5 boosting immunization platform can elicit potent anti-HIV-1 cellular immune responses and anti-HIV-1 neutralizing antibodies (Mascola et al., 2005).
  • Efficacy: In a challenge study, all monkeys were immunized with DNA plasmids at 0, 4, and 8 weeks and boosted with rAd5 at week 26. Serial plasma dilutions were tested against four of the more neutralization-sensitive viruses, and the plasma dilution that produced 50% virus neutralization, which is required to protect 50% of the cells from virus-induced killing, was determined. The data clearly demonstrates that both the vaccine platform and these immunogens elicit IgG-mediated virus neutralization (Mascola et al., 2005).
18. HIV DNA vaccine VlJns-tPA-gp120
a. Vaccine Ontology ID:
VO_0004351
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Rhesus monkey
e. Gene Engineering of gp120
f. Vector:
VlJns (Lekutis et al., 1997)
g. Immunization Route
Intramuscular injection (i.m.)
h. Monkey Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: The secretion of IFN-y stimulated CD4+ Th cell lines and rgp120-stimulated PBL from the vaccinated monkeys suggest that an HIV-1 env plasmid DNA vaccine elicits a Thl-like immune response in primates as well as in rodents (Lekutis et al., 1997)
  • Efficacy: The secondary immune response that arose after repeated plasmid DNA administration was Thl-like, suggesting that the nature of the DNA vaccine-elicited Th cell response was maturation dependent. Evidence from vaccinated nonhuman primates suggests that a vigorous Th cell response, including viral Ag-specific IFN-y production, may be a correlate of protection from HIV- 1 and Simian Human Immunodeficiency Virus infection (Lekutis et al., 1997)
19. HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein
a. Vaccine Ontology ID:
VO_0000789
b. Type:
DNA vaccine
c. Antigen
HIV Env gp160 protein (Xin et al., 2005)
d. Gene Engineering of Env Gp160
  • Type: Recombinant vector construction
  • Description: An Ad5/35 vector was used to express HIV Env gp160 protein (Ad5/35-HIV) (Xin et al., 2005).
  • Detailed Gene Information: Click here.
e. Gene Engineering of env
  • Type: DNA vaccine construction
  • Description: The DNA vaccine contained env and rev from HIV-1 IIIB (Xin et al., 2005).
  • Detailed Gene Information: Click here.
f. Gene Engineering of rev from HIV 1
  • Type: DNA vaccine construction
  • Description: The DNA vaccine contained env and rev from HIV-1 IIIB (Xin et al., 2005).
  • Detailed Gene Information: Click here.
g. Vector:
pCAGGS and a replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35)
h. Preparation
A replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35) was prepared and used to express HIV Env gp160 protein. The product is named Ad5/35-HIV (Xin et al., 2005).
i. Virulence
This novel Ad5/35 vector showed minimal hepatotoxicity after intramuscular administration with the novel Ad5/35 vector (Xin et al., 2005).
j. Description
Replication-defective Ad5 HIV recombinants and replication-defective MVA elicit potent CD8+ T-cell responses and provide a high degree of protection in NHPs. The Ad5 (subgroup C) has well-defined biological properties and has been widely used as a vector for gene therapy and vaccine. The replication-defective Ad5 vector can easily be produced in high titers and is highly effective in boosting HIV-specific immunity. However, this virus uses CAR as its primary attachment receptor, which confers tropism for liver parenchymal cells. This raises important safety concerns. Thus, a replication-defective chimeric Ad5 vector with Ad type 35 fiber (Ad5/35) has been developed, which not only induces strong antigen-specific humoral and cellular immune responses and exhibits minimal hepatotoxicity in both mice and NHPs, but is also significantly less susceptible to the pre-existing Ad5 immunity than a comparable Ad5 vector (Xin et al., 2005).
k. Monkey Response
  • Host Strain: rhesus monkey (Macaca mulatta)
  • Vaccination Protocol: 1011 vp of Ad5/35-HIV vector was injected i.m. into two rhesus monkeys (2 years old, male) at weeks 0 and 8 (Xin et al., 2005).
  • Immune Response: A detectable HIV-specific serum Ab response developed within 2 weeks of the first immunization. At 4 weeks post boosting, titers in excess of 1:50 000 were achieved. Similar results were observed in neutralizing Ab. A increase in the number of HIV-specific IFN-gamma-secreting T cells was also detected in the peripheral blood mononuclear cells (PBMCs). Boosting with Ad5/35-HIV vector further increased this T-cell response (Xin et al., 2005).
  • Side Effects: Liver infection with Ad5 vector was 20- to 40-fold stronger than that with Ad5/35 vector. Ad5-Luc vector was two- and four-fold higher, respectively, than that of the monkeys that received the Ad5/35-Luc vector. The Ad5/35 recombinants exhibits minimal hepatotoxicity in non-human primates but is also significantly less susceptible to the pre-existing Ad5 immunity than a comparable Ad5 vector (Xin et al., 2005).
l. Mouse Response
  • Vaccination Protocol: Mice were injected i.m. with Ad5-Luc or Ad5/35-Luc. Luciferase expression was monitored using an in vivo imaging system (IVIS). The expression of HIV gp160 was confirmed by Western blotting. Mice were immunized with Ad5/35-HIV vector, and the HIV-specific CMI was periodically monitored by the intracellular cytokine staining (ICS) assay (Xin et al., 2005).
  • Immune Response: The animals immunized with Ad5/35-HIV vector developed a high-titered anti-gp160 antibody (Ab) response. The magnitude of this response was not significantly altered by preimmunization with the DNA-HIV vaccine. DNA-HIV vaccination alone generated a low level of HIV-specific serum Ab. HIV-specific neutralizing Ab was only detectable in the Ad5/35-HIV vaccinated mice and DNA prime/Ad5/35-HIV boosted mice. HIV-specific cellular immune responses persisted through 7 months after final immunization (Xin et al., 2005).
  • Side Effects: The hepatotoxicity caused by the Ad5 vector was circumvented by the use of an Ad5/35 vector (Xin et al., 2005).
  • Challenge Protocol: Immunized mice were challenged with vPE16 2 weeks after final immunization. Vaccinated mice were challenged with vPE16 7 weeks after final immunization. The strain vPE16 is HIVBH8 gp160-expressing replication-competent vaccinia virus (WR strain, vPE16; HIVBH8 gp160 has 97.32% amino-acid homology with HIVIIIB gp160) (Xin et al., 2005).
  • Efficacy: The animals that were vaccinated with the Ad5/35 vector alone or in combination with the DNA-HIV vaccine were completely protected from infection; however, the DNA-HIV vaccination alone had little impact on the susceptibility to infection by vPE16. DNA-HIV vaccination by itself was not protective, but the combination of DNA-HIV priming and Ad5/35-HIV boosting yielded a prolonged and complete protection (Xin et al., 2005).
20. HIV recombinant gp160 Protein Vaccine
a. Vaccine Ontology ID:
VO_0004274
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
Recombinant gp160 (Barrett et al., 1989).
e. Adjuvant: DOC/Alum Complex
f. Immunization Route
subcutaneous injection
g. Mouse Response
  • Vaccination Protocol: The potency of the vaccine was determined by injecting mice with serial dilutions of gp160 alone or adjuvanted with different formulations. Groups of 10 mice were injected subcutaneously with 1 ml of fourfold dilutions of the test substance. A total of 50 mice were injected in each test (Barrett et al., 1989).
  • Immune Response: The highest potency in mice was obtained using a preparation with 0.2% Al(OH)3 and 0.25% deoxycholate (Barrett et al., 1989).
21. HIV recombinant vector vaccine MVA-gag encoding gag
a. Vaccine Ontology ID:
VO_0004347
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Macaque
e. Gene Engineering of Gag from HIV 1
  • Type: Recombinant vector construction
  • Description: This recombinant vector vaccine expressed gag from HIV-1 (Casimiro et al., 2003).
  • Detailed Gene Information: Click here.
f. Vector:
pSC59 (Casimiro et al., 2003).
g. Immunization Route
Intramuscular injection (i.m.)
h. Monkey Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Immunization of macaques with MVA-gag resulted in relatively weak antigen-specific T-cell responses; the levels did not exceed 150 spot-forming cells (SFC)/106 PBMCs after three doses and were significantly less than those observed in the Ad5-gag vaccinees. Only one of six MVA-gag vaccinees elicited any detectable Gag-specific antibody response (140 mMU/ml at 4 weeks post-dose 3 for monkey V215) (Casimiro et al., 2003).
  • Efficacy: The study reports that SIV Gag delivered by DNA, MVA, or adenovirus type 5 vectors is able to inhibit viral replication and disease progression in rhesus macaques following challenge with the SHIV89.6P virus. However, only 50% of the animals that received MVA alone or in combination with DNA were able to effectively control viremia (Casimiro et al., 2003).
22. HIV recombinant vector vaccine MVA.HIVA encoding env and rev
a. Vaccine Ontology ID:
VO_0004350
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Human
e. Gene Engineering of env
  • Type: Recombinant vector construction
  • Description: This DNA vaccine encoded env from HIV-1 (Peters et al., 2007).
  • Detailed Gene Information: Click here.
f. Gene Engineering of rev from HIV 1
  • Type: Recombinant vector construction
  • Description: This DNA vaccine expressed rev from HIV-1 (Peters et al., 2007).
  • Detailed Gene Information: Click here.
g. Immunization Route
Intramuscular injection (i.m.)
23. HIV-1 gp120 with mCT E112K
a. Vaccine Ontology ID:
VO_0004268
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
HIV-1LAIEnv gp120 (Yoshino et al., 2004).
e. Adjuvant: non-toxic mutant E112K of Cholera Toxin mCT-E112K
f. Immunization Route
intranasal immunization
g. Monkey Response
  • Host Strain: rhesus macaques
  • Vaccination Protocol: Rhesus macaques were divided into four groups and nasally immunized with vaccine containing: 1) 100 µg of gp120 alone, 2) 100 µg of gp120 plus 10 µg of nCT, 3) 100 µg of gp120 plus 25 µg of mCT E112K, or 4) 100 µg of gp120 plus 100 µg of mCT E112K. Macaques were anesthetized with ketamine and placed in dorsal recumbancy with head tilted back so that the nares were pointed upward. Vaccine solution (0.5 ml) was instilled dropwise into each nostril without inserting the syringe into the nasal cavity. Macaques were kept in that position for 10 min and then placed in lateral recumbancy until they recovered from anesthesia, as described previously (16). Nasal immunization was conducted on days 0, 7, 14, 28, 42, and 56 (Yoshino et al., 2004).
  • Immune Response: Macaques given nasal gp120 with either mCT E112K or nCT showed elevated gp120-specific IgG and IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues and of IL-4-producing Th2-type CD4-positive (CD4(+)) T cells than did controls. Even though significant mucosal adjuvanticity was seen with both mCT E112K and nCT, neuronal damage was observed only in the nCT-treated, but not in the control or mCT E112K-treated groups (Yoshino et al., 2004).
  • Host Gene Response of IgA Fc fragment
    • Gene Response: Macaques given nasal gp120 with either mCT E112K or nCT showed significantly elevated IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues compared to controls, who were vaccinated without the adjuvant (Yoshino et al., 2004).
    • Detailed Gene Information: Click here.
  • Host Gene Response of IgG Fc fragment
    • Gene Response: Macaques given nasal gp120 with either mCT E112K or nCT showed significantly elevated gp120-specific IgG responses with virus-neutralizing activity in both their plasma and mucosal external secretions compared to controls, who were vaccinated without the adjuvant (Yoshino et al., 2004).
    • Detailed Gene Information: Click here.
  • Host Gene Response of IL4
    • Gene Response: Vaccinated animals that received the adjuvant had a greater increase in IL-4-producing Th2-type CD4-positive (CD4(+)) T cells in mesenteric lymph nodes (MLNs) than did controls vaccinated without the adjuvant, which did not produce IL-4 (Yoshino et al., 2004),
    • Detailed Gene Information: Click here.
24. HIV-2 DNA vaccine
a. Vaccine Ontology ID:
VO_0004259
b. Type:
DNA vaccine
c. Status:
Research
d. Antigen
The DNA vaccine constructs were developed based on the gene sequences of the gp140 envelope, p55 Gag, Nef, and Tat proteins from the HIV-2UC2 isolate (GenBank accession number U38293) (Locher et al., 2004).
e. Gene Engineering of gag from HIV 2
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of nef from HIV 2
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Gene Engineering of tat from HIV 2
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
h. Gene Engineering of env from HIV 2
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
i. Adjuvant: B7-2 vaccine adjuvant
j. Adjuvant: GM-CSF vaccine adjuvant
k. Vector:
pND-14 (Locher et al., 2004)
l. Immunization Route
Intramuscular injection (i.m.)
m. Baboon Response
  • Vaccination Protocol: Each baboon was immunized four times with the experimental or control DNA constructs formulated with Vaxfectin. The time intervals were chosen to permit maturation of the immune response (Locher et al., 2004).
  • Challenge Protocol: One month after the fourth immunization, the baboons were challenged twice (6 h apart) by the intravaginal route using 50 baboon infectious dosages (30,000 tissue culture infectious dosages) of HIV-2UC2/9429 for a total of 100 baboon infectious dosages. This virus isolate is a more virulent variant of the HIV-2UC2 isolate and was recovered from a baboon with an AIDS-like disease (Locher et al., 2004).
  • Efficacy: At 2 weeks post-HIV-2 challenge, viral loads ranged from 100 (below the threshold of detection) to 81,000 viral RNA copies in the plasma, with the lowest average viral loads in the group of baboons that received the HIV-2 DNA without the genetic adjuvants (a mean of 852 copies/ml), followed by the group of baboons the received the HIV-2 DNA and the genetic adjuvants (a mean of 2499 copies/ml) (Locher et al., 2004).
25. Inactivated HIV-2 Vaccine with PMMA
a. Vaccine Ontology ID:
VO_0004242
b. Type:
Inactivated or "killed" vaccine
c. Status:
Research
d. Adjuvant: PMMA
e. Immunization Route
subcutaneous injection
f. Mouse Response
  • Host Strain: NMRI
  • Vaccination Protocol: Mice received 0.5 ml of the specified vaccine preparations subcutaneously under the abdominal skin on day 0 (Stieneker et al., 1991).
  • Immune Response: Mice immunized with PMMA adjuvant had higher antibody counts than mice immunized with an alum adjuvant (Stieneker et al., 1991).
26. L. T -HIV-1 Gag
a. Vaccine Ontology ID:
VO_0004629
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Gene Engineering of Gag from HIV 1
  • Type: Recombinant vector construction
  • Description: A non-pathogenic Leishmania tarentolae was used to express full-length HIV-1 Gag protein (Breton et al., 2007).
  • Detailed Gene Information: Click here.
f. Vector:
(Breton et al., 2007)
g. Preparation
A non-pathogenic protozoan parasitic vector, Leishmania tarentolae, which shares common target cells with HIV-1, was used to express full-length HIV-1 Gag protein (Breton et al., 2007).
h. Immunization Route
Intramuscular injection (i.m.)
i. Mouse Response
  • Host Strain: Balb/c
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Immunization of BALB/c mice with recombinant L. tarentolae led to the expansion of HIV-1 Gag-specific T cells and stimulated CD8(+) T cells to produce gamma interferon in response to specific viral Gag epitopes. A booster immunization with recombinant L. tarentolae elicited effector memory HIV-1 Gag-specific CD4(+) T lymphocytes and increased antibody titres against HIV-1 Gag (Breton et al., 2007).
  • Efficacy: Immunization of human tonsillar tissue cultured ex vivo with Gag-expressing L. tarentolae vaccine vector elicited a 75% decrease in virus replication following exposure of the immunized tonsils to HIV-1 infection (Breton et al., 2007).
27. MVA expressing HIV Gag, Pol and Env proteins
a. Vaccine Ontology ID:
VO_0000824
b. Type:
Recombinant vector vaccine
c. Antigen
HIV Gag, Pol, and Env proteins (Liu et al., 2006)
d. Vector:
modified vaccinia Ankara (MVA)
e. Preparation
An rMVA vaccine that expresses HIV Gag, Pol, and Env proteins was constructed (Liu et al., 2006).
f. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: Female BALB/c mice were used for immunizations. All were conducted on anesthetized mice. Immunizations with MVAs were accomplished by inoculating the desired amount of MVA into a single quadriceps muscle. Immunizations with DNA were accomplished by injecting the desired amount of DNA into the quadriceps, half in each leg (Liu et al., 2006).
  • Persistence: Temporal CD8 responses were conducted in BALB/c mice using MVA. Responses were steady for >10 weeks (>6 weeks post-MVA) (Liu et al., 2006).
  • Immune Response: CD8 T cells were boosted more effectively than CD4 T cells with the ratio of elicited CD8 to CD4 cells for the immunodominant CD8 epitope in Gag increasing with boosts. The most effective boost for CD8 T cells resulted in the greatest skewing of the CD8 to CD4 T cell ratio. This could represent better access of CD8 than CD4 T cells to APCs (Liu et al., 2006). The dose–response studies showed good increases for antigen expression with increasing MVA dose. A 1000-fold increase in the dose of MVA resulted in a 300-fold increase in the frequency of antigen-expressing cells. In contrast, dose–response studies for in vivo immunogenicity showed <10-fold increases in elicited T cells and Ab for 100–1000-fold increases in the dose of inoculated MVA. Shallow dose–response curves for immunogenicity were observed post priming as well as post boosting of an MVA or a DNA prime (Liu et al., 2006).
  • Side Effects: No adverse effects were encountered (Liu et al., 2006).
28. NYVAC-HIV-1
a. Vaccine Ontology ID:
VO_0004774
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
Attenuated poxvirus-HIV-1 recombinants followed by protein boosting (Patterson et al., 2000).
f. Immunization Route
Intramuscular injection (i.m.)
g. Macaque Response
  • Vaccination Protocol: Twenty-four macaques were primed with NYVAC (a genetically attenuated Copenhagen vaccinia strain) recombinants with HIV-1 and HIV-2 env and gag-pol or NYVAC vector alone and boosted with homologous, oligomeric gp160 proteins or adjuvant only (Patterson et al., 2000).
  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: One half of each immunization and control group were intravenously challenged with SHIV(HXB2) the other half was challenged with HIV-2SBL6669 (Patterson et al., 2000).
  • Efficacy: Virological assessments verified that both NYVAC-HIV-1 and NYVAC-HIV-2 immunization significantly reduced viral burdens and partially protected against HIV-2 challenge, although cross-protection was not at the level that had been previously reported. Humoral antibody and/or CTL and CD8AA were associated with protection against homologous HIV-2 challenge, while cellular immune responses seemed more important for cross-protection. No significant protection was observed in the SHIV-challenged macaques (Patterson et al., 2000).
29. NYVAC-HIV-2
a. Vaccine Ontology ID:
VO_0004775
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
Attenuated poxvirus-HIV-1 recombinants followed by protein boosting (Patterson et al., 2000).
f. Immunization Route
Intramuscular injection (i.m.)
g. Macaque Response
  • Vaccination Protocol: Twenty-four macaques were primed with NYVAC (a genetically attenuated Copenhagen vaccinia strain) recombinants with HIV-1 and HIV-2 env and gag-pol or NYVAC vector alone and boosted with homologous, oligomeric gp160 proteins or adjuvant only (Patterson et al., 2000).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: One half of each immunization and control group were intravenously challenged with SHIV(HXB2) the other half was challenged with HIV-2SBL6669 (Patterson et al., 2000).
  • Efficacy: Virological assessments verified that both NYVAC-HIV-1 and NYVAC-HIV-2 immunization significantly reduced viral burdens and partially protected against HIV-2 challenge, although cross-protection was not at the level that had been previously reported. Humoral antibody and/or CTL and CD8AA were associated with protection against homologous HIV-2 challenge, while cellular immune responses seemed more important for cross-protection. No significant protection was observed in the SHIV-challenged macaques, although NYVAC-HIV-1 immunization resulted in significantly lower viral burdens compared with controls (Patterson et al., 2000).
30. NYVAC-SIV
a. Vaccine Ontology ID:
VO_0004779
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
The gag, pol, and env genes of SIV(K6W) were expressed in the NYVAC vector (Benson et al., 1998).
f. Immunization Route
Intramuscular injection (i.m.)
g. Macaque Response
  • Vaccination Protocol: The macaques were immunized with NYVAC-SIV and NYVAC-IL-12 or NYVAC-SIV alone (Benson et al., 1998).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: At the end of the immunization regimen, half of the animals were challenged with SIV(mac251) by the intravenous route and the other half were exposed to SIV(mac251) intrarectally (Benson et al., 1998).
  • Efficacy: Significantly, five of the eleven vaccinees exposed mucosally to SIV(mac251) showed a transient peak of viremia 1 week after viral challenge and subsequently appeared to clear viral infection. In contrast, all 12 animals inoculated intravenously became infected, but 5 to 6 months after viral challenge, 4 animals were able to control viral expression and appeared to progress to disease more slowly than control animals. Protection did not appear to be associated with any of the measured immunological parameters. Further modulation of immune responses by coadministration of NYVAC-cytokine recombinants did not appear to influence the outcome of viral challenge (Benson et al., 1998).
31. rBCG-SIVgag and rDIsSIVgag Prime-boost SHIV vaccine
a. Vaccine Ontology ID:
VO_0004600
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
cynomologus macaque
e. Antigen
gag from simian immunodeficiency viruses
f. Gene Engineering of gag from SHIV-89.6
  • Type: Recombinant vector construction
  • Description: The SHIV gag gene was inserted to a recombinant BCG vector and a replication-deficient vaccinia virus strain (DIs) vaccine vector (Ami et al., 2005).
  • Detailed Gene Information: Click here.
g. Vector:
Mycobacterium bovis bacillus Calmette-Guérin (BCG)-Tokyo and a replication-deficient vaccinia virus strain (DIs) (Ami et al., 2005)
h. Immunization Route
Intramuscular injection (i.m.)
i. Macaque Response
  • Host Strain: cynomologus macaque
  • Vaccination Protocol: cynomologus macaques were primed with rBCG-SIVgag, and then boosted with rDIsSIVgag (Ami et al., 2005).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Ten weeks after the second booster immunization, the macaques were challenged by intrarectal inoculation with 2 × 103 TCID50 or 50 50% monkey infectious doses (MID50) of SHIV KS661c, an SHIV-89.6 variant clone (Ami et al., 2005).
  • Efficacy: For the prime-boost vaccination group, plasma viremia levels remained undetectable and CD4+ T-cell counts stayed above 500 cells/μl for the entire year of testing (Ami et al., 2005).
32. Recombinant HIV gp120 with adjuvant NanoEmulsion
a. Vaccine Ontology ID:
VO_0000819
b. Type:
Subunit vaccine
c. Antigen
HIV glycoprotein 120, which has a role in facilitating coreceptor interaction and in mediating virus binding to cellular CD4 (Bielinska et al., 2008).
d. Adjuvant: nanoemulsion vaccine adjuvant
  • VO ID: VO_0001319
  • Description: An oil-in-water nanoemulsion (NE) was used as the mucosal adjuvant for this vaccine (Bielinska et al., 2008).
e. Preparation
The gp120 and NE vaccines were prepared by mixing NE with gp120 protein solution, using pyrogen-free saline as a diluent (Bielinska et al., 2008).
f. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: BALB/c mice were immunized with two or three intranasal administrations of gp120/NE formulation at 3 weeks apart. The immunizations of 10 microliters were performed by slowly applying gp120/NE mixes to the nares.Control mice were immunized with gp120 in saline, with NE alone or saline. Intramuscular immunization was performed with two doses, 3 weeks apart, of 20 micrograms of gp120 injected in 50 microliters of either saline or 1% NE (Bielinska et al., 2008).
  • Immune Response: Immunized mice demonstrated robust serum anti-gp120 IgG, as well as bronchial, vaginal, and serum anti-gp120 IgA . The analysis of gp120-specific CTL proliferation, INF- induction, and prevalence of anti-gp120 IgG2 subclass antibodies indicated that nasal vaccination in NE also induced systemic, Th1-polarized cellular immune responses (Bielinska et al., 2008).
g. Guinea pig Response
  • Host Strain: Hartley
  • Vaccination Protocol: Hartley guinea pigs were immunized intranasally with two administrations (50 microliters per nare) of gp120/NE mix at 3 weeks apart (Bielinska et al., 2008).
  • Immune Response: Immunization produced significant levels of serum anti-gp120 IgG antibodies in all animals, as was seen with the mice. The analysis of gp120-specific CTL proliferation, INF gamma induction, and prevalence of anti-gp120 IgG2 subclass antibodies indicated that nasal vaccination in NE also induced systemic, Th1-polarized cellular immune responses (Bielinska et al., 2008).
33. rgp120 HIV Vaccine with immunoliposomes
a. Vaccine Ontology ID:
VO_0004264
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
rgp120 (Ozpolat et al., 1998).
e. Adjuvant: immunoliposomes containing antibodies to costimulatory molecules
f. Immunization Route
subcutaneous injection
g. Mouse Response
  • Host Strain: C3H/HeN
  • Vaccination Protocol: Groups of five mice were immunized subcutaneously three times at 14-day intervals. The immunoliposomes were suspended in PBS and each mouse received 0.1 ml per injection. Each injection contained 380 &mu;g of PC, 193 &mu;g of CH, 10 pg of PE-B, 2.0 &mu;g of MAb, and 10 &mu;g of rgpl20 (Ozpolat et al., 1998).
  • Immune Response: Mice vaccinated with immunoliposomes were found to have a strong delayed-type hypersensitivity (DTH) response to the weakly immunogenic gp120 that was dependent on the presence of the MAbs. However, this vaccination protocol did not induce humoral immunity (Ozpolat et al., 1998).
34. rMVA-SIV-CD40L
a. Vaccine Ontology ID:
VO_0004792
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
Co-expressed the CD40L with our DNA/SIV vaccine such that the CD40L is anchored on the membrane of SIV virus-like particle (VLP) (Kwa et al., 2014).
f. Immunization Route
Intramuscular injection (i.m.)
g. Macaque Response
  • Vaccination Protocol: The macaques were divided into 3 groups and group 1 was vaccinated with a DNA/MVA SIV vaccine, group 2 was vaccinated with the DNA/MVA SIV vaccine with CD40L in the DNA, and the third group was an unvaccinated control (Kwa et al., 2014).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The macaques were intrarectally challenged with SIVE660 at a dose of 5000 TCID to test the level of protection of the vaccines (Kwa et al., 2014).
  • Efficacy: CD40L adjuvant enhanced the functional quality of anti-Env antibody response and breadth of anti-SIV CD8 and CD4 T cell responses, significantly delayed the acquisition of heterologous mucosal SIV infection and improved viral control. Notably, the CD40L adjuvant enhanced the control of viral replication in the gut at the site of challenge that was associated with lower mucosal CD8 immune activation, one of the strong predictors of disease progression (Kwa et al., 2014).
35. rMVTT-SIV-gpe
a. Vaccine Ontology ID:
VO_0004760
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Gene Engineering of env from SIV
  • Type: Recombinant vector construction
  • Description: A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).
  • Detailed Gene Information: Click here.
f. Gene Engineering of Pol SIV
  • Type: Recombinant vector construction
  • Description: A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).
  • Detailed Gene Information: Click here.
g. Gene Engineering of Pol SIV
  • Type: Recombinant vector construction
  • Description: A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).
  • Detailed Gene Information: Click here.
h. Preparation
(Sun et al., 2013) a modified replicating vaccinia virus Tiantan strain (MVTT(SIVgpe))
i. Immunization Route
Intramuscular injection (i.m.)
j. Monkey Response
  • Vaccination Protocol: Eight monkeys were divided into two groups: (i) four monkeys received the MVTTioin+Adim testing regimen as in study I, and (ii) four monkeys received an empty MVTT control vector (109 PFU) through intraoral (0.5 ml) and intranasal (0.5 ml) routes and an empty Ad5 control vector (1011 vp in 1 ml of PBS) through intramuscular injection (Sun et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: At either week 30 after the initial vaccination or week 24 after the final vaccination, each animal was challenged intrarectally with 5 × 105 50% tissue culture infective doses (TCID50) of Chinese rhesus monkey-adapted and neutralization-resistant SIVmac239. In all cases, the challenge virus stock was administered in 1 ml of PBS (Sun et al., 2013).
  • Efficacy: The reductions in peak and set-point viral loads were significant in most animals, with one other animal being protected fully from high-dose intrarectal inoculation of SIV(mac239). Furthermore, the animals vaccinated with this regimen were healthy, while ~75% of control animals developed simian AIDS. The protective effects correlated with the vaccine-elicited SIV-specific CD8(+) T cell responses against Gag and Pol (Sun et al., 2013).
36. SHIV DNA vaccine encoding env and gag
a. Vaccine Ontology ID:
VO_0004596
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Rhesus macaques
e. Gene Engineering of env from HIV-1 strain Ba-L
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of env from HIV-1 strain 96ZM651
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Gene Engineering of env from HIV-1 strain 976 clone 17
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
h. Gene Engineering of env from HIV-1 isolate 715
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
i. Gene Engineering of gag from HIV-1 vector pNL4-3
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
j. Vector:
pSW3891 (Pal et al., 2006)
k. Immunization Route
Gene gun
l. Macaque Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: The immune response elicited by the multivalent DNA prime/protein boost vaccine was able to protect macaques from rectal challenge with SHIV-Ba-L isolate. This polyvalent vaccine formulation was able to confer protection in four out of six animals against SHIV-Ba-L and significantly reduced plasma viremia in the two remaining animals (Pal et al., 2006).
37. SHIV(Ba-L) DNA vaccine encoding env and gag
a. Vaccine Ontology ID:
VO_0004597
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Macaques
e. Gene Engineering of env from HIV-1 isolate 037 clone 08
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of env from HIV-1 isolate 715
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Gene Engineering of env from HIV-1 strain 96ZM651
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
h. Gene Engineering of env from HIV-1 strain 976 clone 17
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
i. Gene Engineering of env from HIV-1 strain Ba-L
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
j. Gene Engineering of gag from HIV-1 vector pNL4-3
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
k. Vector:
pSW3891 (Pal et al., 2005)
l. Immunization Route
Intramuscular injection (i.m.)
m. Macaque Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: one of six immunized animals was completely protected whereas all six naïve animals were infected. These results demonstrate that a vaccine based on priming with a polyvalent DNA vaccine from multiple HIV-1 subtypes followed by boosting with homologous Env proteins elicits anti-HIV-1 immune responses capable of controlling rectal transmission of SHIV(Ba-L) (Pal et al., 2005).
38. V3 VLPs with Gamma inulin adjuvant
a. Vaccine Ontology ID:
VO_0004232
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
gp120 V3 loop (Harris et al., 1996).
e. Adjuvant: gamma Inulin vaccine adjuvant
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Host Strain: BABL/c
  • Vaccination Protocol: Mice were immunized with 10 μg of V3-VLPs without adjuvant in the muscle of the left leg. At the same time, the mice were immunized in the right leg with the other immunogens (Harris et al., 1996).
  • Immune Response: Mice immunized with V3 VLPs adjuvanted with gamma inulin showed good CTL responses (Harris et al., 1996).
39. YF17D- HIV-1 p24
a. Vaccine Ontology ID:
VO_0004690
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Mouse
e. Preparation
HIV-1 p24 (clade B consensus), was inserted near the 5' end of YF17D, in frame and upstream of the polyprotein (YF-5'/p24) (Franco et al., 2010).
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Vaccination Protocol: Mice were immunized two times subcutaneously at the base of the tail with PBS or 106 pfu of YF17D, YF-E/p24/NS1, or YF-5′/p24 in 100 μl on days 0 and 14 (Franco et al., 2010).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Three weeks after the second immunization, half of the mice in each group were challenged intranasally with 5 × 105 pfu of Gag-expressing recombinant vaccinia virus (Vac-gag). The remaining animals in the groups were challenged intranasally with the same dose of wild-type vaccinia virus (Vac-wt) (Franco et al., 2010).
  • Efficacy: The protective efficacy of the YF17D recombinants, particularly YF-E/p24/NS1, in mice challenged with a vaccinia expressing HIV-1 Gag was demonstrated (Franco et al., 2010).
V. References
1. Aggarwal et al., 2005: Aggarwal P, Kumar S, Vajpayee M, Seth P. Adjuvant action of murine IL-2/Ig plasmid after intramuscular immunization with Indian HIV-1 subtype C recombinant env.gp 120 construct. Viral immunology. 2005; 18(4); 649-656. [PubMed: 16359231].
2. Ami et al., 2005: Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S, Yamada T, Yamazaki S, Yamamoto N, Honda M. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. Journal of virology. 2005; 79(20); 12871-12879. [PubMed: 16188989].
3. Ara et al., 2001: Ara Y, Saito T, Takagi T, Hagiwara E, Miyagi Y, Sugiyama M, Kawamoto S, Ishii N, Yoshida T, Hanashi D, Koshino T, Okada H, Okuda K. Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system. Immunology. 2001; 103(1); 98-9105. [PubMed: 11380697].
4. Ayyavoo et al., 2002: Ayyavoo V, Muthumani K, Kudchodkar S, Zhang D, Ramanathan P, Dayes NS, Kim JJ, Sin JI, Montaner LJ, Weiner DB. HIV-1 viral protein R compromises cellular immune function in vivo. International immunology. 2002 Jan; 14(1); 13-22. [PubMed: 11751747].
5. Bagley et al., 2003: Bagley KC, Shata MT, Onyabe DY, DeVico AL, Fouts TR, Lewis GK, Hone DM. Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin. Vaccine. 2003; 21(23); 3335-3341. [PubMed: 12804865].
6. Barouch et al., 2012: Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(22); 8694-8698. [PubMed: 22586094].
7. Barrett et al., 1989: Barrett N, Mitterer A, Mundt W, Eibl J, Eibl M, Gallo RC, Moss B, Dorner F. Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. AIDS research and human retroviruses. 1989; 5(2); 159-171. [PubMed: 2713166].
8. Benson et al., 1998: Benson J, Chougnet C, Robert-Guroff M, Montefiori D, Markham P, Shearer G, Gallo RC, Cranage M, Paoletti E, Limbach K, Venzon D, Tartaglia J, Franchini G. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. Journal of virology. 1998; 72(5); 4170-4182. [PubMed: 9557706].
9. Bielinska et al., 2008: Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS research and human retroviruses. 2008; 24(2); 271-281. [PubMed: 18260780].
10. Bomford et al., 1992: Bomford R, Stapleton M, Winsor S, McKnight A, Andronova T. The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS research and human retroviruses. 1992; 8(10); 1765-1771. [PubMed: 1457190].
11. Bower et al., 2004: Bower JF, Yang X, Sodroski J, Ross TM. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. Journal of virology. 2004; 78(9); 4710-4719. [PubMed: 15078953].
12. Boyer et al., 1997: Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Williams WV, Refaeli Y, Ciccarelli RB, McCallus D, Coney L, Weiner DB. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature medicine. 1997; 3(5); 526-532. [PubMed: 9142121].
13. Bråve et al., 2007: Bråve A, Hinkula J, Cafaro A, Eriksson LE, Srivastava IK, Magnani M, Ensoli B, Barnett SW, Wahren B, Rollman E. Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. Vaccine. 2007; 25(39-40); 6882-6890. [PubMed: 17707956].
14. Bråve et al., 2005: Bråve A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, Lundgren B, Blomberg P, Hinkula J, Wahren B. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Molecular therapy : the journal of the American Society of Gene Therapy. 2005; 12(6); 1197-1205. [PubMed: 16112909].
15. Breton et al., 2007: Breton M, Zhao C, Ouellette M, Tremblay MJ, Papadopoulou B. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. The Journal of general virology. 2007; 88(Pt 1); 217-225. [PubMed: 17170454].
16. Buchbinder et al., 1994: Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS (London, England). 1994 Aug; 8(8); 1123-8. [PubMed: 7986410].
17. Calarota et al., 1998: Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandström E, Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 1998; 351(9112); 1320-1325. [PubMed: 9643795].
18. Calarota et al., 2008: Calarota SA, Dai A, Trocio JN, Weiner DB, Lori F, Lisziewicz J. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine. 2008; 26(40); 5188-5195. [PubMed: 18462844].
19. Caley et al., 1999: Caley IJ, Betts MR, Davis NL, Swanstrom R, Frelinger JA, Johnston RE. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine. 1999 Aug 6; 17(23-24); 3124-35. [PubMed: 10462249].
20. Caputo et al., 2003: Caputo A, Gavioli R, Altavilla G, Brocca-Cofano E, Boarini C, Betti M, Castaldello A, Lorenzini F, Micheletti F, Cafaro A, Sparnacci K, Laus M, Tondelli L, Ensoli B. Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine. 2003; 21(11-12); 1103-1111. [PubMed: 12559787].
21. Casimiro et al., 2003: Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. Journal of virology. 2003; 77(11); 6305-6313. [PubMed: 12743287].
22. Chan et al., 1997: Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997 Apr 18; 89(2); 263-73. [PubMed: 9108481].
23. Chen et al., 2005: Chen X, Rock MT, Hammonds J, Tartaglia J, Shintani A, Currier J, Slike B, Crowe JE Jr, Marovich M, Spearman P. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. Journal of virology. 2005 May; 79(9); 5537-47. [PubMed: 15827168].
24. Chin'ombe et al., 2009: Chin'ombe N, Bourn WR, Williamson AL, Shephard EG. Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice. Virology journal. 2009; 6; 87. [PubMed: 19555490].
25. Coakley et al., 2005: Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine co-receptor usage in HIV. Current opinion in infectious diseases. 2005 Feb; 18(1); 9-15. [PubMed: 15647694].
26. Coffin et al., 1986: Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P. What to call the AIDS virus?. Nature. 1986 May 1-7; 321(6065); 10. [PubMed: 3010128].
27. Cristillo et al., 2011: Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, Bowen B, Thompson D, Petrovsky N, Markham P, Pal R. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. The Journal of general virology. 2011; 92(Pt 1); 128-140. [PubMed: 21169215].
28. Dale et al., 2004: Dale CJ, De Rose R, Stratov I, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Law M, Kent SJ. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. Journal of virology. 2004; 78(24); 13819-13828. [PubMed: 15564490].
29. Davis et al., 2002: Davis NL, West A, Reap E, MacDonald G, Collier M, Dryga S, Maughan M, Connell M, Walker C, McGrath K, Cecil C, Ping LH, Frelinger J, Olmsted R, Keith P, Swanstrom R, Williamson C, Johnson P, Montefiori D, Johnston RE. Alphavirus replicon particles as candidate HIV vaccines. IUBMB life. 2002 Apr-May; 53(4-5); 209-11. [PubMed: 12120997].
30. Deng et al., 1996: Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996 Jun 20; 381(6584); 661-6. [PubMed: 8649511].
31. Denis-Mize et al., 2000: Denis-Mize KS, Dupuis M, MacKichan ML, Singh M, Doe B, O'Hagan D, Ulmer JB, Donnelly JJ, McDonald DM, Ott G. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene therapy. 2000; 7(24); 2105-2112. [PubMed: 11223992].
32. Duerr et al., 2012: Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, Del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN. Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study). The Journal of infectious diseases. 2012; 206(2); 258-266. [PubMed: 22561365].
33. Durier et al., 2006: Durier C, Launay O, Meiffredy V, Saidi Y, Salmon D, Levy Y, Guillet JG, Pialoux G, Aboulker JP. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS (London, England). 2006 Apr 24; 20(7); 1039-49. [PubMed: 16603857].
34. Flatz et al., 2012: Flatz L, Cheng C, Wang L, Foulds KE, Ko SY, Kong WP, Roychoudhuri R, Shi W, Bao S, Todd JP, Asmal M, Shen L, Donaldson M, Schmidt SD, Gall JG, Pinschewer DD, Letvin NL, Rao S, Mascola JR, Roederer M, Nabel GJ. Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates. Journal of virology. 2012; 86(15); 7760-7770. [PubMed: 22593152].
35. Franco et al., 2010: Franco D, Li W, Qing F, Stoyanov CT, Moran T, Rice CM, Ho DD. Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development. Vaccine. 2010; 28(35); 5676-5685. [PubMed: 20600494].
36. Gu et al., 2010: Gu R, Shampang A, Nashar T, Patil M, Fuller DH, Ramsingh AI. Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses. PloS one. 2010; 5(9); . [PubMed: 20824074].
37. Gudmundsdotter et al., 2009: Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine. 2009; 27(33); 4468-4474. [PubMed: 19450644].
38. Hammer et al., 2009: Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men [http://www.clinicaltrials.gov/ct2/show/NCT00865566?term=Ad5+DNA&rank=3]
39. Hanke et al., 2002: Hanke T, McMichael AJ, Samuel RV, Powell LA, McLoughlin L, Crome SJ, Edlin A. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine. 2002; 21(1-2); 108-114. [PubMed: 12443668].
40. Harris et al., 1996: Harris SJ, Woodrow SA, Gearing AJ, Adams SE, Kingsman AJ, Layton GT. The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3-VLPs) in mice. Vaccine. 1996; 14(10); 971-976. [PubMed: 8873390].
41. Harro et al., 2009: Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Priddy FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, Mehrotra DV. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS research and human retroviruses. 2009; 25(1); 103-114. [PubMed: 19108693].
42. Hawkins et al., 2003: Hawkins WG, Trcka J, Segal N, Blachere NE, Gold JS, Moroi Y, Bowne WB, Lewis JJ, Wolchok JD, Houghton AN. The role of lipopolysaccharide in T-cell responses following DNA vaccination. Vaccine. 2003; 21(13-14); 1548-1553. [PubMed: 12615452].
43. Hejdeman et al., 2004: Hejdeman B, Boström AC, Matsuda R, Calarota S, Lenkei R, Fredriksson EL, Sandström E, Bratt G, Wahren B. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy. AIDS research and human retroviruses. 2004; 20(8); 860-870. [PubMed: 15320990].
44. Hirao et al., 2008: Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, Betts MR, Draghia-Akli R, Weiner DB. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine. 2008; 26(25); 3112-3120. [PubMed: 18430495].
45. Johnson et al., 2012: Johnson MJ, Petrovas C, Yamamoto T, Lindsay RW, Loré K, Gall JG, Gostick E, Lefebvre F, Cameron MJ, Price DA, Haddad E, Sekaly RP, Seder RA, Koup RA. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. Journal of immunology (Baltimore, Md. : 1950). 2012; 188(12); 6109-6118. [PubMed: 22586038].
46. Kaneko et al., 2000: Kaneko H, Bednarek I, Wierzbicki A, Kiszka I, Dmochowski M, Wasik TJ, Kaneko Y, Kozbor D. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology. 2000; 267(1); 8-16. [PubMed: 10648178].
47. Kang et al., 2003: Kang KK, Choi SM, Choi JH, Lee DS, Kim CY, Ahn BO, Kim BM, Kim WB. Safety evaluation of GX-12, a new HIV therapeutic vaccine: investigation of integration into the host genome and expression in the reproductive organs. Intervirology. 2003; 46(5); 270-276. [PubMed: 14555847].
48. Kent et al., 2007: Kent S, De Rose R, Rollman E. Drug evaluation: DNA/MVA prime-boost HIV vaccine. Current opinion in investigational drugs (London, England : 2000). 2007 Feb; 8(2); 159-67. [PubMed: 17328232].
49. Kim et al., 1998: Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, Mahalingam S, Dang K, Ahn L, Doyle NK, Wilson DM, Chattergoon MA, Chalian AA, Boyer JD, Agadjanyan MG, Weiner DB. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. European journal of immunology. 1998; 28(3); 1089-1103. [PubMed: 9541605].
50. Kim et al., 2000: Kim JJ, Yang JS, VanCott TC, Lee DJ, Manson KH, Wyand MS, Boyer JD, Ugen KE, Weiner DB. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants. Journal of virology. 2000; 74(7); 3427-3429. [PubMed: 10708463].
51. Kim et al., 2001: Kim JJ, Yang JS, Manson KH, Weiner DB. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine. 2001; 19(17-19); 2496-2505. [PubMed: 11257383].
52. Knight et al., 1990: Knight SC, Macatonia SE, Patterson S. HIV I infection of dendritic cells. International reviews of immunology. 1990; 6(2-3); 163-75. [PubMed: 2152500].
53. Kutzler et al., 2005: Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, Sidhu M, Roopchand V, Kim JJ, Pavlakis GN, Felber BK, Waldmann TA, Boyer JD, Weiner DB. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. Journal of immunology (Baltimore, Md. : 1950). 2005; 175(1); 112-123. [PubMed: 15972637].
54. Kwa et al., 2014: Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR. CD40L-adjuvanted DNA/MVA SIV239 vaccine enhances SIV-specific humoral and cellular immunity, and improves protection against a heterologous SIVE660 mucosal challenge. Journal of virology. 2014; ; . [PubMed: 24920805].
55. Leclerc et al., 1997: Leclerc C, Dériaud E, Rojas M, Whalen RG. The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cellular immunology. 1997; 179(2); 97-9106. [PubMed: 9268493].
56. Lekutis et al., 1997: Lekutis C, Shiver JW, Liu MA, Letvin NL. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha. Journal of immunology (Baltimore, Md. : 1950). 1997; 158(9); 4471-4477. [PubMed: 9127013].
57. Lena et al., 2002: Lena P, Villinger F, Giavedoni L, Miller CJ, Rhodes G, Luciw P. Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus. Vaccine. 2002; 20 Suppl 4; A69-79. [PubMed: 12477432].
58. Li et al., 2008: Li W, Li S, Hu Y, Tang B, Cui L, He W. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting. Vaccine. 2008; 26(26); 3282-3290. [PubMed: 18472194].
59. Liu et al., 2004: Liu YZ, Zhou L, Wang Q, Ye SQ, Li HX, Zeng Y. [Immune response induced by HIV DNA vaccine combined with recombinant adeno-associated virus]. Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology. 2004 Sep; 18(3); 251-4. [PubMed: 15640860].
60. Liu et al., 2006: Liu J, Wyatt LS, Amara RR, Moss B, Robinson HL. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine. Vaccine. 2006 Apr 12; 24(16); 3332-9. [PubMed: 16472543].
61. Locher et al., 2004: Locher CP, Witt SA, Ashlock BM, Polacino P, Hu SL, Shiboski S, Schmidt AM, Agy MB, Anderson DM, Staprans SI, zur Megede J, Levy JA. Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine. 2004; 22(17-18); 2261-2272. [PubMed: 15149785].
62. Lu et al., 2000: Lu Y, Friedman R, Kushner N, Doling A, Thomas L, Touzjian N, Starnbach M, Lieberman J. Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity. Proceedings of the National Academy of Sciences of the United States of America. 2000 Jul 5; 97(14); 8027-32. [PubMed: 10884430].
63. MacGregor et al., 1998: MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. The Journal of infectious diseases. 1998; 178(1); 92-9100. [PubMed: 9652427].
64. MacGregor et al., 2005: MacGregor RR, Boyer JD, Ugen KE, Tebas P, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, Weiner DB. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine. 2005; 23(17-18); 2066-2073. [PubMed: 15755572].
65. Malm et al., 2005: Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, Wahren B, Blazevic V. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral immunology. 2005; 18(4); 678-88. [PubMed: 16359234].
66. Mascola et al., 2005: Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. Journal of virology. 2005; 79(2); 771-779. [PubMed: 15613305].
67. McElrath et al., 2008: McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008; 372(9653); 1894-1905. [PubMed: 19012957].
68. McEvers et al., 2005: McEvers K, Elrefaei M, Norris P, Deeks S, Martin J, Lu Y, Cao H. Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways. Vaccine. 2005 Jul 14; 23(32); 4128-35. [PubMed: 15964481].
69. Moore et al., 2002: Moore AC, Kong WP, Chakrabarti BK, Nabel GJ. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. Journal of virology. 2002; 76(1); 243-250. [PubMed: 11739689].
70. O'Hagan et al., 2001: O'Hagan D, Singh M, Ugozzoli M, Wild C, Barnett S, Chen M, Schaefer M, Doe B, Otten GR, Ulmer JB. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. Journal of virology. 2001; 75(19); 9037-9043. [PubMed: 11533167].
71. Otero et al., 2004: Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD, Weiner DB. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine. 2004; 22(13-14); 1782-1790. [PubMed: 15068862].
72. Otten et al., 2005: Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede J, Kazzaz J, Lian Y, Singh M, Ugozzoli M, Montefiori D, Lewis M, Driver DA, Dubensky T, Polo JM, Donnelly J, O'Hagan DT, Barnett S, Ulmer JB. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. Journal of virology. 2005 Jul; 79(13); 8189-200. [PubMed: 15956564].
73. Ozpolat et al., 1998: Ozpolat B, Rao XM, Powell MF, Lachman LB. Immunoliposomes containing antibodies to costimulatory molecules as adjuvants for HIV subunit vaccines. AIDS research and human retroviruses. 1998; 14(5); 409-417. [PubMed: 9546800].
74. Pal et al., 2005: Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Cristillo A, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Lu S, Markham P. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. Journal of medical primatology. 2005; 34(5-6); 226-236. [PubMed: 16128917].
75. Pal et al., 2006: Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Markham P, Lu S. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology. 2006; 348(2); 341-353. [PubMed: 16460776].
76. Palella et al., 1998: Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England journal of medicine. 1998 Mar 26; 338(13); 853-60. [PubMed: 9516219].
77. Parker, 2007: Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults [http://clinicaltrials.gov/ct2/show/NCT00528489]
78. Patterson et al., 2000: Patterson LJ, Peng B, Abimiku AG, Aldrich K, Murty L, Markham PD, Kalyanaraman VS, Alvord WG, Tartaglia J, Franchini G, Robert-Guroff M. Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques. AIDS (London, England). 2000; 14(16); 2445-2455. [PubMed: 11101054].
79. Pegu et al., 2013: Pegu P, Vaccari M, Gordon S, Keele BF, Doster M, Guan Y, Ferrari G, Pal R, Ferrari MG, Whitney S, Hudacik L, Billings E, Rao M, Montefiori D, Tomaras G, Alam SM, Fenizia C, Lifson JD, Stablein D, Tartaglia J, Michael N, Kim J, Venzon D, Franchini G. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. Journal of virology. 2013; 87(3); 1708-1719. [PubMed: 23175374].
80. Peters et al., 2007: Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinskis L, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo J. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine. 2007; 25(11); 2120-2127. [PubMed: 17250931].
81. Qiu et al., 1999: Qiu JT, Song R, Dettenhofer M, Tian C, August T, Felber BK, Pavlakis GN, Yu XF. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. Journal of virology. 1999; 73(11); 9145-9152. [PubMed: 10516021].
82. Rerks-Ngarm et al., 2009: Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. The New England journal of medicine. 2009; 361(23); 2209-2220. [PubMed: 19843557].
83. Reynolds et al., 2012: Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine. 2012; 30(30); 4465-4475. [PubMed: 22569124].
84. Robinson et al., 2006: Robinson HL, Montefiori DC, Villinger F, Robinson JE, Sharma S, Wyatt LS, Earl PL, McClure HM, Moss B, Amara RR. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology. 2006; 352(2); 285-294. [PubMed: 16740288].
85. Santra et al., 2004: Santra S, Barouch DH, Korioth-Schmitz B, Lord CI, Krivulka GR, Yu F, Beddall MH, Gorgone DA, Lifton MA, Miura A, Philippon V, Manson K, Markham PD, Parrish J, Kuroda MJ, Schmitz JE, Gelman RS, Shiver JW, Montefiori DC, Panicali D, Letvin NL. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proceedings of the National Academy of Sciences of the United States of America. 2004 Jul 27; 101(30); 11088-93. [PubMed: 15258286].
86. Sheets et al., 2006: Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicological sciences : an official journal of the Society of Toxicology. 2006; 91(2); 610-619. [PubMed: 16569729].
87. Shiver et al., 2002: Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002 Jan 17; 415(6869); 331-5. [PubMed: 11797011].
88. Sizemore et al., 1995: Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science (New York, N.Y.). 1995; 270(5234); 299-302. [PubMed: 7569980].
89. Song et al., 2006: Song R, Liu S, Adams RJ, Leong KW. Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2006; 26(6); 380-389. [PubMed: 16734558].
90. Stieneker et al., 1991: Stieneker F, Kreuter J, Löwer J. High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines. AIDS (London, England). 1991; 5(4); 431-435. [PubMed: 2059385].
91. Sun et al., 2013: Sun C, Chen Z, Tang X, Zhang Y, Feng L, Du Y, Xiao L, Liu L, Zhu W, Chen L, Zhang L. Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys. Journal of virology. 2013; 87(10); 5669-5677. [PubMed: 23487457].
92. Takehisa et al., 2001: Takehisa J, Harada Y, Ndembi N, Mboudjeka I, Taniguchi Y, Ngansop C, Kuate S, Zekeng L, Ibuki K, Shimada T, Bikandou B, Yamaguchi-Kabata Y, Miura T, Ikeda M, Ichimura H, Kaptue L, Hayami M. Natural infection of wild-born mandrills (Mandrillus sphinx) with two different types of simian immunodeficiency virus. AIDS research and human retroviruses. 2001 Aug 10; 17(12); 1143-54. [PubMed: 11522184].
93. Tatalick et al., 2005: Tatalick LM, Gerard CJ, Takeya R, Price DN, Thorne BA, Wyatt LM, Anklesaria P. Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine. Vaccine. 2005 Apr 8; 23(20); 2628-38. [PubMed: 15780446].
94. Vecino et al., 2002: Vecino WH, Morin PM, Agha R, Jacobs WR Jr, Fennelly GJ. Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. Immunology letters. 2002; 82(3); 197-204. [PubMed: 12036602].
95. Vinner et al., 1999: Vinner L, Nielsen HV, Bryder K, Corbet S, Nielsen C, Fomsgaard A. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons. Vaccine. 1999; 17(17); 2166-2175. [PubMed: 10367950].
96. Walther-Jallow et al., 2001: Walther-Jallow L, Nilsson C, Söderlund J, ten Haaft P, Mäkitalo B, Biberfeld P, Böttiger P, Heeney J, Biberfeld G, Thorstensson R. Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. The Journal of general virology. 2001; 82(Pt 7); 1601-1612. [PubMed: 11413371].
97. Wang et al., 1993: Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(9); 4156-4160. [PubMed: 8483929].
98. Wang et al., 1993: Wang B, Boyer J, Srikantan V, Coney L, Carrano R, Phan C, Merva M, Dang K, Agadjanan M, Gilbert L. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA and cell biology. 1993; 12(9); 799-805. [PubMed: 8216851].
99. Wang et al., 2006: Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine. 2006; 24(21); 4531-4540. [PubMed: 16140431].
100. Weber et al., 2001: Weber R, Bossart W, Cone R, Luethy R, Moelling K. Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2001; 20(11); 800-803. [PubMed: 11783696].
101. Xin et al., 2005: Xin KQ, Jounai N, Someya K, Honma K, Mizuguchi H, Naganawa S, Kitamura K, Hayakawa T, Saha S, Takeshita F, Okuda K, Honda M, Klinman DM, Okuda K. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene therapy. 2005 Dec; 12(24); 1769-77. [PubMed: 16079886].
102. Yoshino et al., 2004: Yoshino N, Lü FX, Fujihashi K, Hagiwara Y, Kataoka K, Lu D, Hirst L, Honda M, van Ginkel FW, Takeda Y, Miller CJ, Kiyono H, McGhee JR. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. Journal of immunology (Baltimore, Md. : 1950). 2004; 173(11); 6850-6857. [PubMed: 15557179].
103. Zhang et al., 2009: Zhang H, Hong H, Li D, Ma S, Di Y, Stoten A, Haig N, Di Gleria K, Yu Z, Xu XN, McMichael A, Jiang S. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells. The Journal of biological chemistry. 2009; 284(14); 9184-9191. [PubMed: 19193636].